,proteinID,chain,interval,peptide,description,feature_evidence,evidence_to_pubmed,comment_evidence,associated_function,evidence_pubmed,non_associated_function,reference key,title,authors,pubmed,doi,scope_range,pubmed_id,abstract
0,P01275,,21-89,RSLQDTEEKSRSFSASQADPLSDPDQMNEDKRHSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA,Glicentin,1,"{'7': '11946536', '8': '12651102', '9': '22037645', '10': '2753890', '11': '9287128', '13': '10322410', '14': '10605628', '15': '12554744', '16': '12626323', '17': '14719035'}","{'14', '15'}",May modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life.,12554744,,18,"Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis.","Drucker, D. et al.",12554744,10.1210/me.2002-0306,,12554744,"Peptide hormones are secreted from endocrine cells and neurons and exert their actions through activation of G protein-coupled receptors to regulate a diverse number of physiological systems including control of energy homeostasis, gastrointestinal motility, neuroendocrine circuits, and hormone secretion. The glucagon-like peptides, GLP-1 and GLP-2 are prototype peptide hormones released from gut endocrine cells in response to nutrient ingestion that regulate not only energy absorption and disposal, but also cell proliferation and survival. GLP-1 expands islet mass by stimulating pancreatic beta-cell proliferation and induction of islet neogenesis. GLP-1 also promotes cell differentiation, from exocrine cells or immature islet progenitors, toward a more differentiated beta-cell phenotype. GLP-2 stimulates cell proliferation in the gastrointestinal mucosa, leading to expansion of the normal mucosal epithelium, or attenuation of intestinal injury in experimental models of intestinal disease. Both GLP-1 and GLP-2 exert antiapoptotic actions in vivo, resulting in preservation of beta-cell mass and gut epithelium, respectively. Furthermore, GLP-1 and GLP-2 promote direct resistance to apoptosis in cells expressing GLP-1 or GLP-2 receptors. Moreover, an increasing number of structurally related peptide hormones and neuropeptides exert cytoprotective effects through G protein-coupled receptor activation in diverse cell types. Hence, peptide hormones, as exemplified by GLP-1 and GLP-2, may prove to be useful adjunctive tools for enhancement of cell differentiation, tissue regeneration, and cytoprotection for the treatment of human disease."
1,P01275,,21-89,RSLQDTEEKSRSFSASQADPLSDPDQMNEDKRHSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA,Glicentin,1,"{'7': '11946536', '8': '12651102', '9': '22037645', '10': '2753890', '11': '9287128', '13': '10322410', '14': '10605628', '15': '12554744', '16': '12626323', '17': '14719035'}","{'14', '15'}",May modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life.,10605628,,14,The glucagon-like peptides.,"Kieffer, T. et al.",10605628,10.1210/edrv.20.6.0385,,10605628,
2,P01275,,53-89,HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA,Oxyntomodulin,2,"{'7': '11946536', '8': '12651102', '9': '22037645', '10': '2753890', '11': '9287128', '13': '10322410', '14': '10605628', '15': '12554744', '16': '12626323', '17': '14719035'}","{'14', '15'}","Significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness.",12554744,,18,"Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis.","Drucker, D. et al.",12554744,10.1210/me.2002-0306,,12554744,"Peptide hormones are secreted from endocrine cells and neurons and exert their actions through activation of G protein-coupled receptors to regulate a diverse number of physiological systems including control of energy homeostasis, gastrointestinal motility, neuroendocrine circuits, and hormone secretion. The glucagon-like peptides, GLP-1 and GLP-2 are prototype peptide hormones released from gut endocrine cells in response to nutrient ingestion that regulate not only energy absorption and disposal, but also cell proliferation and survival. GLP-1 expands islet mass by stimulating pancreatic beta-cell proliferation and induction of islet neogenesis. GLP-1 also promotes cell differentiation, from exocrine cells or immature islet progenitors, toward a more differentiated beta-cell phenotype. GLP-2 stimulates cell proliferation in the gastrointestinal mucosa, leading to expansion of the normal mucosal epithelium, or attenuation of intestinal injury in experimental models of intestinal disease. Both GLP-1 and GLP-2 exert antiapoptotic actions in vivo, resulting in preservation of beta-cell mass and gut epithelium, respectively. Furthermore, GLP-1 and GLP-2 promote direct resistance to apoptosis in cells expressing GLP-1 or GLP-2 receptors. Moreover, an increasing number of structurally related peptide hormones and neuropeptides exert cytoprotective effects through G protein-coupled receptor activation in diverse cell types. Hence, peptide hormones, as exemplified by GLP-1 and GLP-2, may prove to be useful adjunctive tools for enhancement of cell differentiation, tissue regeneration, and cytoprotection for the treatment of human disease."
3,P01275,,53-89,HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA,Oxyntomodulin,2,"{'7': '11946536', '8': '12651102', '9': '22037645', '10': '2753890', '11': '9287128', '13': '10322410', '14': '10605628', '15': '12554744', '16': '12626323', '17': '14719035'}","{'14', '15'}","Significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness.",10605628,,14,The glucagon-like peptides.,"Kieffer, T. et al.",10605628,10.1210/edrv.20.6.0385,,10605628,
4,P01275,,53-81,HSQGTFTSDYSKYLDSRRAQDFVQWLMNT,Glucagon,7,"{'7': '11946536', '8': '12651102', '9': '22037645', '10': '2753890', '11': '9287128', '13': '10322410', '14': '10605628', '15': '12554744', '16': '12626323', '17': '14719035'}","{'16', '14'}","Plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes.",12626323,,16,Glucagon and regulation of glucose metabolism.,"Jiang, G. et al.",12626323,10.1152/ajpendo.00492.2002,,12626323,"As a counterregulatory hormone for insulin, glucagon plays a critical role in maintaining glucose homeostasis in vivo in both animals and humans. To increase blood glucose, glucagon promotes hepatic glucose output by increasing glycogenolysis and gluconeogenesis and by decreasing glycogenesis and glycolysis in a concerted fashion via multiple mechanisms. Compared with healthy subjects, diabetic patients and animals have abnormal secretion of not only insulin but also glucagon. Hyperglucagonemia and altered insulin-to-glucagon ratios play important roles in initiating and maintaining pathological hyperglycemic states. Not surprisingly, glucagon and glucagon receptor have been pursued extensively in recent years as potential targets for the therapeutic treatment of diabetes."
5,P01275,,53-81,HSQGTFTSDYSKYLDSRRAQDFVQWLMNT,Glucagon,7,"{'7': '11946536', '8': '12651102', '9': '22037645', '10': '2753890', '11': '9287128', '13': '10322410', '14': '10605628', '15': '12554744', '16': '12626323', '17': '14719035'}","{'16', '14'}","Plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes.",11946536,,7,The amino acid sequence of human glucagon.,"Thomsen, J. et al.",11946536,10.1016/0014-5793(72)80192-3,53-81,11946536,
6,P01275,,53-81,HSQGTFTSDYSKYLDSRRAQDFVQWLMNT,Glucagon,7,"{'7': '11946536', '8': '12651102', '9': '22037645', '10': '2753890', '11': '9287128', '13': '10322410', '14': '10605628', '15': '12554744', '16': '12626323', '17': '14719035'}","{'16', '14'}","Plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes.",10605628,,14,The glucagon-like peptides.,"Kieffer, T. et al.",10605628,10.1210/edrv.20.6.0385,,10605628,
7,P01275,,92-128,HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG,Glucagon-like peptide 1,10,"{'7': '11946536', '8': '12651102', '9': '22037645', '10': '2753890', '11': '9287128', '13': '10322410', '14': '10605628', '15': '12554744', '16': '12626323', '17': '14719035'}","{'9', '14', '17', '15'}","Potent stimulator of glucose-dependent insulin release. Also stimulates insulin release in response to IL6 (PubMed:22037645). Plays important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Has growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation. Inhibits beta cell apoptosis (Probable).",12554744,,18,"Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis.","Drucker, D. et al.",12554744,10.1210/me.2002-0306,,12554744,"Peptide hormones are secreted from endocrine cells and neurons and exert their actions through activation of G protein-coupled receptors to regulate a diverse number of physiological systems including control of energy homeostasis, gastrointestinal motility, neuroendocrine circuits, and hormone secretion. The glucagon-like peptides, GLP-1 and GLP-2 are prototype peptide hormones released from gut endocrine cells in response to nutrient ingestion that regulate not only energy absorption and disposal, but also cell proliferation and survival. GLP-1 expands islet mass by stimulating pancreatic beta-cell proliferation and induction of islet neogenesis. GLP-1 also promotes cell differentiation, from exocrine cells or immature islet progenitors, toward a more differentiated beta-cell phenotype. GLP-2 stimulates cell proliferation in the gastrointestinal mucosa, leading to expansion of the normal mucosal epithelium, or attenuation of intestinal injury in experimental models of intestinal disease. Both GLP-1 and GLP-2 exert antiapoptotic actions in vivo, resulting in preservation of beta-cell mass and gut epithelium, respectively. Furthermore, GLP-1 and GLP-2 promote direct resistance to apoptosis in cells expressing GLP-1 or GLP-2 receptors. Moreover, an increasing number of structurally related peptide hormones and neuropeptides exert cytoprotective effects through G protein-coupled receptor activation in diverse cell types. Hence, peptide hormones, as exemplified by GLP-1 and GLP-2, may prove to be useful adjunctive tools for enhancement of cell differentiation, tissue regeneration, and cytoprotection for the treatment of human disease."
8,P01275,,92-128,HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG,Glucagon-like peptide 1,10,"{'7': '11946536', '8': '12651102', '9': '22037645', '10': '2753890', '11': '9287128', '13': '10322410', '14': '10605628', '15': '12554744', '16': '12626323', '17': '14719035'}","{'9', '14', '17', '15'}","Potent stimulator of glucose-dependent insulin release. Also stimulates insulin release in response to IL6 (PubMed:22037645). Plays important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Has growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation. Inhibits beta cell apoptosis (Probable).",2753890,,8,Complete sequences of glucagon-like peptide-1 from human and pig small intestine.,"Orskov, C. et al.",2753890,10.1016/s0021-9258(18)51561-1,98-127,2753890,"In the small intestine, proglucagon is processed into the previously characterized peptide ""glicentin"" (proglucagon (PG) 1-69) and two smaller peptides showing about 50% homology with glucagon: glucagon-like peptide-1 and -2. It was assumed that the sites of post-translational cleavage in the small intestine of the proglucagon precursor were determined by pairs of basic amino acid residues flanking the two peptides. Earlier studies have shown that synthetic glucagon-like peptide-1 (GLP-1) synthesized according to the proposed structure (proglucagon 71-108 or because residue 108 is Gly, 72-107 amide) had no physiological effects, whereas a truncated from of GLP-1, corresponding to proglucagon 78-107 amide, strongly stimulated insulin secretion and depressed glucagon secretion. To determine the amino acid sequence of the naturally occurring peptide we isolated GLP-1 from human small intestine by hydrophobic, gel permeation, and reverse-phase high performance liquid chromatography. By analysis of composition and sequence it was determined that the peptide corresponded to PG 78-107. By mass spectrometry the molecular mass was determined to be 3295, corresponding to PG 78-107 amide. Furthermore, mass spectrometry of the methyl-esterified peptide showed an increase in mass compatible with the presence of alpha-carboxyl amidation. Thus, the gut-derived insulinotrophic hormone GLP-1 is shown to be PG 78-107 amide."
9,P01275,,92-128,HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG,Glucagon-like peptide 1,10,"{'7': '11946536', '8': '12651102', '9': '22037645', '10': '2753890', '11': '9287128', '13': '10322410', '14': '10605628', '15': '12554744', '16': '12626323', '17': '14719035'}","{'9', '14', '17', '15'}","Potent stimulator of glucose-dependent insulin release. Also stimulates insulin release in response to IL6 (PubMed:22037645). Plays important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Has growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation. Inhibits beta cell apoptosis (Probable).",14719035,,17,Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2.,"Brubaker, P. et al.",14719035,10.1139/y03-107,,14719035,"The proglucagon-derived peptide family consists of three highly related peptides, glucagon and the glucagon-like peptides GLP-1 and GLP-2. Although the biological activity of glucagon as a counter-regulatory hormone has been known for almost a century, studies conducted over the past decade have now also elucidated important roles for GLP-1 as an antidiabetic hormone, and for GLP-2 as a stimulator of intestinal growth. In contrast to pancreatic glucagon, the GLPs are synthesized in the intestinal epithelial L cells, where they are subject to the influences of luminal nutrients, as well as to a variety of neuroendocrine inputs. In this review, we will focus on the complex integrative mechanisms that regulate the secretion of these peptides from L cells, including both direct and indirect regulation by ingested nutrients."
10,P01275,,92-128,HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG,Glucagon-like peptide 1,10,"{'7': '11946536', '8': '12651102', '9': '22037645', '10': '2753890', '11': '9287128', '13': '10322410', '14': '10605628', '15': '12554744', '16': '12626323', '17': '14719035'}","{'9', '14', '17', '15'}","Potent stimulator of glucose-dependent insulin release. Also stimulates insulin release in response to IL6 (PubMed:22037645). Plays important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Has growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation. Inhibits beta cell apoptosis (Probable).",22037645,,19,Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells.,"Ellingsgaard, H. et al.",22037645,10.1038/nm.2513,,22037645,"Exercise, obesity and type 2 diabetes are associated with elevated plasma concentrations of interleukin-6 (IL-6). Glucagon-like peptide-1 (GLP-1) is a hormone that induces insulin secretion. Here we show that administration of IL-6 or elevated IL-6 concentrations in response to exercise stimulate GLP-1 secretion from intestinal L cells and pancreatic alpha cells, improving insulin secretion and glycemia. IL-6 increased GLP-1 production from alpha cells through increased proglucagon (which is encoded by GCG) and prohormone convertase 1/3 expression. In models of type 2 diabetes, the beneficial effects of IL-6 were maintained, and IL-6 neutralization resulted in further elevation of glycemia and reduced pancreatic GLP-1. Hence, IL-6 mediates crosstalk between insulin-sensitive tissues, intestinal L cells and pancreatic islets to adapt to changes in insulin demand. This previously unidentified endocrine loop implicates IL-6 in the regulation of insulin secretion and suggests that drugs modulating this loop may be useful in type 2 diabetes."
11,P01275,,92-128,HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG,Glucagon-like peptide 1,10,"{'7': '11946536', '8': '12651102', '9': '22037645', '10': '2753890', '11': '9287128', '13': '10322410', '14': '10605628', '15': '12554744', '16': '12626323', '17': '14719035'}","{'9', '14', '17', '15'}","Potent stimulator of glucose-dependent insulin release. Also stimulates insulin release in response to IL6 (PubMed:22037645). Plays important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Has growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation. Inhibits beta cell apoptosis (Probable).",10605628,,14,The glucagon-like peptides.,"Kieffer, T. et al.",10605628,10.1210/edrv.20.6.0385,,10605628,
12,P01275,,98-128,HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG,Glucagon-like peptide 1(7-37),10,"{'7': '11946536', '8': '12651102', '9': '22037645', '10': '2753890', '11': '9287128', '13': '10322410', '14': '10605628', '15': '12554744', '16': '12626323', '17': '14719035'}",,,2753890,"['Plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes.', 'Potent stimulator of glucose-dependent insulin release. Also stimulates insulin release in response to IL6 (PubMed:22037645). Plays important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Has growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation. Inhibits beta cell apoptosis (Probable).', 'Stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability.', 'Significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness.', 'May modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life.']",8,Complete sequences of glucagon-like peptide-1 from human and pig small intestine.,"Orskov, C. et al.",2753890,10.1016/s0021-9258(18)51561-1,98-127,2753890,"In the small intestine, proglucagon is processed into the previously characterized peptide ""glicentin"" (proglucagon (PG) 1-69) and two smaller peptides showing about 50% homology with glucagon: glucagon-like peptide-1 and -2. It was assumed that the sites of post-translational cleavage in the small intestine of the proglucagon precursor were determined by pairs of basic amino acid residues flanking the two peptides. Earlier studies have shown that synthetic glucagon-like peptide-1 (GLP-1) synthesized according to the proposed structure (proglucagon 71-108 or because residue 108 is Gly, 72-107 amide) had no physiological effects, whereas a truncated from of GLP-1, corresponding to proglucagon 78-107 amide, strongly stimulated insulin secretion and depressed glucagon secretion. To determine the amino acid sequence of the naturally occurring peptide we isolated GLP-1 from human small intestine by hydrophobic, gel permeation, and reverse-phase high performance liquid chromatography. By analysis of composition and sequence it was determined that the peptide corresponded to PG 78-107. By mass spectrometry the molecular mass was determined to be 3295, corresponding to PG 78-107 amide. Furthermore, mass spectrometry of the methyl-esterified peptide showed an increase in mass compatible with the presence of alpha-carboxyl amidation. Thus, the gut-derived insulinotrophic hormone GLP-1 is shown to be PG 78-107 amide."
13,P01275,,98-127,HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR,Glucagon-like peptide 1(7-36),10,"{'7': '11946536', '8': '12651102', '9': '22037645', '10': '2753890', '11': '9287128', '13': '10322410', '14': '10605628', '15': '12554744', '16': '12626323', '17': '14719035'}",,,2753890,"['Plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes.', 'Potent stimulator of glucose-dependent insulin release. Also stimulates insulin release in response to IL6 (PubMed:22037645). Plays important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Has growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation. Inhibits beta cell apoptosis (Probable).', 'Stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability.', 'Significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness.', 'May modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life.']",8,Complete sequences of glucagon-like peptide-1 from human and pig small intestine.,"Orskov, C. et al.",2753890,10.1016/s0021-9258(18)51561-1,98-127,2753890,"In the small intestine, proglucagon is processed into the previously characterized peptide ""glicentin"" (proglucagon (PG) 1-69) and two smaller peptides showing about 50% homology with glucagon: glucagon-like peptide-1 and -2. It was assumed that the sites of post-translational cleavage in the small intestine of the proglucagon precursor were determined by pairs of basic amino acid residues flanking the two peptides. Earlier studies have shown that synthetic glucagon-like peptide-1 (GLP-1) synthesized according to the proposed structure (proglucagon 71-108 or because residue 108 is Gly, 72-107 amide) had no physiological effects, whereas a truncated from of GLP-1, corresponding to proglucagon 78-107 amide, strongly stimulated insulin secretion and depressed glucagon secretion. To determine the amino acid sequence of the naturally occurring peptide we isolated GLP-1 from human small intestine by hydrophobic, gel permeation, and reverse-phase high performance liquid chromatography. By analysis of composition and sequence it was determined that the peptide corresponded to PG 78-107. By mass spectrometry the molecular mass was determined to be 3295, corresponding to PG 78-107 amide. Furthermore, mass spectrometry of the methyl-esterified peptide showed an increase in mass compatible with the presence of alpha-carboxyl amidation. Thus, the gut-derived insulinotrophic hormone GLP-1 is shown to be PG 78-107 amide."
14,P01275,,146-178,HADGSFSDEMNTILDNLAARDFINWLIQTKITD,Glucagon-like peptide 2,4,"{'7': '11946536', '8': '12651102', '9': '22037645', '10': '2753890', '11': '9287128', '13': '10322410', '14': '10605628', '15': '12554744', '16': '12626323', '17': '14719035'}","{'14', '13', '17', '15'}","Stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability.",14719035,,17,Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2.,"Brubaker, P. et al.",14719035,10.1139/y03-107,,14719035,"The proglucagon-derived peptide family consists of three highly related peptides, glucagon and the glucagon-like peptides GLP-1 and GLP-2. Although the biological activity of glucagon as a counter-regulatory hormone has been known for almost a century, studies conducted over the past decade have now also elucidated important roles for GLP-1 as an antidiabetic hormone, and for GLP-2 as a stimulator of intestinal growth. In contrast to pancreatic glucagon, the GLPs are synthesized in the intestinal epithelial L cells, where they are subject to the influences of luminal nutrients, as well as to a variety of neuroendocrine inputs. In this review, we will focus on the complex integrative mechanisms that regulate the secretion of these peptides from L cells, including both direct and indirect regulation by ingested nutrients."
15,P01275,,146-178,HADGSFSDEMNTILDNLAARDFINWLIQTKITD,Glucagon-like peptide 2,4,"{'7': '11946536', '8': '12651102', '9': '22037645', '10': '2753890', '11': '9287128', '13': '10322410', '14': '10605628', '15': '12554744', '16': '12626323', '17': '14719035'}","{'14', '13', '17', '15'}","Stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability.",12554744,,18,"Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis.","Drucker, D. et al.",12554744,10.1210/me.2002-0306,,12554744,"Peptide hormones are secreted from endocrine cells and neurons and exert their actions through activation of G protein-coupled receptors to regulate a diverse number of physiological systems including control of energy homeostasis, gastrointestinal motility, neuroendocrine circuits, and hormone secretion. The glucagon-like peptides, GLP-1 and GLP-2 are prototype peptide hormones released from gut endocrine cells in response to nutrient ingestion that regulate not only energy absorption and disposal, but also cell proliferation and survival. GLP-1 expands islet mass by stimulating pancreatic beta-cell proliferation and induction of islet neogenesis. GLP-1 also promotes cell differentiation, from exocrine cells or immature islet progenitors, toward a more differentiated beta-cell phenotype. GLP-2 stimulates cell proliferation in the gastrointestinal mucosa, leading to expansion of the normal mucosal epithelium, or attenuation of intestinal injury in experimental models of intestinal disease. Both GLP-1 and GLP-2 exert antiapoptotic actions in vivo, resulting in preservation of beta-cell mass and gut epithelium, respectively. Furthermore, GLP-1 and GLP-2 promote direct resistance to apoptosis in cells expressing GLP-1 or GLP-2 receptors. Moreover, an increasing number of structurally related peptide hormones and neuropeptides exert cytoprotective effects through G protein-coupled receptor activation in diverse cell types. Hence, peptide hormones, as exemplified by GLP-1 and GLP-2, may prove to be useful adjunctive tools for enhancement of cell differentiation, tissue regeneration, and cytoprotection for the treatment of human disease."
16,P01275,,146-178,HADGSFSDEMNTILDNLAARDFINWLIQTKITD,Glucagon-like peptide 2,4,"{'7': '11946536', '8': '12651102', '9': '22037645', '10': '2753890', '11': '9287128', '13': '10322410', '14': '10605628', '15': '12554744', '16': '12626323', '17': '14719035'}","{'14', '13', '17', '15'}","Stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability.",10322410,,15,Glucagon-like peptide 2.,"Drucker, D. et al.",10322410,10.1016/s1043-2760(98)00136-2,,10322410,"Glucagon-like peptide 2 (GLP-2) is secreted in a nutrient-dependent manner from enteroendocrine cells throughout the gastrointestinal tract and is trophic to the intestinal epithelial mucosa. GLP-2 acts via stimulation of crypt cell proliferation and inhibition of cell death. GLP-2 also stimulates intestinal glucose transport, decreases mucosal permeability, and shows therapeutic efficacy in experimental models of short bowel syndrome and both small and large bowel inflammation."
17,P01275,,146-178,HADGSFSDEMNTILDNLAARDFINWLIQTKITD,Glucagon-like peptide 2,4,"{'7': '11946536', '8': '12651102', '9': '22037645', '10': '2753890', '11': '9287128', '13': '10322410', '14': '10605628', '15': '12554744', '16': '12626323', '17': '14719035'}","{'14', '13', '17', '15'}","Stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability.",10605628,,14,The glucagon-like peptides.,"Kieffer, T. et al.",10605628,10.1210/edrv.20.6.0385,,10605628,
18,P01148,Progonadoliberin-1,24-33,QHWSYGLRPG,Gonadoliberin-1,8,"{'1': '10336644', '2': '10391209', '3': '19535795', '4': '23643382', '5': '26190377', '6': '2983326', '7': '6090951', '8': '6760865', '9': '7683654'}",,,6760865,['Stimulates the secretion of gonadotropins; it stimulates the secretion of both luteinizing and follicle-stimulating hormones.'],5,The chemical identity of the immunoreactive LHRH-like peptide biosynthesized in the human placenta.,"Tan, L. et al.",6760865,10.1016/0006-291x(82)92047-2,24-33,6760865,
19,P28799,Progranulin,206-261,VMCPDARSRCPDGSTCCELPSGKYGCCPMPNATCCSDHLHCCPQDTVCDLIQSKCL,Granulin-3,,"{'4': '12526812', '5': '16862116', '6': '16983685', '7': '18183624', '8': '18359860', '9': '18378771', '10': '19159218', '11': '20020531', '12': '20188224', '13': '21092856', '14': '22608501', '15': '23364791', '16': '26370502', '17': '27789271', '18': '28073925', '19': '28453791', '20': '28541286', '21': '28743268', '22': '12526812', '23': '14702039', '24': '1542665', '25': '15489334', '26': '1618805', '27': '16862116'}",{'4'},Inhibits epithelial cell proliferation and induces epithelial cells to secrete IL-8.,12526812,,11,Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair.,"Zhu, J. et al.",12526812,10.1016/s0092-8674(02)01141-8,51-62,12526812,"Increased leukocyte elastase activity in mice lacking secretory leukocyte protease inhibitor (SLPI) leads to impaired wound healing due to enhanced activity of TGFbeta and perhaps additional mechanisms. Proepithelin (PEPI), an epithelial growth factor, can be converted to epithelins (EPIs) in vivo by unknown mechanisms with unknown consequences. We found that PEPI and EPIs exert opposing activities. EPIs inhibit the growth of epithelial cells but induce them to secrete the neutrophil attractant IL-8, while PEPI blocks neutrophil activation by tumor necrosis factor, preventing release of oxidants and proteases. SLPI and PEPI form complexes, preventing elastase from converting PEPI to EPIs. Supplying PEPI corrects the wound-healing defect in SLPI null mice. Thus, SLPI/elastase act via PEPI/EPIs to operate a switch at the interface between innate immunity and wound healing."
20,P28799,Progranulin,518-573,DVECGEGHFCHDNQTCCRDNRQGWACCPYRQGVCCADRRHCCPAGFRCAARGTKCL,Granulin-7,,"{'4': '12526812', '5': '16862116', '6': '16983685', '7': '18183624', '8': '18359860', '9': '18378771', '10': '19159218', '11': '20020531', '12': '20188224', '13': '21092856', '14': '22608501', '15': '23364791', '16': '26370502', '17': '27789271', '18': '28073925', '19': '28453791', '20': '28541286', '21': '28743268', '22': '12526812', '23': '14702039', '24': '1542665', '25': '15489334', '26': '1618805', '27': '16862116'}",{'19'},Stabilizes CTSD through interaction with CTSD leading to maintain its aspartic-type peptidase activity.,28453791,,26,Progranulin functions as a cathepsin D chaperone to stimulate axonal outgrowth in vivo.,"Beel, S. et al.",28453791,10.1093/hmg/ddx162,,28453791,"Loss of function mutations in progranulin (GRN) cause frontotemporal dementia, but how GRN haploinsufficiency causes neuronal dysfunction remains unclear. We previously showed that GRN is neurotrophic in vitro. Here, we used an in vivo axonal outgrowth system and observed a delayed recovery in GRN-/- mice after facial nerve injury. This deficit was rescued by reintroduction of human GRN and relied on its C-terminus and on neuronal GRN production. Transcriptome analysis of the facial motor nucleus post injury identified cathepsin D (CTSD) as the most upregulated gene. In aged GRN-/- cortices, CTSD was also upregulated, but the relative CTSD activity was reduced and improved upon exogenous GRN addition. Moreover, GRN and its C-terminal granulin domain granulinE (GrnE) both stimulated the proteolytic activity of CTSD in vitro. Pull-down experiments confirmed a direct interaction between GRN and CTSD. This interaction was also observed with GrnE and stabilized the CTSD enzyme at different temperatures. Investigating the importance of this interaction for axonal regeneration in vivo we found that, although individually tolerated, a combined reduction of GRN and CTSD synergistically reduced axonal outgrowth. Our data links the neurotrophic effect of GRN and GrnE with a lysosomal chaperone function on CTSD to maintain its proteolytic capacity."
21,P05305,,53-90,CSCSSLMDKECVYFCHLDIIWVNTPEHVVPYGLGSPRS,Big endothelin-1,5,"{'3': '10334806', '4': '10391210', '5': '10438732', '6': '15489334', '7': '17357073', '8': '17446437', '9': '18288492', '10': '1864385', '11': '19086031', '12': '24268655', '13': '7664037', '14': '9284755'}",,,10438732,"['Endothelins are endothelium-derived vasoconstrictor peptides (By similarity). Probable ligand for G-protein coupled receptors EDNRA and EDNRB which activates PTK2B, BCAR1, BCAR3 and, GTPases RAP1 and RHOA cascade in glomerular mesangial cells (PubMed:19086031). Also binds the DEAR/FBXW7-AS1 receptor (PubMed:17446437).']",9,Proteolytic processing of big endothelin-3 by the kell blood group protein.,"Lee, S. et al.",10438732,,,10438732,"Kell blood group protein shares a consensus sequence (H.E.X.X.H) with a large family of zinc-dependent endopeptidases. Kell has closest homology with neutral endopeptidase 24.11, endothelin converting enzyme-1 (ECE-1), and the PEX gene product that, as a group, comprise the M13 subfamily of mammalian neutral endopeptidases. The proteolytic activity of the M13 members, but not of Kell, has been previously demonstrated. A secreted form of wild-type Kell protein (s-Kell), devoid of the intracellular and transmembrane domains, was expressed in sf9 cells. As a negative control, an inactive mutant Kell protein (E582G) was expressed. As determined by N-terminal amino acid sequencing and mass spectrometry of the cleaved products, wild-type s-Kell, but not the control mutant protein, specifically cleaved big endothelin-3 (ET-3) at Trp(21)-Ile(22), yielding ET-3, and, to a much lesser extent, also cleaved big ET-1 and big ET-2 at Trp(21)-Val(22), yielding ET-1 and ET-2. Enzymatic activity was partially inhibited by phosphoramidon. s-Kell has an acidic pH optimum (pH 6.0 to 6.5). Like the recombinant protein, red blood cells of common Kell phenotype also preferentially process big ET-3, in contrast to Ko (null) cells that do not. These data demonstrate that the Kell blood group protein is a proteolytic enzyme that processes big ET-3, generating ET-3, a potent bioactive peptide with multiple biological roles."
22,P05305,,53-73,CSCSSLMDKECVYFCHLDIIW,Endothelin-1,5,"{'3': '10334806', '4': '10391210', '5': '10438732', '6': '15489334', '7': '17357073', '8': '17446437', '9': '18288492', '10': '1864385', '11': '19086031', '12': '24268655', '13': '7664037', '14': '9284755'}",,,10438732,"['Endothelins are endothelium-derived vasoconstrictor peptides (By similarity). Probable ligand for G-protein coupled receptors EDNRA and EDNRB which activates PTK2B, BCAR1, BCAR3 and, GTPases RAP1 and RHOA cascade in glomerular mesangial cells (PubMed:19086031). Also binds the DEAR/FBXW7-AS1 receptor (PubMed:17446437).']",9,Proteolytic processing of big endothelin-3 by the kell blood group protein.,"Lee, S. et al.",10438732,,,10438732,"Kell blood group protein shares a consensus sequence (H.E.X.X.H) with a large family of zinc-dependent endopeptidases. Kell has closest homology with neutral endopeptidase 24.11, endothelin converting enzyme-1 (ECE-1), and the PEX gene product that, as a group, comprise the M13 subfamily of mammalian neutral endopeptidases. The proteolytic activity of the M13 members, but not of Kell, has been previously demonstrated. A secreted form of wild-type Kell protein (s-Kell), devoid of the intracellular and transmembrane domains, was expressed in sf9 cells. As a negative control, an inactive mutant Kell protein (E582G) was expressed. As determined by N-terminal amino acid sequencing and mass spectrometry of the cleaved products, wild-type s-Kell, but not the control mutant protein, specifically cleaved big endothelin-3 (ET-3) at Trp(21)-Ile(22), yielding ET-3, and, to a much lesser extent, also cleaved big ET-1 and big ET-2 at Trp(21)-Val(22), yielding ET-1 and ET-2. Enzymatic activity was partially inhibited by phosphoramidon. s-Kell has an acidic pH optimum (pH 6.0 to 6.5). Like the recombinant protein, red blood cells of common Kell phenotype also preferentially process big ET-3, in contrast to Ko (null) cells that do not. These data demonstrate that the Kell blood group protein is a proteolytic enzyme that processes big ET-3, generating ET-3, a potent bioactive peptide with multiple biological roles."
23,P01160,Natriuretic peptides A,26-55,NPMYNAVSNADLMDFKNLLDHLEEKMPLED,Long-acting natriuretic peptide,61 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '41', '34', '1', '24', '18', '36', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).",7595132,,31,Kaliuretic peptide and long acting natriuretic peptide as well as atrial natriuretic factor inhibit aldosterone secretion.,"Vesely, D. et al.",7595132,10.1677/joe.0.1460373,,7595132,"The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1-30 (long acting natriuretic peptide), 31-67 (vessel dilator) and 79-98 (kaliuretic peptide) as well as 99-126 (atrial natriuretic factor (ANF)) of the 126 amino acid ANF prohormone inhibit aldosterone secretion. Thirty healthy human subjects were studied following infusion of 100 ng/kg body weight/min for 60 min of each of the respective peptides. Kaliuretic peptide decreased plasma aldosterone concentration by the greatest amount (6-fold) and plasma aldosterone was still significantly decreased (P < 0.001) three hours after stopping the infusion. In contrast, within 30 min of cessation of the ANF infusion, plasma aldosterone levels had returned to pre-infusion values. Long acting natriuretic peptide also significantly (P < 0.01) decreased plasma aldosterone levels which remained significantly (P < 0.001) decreased 3 h after cessation of infusion. Vessel dilator did not decrease plasma aldosterone levels. Kaliuretic peptide, ANF and long acting natriuretic peptide also decreased (P < 0.01) urinary aldosterone concentrations. None of these peptides changed the plasma potassium concentration. We conclude that two new peptide hormones (long acting natriuretic peptide and kaliuretic peptide) inhibit aldosterone secretion. The length of time that aldosterone secretion is inhibited following kaliuretic peptide and long acting natriuretic peptide infusion is significantly longer (P < 0.001) than following ANF infusion."
24,P01160,Natriuretic peptides A,26-55,NPMYNAVSNADLMDFKNLLDHLEEKMPLED,Long-acting natriuretic peptide,61 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '41', '34', '1', '24', '18', '36', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).",7955907,,26,"N-terminal atrial natriuretic peptide and atrial natriuretic peptide in human plasma: investigation of plasma levels and molecular circulating form(s) using radioimmunoassays for pro-atrial natriuretic peptide (31-67), pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide (99-126).","Buckley, M. et al.",7955907,10.1042/cs0870311,,7955907,"1. The aim of this study was to determine plasma levels of N-terminal atrial natriuretic peptide and atrial natriuretic peptide in normal subjects and in patients with essential hypertension, cardiac transplant and chronic renal failure, using radioimmunoassays directed towards the mid-portion pro-atrial natriuretic peptide (31-67) and pro-atrial natriuretic peptide (1-30) of the N-terminal atrial natriuretic peptide and atrial natriuretic peptide (99-126). The circulating form(s) of the immunoreactive N-terminal atrial natriuretic peptide in plasma extracts has been investigated using all three radioimmunoassays by means of gel filtration chromatography to further clarify the major immunoreactive molecular circulating form(s) of N-terminal atrial natriuretic peptide in man. 2. The plasma level (mean +/- SEM) of N-terminal pro-atrial natriuretic peptide (31-67) in the normal subjects was 547.2 +/- 32.7 pg/ml (n = 36) and was significantly elevated in patients with essential hypertension (730.2 +/- 72.3 pg/ml, P < 0.025, n = 39), in cardiac transplant recipients (3214.0 +/- 432.2 pg/ml, P < 0.001, n = 9) and in patients with chronic renal failure (3571.8 +/- 474.1 pg/ml, P < 0.001, n = 11). Plasma levels of N-terminal pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide were similarly elevated in the same patient groups when compared with the mean plasma values in the normal subjects.(ABSTRACT TRUNCATED AT 250 WORDS)"
25,P01160,Natriuretic peptides A,26-55,NPMYNAVSNADLMDFKNLLDHLEEKMPLED,Long-acting natriuretic peptide,61 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '41', '34', '1', '24', '18', '36', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).",7720651,,30,Kaliuretic peptide: the most potent inhibitor of Na(+)-K+ ATPase of the atrial natriuretic peptides.,"Chiou, S. et al.",7720651,10.1210/endo.136.5.7720651,,7720651,"The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1-30 (i.e. long-acting natriuretic peptide), 31-67 (vessel dilator), 79-98 (kaliuretic peptide), and 99-126 [atrial natriuretic factor (ANF)] of the 126 amino acid ANF prohormone inhibit sodium-potassium-ATPase as part of their mechanism(s) of action for producing a natriuresis and/or kaliuresis. Kaliuretic peptide, long-acting natriuretic peptide, vessel dilator and ANF at their 10(-11) M concentrations inhibited Na(+)-K(+)-ATPase 39.5%, 27.8%, 19.2%, and 4% respectively, in bovine renal medulla, whereas their inhibition in renal cortical membranes was 37.5%, 27.5%, 20%, and 0%, respectively. Ouabain (0.5 mM) inhibited kidney medullary Na(+)-K(+)-ATPase 45% and in the cortex, 38%. There was no additive effect of any of these peptides with ouabain suggesting that they are interacting with the same site on the Na(+)-K(+)-ATPase as ouabain. To help elucidate the mechanism of these peptides' interaction with Na(+)-K(+)-ATPase, naproxen (0.5 mM), an inhibitor of prostaglandin synthesis, and direct measurement of prostaglandin E2 by RIA were used. Naproxen completely blocked the inhibition of Na(+)-K(+)-ATPase by kaliuretic peptide, long-acting natriuretic peptide, and vessel dilator suggesting that their inhibition of Na(+)-K(+)-ATPase in both the kidney medulla and cortex are mediated by prostaglandins. Direct measurement of prostaglandin E2 revealed that kaliuretic peptide > long-acting natriuretic peptide > vessel dilator increased prostaglandin E2 synthesis, whereas ANF did not have any effect. Of interest, angiotensin II and ouabain inhibition of Na(+)-K(+)-ATPase were also completely blocked by naproxen."
26,P01160,Natriuretic peptides A,26-55,NPMYNAVSNADLMDFKNLLDHLEEKMPLED,Long-acting natriuretic peptide,61 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '41', '34', '1', '24', '18', '36', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).",11145122,,36,"Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance the urinary excretion rate of beta2-microglobulin.","Vesely, D. et al.",11145122,10.1053/meta.2000.18557,,11145122,"The atrial natriuretic peptide (ANP) gene synthesizes a 126-amino acid (aa) prohormone from which four peptide hormones are derived. These 4 peptide hormones consisting of aa 1 to 30 (ie, long-acting natriuretic peptide [LANP]), aa 31 to 67 (vessel dilator), aa 79 to 98 (kaliuretic peptide), and aa 99 to 126 (ie, ANP) have diuretic, natriuretic, and/or kaliuretic properties. ANP has been reported to have its natriuretic and protein-excreting effects via both the proximal and distal tubules, but where in the kidney the other three peptide hormones have their natriuretic and/or diuretic effects is unknown. Further, it has never been investigated as to whether these three other peptide hormones enhance protein excretion. The present investigation was designed to determine (1) if these atrial peptides enhance protein excretion and (2) if their effects involve the proximal tubules of healthy humans by examining the excretion rate of beta2-microglobulin, a marker of proximal tubule function. Twenty-four healthy human subjects were studied following the infusion of 100 ng/kg body weight/min for 60 minutes of each of the respective peptides. LANP enhanced the excretion rate of beta2-microglobulin 2-fold within 20 minutes of beginning its infusion (P < .05) and was 2.5-fold higher than the preinfusion excretion rate at the end of the infusion. The excretion rate of beta2-microglobulin continued to be significantly (P < .01) increased for 3 hours after cessation of the LANP infusion, with the maximal excretion rate (ie, 3.8-fold increase) at 2.5 hours after stopping the infusion. Vessel dilator showed a more marked enhancement of beta2-microglobulin during its infusion, with the excretion rate increasing 2.5-fold at 20 minutes, and was increased 4-fold (P < .01) at the end of the infusion. With cessation of the vessel dilator infusion, the excretion rate of beta2-microglobulin decreased but was still elevated 2-fold (P < .05) 3 hours after stopping the infusion. Kaliuretic peptide enhanced the beta2-microglobulin excretion rate a maximal 3-fold, which occurred at the end of its infusion. The beta2-microglobulin excretion secondary to kaliuretic peptide remained 2-fold (P < .05) above baseline during the 3-hour postinfusion period. These peptide hormones similarly enhanced the albumin and total protein excretion rates 2- to 4-fold. These results indicate that LANP, vessel dilator, and kaliuretic peptide each (1) enhance protein excretion in healthy humans and (2) inhibit proximal tubular protein reabsorption."
27,P01160,Natriuretic peptides A,26-55,NPMYNAVSNADLMDFKNLLDHLEEKMPLED,Long-acting natriuretic peptide,61 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '41', '34', '1', '24', '18', '36', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).",2532366,,18,Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans.,"Vesely, D. et al.",2532366,10.3181/00379727-192-42990,,2532366,"The role of peptides from the N terminus and C terminus of the 126 amino acid atrial natriuretic factor (ANF) prohormone in modulating renal sodium and water handling has not been defined. Since water immersion to the neck (NI) provides an acute central volume expansion identical to that produced by 2 liters of saline but without plasma compositional change, immersion to the neck was used to assess the N-terminal and C-terminal portions of the ANF prohormone response to acute central blood volume expansion in seven seated sodium-replete normal subjects. Both the C terminus, which contains amino acids 99-126 and is identical to ANF, and the whole N terminus (i.e., amino acids 1-98) increased promptly with NI and peaked after 1 hr of immersion. A Mr 3900 peptide from the midportion of the N terminus consistent with amino acids 31-67 (i.e., pro-ANF-31-67) also increased with NI and followed a pattern of increasing circulating concentration nearly identical to that of the whole N terminus of the prohormone, except that its maximal concentration was at the second hour of the 3 hr of NI. With cessation of immersion, ANF decreased to preimmersion levels within 1 hr whereas the N terminus and pro-ANF-31-67, although their circulating concentrations were decreasing, were still significantly elevated at 1 hr. These findings suggest that the increase in plasma ANF, the N terminus of the ANF prohormone, and pro-ANF-31-67 from the midportion of the N terminus, with natriuretic properties similar to ANF, contribute to the natriuretic response to NI, implying a physiologic role for these atrial peptides in modulating volume homeostasis in humans."
28,P01160,Natriuretic peptides A,26-55,NPMYNAVSNADLMDFKNLLDHLEEKMPLED,Long-acting natriuretic peptide,61 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '41', '34', '1', '24', '18', '36', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).",8087923,,25,"Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans.","Vesely, D. et al.",8087923,10.1161/01.cir.90.3.1129,,8087923,"Three peptides consisting of amino acids 1-30, 31-67, and 79-98 of the 126-amino acid atrial natriuretic factor prohormone (proANF), which have blood pressure-lowering, diuretic, natriuretic, and/or kaliuretic properties in animals, were investigated to determine if they have similar properties in humans."
29,P01160,Natriuretic peptides A,26-55,NPMYNAVSNADLMDFKNLLDHLEEKMPLED,Long-acting natriuretic peptide,61 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '41', '34', '1', '24', '18', '36', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).",2825692,,16,"Atrial natriuretic prohormone peptides 1-30, 31-67, and 79-98 vasodilate the aorta.","Vesely, D. et al.",2825692,10.1016/s0006-291x(87)80307-8,,2825692,"Human prohormone atrial natriuretic peptides 1-30, 31-67, and 79-98 caused vasodilation of porcine aortas which began in 30 seconds and was maximal at 10 minutes. These three peptides were found to be equally potent to atrial natriuretic factor in their vasodilatory activity which was found with or without endothelium present. This vasodilation was associated with a 4 to 5 fold increase in cyclic GMP in the aorta secondary to activation of particulate guanylate cyclase [E.C. 4.6.12]. These data demonstrate that three N-terminal peptide segments of the atrial natriuretic factor prohormone cause vasodilation."
30,P01160,Natriuretic peptides A,26-55,NPMYNAVSNADLMDFKNLLDHLEEKMPLED,Long-acting natriuretic peptide,61 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '41', '34', '1', '24', '18', '36', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).",7984506,,27,Molecular forms of circulating atrial natriuretic peptides in human plasma and their metabolites.,"Gower, W. et al.",7984506,10.1016/0196-9781(94)90043-4,,7984506,"High performance gel permeation chromatography (HP-GPC) followed by four radioimmunoassays (RIAs) devised to amino acids (a.a.) 1-30, 31-67, 79-98, and 99-126 of the 126 a.a. atrial natriuretic factor (ANF) prohormone revealed that the proANF(1-30) assay immunoreactivity in plasma is 50% proANF(1-30) and 50% proANF(1-98). The HP-GPC evaluation of plasma followed by proANF(31-67) and ANF [i.e., proANF(99-126)] assays revealed that proANF(31-67) and ANF circulate as distinct peptides. the HP-GPC plasma examination followed by proANF(79-98) assay immunologically recognized three peaks in plasma consistent with proANF(1-98), -(68-98), and -(79-98). Similar HP-GPC evaluation of urine followed by these RIAs indicated that the proANF(1-30), -(79-98), and ANF assays only recognize 500 mol.wt. or less peptides, and the proANF(31-67) RIA recognizes a nearly intact proANF(31-67) with only two to three amino acids removed during processing of this peptide."
31,P01160,Natriuretic peptides A,26-55,NPMYNAVSNADLMDFKNLLDHLEEKMPLED,Long-acting natriuretic peptide,61 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '41', '34', '1', '24', '18', '36', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).",2162527,,20,"Specific binding sites for prohormone atrial natriuretic peptides 1-30, 31-67 and 99-126.","Vesely, D. et al.",2162527,10.1016/0196-9781(90)90070-l,,2162527,"Two peptides with vasodilatory properties consisting of amino acids 1-30 and 31-67 of the 98 a.a. N-terminal end of the prohormone of atrial natriuretic factor (proANF) which circulates in man were investigated to determine if they have specific binding sites on membranes isolated from DDT1 MF-2 smooth muscle cells. Smooth muscle is a known biologic target of these peptides. Competitive binding experiments revealed that proANFs (1-30), (31-67), and (99-126) (i.e., C-terminus; ANF) each had specific and separate binding sites. The dissociation constants for proANFs (1-30), (31-67), and (99-126) binding were 0.11 nM, 4 nM, and 7.3 nM, respectively. The binding site concentrations for proANFs (1-30), (31-67), and ANF were 2.57, 59.91 and 40 fmols/10(6) cells, respectively. The number of binding sites per cell were 1548, 36,087, and 24,090, respectively, for proANFs (1-30), (31-67), and (99-126) (ANF). Each peptide bound to DDT1 MF-2 membranes between 10(-8) to 10(-11) M but could only bind to the other peptides' receptors at concentrations of 10(-6) and 10(-7)M. These results suggest that proANF(1-30) and proANF(31-67) do not work through the ANF receptor but rather have their own separate and distinct receptors that mediate their biologic effects."
32,P01160,Natriuretic peptides A,26-55,NPMYNAVSNADLMDFKNLLDHLEEKMPLED,Long-acting natriuretic peptide,61 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '41', '34', '1', '24', '18', '36', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).",8653797,,29,Temporal (circadian) and functional relationship between atrial natriuretic peptides and blood pressure.,"Sothern, R. et al.",8653797,10.3109/07420529509064506,,8653797,"Long-acting natriuretic peptide, vessel dilator, and atrial natriuretic factor consisting of amino acids (a.a.) 1 to 30, 31 to 67, and 99 to 126 of the 126-a.a. atrial natriuretic factor (ANF) prohormone, respectively, circulate in humans and have potent vasodilatory properties. To determine if these atrial natriuretic peptides are directly related to blood pressure in clinically healthy normotensive humans, we obtained 24-h profiles of vessel dilator, long-acting natriuretic peptide, ANF, and blood pressure in 10 men in 1988 and 11 men in 1993 (seven men were studied twice) to compare circulating concentrations of atrial natriuretic peptides with naturally occurring changes in blood pressure. Overall, vessel dilator, long-acting natriuretic peptide, and ANF each had significant (p<0.001) circadian rhythms, with peak concentrations late during sleep (at 04:00 h) being nearly twice their concentrations in the afternoon and evening. This high-amplitude circadian change allowed for the refinement of normal limits for ANF peptides by computing 3-hourly tolerance intervals (chronodesms) against which to compare time-specified single samples for normality. Systolic, diastolic, and mean arterial blood pressure also had significant circadian rhythms (p<0.001) with peaks and troughs that were exactly opposite those of the ANF peptides. In addition to this inverse temporal relationship, there was a significant inverse correlation between absolute values for blood pressure and each ANF peptide (p<0.001), implying a functional relationship. These data suggest that in addition to other well-established neurochemical factors, the ANF peptides (vessel dilator, long-acting natriuretic peptide, and ANF) are important for the maintenance of blood pressure and modulation of its circadian rhythm."
33,P01160,Natriuretic peptides A,56-92,EVVPPQVLSEPNEEAGAALSPLPEVPPWTGEVSPAQR,Vessel dilator,61 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '35', '41', '34', '24', '18', '36', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, and vasodilation (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2532366, PubMed:7595132). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651, PubMed:7595132). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (PubMed:7831500). Appears to bind to specific receptors that are distinct from the receptors bound by the atrial natriuretic and long-acting natriuretic peptides (PubMed:2162527, PubMed:2825692). Possibly functions in protein excretion in urine by maintaining the integrity of the proximal tubules and enhancing protein excretion by decreasing proximal tubular protein reabsorption (PubMed:11145122).",7595132,,31,Kaliuretic peptide and long acting natriuretic peptide as well as atrial natriuretic factor inhibit aldosterone secretion.,"Vesely, D. et al.",7595132,10.1677/joe.0.1460373,,7595132,"The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1-30 (long acting natriuretic peptide), 31-67 (vessel dilator) and 79-98 (kaliuretic peptide) as well as 99-126 (atrial natriuretic factor (ANF)) of the 126 amino acid ANF prohormone inhibit aldosterone secretion. Thirty healthy human subjects were studied following infusion of 100 ng/kg body weight/min for 60 min of each of the respective peptides. Kaliuretic peptide decreased plasma aldosterone concentration by the greatest amount (6-fold) and plasma aldosterone was still significantly decreased (P < 0.001) three hours after stopping the infusion. In contrast, within 30 min of cessation of the ANF infusion, plasma aldosterone levels had returned to pre-infusion values. Long acting natriuretic peptide also significantly (P < 0.01) decreased plasma aldosterone levels which remained significantly (P < 0.001) decreased 3 h after cessation of infusion. Vessel dilator did not decrease plasma aldosterone levels. Kaliuretic peptide, ANF and long acting natriuretic peptide also decreased (P < 0.01) urinary aldosterone concentrations. None of these peptides changed the plasma potassium concentration. We conclude that two new peptide hormones (long acting natriuretic peptide and kaliuretic peptide) inhibit aldosterone secretion. The length of time that aldosterone secretion is inhibited following kaliuretic peptide and long acting natriuretic peptide infusion is significantly longer (P < 0.001) than following ANF infusion."
34,P01160,Natriuretic peptides A,56-92,EVVPPQVLSEPNEEAGAALSPLPEVPPWTGEVSPAQR,Vessel dilator,61 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '35', '41', '34', '24', '18', '36', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, and vasodilation (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2532366, PubMed:7595132). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651, PubMed:7595132). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (PubMed:7831500). Appears to bind to specific receptors that are distinct from the receptors bound by the atrial natriuretic and long-acting natriuretic peptides (PubMed:2162527, PubMed:2825692). Possibly functions in protein excretion in urine by maintaining the integrity of the proximal tubules and enhancing protein excretion by decreasing proximal tubular protein reabsorption (PubMed:11145122).",7955907,,26,"N-terminal atrial natriuretic peptide and atrial natriuretic peptide in human plasma: investigation of plasma levels and molecular circulating form(s) using radioimmunoassays for pro-atrial natriuretic peptide (31-67), pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide (99-126).","Buckley, M. et al.",7955907,10.1042/cs0870311,,7955907,"1. The aim of this study was to determine plasma levels of N-terminal atrial natriuretic peptide and atrial natriuretic peptide in normal subjects and in patients with essential hypertension, cardiac transplant and chronic renal failure, using radioimmunoassays directed towards the mid-portion pro-atrial natriuretic peptide (31-67) and pro-atrial natriuretic peptide (1-30) of the N-terminal atrial natriuretic peptide and atrial natriuretic peptide (99-126). The circulating form(s) of the immunoreactive N-terminal atrial natriuretic peptide in plasma extracts has been investigated using all three radioimmunoassays by means of gel filtration chromatography to further clarify the major immunoreactive molecular circulating form(s) of N-terminal atrial natriuretic peptide in man. 2. The plasma level (mean +/- SEM) of N-terminal pro-atrial natriuretic peptide (31-67) in the normal subjects was 547.2 +/- 32.7 pg/ml (n = 36) and was significantly elevated in patients with essential hypertension (730.2 +/- 72.3 pg/ml, P < 0.025, n = 39), in cardiac transplant recipients (3214.0 +/- 432.2 pg/ml, P < 0.001, n = 9) and in patients with chronic renal failure (3571.8 +/- 474.1 pg/ml, P < 0.001, n = 11). Plasma levels of N-terminal pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide were similarly elevated in the same patient groups when compared with the mean plasma values in the normal subjects.(ABSTRACT TRUNCATED AT 250 WORDS)"
35,P01160,Natriuretic peptides A,56-92,EVVPPQVLSEPNEEAGAALSPLPEVPPWTGEVSPAQR,Vessel dilator,61 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '35', '41', '34', '24', '18', '36', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, and vasodilation (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2532366, PubMed:7595132). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651, PubMed:7595132). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (PubMed:7831500). Appears to bind to specific receptors that are distinct from the receptors bound by the atrial natriuretic and long-acting natriuretic peptides (PubMed:2162527, PubMed:2825692). Possibly functions in protein excretion in urine by maintaining the integrity of the proximal tubules and enhancing protein excretion by decreasing proximal tubular protein reabsorption (PubMed:11145122).",7720651,,30,Kaliuretic peptide: the most potent inhibitor of Na(+)-K+ ATPase of the atrial natriuretic peptides.,"Chiou, S. et al.",7720651,10.1210/endo.136.5.7720651,,7720651,"The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1-30 (i.e. long-acting natriuretic peptide), 31-67 (vessel dilator), 79-98 (kaliuretic peptide), and 99-126 [atrial natriuretic factor (ANF)] of the 126 amino acid ANF prohormone inhibit sodium-potassium-ATPase as part of their mechanism(s) of action for producing a natriuresis and/or kaliuresis. Kaliuretic peptide, long-acting natriuretic peptide, vessel dilator and ANF at their 10(-11) M concentrations inhibited Na(+)-K(+)-ATPase 39.5%, 27.8%, 19.2%, and 4% respectively, in bovine renal medulla, whereas their inhibition in renal cortical membranes was 37.5%, 27.5%, 20%, and 0%, respectively. Ouabain (0.5 mM) inhibited kidney medullary Na(+)-K(+)-ATPase 45% and in the cortex, 38%. There was no additive effect of any of these peptides with ouabain suggesting that they are interacting with the same site on the Na(+)-K(+)-ATPase as ouabain. To help elucidate the mechanism of these peptides' interaction with Na(+)-K(+)-ATPase, naproxen (0.5 mM), an inhibitor of prostaglandin synthesis, and direct measurement of prostaglandin E2 by RIA were used. Naproxen completely blocked the inhibition of Na(+)-K(+)-ATPase by kaliuretic peptide, long-acting natriuretic peptide, and vessel dilator suggesting that their inhibition of Na(+)-K(+)-ATPase in both the kidney medulla and cortex are mediated by prostaglandins. Direct measurement of prostaglandin E2 revealed that kaliuretic peptide > long-acting natriuretic peptide > vessel dilator increased prostaglandin E2 synthesis, whereas ANF did not have any effect. Of interest, angiotensin II and ouabain inhibition of Na(+)-K(+)-ATPase were also completely blocked by naproxen."
36,P01160,Natriuretic peptides A,56-92,EVVPPQVLSEPNEEAGAALSPLPEVPPWTGEVSPAQR,Vessel dilator,61 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '35', '41', '34', '24', '18', '36', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, and vasodilation (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2532366, PubMed:7595132). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651, PubMed:7595132). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (PubMed:7831500). Appears to bind to specific receptors that are distinct from the receptors bound by the atrial natriuretic and long-acting natriuretic peptides (PubMed:2162527, PubMed:2825692). Possibly functions in protein excretion in urine by maintaining the integrity of the proximal tubules and enhancing protein excretion by decreasing proximal tubular protein reabsorption (PubMed:11145122).",7831500,,28,Lack of biologic activity or specific binding of amino-terminal pro-ANP segments in the rat.,"Weir, M. et al.",7831500,10.1016/0167-0115(94)90612-2,,7831500,"In addition to atrial natriuretic peptide (ANP99-126) itself, linear peptide fragments from its N-terminal prohormone segment (pro-ANP) have been reported to have biological activity. In vivo, diuresis and natriuresis, as well as hypotension have been observed. In vitro, sodium uptake into medullary collecting duct cells was inhibited, and tone of vascular smooth muscle was reduced, associated with activation of guanylate cyclase. Such previous studies have used heterologous peptides and species, e.g., human pro-ANP1-30 or pro-ANP31-67, tested in rat, pig, or dog. The present experiments were designed to test whether rat pro-ANP1-30 or pro-ANP31-67 were natriuretic and hypotensive in rats, whether the two peptides showed specific binding to plasma membranes from rat kidney cortex or aorta, and whether they affected particulate guanylate cyclase activity in rat glomerular membranes. To extend in vitro results from the literature, the effect of human pro-ANP31-67 on transport in the rat medullary collecting duct in vivo was also tested. Although rat ANP99-126, as expected, increased diuresis and natriuresis, associated with inhibition of transport in the medullary collecting duct, in identically treated rats human pro-ANP31-67 was without effect. Similarly, only the ANP99-126 infusion resulted in reduction of arterial blood pressure. Furthermore, no diuretic, natriuretic, or hypotensive responses were observed in rats infused with either rat pro-ANP31-67 or pro-ANP1-30. In plasma membranes from rat kidney cortex or aorta, neither of the rat prosegments showed specific binding, or interference with ANP99-126 receptors. Finally, in contrast to ANP99-126, neither of the prosegments was able to increase basal guanylate cyclase activity in rat glomerular membranes. Therefore, under our experimental conditions we were unable to replicate the earlier results. This study thus does not support a regulatory role for pro-ANP fragments in blood volume or blood pressure homeostasis."
37,P01160,Natriuretic peptides A,56-92,EVVPPQVLSEPNEEAGAALSPLPEVPPWTGEVSPAQR,Vessel dilator,61 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '35', '41', '34', '24', '18', '36', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, and vasodilation (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2532366, PubMed:7595132). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651, PubMed:7595132). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (PubMed:7831500). Appears to bind to specific receptors that are distinct from the receptors bound by the atrial natriuretic and long-acting natriuretic peptides (PubMed:2162527, PubMed:2825692). Possibly functions in protein excretion in urine by maintaining the integrity of the proximal tubules and enhancing protein excretion by decreasing proximal tubular protein reabsorption (PubMed:11145122).",11145122,,36,"Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance the urinary excretion rate of beta2-microglobulin.","Vesely, D. et al.",11145122,10.1053/meta.2000.18557,,11145122,"The atrial natriuretic peptide (ANP) gene synthesizes a 126-amino acid (aa) prohormone from which four peptide hormones are derived. These 4 peptide hormones consisting of aa 1 to 30 (ie, long-acting natriuretic peptide [LANP]), aa 31 to 67 (vessel dilator), aa 79 to 98 (kaliuretic peptide), and aa 99 to 126 (ie, ANP) have diuretic, natriuretic, and/or kaliuretic properties. ANP has been reported to have its natriuretic and protein-excreting effects via both the proximal and distal tubules, but where in the kidney the other three peptide hormones have their natriuretic and/or diuretic effects is unknown. Further, it has never been investigated as to whether these three other peptide hormones enhance protein excretion. The present investigation was designed to determine (1) if these atrial peptides enhance protein excretion and (2) if their effects involve the proximal tubules of healthy humans by examining the excretion rate of beta2-microglobulin, a marker of proximal tubule function. Twenty-four healthy human subjects were studied following the infusion of 100 ng/kg body weight/min for 60 minutes of each of the respective peptides. LANP enhanced the excretion rate of beta2-microglobulin 2-fold within 20 minutes of beginning its infusion (P < .05) and was 2.5-fold higher than the preinfusion excretion rate at the end of the infusion. The excretion rate of beta2-microglobulin continued to be significantly (P < .01) increased for 3 hours after cessation of the LANP infusion, with the maximal excretion rate (ie, 3.8-fold increase) at 2.5 hours after stopping the infusion. Vessel dilator showed a more marked enhancement of beta2-microglobulin during its infusion, with the excretion rate increasing 2.5-fold at 20 minutes, and was increased 4-fold (P < .01) at the end of the infusion. With cessation of the vessel dilator infusion, the excretion rate of beta2-microglobulin decreased but was still elevated 2-fold (P < .05) 3 hours after stopping the infusion. Kaliuretic peptide enhanced the beta2-microglobulin excretion rate a maximal 3-fold, which occurred at the end of its infusion. The beta2-microglobulin excretion secondary to kaliuretic peptide remained 2-fold (P < .05) above baseline during the 3-hour postinfusion period. These peptide hormones similarly enhanced the albumin and total protein excretion rates 2- to 4-fold. These results indicate that LANP, vessel dilator, and kaliuretic peptide each (1) enhance protein excretion in healthy humans and (2) inhibit proximal tubular protein reabsorption."
38,P01160,Natriuretic peptides A,56-92,EVVPPQVLSEPNEEAGAALSPLPEVPPWTGEVSPAQR,Vessel dilator,61 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '35', '41', '34', '24', '18', '36', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, and vasodilation (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2532366, PubMed:7595132). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651, PubMed:7595132). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (PubMed:7831500). Appears to bind to specific receptors that are distinct from the receptors bound by the atrial natriuretic and long-acting natriuretic peptides (PubMed:2162527, PubMed:2825692). Possibly functions in protein excretion in urine by maintaining the integrity of the proximal tubules and enhancing protein excretion by decreasing proximal tubular protein reabsorption (PubMed:11145122).",2532366,,18,Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans.,"Vesely, D. et al.",2532366,10.3181/00379727-192-42990,,2532366,"The role of peptides from the N terminus and C terminus of the 126 amino acid atrial natriuretic factor (ANF) prohormone in modulating renal sodium and water handling has not been defined. Since water immersion to the neck (NI) provides an acute central volume expansion identical to that produced by 2 liters of saline but without plasma compositional change, immersion to the neck was used to assess the N-terminal and C-terminal portions of the ANF prohormone response to acute central blood volume expansion in seven seated sodium-replete normal subjects. Both the C terminus, which contains amino acids 99-126 and is identical to ANF, and the whole N terminus (i.e., amino acids 1-98) increased promptly with NI and peaked after 1 hr of immersion. A Mr 3900 peptide from the midportion of the N terminus consistent with amino acids 31-67 (i.e., pro-ANF-31-67) also increased with NI and followed a pattern of increasing circulating concentration nearly identical to that of the whole N terminus of the prohormone, except that its maximal concentration was at the second hour of the 3 hr of NI. With cessation of immersion, ANF decreased to preimmersion levels within 1 hr whereas the N terminus and pro-ANF-31-67, although their circulating concentrations were decreasing, were still significantly elevated at 1 hr. These findings suggest that the increase in plasma ANF, the N terminus of the ANF prohormone, and pro-ANF-31-67 from the midportion of the N terminus, with natriuretic properties similar to ANF, contribute to the natriuretic response to NI, implying a physiologic role for these atrial peptides in modulating volume homeostasis in humans."
39,P01160,Natriuretic peptides A,56-92,EVVPPQVLSEPNEEAGAALSPLPEVPPWTGEVSPAQR,Vessel dilator,61 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '35', '41', '34', '24', '18', '36', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, and vasodilation (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2532366, PubMed:7595132). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651, PubMed:7595132). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (PubMed:7831500). Appears to bind to specific receptors that are distinct from the receptors bound by the atrial natriuretic and long-acting natriuretic peptides (PubMed:2162527, PubMed:2825692). Possibly functions in protein excretion in urine by maintaining the integrity of the proximal tubules and enhancing protein excretion by decreasing proximal tubular protein reabsorption (PubMed:11145122).",8087923,,25,"Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans.","Vesely, D. et al.",8087923,10.1161/01.cir.90.3.1129,,8087923,"Three peptides consisting of amino acids 1-30, 31-67, and 79-98 of the 126-amino acid atrial natriuretic factor prohormone (proANF), which have blood pressure-lowering, diuretic, natriuretic, and/or kaliuretic properties in animals, were investigated to determine if they have similar properties in humans."
40,P01160,Natriuretic peptides A,56-92,EVVPPQVLSEPNEEAGAALSPLPEVPPWTGEVSPAQR,Vessel dilator,61 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '35', '41', '34', '24', '18', '36', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, and vasodilation (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2532366, PubMed:7595132). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651, PubMed:7595132). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (PubMed:7831500). Appears to bind to specific receptors that are distinct from the receptors bound by the atrial natriuretic and long-acting natriuretic peptides (PubMed:2162527, PubMed:2825692). Possibly functions in protein excretion in urine by maintaining the integrity of the proximal tubules and enhancing protein excretion by decreasing proximal tubular protein reabsorption (PubMed:11145122).",2825692,,16,"Atrial natriuretic prohormone peptides 1-30, 31-67, and 79-98 vasodilate the aorta.","Vesely, D. et al.",2825692,10.1016/s0006-291x(87)80307-8,,2825692,"Human prohormone atrial natriuretic peptides 1-30, 31-67, and 79-98 caused vasodilation of porcine aortas which began in 30 seconds and was maximal at 10 minutes. These three peptides were found to be equally potent to atrial natriuretic factor in their vasodilatory activity which was found with or without endothelium present. This vasodilation was associated with a 4 to 5 fold increase in cyclic GMP in the aorta secondary to activation of particulate guanylate cyclase [E.C. 4.6.12]. These data demonstrate that three N-terminal peptide segments of the atrial natriuretic factor prohormone cause vasodilation."
41,P01160,Natriuretic peptides A,56-92,EVVPPQVLSEPNEEAGAALSPLPEVPPWTGEVSPAQR,Vessel dilator,61 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '35', '41', '34', '24', '18', '36', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, and vasodilation (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2532366, PubMed:7595132). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651, PubMed:7595132). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (PubMed:7831500). Appears to bind to specific receptors that are distinct from the receptors bound by the atrial natriuretic and long-acting natriuretic peptides (PubMed:2162527, PubMed:2825692). Possibly functions in protein excretion in urine by maintaining the integrity of the proximal tubules and enhancing protein excretion by decreasing proximal tubular protein reabsorption (PubMed:11145122).",7984506,,27,Molecular forms of circulating atrial natriuretic peptides in human plasma and their metabolites.,"Gower, W. et al.",7984506,10.1016/0196-9781(94)90043-4,,7984506,"High performance gel permeation chromatography (HP-GPC) followed by four radioimmunoassays (RIAs) devised to amino acids (a.a.) 1-30, 31-67, 79-98, and 99-126 of the 126 a.a. atrial natriuretic factor (ANF) prohormone revealed that the proANF(1-30) assay immunoreactivity in plasma is 50% proANF(1-30) and 50% proANF(1-98). The HP-GPC evaluation of plasma followed by proANF(31-67) and ANF [i.e., proANF(99-126)] assays revealed that proANF(31-67) and ANF circulate as distinct peptides. the HP-GPC plasma examination followed by proANF(79-98) assay immunologically recognized three peaks in plasma consistent with proANF(1-98), -(68-98), and -(79-98). Similar HP-GPC evaluation of urine followed by these RIAs indicated that the proANF(1-30), -(79-98), and ANF assays only recognize 500 mol.wt. or less peptides, and the proANF(31-67) RIA recognizes a nearly intact proANF(31-67) with only two to three amino acids removed during processing of this peptide."
42,P01160,Natriuretic peptides A,56-92,EVVPPQVLSEPNEEAGAALSPLPEVPPWTGEVSPAQR,Vessel dilator,61 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '35', '41', '34', '24', '18', '36', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, and vasodilation (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2532366, PubMed:7595132). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651, PubMed:7595132). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (PubMed:7831500). Appears to bind to specific receptors that are distinct from the receptors bound by the atrial natriuretic and long-acting natriuretic peptides (PubMed:2162527, PubMed:2825692). Possibly functions in protein excretion in urine by maintaining the integrity of the proximal tubules and enhancing protein excretion by decreasing proximal tubular protein reabsorption (PubMed:11145122).",2162527,,20,"Specific binding sites for prohormone atrial natriuretic peptides 1-30, 31-67 and 99-126.","Vesely, D. et al.",2162527,10.1016/0196-9781(90)90070-l,,2162527,"Two peptides with vasodilatory properties consisting of amino acids 1-30 and 31-67 of the 98 a.a. N-terminal end of the prohormone of atrial natriuretic factor (proANF) which circulates in man were investigated to determine if they have specific binding sites on membranes isolated from DDT1 MF-2 smooth muscle cells. Smooth muscle is a known biologic target of these peptides. Competitive binding experiments revealed that proANFs (1-30), (31-67), and (99-126) (i.e., C-terminus; ANF) each had specific and separate binding sites. The dissociation constants for proANFs (1-30), (31-67), and (99-126) binding were 0.11 nM, 4 nM, and 7.3 nM, respectively. The binding site concentrations for proANFs (1-30), (31-67), and ANF were 2.57, 59.91 and 40 fmols/10(6) cells, respectively. The number of binding sites per cell were 1548, 36,087, and 24,090, respectively, for proANFs (1-30), (31-67), and (99-126) (ANF). Each peptide bound to DDT1 MF-2 membranes between 10(-8) to 10(-11) M but could only bind to the other peptides' receptors at concentrations of 10(-6) and 10(-7)M. These results suggest that proANF(1-30) and proANF(31-67) do not work through the ANF receptor but rather have their own separate and distinct receptors that mediate their biologic effects."
43,P01160,Natriuretic peptides A,56-92,EVVPPQVLSEPNEEAGAALSPLPEVPPWTGEVSPAQR,Vessel dilator,61 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '35', '41', '34', '24', '18', '36', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, and vasodilation (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2532366, PubMed:7595132). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651, PubMed:7595132). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (PubMed:7831500). Appears to bind to specific receptors that are distinct from the receptors bound by the atrial natriuretic and long-acting natriuretic peptides (PubMed:2162527, PubMed:2825692). Possibly functions in protein excretion in urine by maintaining the integrity of the proximal tubules and enhancing protein excretion by decreasing proximal tubular protein reabsorption (PubMed:11145122).",8653797,,29,Temporal (circadian) and functional relationship between atrial natriuretic peptides and blood pressure.,"Sothern, R. et al.",8653797,10.3109/07420529509064506,,8653797,"Long-acting natriuretic peptide, vessel dilator, and atrial natriuretic factor consisting of amino acids (a.a.) 1 to 30, 31 to 67, and 99 to 126 of the 126-a.a. atrial natriuretic factor (ANF) prohormone, respectively, circulate in humans and have potent vasodilatory properties. To determine if these atrial natriuretic peptides are directly related to blood pressure in clinically healthy normotensive humans, we obtained 24-h profiles of vessel dilator, long-acting natriuretic peptide, ANF, and blood pressure in 10 men in 1988 and 11 men in 1993 (seven men were studied twice) to compare circulating concentrations of atrial natriuretic peptides with naturally occurring changes in blood pressure. Overall, vessel dilator, long-acting natriuretic peptide, and ANF each had significant (p<0.001) circadian rhythms, with peak concentrations late during sleep (at 04:00 h) being nearly twice their concentrations in the afternoon and evening. This high-amplitude circadian change allowed for the refinement of normal limits for ANF peptides by computing 3-hourly tolerance intervals (chronodesms) against which to compare time-specified single samples for normality. Systolic, diastolic, and mean arterial blood pressure also had significant circadian rhythms (p<0.001) with peaks and troughs that were exactly opposite those of the ANF peptides. In addition to this inverse temporal relationship, there was a significant inverse correlation between absolute values for blood pressure and each ANF peptide (p<0.001), implying a functional relationship. These data suggest that in addition to other well-established neurochemical factors, the ANF peptides (vessel dilator, long-acting natriuretic peptide, and ANF) are important for the maintenance of blood pressure and modulation of its circadian rhythm."
44,P01160,Natriuretic peptides A,104-123,SSDRSALLKSKLRALLTAPR,Kaliuretic peptide,60 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '34', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of diuresis and inhibiting aldosterone synthesis (PubMed:8087923, PubMed:2825692, PubMed:7595132). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651, PubMed:7595132). May have a role in potassium excretion but not sodium excretion (natriuresis) (PubMed:8087923). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).",7595132,,31,Kaliuretic peptide and long acting natriuretic peptide as well as atrial natriuretic factor inhibit aldosterone secretion.,"Vesely, D. et al.",7595132,10.1677/joe.0.1460373,,7595132,"The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1-30 (long acting natriuretic peptide), 31-67 (vessel dilator) and 79-98 (kaliuretic peptide) as well as 99-126 (atrial natriuretic factor (ANF)) of the 126 amino acid ANF prohormone inhibit aldosterone secretion. Thirty healthy human subjects were studied following infusion of 100 ng/kg body weight/min for 60 min of each of the respective peptides. Kaliuretic peptide decreased plasma aldosterone concentration by the greatest amount (6-fold) and plasma aldosterone was still significantly decreased (P < 0.001) three hours after stopping the infusion. In contrast, within 30 min of cessation of the ANF infusion, plasma aldosterone levels had returned to pre-infusion values. Long acting natriuretic peptide also significantly (P < 0.01) decreased plasma aldosterone levels which remained significantly (P < 0.001) decreased 3 h after cessation of infusion. Vessel dilator did not decrease plasma aldosterone levels. Kaliuretic peptide, ANF and long acting natriuretic peptide also decreased (P < 0.01) urinary aldosterone concentrations. None of these peptides changed the plasma potassium concentration. We conclude that two new peptide hormones (long acting natriuretic peptide and kaliuretic peptide) inhibit aldosterone secretion. The length of time that aldosterone secretion is inhibited following kaliuretic peptide and long acting natriuretic peptide infusion is significantly longer (P < 0.001) than following ANF infusion."
45,P01160,Natriuretic peptides A,104-123,SSDRSALLKSKLRALLTAPR,Kaliuretic peptide,60 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '34', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of diuresis and inhibiting aldosterone synthesis (PubMed:8087923, PubMed:2825692, PubMed:7595132). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651, PubMed:7595132). May have a role in potassium excretion but not sodium excretion (natriuresis) (PubMed:8087923). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).",7720651,,30,Kaliuretic peptide: the most potent inhibitor of Na(+)-K+ ATPase of the atrial natriuretic peptides.,"Chiou, S. et al.",7720651,10.1210/endo.136.5.7720651,,7720651,"The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1-30 (i.e. long-acting natriuretic peptide), 31-67 (vessel dilator), 79-98 (kaliuretic peptide), and 99-126 [atrial natriuretic factor (ANF)] of the 126 amino acid ANF prohormone inhibit sodium-potassium-ATPase as part of their mechanism(s) of action for producing a natriuresis and/or kaliuresis. Kaliuretic peptide, long-acting natriuretic peptide, vessel dilator and ANF at their 10(-11) M concentrations inhibited Na(+)-K(+)-ATPase 39.5%, 27.8%, 19.2%, and 4% respectively, in bovine renal medulla, whereas their inhibition in renal cortical membranes was 37.5%, 27.5%, 20%, and 0%, respectively. Ouabain (0.5 mM) inhibited kidney medullary Na(+)-K(+)-ATPase 45% and in the cortex, 38%. There was no additive effect of any of these peptides with ouabain suggesting that they are interacting with the same site on the Na(+)-K(+)-ATPase as ouabain. To help elucidate the mechanism of these peptides' interaction with Na(+)-K(+)-ATPase, naproxen (0.5 mM), an inhibitor of prostaglandin synthesis, and direct measurement of prostaglandin E2 by RIA were used. Naproxen completely blocked the inhibition of Na(+)-K(+)-ATPase by kaliuretic peptide, long-acting natriuretic peptide, and vessel dilator suggesting that their inhibition of Na(+)-K(+)-ATPase in both the kidney medulla and cortex are mediated by prostaglandins. Direct measurement of prostaglandin E2 revealed that kaliuretic peptide > long-acting natriuretic peptide > vessel dilator increased prostaglandin E2 synthesis, whereas ANF did not have any effect. Of interest, angiotensin II and ouabain inhibition of Na(+)-K(+)-ATPase were also completely blocked by naproxen."
46,P01160,Natriuretic peptides A,104-123,SSDRSALLKSKLRALLTAPR,Kaliuretic peptide,60 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '34', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of diuresis and inhibiting aldosterone synthesis (PubMed:8087923, PubMed:2825692, PubMed:7595132). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651, PubMed:7595132). May have a role in potassium excretion but not sodium excretion (natriuresis) (PubMed:8087923). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).",11145122,,36,"Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance the urinary excretion rate of beta2-microglobulin.","Vesely, D. et al.",11145122,10.1053/meta.2000.18557,,11145122,"The atrial natriuretic peptide (ANP) gene synthesizes a 126-amino acid (aa) prohormone from which four peptide hormones are derived. These 4 peptide hormones consisting of aa 1 to 30 (ie, long-acting natriuretic peptide [LANP]), aa 31 to 67 (vessel dilator), aa 79 to 98 (kaliuretic peptide), and aa 99 to 126 (ie, ANP) have diuretic, natriuretic, and/or kaliuretic properties. ANP has been reported to have its natriuretic and protein-excreting effects via both the proximal and distal tubules, but where in the kidney the other three peptide hormones have their natriuretic and/or diuretic effects is unknown. Further, it has never been investigated as to whether these three other peptide hormones enhance protein excretion. The present investigation was designed to determine (1) if these atrial peptides enhance protein excretion and (2) if their effects involve the proximal tubules of healthy humans by examining the excretion rate of beta2-microglobulin, a marker of proximal tubule function. Twenty-four healthy human subjects were studied following the infusion of 100 ng/kg body weight/min for 60 minutes of each of the respective peptides. LANP enhanced the excretion rate of beta2-microglobulin 2-fold within 20 minutes of beginning its infusion (P < .05) and was 2.5-fold higher than the preinfusion excretion rate at the end of the infusion. The excretion rate of beta2-microglobulin continued to be significantly (P < .01) increased for 3 hours after cessation of the LANP infusion, with the maximal excretion rate (ie, 3.8-fold increase) at 2.5 hours after stopping the infusion. Vessel dilator showed a more marked enhancement of beta2-microglobulin during its infusion, with the excretion rate increasing 2.5-fold at 20 minutes, and was increased 4-fold (P < .01) at the end of the infusion. With cessation of the vessel dilator infusion, the excretion rate of beta2-microglobulin decreased but was still elevated 2-fold (P < .05) 3 hours after stopping the infusion. Kaliuretic peptide enhanced the beta2-microglobulin excretion rate a maximal 3-fold, which occurred at the end of its infusion. The beta2-microglobulin excretion secondary to kaliuretic peptide remained 2-fold (P < .05) above baseline during the 3-hour postinfusion period. These peptide hormones similarly enhanced the albumin and total protein excretion rates 2- to 4-fold. These results indicate that LANP, vessel dilator, and kaliuretic peptide each (1) enhance protein excretion in healthy humans and (2) inhibit proximal tubular protein reabsorption."
47,P01160,Natriuretic peptides A,104-123,SSDRSALLKSKLRALLTAPR,Kaliuretic peptide,60 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '34', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of diuresis and inhibiting aldosterone synthesis (PubMed:8087923, PubMed:2825692, PubMed:7595132). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651, PubMed:7595132). May have a role in potassium excretion but not sodium excretion (natriuresis) (PubMed:8087923). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).",8087923,,25,"Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans.","Vesely, D. et al.",8087923,10.1161/01.cir.90.3.1129,,8087923,"Three peptides consisting of amino acids 1-30, 31-67, and 79-98 of the 126-amino acid atrial natriuretic factor prohormone (proANF), which have blood pressure-lowering, diuretic, natriuretic, and/or kaliuretic properties in animals, were investigated to determine if they have similar properties in humans."
48,P01160,Natriuretic peptides A,104-123,SSDRSALLKSKLRALLTAPR,Kaliuretic peptide,60 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '34', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of diuresis and inhibiting aldosterone synthesis (PubMed:8087923, PubMed:2825692, PubMed:7595132). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651, PubMed:7595132). May have a role in potassium excretion but not sodium excretion (natriuresis) (PubMed:8087923). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).",2825692,,16,"Atrial natriuretic prohormone peptides 1-30, 31-67, and 79-98 vasodilate the aorta.","Vesely, D. et al.",2825692,10.1016/s0006-291x(87)80307-8,,2825692,"Human prohormone atrial natriuretic peptides 1-30, 31-67, and 79-98 caused vasodilation of porcine aortas which began in 30 seconds and was maximal at 10 minutes. These three peptides were found to be equally potent to atrial natriuretic factor in their vasodilatory activity which was found with or without endothelium present. This vasodilation was associated with a 4 to 5 fold increase in cyclic GMP in the aorta secondary to activation of particulate guanylate cyclase [E.C. 4.6.12]. These data demonstrate that three N-terminal peptide segments of the atrial natriuretic factor prohormone cause vasodilation."
49,P01160,Natriuretic peptides A,104-123,SSDRSALLKSKLRALLTAPR,Kaliuretic peptide,60 62 63,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'33', '34', '6', '26', '38'}","May have a role in cardio-renal homeostasis through regulation of diuresis and inhibiting aldosterone synthesis (PubMed:8087923, PubMed:2825692, PubMed:7595132). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651, PubMed:7595132). May have a role in potassium excretion but not sodium excretion (natriuresis) (PubMed:8087923). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).",7984506,,27,Molecular forms of circulating atrial natriuretic peptides in human plasma and their metabolites.,"Gower, W. et al.",7984506,10.1016/0196-9781(94)90043-4,,7984506,"High performance gel permeation chromatography (HP-GPC) followed by four radioimmunoassays (RIAs) devised to amino acids (a.a.) 1-30, 31-67, 79-98, and 99-126 of the 126 a.a. atrial natriuretic factor (ANF) prohormone revealed that the proANF(1-30) assay immunoreactivity in plasma is 50% proANF(1-30) and 50% proANF(1-98). The HP-GPC evaluation of plasma followed by proANF(31-67) and ANF [i.e., proANF(99-126)] assays revealed that proANF(31-67) and ANF circulate as distinct peptides. the HP-GPC plasma examination followed by proANF(79-98) assay immunologically recognized three peaks in plasma consistent with proANF(1-98), -(68-98), and -(79-98). Similar HP-GPC evaluation of urine followed by these RIAs indicated that the proANF(1-30), -(79-98), and ANF assays only recognize 500 mol.wt. or less peptides, and the proANF(31-67) RIA recognizes a nearly intact proANF(31-67) with only two to three amino acids removed during processing of this peptide."
50,P01160,Natriuretic peptides A,119-151,LTAPRSLRRSSCFGGRMDRIGAQSGLGCNSFRY,Auriculin-C,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",7595132,,31,Kaliuretic peptide and long acting natriuretic peptide as well as atrial natriuretic factor inhibit aldosterone secretion.,"Vesely, D. et al.",7595132,10.1677/joe.0.1460373,,7595132,"The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1-30 (long acting natriuretic peptide), 31-67 (vessel dilator) and 79-98 (kaliuretic peptide) as well as 99-126 (atrial natriuretic factor (ANF)) of the 126 amino acid ANF prohormone inhibit aldosterone secretion. Thirty healthy human subjects were studied following infusion of 100 ng/kg body weight/min for 60 min of each of the respective peptides. Kaliuretic peptide decreased plasma aldosterone concentration by the greatest amount (6-fold) and plasma aldosterone was still significantly decreased (P < 0.001) three hours after stopping the infusion. In contrast, within 30 min of cessation of the ANF infusion, plasma aldosterone levels had returned to pre-infusion values. Long acting natriuretic peptide also significantly (P < 0.01) decreased plasma aldosterone levels which remained significantly (P < 0.001) decreased 3 h after cessation of infusion. Vessel dilator did not decrease plasma aldosterone levels. Kaliuretic peptide, ANF and long acting natriuretic peptide also decreased (P < 0.01) urinary aldosterone concentrations. None of these peptides changed the plasma potassium concentration. We conclude that two new peptide hormones (long acting natriuretic peptide and kaliuretic peptide) inhibit aldosterone secretion. The length of time that aldosterone secretion is inhibited following kaliuretic peptide and long acting natriuretic peptide infusion is significantly longer (P < 0.001) than following ANF infusion."
51,P01160,Natriuretic peptides A,119-151,LTAPRSLRRSSCFGGRMDRIGAQSGLGCNSFRY,Auriculin-C,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",7720651,,30,Kaliuretic peptide: the most potent inhibitor of Na(+)-K+ ATPase of the atrial natriuretic peptides.,"Chiou, S. et al.",7720651,10.1210/endo.136.5.7720651,,7720651,"The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1-30 (i.e. long-acting natriuretic peptide), 31-67 (vessel dilator), 79-98 (kaliuretic peptide), and 99-126 [atrial natriuretic factor (ANF)] of the 126 amino acid ANF prohormone inhibit sodium-potassium-ATPase as part of their mechanism(s) of action for producing a natriuresis and/or kaliuresis. Kaliuretic peptide, long-acting natriuretic peptide, vessel dilator and ANF at their 10(-11) M concentrations inhibited Na(+)-K(+)-ATPase 39.5%, 27.8%, 19.2%, and 4% respectively, in bovine renal medulla, whereas their inhibition in renal cortical membranes was 37.5%, 27.5%, 20%, and 0%, respectively. Ouabain (0.5 mM) inhibited kidney medullary Na(+)-K(+)-ATPase 45% and in the cortex, 38%. There was no additive effect of any of these peptides with ouabain suggesting that they are interacting with the same site on the Na(+)-K(+)-ATPase as ouabain. To help elucidate the mechanism of these peptides' interaction with Na(+)-K(+)-ATPase, naproxen (0.5 mM), an inhibitor of prostaglandin synthesis, and direct measurement of prostaglandin E2 by RIA were used. Naproxen completely blocked the inhibition of Na(+)-K(+)-ATPase by kaliuretic peptide, long-acting natriuretic peptide, and vessel dilator suggesting that their inhibition of Na(+)-K(+)-ATPase in both the kidney medulla and cortex are mediated by prostaglandins. Direct measurement of prostaglandin E2 revealed that kaliuretic peptide > long-acting natriuretic peptide > vessel dilator increased prostaglandin E2 synthesis, whereas ANF did not have any effect. Of interest, angiotensin II and ouabain inhibition of Na(+)-K(+)-ATPase were also completely blocked by naproxen."
52,P01160,Natriuretic peptides A,119-151,LTAPRSLRRSSCFGGRMDRIGAQSGLGCNSFRY,Auriculin-C,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",7955907,,26,"N-terminal atrial natriuretic peptide and atrial natriuretic peptide in human plasma: investigation of plasma levels and molecular circulating form(s) using radioimmunoassays for pro-atrial natriuretic peptide (31-67), pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide (99-126).","Buckley, M. et al.",7955907,10.1042/cs0870311,,7955907,"1. The aim of this study was to determine plasma levels of N-terminal atrial natriuretic peptide and atrial natriuretic peptide in normal subjects and in patients with essential hypertension, cardiac transplant and chronic renal failure, using radioimmunoassays directed towards the mid-portion pro-atrial natriuretic peptide (31-67) and pro-atrial natriuretic peptide (1-30) of the N-terminal atrial natriuretic peptide and atrial natriuretic peptide (99-126). The circulating form(s) of the immunoreactive N-terminal atrial natriuretic peptide in plasma extracts has been investigated using all three radioimmunoassays by means of gel filtration chromatography to further clarify the major immunoreactive molecular circulating form(s) of N-terminal atrial natriuretic peptide in man. 2. The plasma level (mean +/- SEM) of N-terminal pro-atrial natriuretic peptide (31-67) in the normal subjects was 547.2 +/- 32.7 pg/ml (n = 36) and was significantly elevated in patients with essential hypertension (730.2 +/- 72.3 pg/ml, P < 0.025, n = 39), in cardiac transplant recipients (3214.0 +/- 432.2 pg/ml, P < 0.001, n = 9) and in patients with chronic renal failure (3571.8 +/- 474.1 pg/ml, P < 0.001, n = 11). Plasma levels of N-terminal pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide were similarly elevated in the same patient groups when compared with the mean plasma values in the normal subjects.(ABSTRACT TRUNCATED AT 250 WORDS)"
53,P01160,Natriuretic peptides A,119-151,LTAPRSLRRSSCFGGRMDRIGAQSGLGCNSFRY,Auriculin-C,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",11145122,,36,"Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance the urinary excretion rate of beta2-microglobulin.","Vesely, D. et al.",11145122,10.1053/meta.2000.18557,,11145122,"The atrial natriuretic peptide (ANP) gene synthesizes a 126-amino acid (aa) prohormone from which four peptide hormones are derived. These 4 peptide hormones consisting of aa 1 to 30 (ie, long-acting natriuretic peptide [LANP]), aa 31 to 67 (vessel dilator), aa 79 to 98 (kaliuretic peptide), and aa 99 to 126 (ie, ANP) have diuretic, natriuretic, and/or kaliuretic properties. ANP has been reported to have its natriuretic and protein-excreting effects via both the proximal and distal tubules, but where in the kidney the other three peptide hormones have their natriuretic and/or diuretic effects is unknown. Further, it has never been investigated as to whether these three other peptide hormones enhance protein excretion. The present investigation was designed to determine (1) if these atrial peptides enhance protein excretion and (2) if their effects involve the proximal tubules of healthy humans by examining the excretion rate of beta2-microglobulin, a marker of proximal tubule function. Twenty-four healthy human subjects were studied following the infusion of 100 ng/kg body weight/min for 60 minutes of each of the respective peptides. LANP enhanced the excretion rate of beta2-microglobulin 2-fold within 20 minutes of beginning its infusion (P < .05) and was 2.5-fold higher than the preinfusion excretion rate at the end of the infusion. The excretion rate of beta2-microglobulin continued to be significantly (P < .01) increased for 3 hours after cessation of the LANP infusion, with the maximal excretion rate (ie, 3.8-fold increase) at 2.5 hours after stopping the infusion. Vessel dilator showed a more marked enhancement of beta2-microglobulin during its infusion, with the excretion rate increasing 2.5-fold at 20 minutes, and was increased 4-fold (P < .01) at the end of the infusion. With cessation of the vessel dilator infusion, the excretion rate of beta2-microglobulin decreased but was still elevated 2-fold (P < .05) 3 hours after stopping the infusion. Kaliuretic peptide enhanced the beta2-microglobulin excretion rate a maximal 3-fold, which occurred at the end of its infusion. The beta2-microglobulin excretion secondary to kaliuretic peptide remained 2-fold (P < .05) above baseline during the 3-hour postinfusion period. These peptide hormones similarly enhanced the albumin and total protein excretion rates 2- to 4-fold. These results indicate that LANP, vessel dilator, and kaliuretic peptide each (1) enhance protein excretion in healthy humans and (2) inhibit proximal tubular protein reabsorption."
54,P01160,Natriuretic peptides A,119-151,LTAPRSLRRSSCFGGRMDRIGAQSGLGCNSFRY,Auriculin-C,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",2532366,,18,Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans.,"Vesely, D. et al.",2532366,10.3181/00379727-192-42990,,2532366,"The role of peptides from the N terminus and C terminus of the 126 amino acid atrial natriuretic factor (ANF) prohormone in modulating renal sodium and water handling has not been defined. Since water immersion to the neck (NI) provides an acute central volume expansion identical to that produced by 2 liters of saline but without plasma compositional change, immersion to the neck was used to assess the N-terminal and C-terminal portions of the ANF prohormone response to acute central blood volume expansion in seven seated sodium-replete normal subjects. Both the C terminus, which contains amino acids 99-126 and is identical to ANF, and the whole N terminus (i.e., amino acids 1-98) increased promptly with NI and peaked after 1 hr of immersion. A Mr 3900 peptide from the midportion of the N terminus consistent with amino acids 31-67 (i.e., pro-ANF-31-67) also increased with NI and followed a pattern of increasing circulating concentration nearly identical to that of the whole N terminus of the prohormone, except that its maximal concentration was at the second hour of the 3 hr of NI. With cessation of immersion, ANF decreased to preimmersion levels within 1 hr whereas the N terminus and pro-ANF-31-67, although their circulating concentrations were decreasing, were still significantly elevated at 1 hr. These findings suggest that the increase in plasma ANF, the N terminus of the ANF prohormone, and pro-ANF-31-67 from the midportion of the N terminus, with natriuretic properties similar to ANF, contribute to the natriuretic response to NI, implying a physiologic role for these atrial peptides in modulating volume homeostasis in humans."
55,P01160,Natriuretic peptides A,119-151,LTAPRSLRRSSCFGGRMDRIGAQSGLGCNSFRY,Auriculin-C,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",8087923,,25,"Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans.","Vesely, D. et al.",8087923,10.1161/01.cir.90.3.1129,,8087923,"Three peptides consisting of amino acids 1-30, 31-67, and 79-98 of the 126-amino acid atrial natriuretic factor prohormone (proANF), which have blood pressure-lowering, diuretic, natriuretic, and/or kaliuretic properties in animals, were investigated to determine if they have similar properties in humans."
56,P01160,Natriuretic peptides A,119-151,LTAPRSLRRSSCFGGRMDRIGAQSGLGCNSFRY,Auriculin-C,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",2825692,,16,"Atrial natriuretic prohormone peptides 1-30, 31-67, and 79-98 vasodilate the aorta.","Vesely, D. et al.",2825692,10.1016/s0006-291x(87)80307-8,,2825692,"Human prohormone atrial natriuretic peptides 1-30, 31-67, and 79-98 caused vasodilation of porcine aortas which began in 30 seconds and was maximal at 10 minutes. These three peptides were found to be equally potent to atrial natriuretic factor in their vasodilatory activity which was found with or without endothelium present. This vasodilation was associated with a 4 to 5 fold increase in cyclic GMP in the aorta secondary to activation of particulate guanylate cyclase [E.C. 4.6.12]. These data demonstrate that three N-terminal peptide segments of the atrial natriuretic factor prohormone cause vasodilation."
57,P01160,Natriuretic peptides A,119-151,LTAPRSLRRSSCFGGRMDRIGAQSGLGCNSFRY,Auriculin-C,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",2162527,,20,"Specific binding sites for prohormone atrial natriuretic peptides 1-30, 31-67 and 99-126.","Vesely, D. et al.",2162527,10.1016/0196-9781(90)90070-l,,2162527,"Two peptides with vasodilatory properties consisting of amino acids 1-30 and 31-67 of the 98 a.a. N-terminal end of the prohormone of atrial natriuretic factor (proANF) which circulates in man were investigated to determine if they have specific binding sites on membranes isolated from DDT1 MF-2 smooth muscle cells. Smooth muscle is a known biologic target of these peptides. Competitive binding experiments revealed that proANFs (1-30), (31-67), and (99-126) (i.e., C-terminus; ANF) each had specific and separate binding sites. The dissociation constants for proANFs (1-30), (31-67), and (99-126) binding were 0.11 nM, 4 nM, and 7.3 nM, respectively. The binding site concentrations for proANFs (1-30), (31-67), and ANF were 2.57, 59.91 and 40 fmols/10(6) cells, respectively. The number of binding sites per cell were 1548, 36,087, and 24,090, respectively, for proANFs (1-30), (31-67), and (99-126) (ANF). Each peptide bound to DDT1 MF-2 membranes between 10(-8) to 10(-11) M but could only bind to the other peptides' receptors at concentrations of 10(-6) and 10(-7)M. These results suggest that proANF(1-30) and proANF(31-67) do not work through the ANF receptor but rather have their own separate and distinct receptors that mediate their biologic effects."
58,P01160,Natriuretic peptides A,119-151,LTAPRSLRRSSCFGGRMDRIGAQSGLGCNSFRY,Auriculin-C,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",8653797,,29,Temporal (circadian) and functional relationship between atrial natriuretic peptides and blood pressure.,"Sothern, R. et al.",8653797,10.3109/07420529509064506,,8653797,"Long-acting natriuretic peptide, vessel dilator, and atrial natriuretic factor consisting of amino acids (a.a.) 1 to 30, 31 to 67, and 99 to 126 of the 126-a.a. atrial natriuretic factor (ANF) prohormone, respectively, circulate in humans and have potent vasodilatory properties. To determine if these atrial natriuretic peptides are directly related to blood pressure in clinically healthy normotensive humans, we obtained 24-h profiles of vessel dilator, long-acting natriuretic peptide, ANF, and blood pressure in 10 men in 1988 and 11 men in 1993 (seven men were studied twice) to compare circulating concentrations of atrial natriuretic peptides with naturally occurring changes in blood pressure. Overall, vessel dilator, long-acting natriuretic peptide, and ANF each had significant (p<0.001) circadian rhythms, with peak concentrations late during sleep (at 04:00 h) being nearly twice their concentrations in the afternoon and evening. This high-amplitude circadian change allowed for the refinement of normal limits for ANF peptides by computing 3-hourly tolerance intervals (chronodesms) against which to compare time-specified single samples for normality. Systolic, diastolic, and mean arterial blood pressure also had significant circadian rhythms (p<0.001) with peaks and troughs that were exactly opposite those of the ANF peptides. In addition to this inverse temporal relationship, there was a significant inverse correlation between absolute values for blood pressure and each ANF peptide (p<0.001), implying a functional relationship. These data suggest that in addition to other well-established neurochemical factors, the ANF peptides (vessel dilator, long-acting natriuretic peptide, and ANF) are important for the maintenance of blood pressure and modulation of its circadian rhythm."
59,P01160,Natriuretic peptides A,120-151,TAPRSLRRSSCFGGRMDRIGAQSGLGCNSFRY,Urodilatin,28,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '23', '45', '42', '43', '39'}","Hormone produced in the kidneys that appears to be important for maintaining cardio-renal homeostasis (PubMed:8351194, PubMed:8853410, PubMed:8779891). Mediates vasodilation, natriuresis and diuresis primarily in the renal system, in order to maintain the extracellular fluid volume and control the fluid-electrolyte balance (PubMed:2528951, PubMed:8351194, PubMed:8853410, PubMed:8779891). Specifically binds and stimulates cGMP production by renal transmembrane receptors, likely NPR1 (PubMed:8384600, PubMed:9893117). Urodilatin not ANP, may be the natriuretic peptide responsible for the regulation of sodium and water homeostasis in the kidney (PubMed:8779891, PubMed:8384600).",2972874,,14,"Isolation and structural analysis of 'urodilatin', a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine.","Schulz-Knappe, P. et al.",2972874,10.1007/bf01726570,120-151,2972874,"Two major forms of cardiac peptides have been established in the last few years: (a) a prohormone of 126 amino acids (CDD/ANP-1-126) in the endocrine heart and (b) the circulating CDD/ANP-99-126 (= alpha ANP) in blood plasma. The method we applied earlier to isolate the circulating form of cardiodilatin from human blood was used to detect and analyze the biologically active, predominant form of the same polypeptide family excreted by the kidneys. Each step of the isolation procedure was followed up by a bioassay using an in vitro vascular smooth muscle relaxation test and a highly specific RIA against cardiodilatin (CDD-99-126) for the initial purification steps. The polypeptides excreted in 1000 l of normal human urine were adsorbed to 2.5 kg of alginic acid, and after elution and lyophilization processed on a G-25 Sephadex column. The obtained crude polypeptide fractions were applied to ion-exchange chromatography. Thereafter four steps of HPLC were carried out to purify the polypeptide which was the suggested form of cardiodilatin (CDD) in human urine. The amino acid analysis and gas phase sequence analysis showed that the main form of urinary cardiodilatin is a 32 amino acid residue containing molecule, cardiodilatin-95-126. The molecule is N-terminally extended compared to the circulating CDD-99-126. This suggests that the analyzed urinary peptide is not the residual plasma form, filtrated and renally cleared from blood, but probably a polypeptide produced and processed in the kidney tubules and cleaved by a different postranslational process. Therefore, this vasorelaxant polypeptide is called urodilatin."
60,P01160,Natriuretic peptides A,120-151,TAPRSLRRSSCFGGRMDRIGAQSGLGCNSFRY,Urodilatin,28,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '23', '45', '42', '43', '39'}","Hormone produced in the kidneys that appears to be important for maintaining cardio-renal homeostasis (PubMed:8351194, PubMed:8853410, PubMed:8779891). Mediates vasodilation, natriuresis and diuresis primarily in the renal system, in order to maintain the extracellular fluid volume and control the fluid-electrolyte balance (PubMed:2528951, PubMed:8351194, PubMed:8853410, PubMed:8779891). Specifically binds and stimulates cGMP production by renal transmembrane receptors, likely NPR1 (PubMed:8384600, PubMed:9893117). Urodilatin not ANP, may be the natriuretic peptide responsible for the regulation of sodium and water homeostasis in the kidney (PubMed:8779891, PubMed:8384600).",8853410,,33,Urodilatin is involved in sodium homeostasis and exerts sodium-state-dependent natriuretic and diuretic effects.,"Meyer, M. et al.",8853410,10.1152/ajprenal.1996.271.3.f489,,8853410,"Urodilatin is involved in sodium homeostasis exerts sodium-state-dependent natriuretic and diuretic cts. Eight male volunteers participated in a study consisting of three consecutive phases of 7 days each. The volunteers a sodium diet with 52, 172.6, and 347.8 mmol um/day. Sodium excretion increased from 57.4 +/- 3.7 via .8 +/- 4.6 (P < 0.001) to 322.5 +/- 10.2 mmol/24 h (P < 0.001) at the end of each sodium diet. Urinary urodilatin excretion increased from 24.8 +/- 3.0 via 35.5 +/- 9.0 (P = 0.07) to 49.0 = mol/min (P < 0.01). At the end of each diet, urodilatin was infused for 2 h at 20 ng.kg body wt-1.min-1. Natriuresis increased after low- (4.1 to 52.9 mmol/h, P < 0.001), normal (6.9 to 44.9 mmol/h, P < 0.05), and high-sodium diet (20.1 to 102.9 mmol/h, P < 0.001). Diuresis increased from 174 to 709 (P < 0.001), 395 to 1,026 (P < 0.05), and 266 to 1,339 ml/h < 0.001). The present results indicate that endogenous urodilatin plays an important role in sodium homeostasis and that renal response to exogenous urodilatin is modulated by sodium balance."
61,P01160,Natriuretic peptides A,120-151,TAPRSLRRSSCFGGRMDRIGAQSGLGCNSFRY,Urodilatin,28,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '23', '45', '42', '43', '39'}","Hormone produced in the kidneys that appears to be important for maintaining cardio-renal homeostasis (PubMed:8351194, PubMed:8853410, PubMed:8779891). Mediates vasodilation, natriuresis and diuresis primarily in the renal system, in order to maintain the extracellular fluid volume and control the fluid-electrolyte balance (PubMed:2528951, PubMed:8351194, PubMed:8853410, PubMed:8779891). Specifically binds and stimulates cGMP production by renal transmembrane receptors, likely NPR1 (PubMed:8384600, PubMed:9893117). Urodilatin not ANP, may be the natriuretic peptide responsible for the regulation of sodium and water homeostasis in the kidney (PubMed:8779891, PubMed:8384600).",2528951,,19,Phosphorylation and dephosphorylation of the natriuretic peptide urodilatin (CDD-/ANP-95-126) and the effect on biological activity.,"Doerner, T. et al.",2528951,10.1016/0006-291x(89)92297-3,,2528951,"Urodilatin (CDD-/ANP-95-126), a new peptide hormone from human urine, is comprised of the same amino acid sequence as cardiodilatin (CDD-99-126/alpha-hANP) except for N-terminal extention by four amino acid residues. The presence of the recognition sequence Arg101-Arg-Ser-Ser104 for the cyclic AMP-dependent protein kinase enables rapid phosphorylation in the Ser104-position. Phosphorylation of urodilatin is associated with decreased vasorelaxant potency, while dephosphorylation of ""phospho-urodilatin"" by acidic phosphatase completely restores bioactivity."
62,P01160,Natriuretic peptides A,120-151,TAPRSLRRSSCFGGRMDRIGAQSGLGCNSFRY,Urodilatin,28,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '23', '45', '42', '43', '39'}","Hormone produced in the kidneys that appears to be important for maintaining cardio-renal homeostasis (PubMed:8351194, PubMed:8853410, PubMed:8779891). Mediates vasodilation, natriuresis and diuresis primarily in the renal system, in order to maintain the extracellular fluid volume and control the fluid-electrolyte balance (PubMed:2528951, PubMed:8351194, PubMed:8853410, PubMed:8779891). Specifically binds and stimulates cGMP production by renal transmembrane receptors, likely NPR1 (PubMed:8384600, PubMed:9893117). Urodilatin not ANP, may be the natriuretic peptide responsible for the regulation of sodium and water homeostasis in the kidney (PubMed:8779891, PubMed:8384600).",8384600,,23,Urodilatin binds to and activates renal receptors for atrial natriuretic peptide.,"Valentin, J. et al.",8384600,10.1161/01.hyp.21.4.432,,8384600,"Urodilatin is a recently described member of the atrial natriuretic peptide family, thought possibly to be synthesized in the kidney. To determine if urodilatin binding sites are present in rat and human kidney, we evaluated the effect of urodilatin on iodine-125-labeled atrial natriuretic peptide (ANP) (100 pM) binding to tissue sections using an in situ autoradiographic technique. 125I-ANP binding occurred primarily in glomeruli and medullary structures of both rat and human kidney. Increasing concentrations of urodilatin yielded a monophasic displacement of 125I-ANP binding with an IC50 of 4.2 nM, a value nearly identical to that achieved with unlabeled ANP (7.2 nM). In additional experiments, rat glomeruli and inner medullary collecting duct cells were isolated and incubated in vitro with either ANP or urodilatin (10(-11) to 10(-6) M) and cyclic guanosine-3',5'-monophosphate accumulation measured by radioimmunoassay. Dose-response curves for the two peptides were superimposable in each tissue; at 10(-6) M, ANP generated 613 +/- 41 and urodilatin 603 +/- 55 fmol cyclic guanosine monophosphate per 10 minutes per milligram protein in inner medullary collecting duct cells (p = NS). Thus, urodilatin is as effective as ANP in displacing 125I-ANP binding to both rat and human renal tissue and in generating cyclic guanosine monophosphate in renal target cells in the rat, suggesting that its physiological effects may occur through the same receptors and signaling pathways that mediate the actions of ANP."
63,P01160,Natriuretic peptides A,120-151,TAPRSLRRSSCFGGRMDRIGAQSGLGCNSFRY,Urodilatin,28,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '23', '45', '42', '43', '39'}","Hormone produced in the kidneys that appears to be important for maintaining cardio-renal homeostasis (PubMed:8351194, PubMed:8853410, PubMed:8779891). Mediates vasodilation, natriuresis and diuresis primarily in the renal system, in order to maintain the extracellular fluid volume and control the fluid-electrolyte balance (PubMed:2528951, PubMed:8351194, PubMed:8853410, PubMed:8779891). Specifically binds and stimulates cGMP production by renal transmembrane receptors, likely NPR1 (PubMed:8384600, PubMed:9893117). Urodilatin not ANP, may be the natriuretic peptide responsible for the regulation of sodium and water homeostasis in the kidney (PubMed:8779891, PubMed:8384600).",8779891,,32,"Postprandial natriuresis in humans: further evidence that urodilatin, not ANP, modulates sodium excretion.","Drummer, C. et al.",8779891,10.1152/ajprenal.1996.270.2.f301,,8779891,"We examined the effects of a high-salt (100 mmol NaCl) and a low-salt (5 mmol NaCl) meal on the renal excretion of sodium and chloride in 12 healthy male upright subjects. We also measured the urinary excretion of urodilatin [ANP-(95-126)], and the plasma or serum concentrations of atrial natriuretic peptide [ANP-(99-126)], aldosterone, and renin. The high-salt meal produced a postprandial natriuresis (urinary sodium excretion from 59.0 to a peak rate of 204.6 mumol/min in 3rd h after ingestion of meal) and chloride excretion. In parallel, the urinary excretion of urodilatin increased from 35.7 to a peak rate of 105 fmol/min. The effect of high-salt intake on urinary sodium, chloride, and urodilatin excretion was significant (analysis of variance, P < 0.01), and close significant correlations were observed between urodilatin and sodium excretion (mean R = 0.702) as well as between urodilatin and chloride excretion (mean R = 0.776). In contrast, plasma ANP, which was acutely elevated 15 min after high-salt intake, was already back to low-salt values 1 h later. It did not parallel the postprandial natriuretic profile, and no positive correlation between plasma ANP and sodium excretion was observed. These results provide further evidence that urodilatin, not ANP, is the member of this peptide family primarily involved in the regulation of the excretion of sodium and chloride."
64,P01160,Natriuretic peptides A,120-151,TAPRSLRRSSCFGGRMDRIGAQSGLGCNSFRY,Urodilatin,28,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '23', '45', '42', '43', '39'}","Hormone produced in the kidneys that appears to be important for maintaining cardio-renal homeostasis (PubMed:8351194, PubMed:8853410, PubMed:8779891). Mediates vasodilation, natriuresis and diuresis primarily in the renal system, in order to maintain the extracellular fluid volume and control the fluid-electrolyte balance (PubMed:2528951, PubMed:8351194, PubMed:8853410, PubMed:8779891). Specifically binds and stimulates cGMP production by renal transmembrane receptors, likely NPR1 (PubMed:8384600, PubMed:9893117). Urodilatin not ANP, may be the natriuretic peptide responsible for the regulation of sodium and water homeostasis in the kidney (PubMed:8779891, PubMed:8384600).",8351194,,24,Development and application of a urodilatin (CDD/ANP-95-126)-specific radioimmunoassay.,"Drummer, C. et al.",8351194,10.1007/bf00374930,,8351194,"Urodilatin, a renal natriuretic peptide that is an analogue to circulating atrial natriuretic peptide [alpha-ANP(99-126)], is measurable with a highly specific and sensitive radioimmunoassay. While most ANP antibodies cannot distinguish between urodilatin and other ANP analogues, the polyclonal urodilatin antibody specifically measures human urodilatin without any cross-reactivity to other ANP analogues. Urodilatin is not detected in blood from healthy volunteers nor from cardiac patients. Urinary urodilatin accounts for only a part of total urinary ANP immunoreactivity. Urodilatin excretion closely parallels sodium excretion in response to an acute volume load while changes in urinary immunoreactive ANP excretion do not reflect this renal response. We conclude that specific urodilatin assays are required to explore further the physiological role of the renal natriuretic peptide."
65,P01160,Natriuretic peptides A,120-151,TAPRSLRRSSCFGGRMDRIGAQSGLGCNSFRY,Urodilatin,28,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '23', '45', '42', '43', '39'}","Hormone produced in the kidneys that appears to be important for maintaining cardio-renal homeostasis (PubMed:8351194, PubMed:8853410, PubMed:8779891). Mediates vasodilation, natriuresis and diuresis primarily in the renal system, in order to maintain the extracellular fluid volume and control the fluid-electrolyte balance (PubMed:2528951, PubMed:8351194, PubMed:8853410, PubMed:8779891). Specifically binds and stimulates cGMP production by renal transmembrane receptors, likely NPR1 (PubMed:8384600, PubMed:9893117). Urodilatin not ANP, may be the natriuretic peptide responsible for the regulation of sodium and water homeostasis in the kidney (PubMed:8779891, PubMed:8384600).",9893117,,35,Regulation of natriuretic peptide (urodilatin) release in a human kidney cell line.,"Lenz, W. et al.",9893117,10.1046/j.1523-1755.1999.00242.x,,9893117,To identify the molecular mechanisms underlying the release of a renal natriuretic peptide (NP) we selected a human kidney cell line (HEK 293) that displays several characteristics of distal tubular cells.
66,P01160,Natriuretic peptides A,121-145,APRSLRRSSCFGGRMDRIGAQSGLG,Auriculin-D,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",7595132,,31,Kaliuretic peptide and long acting natriuretic peptide as well as atrial natriuretic factor inhibit aldosterone secretion.,"Vesely, D. et al.",7595132,10.1677/joe.0.1460373,,7595132,"The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1-30 (long acting natriuretic peptide), 31-67 (vessel dilator) and 79-98 (kaliuretic peptide) as well as 99-126 (atrial natriuretic factor (ANF)) of the 126 amino acid ANF prohormone inhibit aldosterone secretion. Thirty healthy human subjects were studied following infusion of 100 ng/kg body weight/min for 60 min of each of the respective peptides. Kaliuretic peptide decreased plasma aldosterone concentration by the greatest amount (6-fold) and plasma aldosterone was still significantly decreased (P < 0.001) three hours after stopping the infusion. In contrast, within 30 min of cessation of the ANF infusion, plasma aldosterone levels had returned to pre-infusion values. Long acting natriuretic peptide also significantly (P < 0.01) decreased plasma aldosterone levels which remained significantly (P < 0.001) decreased 3 h after cessation of infusion. Vessel dilator did not decrease plasma aldosterone levels. Kaliuretic peptide, ANF and long acting natriuretic peptide also decreased (P < 0.01) urinary aldosterone concentrations. None of these peptides changed the plasma potassium concentration. We conclude that two new peptide hormones (long acting natriuretic peptide and kaliuretic peptide) inhibit aldosterone secretion. The length of time that aldosterone secretion is inhibited following kaliuretic peptide and long acting natriuretic peptide infusion is significantly longer (P < 0.001) than following ANF infusion."
67,P01160,Natriuretic peptides A,121-145,APRSLRRSSCFGGRMDRIGAQSGLG,Auriculin-D,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",7720651,,30,Kaliuretic peptide: the most potent inhibitor of Na(+)-K+ ATPase of the atrial natriuretic peptides.,"Chiou, S. et al.",7720651,10.1210/endo.136.5.7720651,,7720651,"The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1-30 (i.e. long-acting natriuretic peptide), 31-67 (vessel dilator), 79-98 (kaliuretic peptide), and 99-126 [atrial natriuretic factor (ANF)] of the 126 amino acid ANF prohormone inhibit sodium-potassium-ATPase as part of their mechanism(s) of action for producing a natriuresis and/or kaliuresis. Kaliuretic peptide, long-acting natriuretic peptide, vessel dilator and ANF at their 10(-11) M concentrations inhibited Na(+)-K(+)-ATPase 39.5%, 27.8%, 19.2%, and 4% respectively, in bovine renal medulla, whereas their inhibition in renal cortical membranes was 37.5%, 27.5%, 20%, and 0%, respectively. Ouabain (0.5 mM) inhibited kidney medullary Na(+)-K(+)-ATPase 45% and in the cortex, 38%. There was no additive effect of any of these peptides with ouabain suggesting that they are interacting with the same site on the Na(+)-K(+)-ATPase as ouabain. To help elucidate the mechanism of these peptides' interaction with Na(+)-K(+)-ATPase, naproxen (0.5 mM), an inhibitor of prostaglandin synthesis, and direct measurement of prostaglandin E2 by RIA were used. Naproxen completely blocked the inhibition of Na(+)-K(+)-ATPase by kaliuretic peptide, long-acting natriuretic peptide, and vessel dilator suggesting that their inhibition of Na(+)-K(+)-ATPase in both the kidney medulla and cortex are mediated by prostaglandins. Direct measurement of prostaglandin E2 revealed that kaliuretic peptide > long-acting natriuretic peptide > vessel dilator increased prostaglandin E2 synthesis, whereas ANF did not have any effect. Of interest, angiotensin II and ouabain inhibition of Na(+)-K(+)-ATPase were also completely blocked by naproxen."
68,P01160,Natriuretic peptides A,121-145,APRSLRRSSCFGGRMDRIGAQSGLG,Auriculin-D,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",7955907,,26,"N-terminal atrial natriuretic peptide and atrial natriuretic peptide in human plasma: investigation of plasma levels and molecular circulating form(s) using radioimmunoassays for pro-atrial natriuretic peptide (31-67), pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide (99-126).","Buckley, M. et al.",7955907,10.1042/cs0870311,,7955907,"1. The aim of this study was to determine plasma levels of N-terminal atrial natriuretic peptide and atrial natriuretic peptide in normal subjects and in patients with essential hypertension, cardiac transplant and chronic renal failure, using radioimmunoassays directed towards the mid-portion pro-atrial natriuretic peptide (31-67) and pro-atrial natriuretic peptide (1-30) of the N-terminal atrial natriuretic peptide and atrial natriuretic peptide (99-126). The circulating form(s) of the immunoreactive N-terminal atrial natriuretic peptide in plasma extracts has been investigated using all three radioimmunoassays by means of gel filtration chromatography to further clarify the major immunoreactive molecular circulating form(s) of N-terminal atrial natriuretic peptide in man. 2. The plasma level (mean +/- SEM) of N-terminal pro-atrial natriuretic peptide (31-67) in the normal subjects was 547.2 +/- 32.7 pg/ml (n = 36) and was significantly elevated in patients with essential hypertension (730.2 +/- 72.3 pg/ml, P < 0.025, n = 39), in cardiac transplant recipients (3214.0 +/- 432.2 pg/ml, P < 0.001, n = 9) and in patients with chronic renal failure (3571.8 +/- 474.1 pg/ml, P < 0.001, n = 11). Plasma levels of N-terminal pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide were similarly elevated in the same patient groups when compared with the mean plasma values in the normal subjects.(ABSTRACT TRUNCATED AT 250 WORDS)"
69,P01160,Natriuretic peptides A,121-145,APRSLRRSSCFGGRMDRIGAQSGLG,Auriculin-D,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",11145122,,36,"Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance the urinary excretion rate of beta2-microglobulin.","Vesely, D. et al.",11145122,10.1053/meta.2000.18557,,11145122,"The atrial natriuretic peptide (ANP) gene synthesizes a 126-amino acid (aa) prohormone from which four peptide hormones are derived. These 4 peptide hormones consisting of aa 1 to 30 (ie, long-acting natriuretic peptide [LANP]), aa 31 to 67 (vessel dilator), aa 79 to 98 (kaliuretic peptide), and aa 99 to 126 (ie, ANP) have diuretic, natriuretic, and/or kaliuretic properties. ANP has been reported to have its natriuretic and protein-excreting effects via both the proximal and distal tubules, but where in the kidney the other three peptide hormones have their natriuretic and/or diuretic effects is unknown. Further, it has never been investigated as to whether these three other peptide hormones enhance protein excretion. The present investigation was designed to determine (1) if these atrial peptides enhance protein excretion and (2) if their effects involve the proximal tubules of healthy humans by examining the excretion rate of beta2-microglobulin, a marker of proximal tubule function. Twenty-four healthy human subjects were studied following the infusion of 100 ng/kg body weight/min for 60 minutes of each of the respective peptides. LANP enhanced the excretion rate of beta2-microglobulin 2-fold within 20 minutes of beginning its infusion (P < .05) and was 2.5-fold higher than the preinfusion excretion rate at the end of the infusion. The excretion rate of beta2-microglobulin continued to be significantly (P < .01) increased for 3 hours after cessation of the LANP infusion, with the maximal excretion rate (ie, 3.8-fold increase) at 2.5 hours after stopping the infusion. Vessel dilator showed a more marked enhancement of beta2-microglobulin during its infusion, with the excretion rate increasing 2.5-fold at 20 minutes, and was increased 4-fold (P < .01) at the end of the infusion. With cessation of the vessel dilator infusion, the excretion rate of beta2-microglobulin decreased but was still elevated 2-fold (P < .05) 3 hours after stopping the infusion. Kaliuretic peptide enhanced the beta2-microglobulin excretion rate a maximal 3-fold, which occurred at the end of its infusion. The beta2-microglobulin excretion secondary to kaliuretic peptide remained 2-fold (P < .05) above baseline during the 3-hour postinfusion period. These peptide hormones similarly enhanced the albumin and total protein excretion rates 2- to 4-fold. These results indicate that LANP, vessel dilator, and kaliuretic peptide each (1) enhance protein excretion in healthy humans and (2) inhibit proximal tubular protein reabsorption."
70,P01160,Natriuretic peptides A,121-145,APRSLRRSSCFGGRMDRIGAQSGLG,Auriculin-D,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",2532366,,18,Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans.,"Vesely, D. et al.",2532366,10.3181/00379727-192-42990,,2532366,"The role of peptides from the N terminus and C terminus of the 126 amino acid atrial natriuretic factor (ANF) prohormone in modulating renal sodium and water handling has not been defined. Since water immersion to the neck (NI) provides an acute central volume expansion identical to that produced by 2 liters of saline but without plasma compositional change, immersion to the neck was used to assess the N-terminal and C-terminal portions of the ANF prohormone response to acute central blood volume expansion in seven seated sodium-replete normal subjects. Both the C terminus, which contains amino acids 99-126 and is identical to ANF, and the whole N terminus (i.e., amino acids 1-98) increased promptly with NI and peaked after 1 hr of immersion. A Mr 3900 peptide from the midportion of the N terminus consistent with amino acids 31-67 (i.e., pro-ANF-31-67) also increased with NI and followed a pattern of increasing circulating concentration nearly identical to that of the whole N terminus of the prohormone, except that its maximal concentration was at the second hour of the 3 hr of NI. With cessation of immersion, ANF decreased to preimmersion levels within 1 hr whereas the N terminus and pro-ANF-31-67, although their circulating concentrations were decreasing, were still significantly elevated at 1 hr. These findings suggest that the increase in plasma ANF, the N terminus of the ANF prohormone, and pro-ANF-31-67 from the midportion of the N terminus, with natriuretic properties similar to ANF, contribute to the natriuretic response to NI, implying a physiologic role for these atrial peptides in modulating volume homeostasis in humans."
71,P01160,Natriuretic peptides A,121-145,APRSLRRSSCFGGRMDRIGAQSGLG,Auriculin-D,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",8087923,,25,"Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans.","Vesely, D. et al.",8087923,10.1161/01.cir.90.3.1129,,8087923,"Three peptides consisting of amino acids 1-30, 31-67, and 79-98 of the 126-amino acid atrial natriuretic factor prohormone (proANF), which have blood pressure-lowering, diuretic, natriuretic, and/or kaliuretic properties in animals, were investigated to determine if they have similar properties in humans."
72,P01160,Natriuretic peptides A,121-145,APRSLRRSSCFGGRMDRIGAQSGLG,Auriculin-D,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",2825692,,16,"Atrial natriuretic prohormone peptides 1-30, 31-67, and 79-98 vasodilate the aorta.","Vesely, D. et al.",2825692,10.1016/s0006-291x(87)80307-8,,2825692,"Human prohormone atrial natriuretic peptides 1-30, 31-67, and 79-98 caused vasodilation of porcine aortas which began in 30 seconds and was maximal at 10 minutes. These three peptides were found to be equally potent to atrial natriuretic factor in their vasodilatory activity which was found with or without endothelium present. This vasodilation was associated with a 4 to 5 fold increase in cyclic GMP in the aorta secondary to activation of particulate guanylate cyclase [E.C. 4.6.12]. These data demonstrate that three N-terminal peptide segments of the atrial natriuretic factor prohormone cause vasodilation."
73,P01160,Natriuretic peptides A,121-145,APRSLRRSSCFGGRMDRIGAQSGLG,Auriculin-D,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",2162527,,20,"Specific binding sites for prohormone atrial natriuretic peptides 1-30, 31-67 and 99-126.","Vesely, D. et al.",2162527,10.1016/0196-9781(90)90070-l,,2162527,"Two peptides with vasodilatory properties consisting of amino acids 1-30 and 31-67 of the 98 a.a. N-terminal end of the prohormone of atrial natriuretic factor (proANF) which circulates in man were investigated to determine if they have specific binding sites on membranes isolated from DDT1 MF-2 smooth muscle cells. Smooth muscle is a known biologic target of these peptides. Competitive binding experiments revealed that proANFs (1-30), (31-67), and (99-126) (i.e., C-terminus; ANF) each had specific and separate binding sites. The dissociation constants for proANFs (1-30), (31-67), and (99-126) binding were 0.11 nM, 4 nM, and 7.3 nM, respectively. The binding site concentrations for proANFs (1-30), (31-67), and ANF were 2.57, 59.91 and 40 fmols/10(6) cells, respectively. The number of binding sites per cell were 1548, 36,087, and 24,090, respectively, for proANFs (1-30), (31-67), and (99-126) (ANF). Each peptide bound to DDT1 MF-2 membranes between 10(-8) to 10(-11) M but could only bind to the other peptides' receptors at concentrations of 10(-6) and 10(-7)M. These results suggest that proANF(1-30) and proANF(31-67) do not work through the ANF receptor but rather have their own separate and distinct receptors that mediate their biologic effects."
74,P01160,Natriuretic peptides A,121-145,APRSLRRSSCFGGRMDRIGAQSGLG,Auriculin-D,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",8653797,,29,Temporal (circadian) and functional relationship between atrial natriuretic peptides and blood pressure.,"Sothern, R. et al.",8653797,10.3109/07420529509064506,,8653797,"Long-acting natriuretic peptide, vessel dilator, and atrial natriuretic factor consisting of amino acids (a.a.) 1 to 30, 31 to 67, and 99 to 126 of the 126-a.a. atrial natriuretic factor (ANF) prohormone, respectively, circulate in humans and have potent vasodilatory properties. To determine if these atrial natriuretic peptides are directly related to blood pressure in clinically healthy normotensive humans, we obtained 24-h profiles of vessel dilator, long-acting natriuretic peptide, ANF, and blood pressure in 10 men in 1988 and 11 men in 1993 (seven men were studied twice) to compare circulating concentrations of atrial natriuretic peptides with naturally occurring changes in blood pressure. Overall, vessel dilator, long-acting natriuretic peptide, and ANF each had significant (p<0.001) circadian rhythms, with peak concentrations late during sleep (at 04:00 h) being nearly twice their concentrations in the afternoon and evening. This high-amplitude circadian change allowed for the refinement of normal limits for ANF peptides by computing 3-hourly tolerance intervals (chronodesms) against which to compare time-specified single samples for normality. Systolic, diastolic, and mean arterial blood pressure also had significant circadian rhythms (p<0.001) with peaks and troughs that were exactly opposite those of the ANF peptides. In addition to this inverse temporal relationship, there was a significant inverse correlation between absolute values for blood pressure and each ANF peptide (p<0.001), implying a functional relationship. These data suggest that in addition to other well-established neurochemical factors, the ANF peptides (vessel dilator, long-acting natriuretic peptide, and ANF) are important for the maintenance of blood pressure and modulation of its circadian rhythm."
75,P01160,Natriuretic peptides A,124-151,SLRRSSCFGGRMDRIGAQSGLGCNSFRY,Atrial natriuretic peptide,5 14 30 31,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '45', '10', '11', '13', '19', '21', '25', '24', '2', '26', '38', '8', '17', '33', '41', '34', '18', '16'}","Hormone that plays a key role in mediating cardio-renal homeostasis, and is involved in vascular remodeling and regulating energy metabolism (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:8087923, PubMed:2532366, PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263, PubMed:16875975). Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins, such as PRKG1, that drive various biological responses (PubMed:25401746, PubMed:9893117, PubMed:1672777, PubMed:1660465, PubMed:2162527, PubMed:2825692, PubMed:7720651, PubMed:22307324, PubMed:8384600, PubMed:21098034). Regulates vasodilation, natriuresis, diuresis and aldosterone synthesis and is therefore essential for regulating blood pressure, controlling the extracellular fluid volume and maintaining the fluid-electrolyte balance (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:2532366, PubMed:8087923). Also involved in inhibiting cardiac remodeling and cardiac hypertrophy by inducing cardiomyocyte apoptosis and attenuating the growth of cardiomyocytes and fibroblasts (PubMed:16875975). Plays a role in female pregnancy by promoting trophoblast invasion and spiral artery remodeling in uterus, and thus prevents pregnancy-induced hypertension (By similarity). In adipose tissue, acts in various cGMP- and PKG-dependent pathways to regulate lipid metabolism and energy homeostasis (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). This includes up-regulating lipid metabolism and mitochondrial oxygen utilization by activating the AMP-activated protein kinase (AMPK), and increasing energy expenditure by acting via MAPK11 to promote the UCP1-dependent thermogenesis of brown adipose tissue (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). Binds the clearance receptor NPR3 which removes the hormone from circulation (PubMed:1672777).",18835931,,42,Atrial natriuretic peptide induces postprandial lipid oxidation in humans.,"Birkenfeld, A. et al.",18835931,10.2337/db08-0649,,18835931,"Atrial natriuretic peptide (ANP) regulates arterial blood pressure. In addition, ANP has recently been shown to promote human adipose tissue lipolysis through cGMP-mediated hormone-sensitive lipase activation. We hypothesized that ANP increases postprandial free fatty acid (FFA) availability and energy expenditure while decreasing arterial blood pressure."
76,P01160,Natriuretic peptides A,124-151,SLRRSSCFGGRMDRIGAQSGLGCNSFRY,Atrial natriuretic peptide,5 14 30 31,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '45', '10', '11', '13', '19', '21', '25', '24', '2', '26', '38', '8', '17', '33', '41', '34', '18', '16'}","Hormone that plays a key role in mediating cardio-renal homeostasis, and is involved in vascular remodeling and regulating energy metabolism (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:8087923, PubMed:2532366, PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263, PubMed:16875975). Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins, such as PRKG1, that drive various biological responses (PubMed:25401746, PubMed:9893117, PubMed:1672777, PubMed:1660465, PubMed:2162527, PubMed:2825692, PubMed:7720651, PubMed:22307324, PubMed:8384600, PubMed:21098034). Regulates vasodilation, natriuresis, diuresis and aldosterone synthesis and is therefore essential for regulating blood pressure, controlling the extracellular fluid volume and maintaining the fluid-electrolyte balance (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:2532366, PubMed:8087923). Also involved in inhibiting cardiac remodeling and cardiac hypertrophy by inducing cardiomyocyte apoptosis and attenuating the growth of cardiomyocytes and fibroblasts (PubMed:16875975). Plays a role in female pregnancy by promoting trophoblast invasion and spiral artery remodeling in uterus, and thus prevents pregnancy-induced hypertension (By similarity). In adipose tissue, acts in various cGMP- and PKG-dependent pathways to regulate lipid metabolism and energy homeostasis (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). This includes up-regulating lipid metabolism and mitochondrial oxygen utilization by activating the AMP-activated protein kinase (AMPK), and increasing energy expenditure by acting via MAPK11 to promote the UCP1-dependent thermogenesis of brown adipose tissue (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). Binds the clearance receptor NPR3 which removes the hormone from circulation (PubMed:1672777).",16875975,,41,Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension.,"Rubattu, S. et al.",16875975,10.1016/j.jacc.2005.12.081,,16875975,"The goal of our study was to investigate the relationships between atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and type A natriuretic peptide receptor (NPRA) gene polymorphisms and left ventricular structure in human essential hypertension."
77,P01160,Natriuretic peptides A,124-151,SLRRSSCFGGRMDRIGAQSGLGCNSFRY,Atrial natriuretic peptide,5 14 30 31,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '45', '10', '11', '13', '19', '21', '25', '24', '2', '26', '38', '8', '17', '33', '41', '34', '18', '16'}","Hormone that plays a key role in mediating cardio-renal homeostasis, and is involved in vascular remodeling and regulating energy metabolism (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:8087923, PubMed:2532366, PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263, PubMed:16875975). Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins, such as PRKG1, that drive various biological responses (PubMed:25401746, PubMed:9893117, PubMed:1672777, PubMed:1660465, PubMed:2162527, PubMed:2825692, PubMed:7720651, PubMed:22307324, PubMed:8384600, PubMed:21098034). Regulates vasodilation, natriuresis, diuresis and aldosterone synthesis and is therefore essential for regulating blood pressure, controlling the extracellular fluid volume and maintaining the fluid-electrolyte balance (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:2532366, PubMed:8087923). Also involved in inhibiting cardiac remodeling and cardiac hypertrophy by inducing cardiomyocyte apoptosis and attenuating the growth of cardiomyocytes and fibroblasts (PubMed:16875975). Plays a role in female pregnancy by promoting trophoblast invasion and spiral artery remodeling in uterus, and thus prevents pregnancy-induced hypertension (By similarity). In adipose tissue, acts in various cGMP- and PKG-dependent pathways to regulate lipid metabolism and energy homeostasis (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). This includes up-regulating lipid metabolism and mitochondrial oxygen utilization by activating the AMP-activated protein kinase (AMPK), and increasing energy expenditure by acting via MAPK11 to promote the UCP1-dependent thermogenesis of brown adipose tissue (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). Binds the clearance receptor NPR3 which removes the hormone from circulation (PubMed:1672777).",9893117,,35,Regulation of natriuretic peptide (urodilatin) release in a human kidney cell line.,"Lenz, W. et al.",9893117,10.1046/j.1523-1755.1999.00242.x,,9893117,To identify the molecular mechanisms underlying the release of a renal natriuretic peptide (NP) we selected a human kidney cell line (HEK 293) that displays several characteristics of distal tubular cells.
78,P01160,Natriuretic peptides A,124-151,SLRRSSCFGGRMDRIGAQSGLGCNSFRY,Atrial natriuretic peptide,5 14 30 31,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '45', '10', '11', '13', '19', '21', '25', '24', '2', '26', '38', '8', '17', '33', '41', '34', '18', '16'}","Hormone that plays a key role in mediating cardio-renal homeostasis, and is involved in vascular remodeling and regulating energy metabolism (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:8087923, PubMed:2532366, PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263, PubMed:16875975). Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins, such as PRKG1, that drive various biological responses (PubMed:25401746, PubMed:9893117, PubMed:1672777, PubMed:1660465, PubMed:2162527, PubMed:2825692, PubMed:7720651, PubMed:22307324, PubMed:8384600, PubMed:21098034). Regulates vasodilation, natriuresis, diuresis and aldosterone synthesis and is therefore essential for regulating blood pressure, controlling the extracellular fluid volume and maintaining the fluid-electrolyte balance (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:2532366, PubMed:8087923). Also involved in inhibiting cardiac remodeling and cardiac hypertrophy by inducing cardiomyocyte apoptosis and attenuating the growth of cardiomyocytes and fibroblasts (PubMed:16875975). Plays a role in female pregnancy by promoting trophoblast invasion and spiral artery remodeling in uterus, and thus prevents pregnancy-induced hypertension (By similarity). In adipose tissue, acts in various cGMP- and PKG-dependent pathways to regulate lipid metabolism and energy homeostasis (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). This includes up-regulating lipid metabolism and mitochondrial oxygen utilization by activating the AMP-activated protein kinase (AMPK), and increasing energy expenditure by acting via MAPK11 to promote the UCP1-dependent thermogenesis of brown adipose tissue (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). Binds the clearance receptor NPR3 which removes the hormone from circulation (PubMed:1672777).",1672777,,22,Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP).,"Koller, K. et al.",1672777,10.1126/science.1672777,,1672777,"The natriuretic peptides are hormones that can stimulate natriuretic, diuretic, and vasorelaxant activity in vivo, presumably through the activation of two known cell surface receptor guanylyl cyclases (ANPR-A and ANPR-B). Although atrial natriuretic peptide (ANP) and, to a lesser extent, brain natriuretic peptide (BNP) are efficient activators of the ANPR-A guanylyl cyclase, neither hormone can significantly stimulate ANPR-B. A member of this hormone family, C-type natriuretic peptide (CNP), potently and selectively activated the human ANPR-B guanylyl cyclase. CNP does not increase guanosine 3',5'-monophosphate accumulation in cells expressing human ANPR-A. The affinity of CNP for ANPR-B is 50- or 500-fold higher than ANP or BNP, respectively. This ligand-receptor pair may be involved in the regulation of fluid homeostasis by the central nervous system."
79,P01160,Natriuretic peptides A,124-151,SLRRSSCFGGRMDRIGAQSGLGCNSFRY,Atrial natriuretic peptide,5 14 30 31,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '45', '10', '11', '13', '19', '21', '25', '24', '2', '26', '38', '8', '17', '33', '41', '34', '18', '16'}","Hormone that plays a key role in mediating cardio-renal homeostasis, and is involved in vascular remodeling and regulating energy metabolism (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:8087923, PubMed:2532366, PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263, PubMed:16875975). Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins, such as PRKG1, that drive various biological responses (PubMed:25401746, PubMed:9893117, PubMed:1672777, PubMed:1660465, PubMed:2162527, PubMed:2825692, PubMed:7720651, PubMed:22307324, PubMed:8384600, PubMed:21098034). Regulates vasodilation, natriuresis, diuresis and aldosterone synthesis and is therefore essential for regulating blood pressure, controlling the extracellular fluid volume and maintaining the fluid-electrolyte balance (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:2532366, PubMed:8087923). Also involved in inhibiting cardiac remodeling and cardiac hypertrophy by inducing cardiomyocyte apoptosis and attenuating the growth of cardiomyocytes and fibroblasts (PubMed:16875975). Plays a role in female pregnancy by promoting trophoblast invasion and spiral artery remodeling in uterus, and thus prevents pregnancy-induced hypertension (By similarity). In adipose tissue, acts in various cGMP- and PKG-dependent pathways to regulate lipid metabolism and energy homeostasis (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). This includes up-regulating lipid metabolism and mitochondrial oxygen utilization by activating the AMP-activated protein kinase (AMPK), and increasing energy expenditure by acting via MAPK11 to promote the UCP1-dependent thermogenesis of brown adipose tissue (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). Binds the clearance receptor NPR3 which removes the hormone from circulation (PubMed:1672777).",21672517,,43,Atrial natriuretic peptide regulates lipid mobilization and oxygen consumption in human adipocytes by activating AMPK.,"Souza, S. et al.",21672517,10.1016/j.bbrc.2011.05.143,,21672517,"Atrial natriuretic peptide (ANP) has been shown to regulate lipid and carbohydrate metabolism providing a possible link between cardiovascular function and metabolism by mediating the switch from carbohydrate to lipid mobilization and oxidation. ANP exerts a potent lipolytic effect via cGMP-dependent protein kinase (cGK)-I mediated-stimulation of AMP-activated protein kinase (AMPK). Activation of the ANP/cGK signaling cascade also promotes muscle mitochondrial biogenesis and fat oxidation. Here we demonstrate that ANP regulates lipid metabolism and oxygen utilization in differentiated human adipocytes by activating the alpha2 subunit of AMPK. ANP treatment increased lipolysis by seven fold and oxygen consumption by two fold, both of which were attenuated by inhibition of AMPK activity. ANP-induced lipolysis was shown to be mediated by the alpha2 subunit of AMPK as introduction of dominant-negative alpha2 subunit of AMPK attenuated ANP effects on lipolysis. ANP-induced activation of AMPK enhanced mitochondrial oxidative capacity as evidenced by a two fold increase in oxygen consumption and induction of mitochondrial genes, including carnitine palmitoyltransferase 1A (CPT1a) by 1.4-fold, cytochrome C (CytC) by 1.3-fold, and peroxisome proliferator-activated receptor- coactivator-1 (PGC-1) by 1.4-fold. Treatment of human adipocytes with fatty acids and tumor necrosis factor  (TNF) induced insulin resistance and down-regulation of mitochondrial genes, which was restored by ANP treatment. These results show that ANP regulates lipid catabolism and enhances energy dissipation through AMPK activation in human adipocytes."
80,P01160,Natriuretic peptides A,124-151,SLRRSSCFGGRMDRIGAQSGLGCNSFRY,Atrial natriuretic peptide,5 14 30 31,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '45', '10', '11', '13', '19', '21', '25', '24', '2', '26', '38', '8', '17', '33', '41', '34', '18', '16'}","Hormone that plays a key role in mediating cardio-renal homeostasis, and is involved in vascular remodeling and regulating energy metabolism (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:8087923, PubMed:2532366, PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263, PubMed:16875975). Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins, such as PRKG1, that drive various biological responses (PubMed:25401746, PubMed:9893117, PubMed:1672777, PubMed:1660465, PubMed:2162527, PubMed:2825692, PubMed:7720651, PubMed:22307324, PubMed:8384600, PubMed:21098034). Regulates vasodilation, natriuresis, diuresis and aldosterone synthesis and is therefore essential for regulating blood pressure, controlling the extracellular fluid volume and maintaining the fluid-electrolyte balance (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:2532366, PubMed:8087923). Also involved in inhibiting cardiac remodeling and cardiac hypertrophy by inducing cardiomyocyte apoptosis and attenuating the growth of cardiomyocytes and fibroblasts (PubMed:16875975). Plays a role in female pregnancy by promoting trophoblast invasion and spiral artery remodeling in uterus, and thus prevents pregnancy-induced hypertension (By similarity). In adipose tissue, acts in various cGMP- and PKG-dependent pathways to regulate lipid metabolism and energy homeostasis (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). This includes up-regulating lipid metabolism and mitochondrial oxygen utilization by activating the AMP-activated protein kinase (AMPK), and increasing energy expenditure by acting via MAPK11 to promote the UCP1-dependent thermogenesis of brown adipose tissue (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). Binds the clearance receptor NPR3 which removes the hormone from circulation (PubMed:1672777).",2162527,,20,"Specific binding sites for prohormone atrial natriuretic peptides 1-30, 31-67 and 99-126.","Vesely, D. et al.",2162527,10.1016/0196-9781(90)90070-l,,2162527,"Two peptides with vasodilatory properties consisting of amino acids 1-30 and 31-67 of the 98 a.a. N-terminal end of the prohormone of atrial natriuretic factor (proANF) which circulates in man were investigated to determine if they have specific binding sites on membranes isolated from DDT1 MF-2 smooth muscle cells. Smooth muscle is a known biologic target of these peptides. Competitive binding experiments revealed that proANFs (1-30), (31-67), and (99-126) (i.e., C-terminus; ANF) each had specific and separate binding sites. The dissociation constants for proANFs (1-30), (31-67), and (99-126) binding were 0.11 nM, 4 nM, and 7.3 nM, respectively. The binding site concentrations for proANFs (1-30), (31-67), and ANF were 2.57, 59.91 and 40 fmols/10(6) cells, respectively. The number of binding sites per cell were 1548, 36,087, and 24,090, respectively, for proANFs (1-30), (31-67), and (99-126) (ANF). Each peptide bound to DDT1 MF-2 membranes between 10(-8) to 10(-11) M but could only bind to the other peptides' receptors at concentrations of 10(-6) and 10(-7)M. These results suggest that proANF(1-30) and proANF(31-67) do not work through the ANF receptor but rather have their own separate and distinct receptors that mediate their biologic effects."
81,P01160,Natriuretic peptides A,124-151,SLRRSSCFGGRMDRIGAQSGLGCNSFRY,Atrial natriuretic peptide,5 14 30 31,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '45', '10', '11', '13', '19', '21', '25', '24', '2', '26', '38', '8', '17', '33', '41', '34', '18', '16'}","Hormone that plays a key role in mediating cardio-renal homeostasis, and is involved in vascular remodeling and regulating energy metabolism (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:8087923, PubMed:2532366, PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263, PubMed:16875975). Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins, such as PRKG1, that drive various biological responses (PubMed:25401746, PubMed:9893117, PubMed:1672777, PubMed:1660465, PubMed:2162527, PubMed:2825692, PubMed:7720651, PubMed:22307324, PubMed:8384600, PubMed:21098034). Regulates vasodilation, natriuresis, diuresis and aldosterone synthesis and is therefore essential for regulating blood pressure, controlling the extracellular fluid volume and maintaining the fluid-electrolyte balance (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:2532366, PubMed:8087923). Also involved in inhibiting cardiac remodeling and cardiac hypertrophy by inducing cardiomyocyte apoptosis and attenuating the growth of cardiomyocytes and fibroblasts (PubMed:16875975). Plays a role in female pregnancy by promoting trophoblast invasion and spiral artery remodeling in uterus, and thus prevents pregnancy-induced hypertension (By similarity). In adipose tissue, acts in various cGMP- and PKG-dependent pathways to regulate lipid metabolism and energy homeostasis (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). This includes up-regulating lipid metabolism and mitochondrial oxygen utilization by activating the AMP-activated protein kinase (AMPK), and increasing energy expenditure by acting via MAPK11 to promote the UCP1-dependent thermogenesis of brown adipose tissue (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). Binds the clearance receptor NPR3 which removes the hormone from circulation (PubMed:1672777).",22307324,,45,Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes.,"Bordicchia, M. et al.",22307324,10.1172/jci59701,,22307324,"The ability of mammals to resist body fat accumulation is linked to their ability to expand the number and activity of ""brown adipocytes"" within white fat depots. Activation of -adrenergic receptors (-ARs) can induce a functional ""brown-like"" adipocyte phenotype. As cardiac natriuretic peptides (NPs) and -AR agonists are similarly potent at stimulating lipolysis in human adipocytes, we investigated whether NPs could induce human and mouse adipocytes to acquire brown adipocyte features, including a capacity for thermogenic energy expenditure mediated by uncoupling protein 1 (UCP1). In human adipocytes, atrial NP (ANP) and ventricular NP (BNP) activated PPAR coactivator-1 (PGC-1) and UCP1 expression, induced mitochondriogenesis, and increased uncoupled and total respiration. At low concentrations, ANP and -AR agonists additively enhanced expression of brown fat and mitochondrial markers in a p38 MAPK-dependent manner. Mice exposed to cold temperatures had increased levels of circulating NPs as well as higher expression of NP signaling receptor and lower expression of the NP clearance receptor (Nprc) in brown adipose tissue (BAT) and white adipose tissue (WAT). NPR-C(-/-) mice had markedly smaller WAT and BAT depots but higher expression of thermogenic genes such as Ucp1. Infusion of BNP into mice robustly increased Ucp1 and Pgc-1 expression in WAT and BAT, with corresponding elevation of respiration and energy expenditure. These results suggest that NPs promote ""browning"" of white adipocytes to increase energy expenditure, defining the heart as a central regulator of adipose tissue biology."
82,P01160,Natriuretic peptides A,124-151,SLRRSSCFGGRMDRIGAQSGLGCNSFRY,Atrial natriuretic peptide,5 14 30 31,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '45', '10', '11', '13', '19', '21', '25', '24', '2', '26', '38', '8', '17', '33', '41', '34', '18', '16'}","Hormone that plays a key role in mediating cardio-renal homeostasis, and is involved in vascular remodeling and regulating energy metabolism (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:8087923, PubMed:2532366, PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263, PubMed:16875975). Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins, such as PRKG1, that drive various biological responses (PubMed:25401746, PubMed:9893117, PubMed:1672777, PubMed:1660465, PubMed:2162527, PubMed:2825692, PubMed:7720651, PubMed:22307324, PubMed:8384600, PubMed:21098034). Regulates vasodilation, natriuresis, diuresis and aldosterone synthesis and is therefore essential for regulating blood pressure, controlling the extracellular fluid volume and maintaining the fluid-electrolyte balance (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:2532366, PubMed:8087923). Also involved in inhibiting cardiac remodeling and cardiac hypertrophy by inducing cardiomyocyte apoptosis and attenuating the growth of cardiomyocytes and fibroblasts (PubMed:16875975). Plays a role in female pregnancy by promoting trophoblast invasion and spiral artery remodeling in uterus, and thus prevents pregnancy-induced hypertension (By similarity). In adipose tissue, acts in various cGMP- and PKG-dependent pathways to regulate lipid metabolism and energy homeostasis (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). This includes up-regulating lipid metabolism and mitochondrial oxygen utilization by activating the AMP-activated protein kinase (AMPK), and increasing energy expenditure by acting via MAPK11 to promote the UCP1-dependent thermogenesis of brown adipose tissue (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). Binds the clearance receptor NPR3 which removes the hormone from circulation (PubMed:1672777).",8653797,,29,Temporal (circadian) and functional relationship between atrial natriuretic peptides and blood pressure.,"Sothern, R. et al.",8653797,10.3109/07420529509064506,,8653797,"Long-acting natriuretic peptide, vessel dilator, and atrial natriuretic factor consisting of amino acids (a.a.) 1 to 30, 31 to 67, and 99 to 126 of the 126-a.a. atrial natriuretic factor (ANF) prohormone, respectively, circulate in humans and have potent vasodilatory properties. To determine if these atrial natriuretic peptides are directly related to blood pressure in clinically healthy normotensive humans, we obtained 24-h profiles of vessel dilator, long-acting natriuretic peptide, ANF, and blood pressure in 10 men in 1988 and 11 men in 1993 (seven men were studied twice) to compare circulating concentrations of atrial natriuretic peptides with naturally occurring changes in blood pressure. Overall, vessel dilator, long-acting natriuretic peptide, and ANF each had significant (p<0.001) circadian rhythms, with peak concentrations late during sleep (at 04:00 h) being nearly twice their concentrations in the afternoon and evening. This high-amplitude circadian change allowed for the refinement of normal limits for ANF peptides by computing 3-hourly tolerance intervals (chronodesms) against which to compare time-specified single samples for normality. Systolic, diastolic, and mean arterial blood pressure also had significant circadian rhythms (p<0.001) with peaks and troughs that were exactly opposite those of the ANF peptides. In addition to this inverse temporal relationship, there was a significant inverse correlation between absolute values for blood pressure and each ANF peptide (p<0.001), implying a functional relationship. These data suggest that in addition to other well-established neurochemical factors, the ANF peptides (vessel dilator, long-acting natriuretic peptide, and ANF) are important for the maintenance of blood pressure and modulation of its circadian rhythm."
83,P01160,Natriuretic peptides A,124-151,SLRRSSCFGGRMDRIGAQSGLGCNSFRY,Atrial natriuretic peptide,5 14 30 31,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '45', '10', '11', '13', '19', '21', '25', '24', '2', '26', '38', '8', '17', '33', '41', '34', '18', '16'}","Hormone that plays a key role in mediating cardio-renal homeostasis, and is involved in vascular remodeling and regulating energy metabolism (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:8087923, PubMed:2532366, PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263, PubMed:16875975). Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins, such as PRKG1, that drive various biological responses (PubMed:25401746, PubMed:9893117, PubMed:1672777, PubMed:1660465, PubMed:2162527, PubMed:2825692, PubMed:7720651, PubMed:22307324, PubMed:8384600, PubMed:21098034). Regulates vasodilation, natriuresis, diuresis and aldosterone synthesis and is therefore essential for regulating blood pressure, controlling the extracellular fluid volume and maintaining the fluid-electrolyte balance (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:2532366, PubMed:8087923). Also involved in inhibiting cardiac remodeling and cardiac hypertrophy by inducing cardiomyocyte apoptosis and attenuating the growth of cardiomyocytes and fibroblasts (PubMed:16875975). Plays a role in female pregnancy by promoting trophoblast invasion and spiral artery remodeling in uterus, and thus prevents pregnancy-induced hypertension (By similarity). In adipose tissue, acts in various cGMP- and PKG-dependent pathways to regulate lipid metabolism and energy homeostasis (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). This includes up-regulating lipid metabolism and mitochondrial oxygen utilization by activating the AMP-activated protein kinase (AMPK), and increasing energy expenditure by acting via MAPK11 to promote the UCP1-dependent thermogenesis of brown adipose tissue (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). Binds the clearance receptor NPR3 which removes the hormone from circulation (PubMed:1672777).",1660465,,21,Extracellular domain-IgG fusion proteins for three human natriuretic peptide receptors. Hormone pharmacology and application to solid phase screening of synthetic peptide antisera.,"Bennett, B. et al.",1660465,10.1016/s0021-9258(18)54463-x,,1660465,"The natriuretic peptide receptors (NPRs) are a family of three cell surface glycoproteins, each with a single transmembrane domain. Two of these receptors, designated NPR-A and NPR-B, are membrane guanylyl cyclases that synthesize cGMP in response to hormone stimulation. The third receptor, NPR-C, has been reported to function in the metabolic clearance of ligand and in guanylyl cyclase-independent signal transduction. We engineered three chimeric proteins consisting of the natriuretic peptide receptor extracellular domains fused to the Fc portion of human IgG-gamma 1. These molecules provide material for detailed studies of the human receptor's extracellular domain structure and interaction with the three human natriuretic peptides, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and type-C natriuretic peptide (CNP). The homodimeric fusion proteins, designated A-IgG, B-IgG, and C-IgG, were secreted from Chinese hamster ovary cells and purified by protein-A affinity chromatography. We present here the primary characterization of these fusion proteins as represented by the intrinsic hormone affinities measured by saturation binding and competition assays. The dissociation constant of 125I-ANP for A-IgG was 1.6 pM and for C-IgG, 1.2 pM. The dissociation constant of 125I-Y0-CNP (CNP with addition of tyrosine at the amino terminus) for B-IgG was 23 pM. The rank order of potency in competitive binding for A-IgG was ANP greater than BNP much greater than CNP, whereas for B-IgG the ranking was CNP much greater than ANP greater than BNP. For C-IgG, we observed ANP greater than CNP greater than or equal to BNP. These data demonstrate that the receptor-IgG fusion proteins discriminate among the natriuretic peptides in the same manner as the native receptors and provide a basis for future structural studies with these molecules. The purified fusion proteins have a variety of potential applications, one of which we illustrate by a solid phase screening assay in which rabbit sera from a series of synthetic-peptide immunizations were titered for receptor reactivity and selectivity."
84,P01160,Natriuretic peptides A,124-151,SLRRSSCFGGRMDRIGAQSGLGCNSFRY,Atrial natriuretic peptide,5 14 30 31,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '45', '10', '11', '13', '19', '21', '25', '24', '2', '26', '38', '8', '17', '33', '41', '34', '18', '16'}","Hormone that plays a key role in mediating cardio-renal homeostasis, and is involved in vascular remodeling and regulating energy metabolism (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:8087923, PubMed:2532366, PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263, PubMed:16875975). Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins, such as PRKG1, that drive various biological responses (PubMed:25401746, PubMed:9893117, PubMed:1672777, PubMed:1660465, PubMed:2162527, PubMed:2825692, PubMed:7720651, PubMed:22307324, PubMed:8384600, PubMed:21098034). Regulates vasodilation, natriuresis, diuresis and aldosterone synthesis and is therefore essential for regulating blood pressure, controlling the extracellular fluid volume and maintaining the fluid-electrolyte balance (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:2532366, PubMed:8087923). Also involved in inhibiting cardiac remodeling and cardiac hypertrophy by inducing cardiomyocyte apoptosis and attenuating the growth of cardiomyocytes and fibroblasts (PubMed:16875975). Plays a role in female pregnancy by promoting trophoblast invasion and spiral artery remodeling in uterus, and thus prevents pregnancy-induced hypertension (By similarity). In adipose tissue, acts in various cGMP- and PKG-dependent pathways to regulate lipid metabolism and energy homeostasis (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). This includes up-regulating lipid metabolism and mitochondrial oxygen utilization by activating the AMP-activated protein kinase (AMPK), and increasing energy expenditure by acting via MAPK11 to promote the UCP1-dependent thermogenesis of brown adipose tissue (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). Binds the clearance receptor NPR3 which removes the hormone from circulation (PubMed:1672777).",7595132,,31,Kaliuretic peptide and long acting natriuretic peptide as well as atrial natriuretic factor inhibit aldosterone secretion.,"Vesely, D. et al.",7595132,10.1677/joe.0.1460373,,7595132,"The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1-30 (long acting natriuretic peptide), 31-67 (vessel dilator) and 79-98 (kaliuretic peptide) as well as 99-126 (atrial natriuretic factor (ANF)) of the 126 amino acid ANF prohormone inhibit aldosterone secretion. Thirty healthy human subjects were studied following infusion of 100 ng/kg body weight/min for 60 min of each of the respective peptides. Kaliuretic peptide decreased plasma aldosterone concentration by the greatest amount (6-fold) and plasma aldosterone was still significantly decreased (P < 0.001) three hours after stopping the infusion. In contrast, within 30 min of cessation of the ANF infusion, plasma aldosterone levels had returned to pre-infusion values. Long acting natriuretic peptide also significantly (P < 0.01) decreased plasma aldosterone levels which remained significantly (P < 0.001) decreased 3 h after cessation of infusion. Vessel dilator did not decrease plasma aldosterone levels. Kaliuretic peptide, ANF and long acting natriuretic peptide also decreased (P < 0.01) urinary aldosterone concentrations. None of these peptides changed the plasma potassium concentration. We conclude that two new peptide hormones (long acting natriuretic peptide and kaliuretic peptide) inhibit aldosterone secretion. The length of time that aldosterone secretion is inhibited following kaliuretic peptide and long acting natriuretic peptide infusion is significantly longer (P < 0.001) than following ANF infusion."
85,P01160,Natriuretic peptides A,124-151,SLRRSSCFGGRMDRIGAQSGLGCNSFRY,Atrial natriuretic peptide,5 14 30 31,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '45', '10', '11', '13', '19', '21', '25', '24', '2', '26', '38', '8', '17', '33', '41', '34', '18', '16'}","Hormone that plays a key role in mediating cardio-renal homeostasis, and is involved in vascular remodeling and regulating energy metabolism (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:8087923, PubMed:2532366, PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263, PubMed:16875975). Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins, such as PRKG1, that drive various biological responses (PubMed:25401746, PubMed:9893117, PubMed:1672777, PubMed:1660465, PubMed:2162527, PubMed:2825692, PubMed:7720651, PubMed:22307324, PubMed:8384600, PubMed:21098034). Regulates vasodilation, natriuresis, diuresis and aldosterone synthesis and is therefore essential for regulating blood pressure, controlling the extracellular fluid volume and maintaining the fluid-electrolyte balance (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:2532366, PubMed:8087923). Also involved in inhibiting cardiac remodeling and cardiac hypertrophy by inducing cardiomyocyte apoptosis and attenuating the growth of cardiomyocytes and fibroblasts (PubMed:16875975). Plays a role in female pregnancy by promoting trophoblast invasion and spiral artery remodeling in uterus, and thus prevents pregnancy-induced hypertension (By similarity). In adipose tissue, acts in various cGMP- and PKG-dependent pathways to regulate lipid metabolism and energy homeostasis (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). This includes up-regulating lipid metabolism and mitochondrial oxygen utilization by activating the AMP-activated protein kinase (AMPK), and increasing energy expenditure by acting via MAPK11 to promote the UCP1-dependent thermogenesis of brown adipose tissue (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). Binds the clearance receptor NPR3 which removes the hormone from circulation (PubMed:1672777).",6230082,,12,Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP).,"Kangawa, K. et al.",6230082,10.1016/0006-291x(84)91077-5,124-151,6230082,"The present survey for natriuretic factors in human atrial extract was performed by using in vitro assay for the relaxant effect on the contractility of chick rectum. Three distinct components (alpha, beta and gamma) of a potent relaxant activity were found in the chromatographic regions of the crude extract. As alpha-component of Mr 3,000 daltons, a 28-amino acid peptide has been isolated in a pure state and found to elicit potent diuretic and natriuretic activities as well as vasorelaxant activity, when injected into the assay rats. Accordingly, we proposed a name ""alpha-human atrial natriuretic polypeptide (alpha-hANP)"" for the peptide. The complete amino acid sequence of the peptide has been established by microsequencing as well as synthesis."
86,P01160,Natriuretic peptides A,124-151,SLRRSSCFGGRMDRIGAQSGLGCNSFRY,Atrial natriuretic peptide,5 14 30 31,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '45', '10', '11', '13', '19', '21', '25', '24', '2', '26', '38', '8', '17', '33', '41', '34', '18', '16'}","Hormone that plays a key role in mediating cardio-renal homeostasis, and is involved in vascular remodeling and regulating energy metabolism (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:8087923, PubMed:2532366, PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263, PubMed:16875975). Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins, such as PRKG1, that drive various biological responses (PubMed:25401746, PubMed:9893117, PubMed:1672777, PubMed:1660465, PubMed:2162527, PubMed:2825692, PubMed:7720651, PubMed:22307324, PubMed:8384600, PubMed:21098034). Regulates vasodilation, natriuresis, diuresis and aldosterone synthesis and is therefore essential for regulating blood pressure, controlling the extracellular fluid volume and maintaining the fluid-electrolyte balance (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:2532366, PubMed:8087923). Also involved in inhibiting cardiac remodeling and cardiac hypertrophy by inducing cardiomyocyte apoptosis and attenuating the growth of cardiomyocytes and fibroblasts (PubMed:16875975). Plays a role in female pregnancy by promoting trophoblast invasion and spiral artery remodeling in uterus, and thus prevents pregnancy-induced hypertension (By similarity). In adipose tissue, acts in various cGMP- and PKG-dependent pathways to regulate lipid metabolism and energy homeostasis (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). This includes up-regulating lipid metabolism and mitochondrial oxygen utilization by activating the AMP-activated protein kinase (AMPK), and increasing energy expenditure by acting via MAPK11 to promote the UCP1-dependent thermogenesis of brown adipose tissue (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). Binds the clearance receptor NPR3 which removes the hormone from circulation (PubMed:1672777).",8384600,,23,Urodilatin binds to and activates renal receptors for atrial natriuretic peptide.,"Valentin, J. et al.",8384600,10.1161/01.hyp.21.4.432,,8384600,"Urodilatin is a recently described member of the atrial natriuretic peptide family, thought possibly to be synthesized in the kidney. To determine if urodilatin binding sites are present in rat and human kidney, we evaluated the effect of urodilatin on iodine-125-labeled atrial natriuretic peptide (ANP) (100 pM) binding to tissue sections using an in situ autoradiographic technique. 125I-ANP binding occurred primarily in glomeruli and medullary structures of both rat and human kidney. Increasing concentrations of urodilatin yielded a monophasic displacement of 125I-ANP binding with an IC50 of 4.2 nM, a value nearly identical to that achieved with unlabeled ANP (7.2 nM). In additional experiments, rat glomeruli and inner medullary collecting duct cells were isolated and incubated in vitro with either ANP or urodilatin (10(-11) to 10(-6) M) and cyclic guanosine-3',5'-monophosphate accumulation measured by radioimmunoassay. Dose-response curves for the two peptides were superimposable in each tissue; at 10(-6) M, ANP generated 613 +/- 41 and urodilatin 603 +/- 55 fmol cyclic guanosine monophosphate per 10 minutes per milligram protein in inner medullary collecting duct cells (p = NS). Thus, urodilatin is as effective as ANP in displacing 125I-ANP binding to both rat and human renal tissue and in generating cyclic guanosine monophosphate in renal target cells in the rat, suggesting that its physiological effects may occur through the same receptors and signaling pathways that mediate the actions of ANP."
87,P01160,Natriuretic peptides A,124-151,SLRRSSCFGGRMDRIGAQSGLGCNSFRY,Atrial natriuretic peptide,5 14 30 31,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '45', '10', '11', '13', '19', '21', '25', '24', '2', '26', '38', '8', '17', '33', '41', '34', '18', '16'}","Hormone that plays a key role in mediating cardio-renal homeostasis, and is involved in vascular remodeling and regulating energy metabolism (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:8087923, PubMed:2532366, PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263, PubMed:16875975). Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins, such as PRKG1, that drive various biological responses (PubMed:25401746, PubMed:9893117, PubMed:1672777, PubMed:1660465, PubMed:2162527, PubMed:2825692, PubMed:7720651, PubMed:22307324, PubMed:8384600, PubMed:21098034). Regulates vasodilation, natriuresis, diuresis and aldosterone synthesis and is therefore essential for regulating blood pressure, controlling the extracellular fluid volume and maintaining the fluid-electrolyte balance (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:2532366, PubMed:8087923). Also involved in inhibiting cardiac remodeling and cardiac hypertrophy by inducing cardiomyocyte apoptosis and attenuating the growth of cardiomyocytes and fibroblasts (PubMed:16875975). Plays a role in female pregnancy by promoting trophoblast invasion and spiral artery remodeling in uterus, and thus prevents pregnancy-induced hypertension (By similarity). In adipose tissue, acts in various cGMP- and PKG-dependent pathways to regulate lipid metabolism and energy homeostasis (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). This includes up-regulating lipid metabolism and mitochondrial oxygen utilization by activating the AMP-activated protein kinase (AMPK), and increasing energy expenditure by acting via MAPK11 to promote the UCP1-dependent thermogenesis of brown adipose tissue (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). Binds the clearance receptor NPR3 which removes the hormone from circulation (PubMed:1672777).",3838202,,13,Structural identification of beta- and gamma-human atrial natriuretic polypeptides.,"Kangawa, K. et al.",3838202,10.1038/313397a0,26-151,3838202,"Atrial natriuretic polypeptides (ANPs) of varying chain length have been identified recently in human and rat atrial tissue. Their potent natriuretic-diuretic activities indicate their key role in the regulation of extracellular fluid volume and electrolyte balance. Furthermore, human and rat cDNAs encoding their precursor have been cloned and identified. Natriuretic-diuretic activity in human atrial extract comprises three distinct components (alpha, relative molecular mass (Mr) approximately 3,000; beta, Mr approximately 6,000; gamma, Mr approximately 13,000). However, only the 3,000-Mr peptide, alpha-human atrial polypeptide (alpha-hANP), comprising 28 amino acids, has so far been identified. We report here the purification and sequence analysis of two novel hANPs of higher Mr, beta- and gamma-hANP, both of which exhibit natriuretic and hypotensive activity. gamma-hANP, composed of 126 amino acids, carries the alpha-hANP sequence at its carboxy terminus. The identification of gamma-hANP reveals that the peptide, being the largest form of hANP, is processed directly from a 151-residue precursor by removal of a 26-residue signal peptide. In contrast, beta-hANP (56 residues) comprises an anti-parallel dimer of alpha-hANP; such a dimeric peptide possessing bioactivity has never been found in the tissue as an endogenous entity."
88,P01160,Natriuretic peptides A,124-151,SLRRSSCFGGRMDRIGAQSGLGCNSFRY,Atrial natriuretic peptide,5 14 30 31,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '45', '10', '11', '13', '19', '21', '25', '24', '2', '26', '38', '8', '17', '33', '41', '34', '18', '16'}","Hormone that plays a key role in mediating cardio-renal homeostasis, and is involved in vascular remodeling and regulating energy metabolism (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:8087923, PubMed:2532366, PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263, PubMed:16875975). Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins, such as PRKG1, that drive various biological responses (PubMed:25401746, PubMed:9893117, PubMed:1672777, PubMed:1660465, PubMed:2162527, PubMed:2825692, PubMed:7720651, PubMed:22307324, PubMed:8384600, PubMed:21098034). Regulates vasodilation, natriuresis, diuresis and aldosterone synthesis and is therefore essential for regulating blood pressure, controlling the extracellular fluid volume and maintaining the fluid-electrolyte balance (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:2532366, PubMed:8087923). Also involved in inhibiting cardiac remodeling and cardiac hypertrophy by inducing cardiomyocyte apoptosis and attenuating the growth of cardiomyocytes and fibroblasts (PubMed:16875975). Plays a role in female pregnancy by promoting trophoblast invasion and spiral artery remodeling in uterus, and thus prevents pregnancy-induced hypertension (By similarity). In adipose tissue, acts in various cGMP- and PKG-dependent pathways to regulate lipid metabolism and energy homeostasis (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). This includes up-regulating lipid metabolism and mitochondrial oxygen utilization by activating the AMP-activated protein kinase (AMPK), and increasing energy expenditure by acting via MAPK11 to promote the UCP1-dependent thermogenesis of brown adipose tissue (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). Binds the clearance receptor NPR3 which removes the hormone from circulation (PubMed:1672777).",7720651,,30,Kaliuretic peptide: the most potent inhibitor of Na(+)-K+ ATPase of the atrial natriuretic peptides.,"Chiou, S. et al.",7720651,10.1210/endo.136.5.7720651,,7720651,"The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1-30 (i.e. long-acting natriuretic peptide), 31-67 (vessel dilator), 79-98 (kaliuretic peptide), and 99-126 [atrial natriuretic factor (ANF)] of the 126 amino acid ANF prohormone inhibit sodium-potassium-ATPase as part of their mechanism(s) of action for producing a natriuresis and/or kaliuresis. Kaliuretic peptide, long-acting natriuretic peptide, vessel dilator and ANF at their 10(-11) M concentrations inhibited Na(+)-K(+)-ATPase 39.5%, 27.8%, 19.2%, and 4% respectively, in bovine renal medulla, whereas their inhibition in renal cortical membranes was 37.5%, 27.5%, 20%, and 0%, respectively. Ouabain (0.5 mM) inhibited kidney medullary Na(+)-K(+)-ATPase 45% and in the cortex, 38%. There was no additive effect of any of these peptides with ouabain suggesting that they are interacting with the same site on the Na(+)-K(+)-ATPase as ouabain. To help elucidate the mechanism of these peptides' interaction with Na(+)-K(+)-ATPase, naproxen (0.5 mM), an inhibitor of prostaglandin synthesis, and direct measurement of prostaglandin E2 by RIA were used. Naproxen completely blocked the inhibition of Na(+)-K(+)-ATPase by kaliuretic peptide, long-acting natriuretic peptide, and vessel dilator suggesting that their inhibition of Na(+)-K(+)-ATPase in both the kidney medulla and cortex are mediated by prostaglandins. Direct measurement of prostaglandin E2 revealed that kaliuretic peptide > long-acting natriuretic peptide > vessel dilator increased prostaglandin E2 synthesis, whereas ANF did not have any effect. Of interest, angiotensin II and ouabain inhibition of Na(+)-K(+)-ATPase were also completely blocked by naproxen."
89,P01160,Natriuretic peptides A,124-151,SLRRSSCFGGRMDRIGAQSGLGCNSFRY,Atrial natriuretic peptide,5 14 30 31,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '45', '10', '11', '13', '19', '21', '25', '24', '2', '26', '38', '8', '17', '33', '41', '34', '18', '16'}","Hormone that plays a key role in mediating cardio-renal homeostasis, and is involved in vascular remodeling and regulating energy metabolism (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:8087923, PubMed:2532366, PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263, PubMed:16875975). Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins, such as PRKG1, that drive various biological responses (PubMed:25401746, PubMed:9893117, PubMed:1672777, PubMed:1660465, PubMed:2162527, PubMed:2825692, PubMed:7720651, PubMed:22307324, PubMed:8384600, PubMed:21098034). Regulates vasodilation, natriuresis, diuresis and aldosterone synthesis and is therefore essential for regulating blood pressure, controlling the extracellular fluid volume and maintaining the fluid-electrolyte balance (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:2532366, PubMed:8087923). Also involved in inhibiting cardiac remodeling and cardiac hypertrophy by inducing cardiomyocyte apoptosis and attenuating the growth of cardiomyocytes and fibroblasts (PubMed:16875975). Plays a role in female pregnancy by promoting trophoblast invasion and spiral artery remodeling in uterus, and thus prevents pregnancy-induced hypertension (By similarity). In adipose tissue, acts in various cGMP- and PKG-dependent pathways to regulate lipid metabolism and energy homeostasis (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). This includes up-regulating lipid metabolism and mitochondrial oxygen utilization by activating the AMP-activated protein kinase (AMPK), and increasing energy expenditure by acting via MAPK11 to promote the UCP1-dependent thermogenesis of brown adipose tissue (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). Binds the clearance receptor NPR3 which removes the hormone from circulation (PubMed:1672777).",21098034,,,,,,,,21098034,
90,P01160,Natriuretic peptides A,124-151,SLRRSSCFGGRMDRIGAQSGLGCNSFRY,Atrial natriuretic peptide,5 14 30 31,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '45', '10', '11', '13', '19', '21', '25', '24', '2', '26', '38', '8', '17', '33', '41', '34', '18', '16'}","Hormone that plays a key role in mediating cardio-renal homeostasis, and is involved in vascular remodeling and regulating energy metabolism (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:8087923, PubMed:2532366, PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263, PubMed:16875975). Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins, such as PRKG1, that drive various biological responses (PubMed:25401746, PubMed:9893117, PubMed:1672777, PubMed:1660465, PubMed:2162527, PubMed:2825692, PubMed:7720651, PubMed:22307324, PubMed:8384600, PubMed:21098034). Regulates vasodilation, natriuresis, diuresis and aldosterone synthesis and is therefore essential for regulating blood pressure, controlling the extracellular fluid volume and maintaining the fluid-electrolyte balance (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:2532366, PubMed:8087923). Also involved in inhibiting cardiac remodeling and cardiac hypertrophy by inducing cardiomyocyte apoptosis and attenuating the growth of cardiomyocytes and fibroblasts (PubMed:16875975). Plays a role in female pregnancy by promoting trophoblast invasion and spiral artery remodeling in uterus, and thus prevents pregnancy-induced hypertension (By similarity). In adipose tissue, acts in various cGMP- and PKG-dependent pathways to regulate lipid metabolism and energy homeostasis (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). This includes up-regulating lipid metabolism and mitochondrial oxygen utilization by activating the AMP-activated protein kinase (AMPK), and increasing energy expenditure by acting via MAPK11 to promote the UCP1-dependent thermogenesis of brown adipose tissue (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). Binds the clearance receptor NPR3 which removes the hormone from circulation (PubMed:1672777).",2532366,,18,Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans.,"Vesely, D. et al.",2532366,10.3181/00379727-192-42990,,2532366,"The role of peptides from the N terminus and C terminus of the 126 amino acid atrial natriuretic factor (ANF) prohormone in modulating renal sodium and water handling has not been defined. Since water immersion to the neck (NI) provides an acute central volume expansion identical to that produced by 2 liters of saline but without plasma compositional change, immersion to the neck was used to assess the N-terminal and C-terminal portions of the ANF prohormone response to acute central blood volume expansion in seven seated sodium-replete normal subjects. Both the C terminus, which contains amino acids 99-126 and is identical to ANF, and the whole N terminus (i.e., amino acids 1-98) increased promptly with NI and peaked after 1 hr of immersion. A Mr 3900 peptide from the midportion of the N terminus consistent with amino acids 31-67 (i.e., pro-ANF-31-67) also increased with NI and followed a pattern of increasing circulating concentration nearly identical to that of the whole N terminus of the prohormone, except that its maximal concentration was at the second hour of the 3 hr of NI. With cessation of immersion, ANF decreased to preimmersion levels within 1 hr whereas the N terminus and pro-ANF-31-67, although their circulating concentrations were decreasing, were still significantly elevated at 1 hr. These findings suggest that the increase in plasma ANF, the N terminus of the ANF prohormone, and pro-ANF-31-67 from the midportion of the N terminus, with natriuretic properties similar to ANF, contribute to the natriuretic response to NI, implying a physiologic role for these atrial peptides in modulating volume homeostasis in humans."
91,P01160,Natriuretic peptides A,124-151,SLRRSSCFGGRMDRIGAQSGLGCNSFRY,Atrial natriuretic peptide,5 14 30 31,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '45', '10', '11', '13', '19', '21', '25', '24', '2', '26', '38', '8', '17', '33', '41', '34', '18', '16'}","Hormone that plays a key role in mediating cardio-renal homeostasis, and is involved in vascular remodeling and regulating energy metabolism (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:8087923, PubMed:2532366, PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263, PubMed:16875975). Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins, such as PRKG1, that drive various biological responses (PubMed:25401746, PubMed:9893117, PubMed:1672777, PubMed:1660465, PubMed:2162527, PubMed:2825692, PubMed:7720651, PubMed:22307324, PubMed:8384600, PubMed:21098034). Regulates vasodilation, natriuresis, diuresis and aldosterone synthesis and is therefore essential for regulating blood pressure, controlling the extracellular fluid volume and maintaining the fluid-electrolyte balance (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:2532366, PubMed:8087923). Also involved in inhibiting cardiac remodeling and cardiac hypertrophy by inducing cardiomyocyte apoptosis and attenuating the growth of cardiomyocytes and fibroblasts (PubMed:16875975). Plays a role in female pregnancy by promoting trophoblast invasion and spiral artery remodeling in uterus, and thus prevents pregnancy-induced hypertension (By similarity). In adipose tissue, acts in various cGMP- and PKG-dependent pathways to regulate lipid metabolism and energy homeostasis (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). This includes up-regulating lipid metabolism and mitochondrial oxygen utilization by activating the AMP-activated protein kinase (AMPK), and increasing energy expenditure by acting via MAPK11 to promote the UCP1-dependent thermogenesis of brown adipose tissue (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). Binds the clearance receptor NPR3 which removes the hormone from circulation (PubMed:1672777).",8087923,,25,"Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans.","Vesely, D. et al.",8087923,10.1161/01.cir.90.3.1129,,8087923,"Three peptides consisting of amino acids 1-30, 31-67, and 79-98 of the 126-amino acid atrial natriuretic factor prohormone (proANF), which have blood pressure-lowering, diuretic, natriuretic, and/or kaliuretic properties in animals, were investigated to determine if they have similar properties in humans."
92,P01160,Natriuretic peptides A,124-151,SLRRSSCFGGRMDRIGAQSGLGCNSFRY,Atrial natriuretic peptide,5 14 30 31,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '45', '10', '11', '13', '19', '21', '25', '24', '2', '26', '38', '8', '17', '33', '41', '34', '18', '16'}","Hormone that plays a key role in mediating cardio-renal homeostasis, and is involved in vascular remodeling and regulating energy metabolism (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:8087923, PubMed:2532366, PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263, PubMed:16875975). Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins, such as PRKG1, that drive various biological responses (PubMed:25401746, PubMed:9893117, PubMed:1672777, PubMed:1660465, PubMed:2162527, PubMed:2825692, PubMed:7720651, PubMed:22307324, PubMed:8384600, PubMed:21098034). Regulates vasodilation, natriuresis, diuresis and aldosterone synthesis and is therefore essential for regulating blood pressure, controlling the extracellular fluid volume and maintaining the fluid-electrolyte balance (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:2532366, PubMed:8087923). Also involved in inhibiting cardiac remodeling and cardiac hypertrophy by inducing cardiomyocyte apoptosis and attenuating the growth of cardiomyocytes and fibroblasts (PubMed:16875975). Plays a role in female pregnancy by promoting trophoblast invasion and spiral artery remodeling in uterus, and thus prevents pregnancy-induced hypertension (By similarity). In adipose tissue, acts in various cGMP- and PKG-dependent pathways to regulate lipid metabolism and energy homeostasis (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). This includes up-regulating lipid metabolism and mitochondrial oxygen utilization by activating the AMP-activated protein kinase (AMPK), and increasing energy expenditure by acting via MAPK11 to promote the UCP1-dependent thermogenesis of brown adipose tissue (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). Binds the clearance receptor NPR3 which removes the hormone from circulation (PubMed:1672777).",2825692,,16,"Atrial natriuretic prohormone peptides 1-30, 31-67, and 79-98 vasodilate the aorta.","Vesely, D. et al.",2825692,10.1016/s0006-291x(87)80307-8,,2825692,"Human prohormone atrial natriuretic peptides 1-30, 31-67, and 79-98 caused vasodilation of porcine aortas which began in 30 seconds and was maximal at 10 minutes. These three peptides were found to be equally potent to atrial natriuretic factor in their vasodilatory activity which was found with or without endothelium present. This vasodilation was associated with a 4 to 5 fold increase in cyclic GMP in the aorta secondary to activation of particulate guanylate cyclase [E.C. 4.6.12]. These data demonstrate that three N-terminal peptide segments of the atrial natriuretic factor prohormone cause vasodilation."
93,P01160,Natriuretic peptides A,124-151,SLRRSSCFGGRMDRIGAQSGLGCNSFRY,Atrial natriuretic peptide,5 14 30 31,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '45', '10', '11', '13', '19', '21', '25', '24', '2', '26', '38', '8', '17', '33', '41', '34', '18', '16'}","Hormone that plays a key role in mediating cardio-renal homeostasis, and is involved in vascular remodeling and regulating energy metabolism (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:8087923, PubMed:2532366, PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263, PubMed:16875975). Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins, such as PRKG1, that drive various biological responses (PubMed:25401746, PubMed:9893117, PubMed:1672777, PubMed:1660465, PubMed:2162527, PubMed:2825692, PubMed:7720651, PubMed:22307324, PubMed:8384600, PubMed:21098034). Regulates vasodilation, natriuresis, diuresis and aldosterone synthesis and is therefore essential for regulating blood pressure, controlling the extracellular fluid volume and maintaining the fluid-electrolyte balance (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:2532366, PubMed:8087923). Also involved in inhibiting cardiac remodeling and cardiac hypertrophy by inducing cardiomyocyte apoptosis and attenuating the growth of cardiomyocytes and fibroblasts (PubMed:16875975). Plays a role in female pregnancy by promoting trophoblast invasion and spiral artery remodeling in uterus, and thus prevents pregnancy-induced hypertension (By similarity). In adipose tissue, acts in various cGMP- and PKG-dependent pathways to regulate lipid metabolism and energy homeostasis (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). This includes up-regulating lipid metabolism and mitochondrial oxygen utilization by activating the AMP-activated protein kinase (AMPK), and increasing energy expenditure by acting via MAPK11 to promote the UCP1-dependent thermogenesis of brown adipose tissue (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). Binds the clearance receptor NPR3 which removes the hormone from circulation (PubMed:1672777).",15741263,,39,Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans.,"Birkenfeld, A. et al.",15741263,10.1210/jc.2004-1953,,15741263,Atrial natriuretic peptide (ANP) in pharmacological concentrations stimulates lipid mobilization in humans.
94,P01160,Natriuretic peptides A,124-151,SLRRSSCFGGRMDRIGAQSGLGCNSFRY,Atrial natriuretic peptide,5 14 30 31,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '45', '10', '11', '13', '19', '21', '25', '24', '2', '26', '38', '8', '17', '33', '41', '34', '18', '16'}","Hormone that plays a key role in mediating cardio-renal homeostasis, and is involved in vascular remodeling and regulating energy metabolism (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:8087923, PubMed:2532366, PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263, PubMed:16875975). Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins, such as PRKG1, that drive various biological responses (PubMed:25401746, PubMed:9893117, PubMed:1672777, PubMed:1660465, PubMed:2162527, PubMed:2825692, PubMed:7720651, PubMed:22307324, PubMed:8384600, PubMed:21098034). Regulates vasodilation, natriuresis, diuresis and aldosterone synthesis and is therefore essential for regulating blood pressure, controlling the extracellular fluid volume and maintaining the fluid-electrolyte balance (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:2532366, PubMed:8087923). Also involved in inhibiting cardiac remodeling and cardiac hypertrophy by inducing cardiomyocyte apoptosis and attenuating the growth of cardiomyocytes and fibroblasts (PubMed:16875975). Plays a role in female pregnancy by promoting trophoblast invasion and spiral artery remodeling in uterus, and thus prevents pregnancy-induced hypertension (By similarity). In adipose tissue, acts in various cGMP- and PKG-dependent pathways to regulate lipid metabolism and energy homeostasis (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). This includes up-regulating lipid metabolism and mitochondrial oxygen utilization by activating the AMP-activated protein kinase (AMPK), and increasing energy expenditure by acting via MAPK11 to promote the UCP1-dependent thermogenesis of brown adipose tissue (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). Binds the clearance receptor NPR3 which removes the hormone from circulation (PubMed:1672777).",25401746,,46,The C2238/alphaANP variant is a negative modulator of both viability and function of coronary artery smooth muscle cells.,"Rubattu, S. et al.",25401746,10.1371/journal.pone.0113108,,25401746,Abnormalities of vascular smooth muscle cells (VSMCs) contribute to development of vascular disease. Atrial natriuretic peptide (ANP) exerts important effects on VSMCs. A common ANP molecular variant (T2238C/ANP) has recently emerged as a novel vascular risk factor.
95,P01160,Natriuretic peptides A,124-151,SLRRSSCFGGRMDRIGAQSGLGCNSFRY,Atrial natriuretic peptide,5 14 30 31,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '45', '10', '11', '13', '19', '21', '25', '24', '2', '26', '38', '8', '17', '33', '41', '34', '18', '16'}","Hormone that plays a key role in mediating cardio-renal homeostasis, and is involved in vascular remodeling and regulating energy metabolism (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:8087923, PubMed:2532366, PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263, PubMed:16875975). Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins, such as PRKG1, that drive various biological responses (PubMed:25401746, PubMed:9893117, PubMed:1672777, PubMed:1660465, PubMed:2162527, PubMed:2825692, PubMed:7720651, PubMed:22307324, PubMed:8384600, PubMed:21098034). Regulates vasodilation, natriuresis, diuresis and aldosterone synthesis and is therefore essential for regulating blood pressure, controlling the extracellular fluid volume and maintaining the fluid-electrolyte balance (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:2532366, PubMed:8087923). Also involved in inhibiting cardiac remodeling and cardiac hypertrophy by inducing cardiomyocyte apoptosis and attenuating the growth of cardiomyocytes and fibroblasts (PubMed:16875975). Plays a role in female pregnancy by promoting trophoblast invasion and spiral artery remodeling in uterus, and thus prevents pregnancy-induced hypertension (By similarity). In adipose tissue, acts in various cGMP- and PKG-dependent pathways to regulate lipid metabolism and energy homeostasis (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). This includes up-regulating lipid metabolism and mitochondrial oxygen utilization by activating the AMP-activated protein kinase (AMPK), and increasing energy expenditure by acting via MAPK11 to promote the UCP1-dependent thermogenesis of brown adipose tissue (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). Binds the clearance receptor NPR3 which removes the hormone from circulation (PubMed:1672777).",1826098,,15,Hydrolysis of intact and Cys-Phe-cleaved human atrial natriuretic peptide in vitro by human tissue kallikrein.,"Vanneste, Y. et al.",1826098,10.1111/j.1432-1033.1991.tb15815.x,124-151,1826098,"Atrial natriuretic peptide (ANP) is a 28-amino-acid hormone involved in the regulation of fluid balance. In circulation, the proteolytic inactivation of ANP has been demonstrated to involve both membrane metalloendopeptidase and an aprotonin-sensitive activity, probably corresponding to kallikrein [Vanneste, Y., Pauwels, S., Lambotte, L., Michel, A., Dimaline, R. & Deschodt-Lanckman, M. (1990) Biochem. J. 269, 801-806]. In the present study, we focused on the aprotinin-sensitive pathway of ANP metabolism. In order to identify the cleavage sites recognized by kallikrein within the sequence of the hormone, tissue kallikrein was purified to homogeneity from human urine and the degradation of human ANP by the enzyme preparation was studied. Our results demonstrate that both intact and Cys7-Phe8-cleaved ANP, the initial metabolite produced in circulation by the metallo-endopeptidase, are substrates in vitro for purified tissue kallikrein. However, the Cys-Phe-cleaved peptide was degraded approximately fourfold faster than the intact hormone by the purified enzyme. The first degradation step of ANP by tissue kallikrein involves two cleavages occurring at the bonds Arg3-Arg4 and Gly16-Ala17, generating an inactive, open-ring metabolite. Incubation of ANP for a longer period with the enzyme led to the generation of several additional degradation fragments. Ten peaks were separated by HPLC and characterized by amino acid analysis. The results allowed the identification of a total of eight peptide bonds susceptible to hydrolysis by tissue kallikrein in the sequence of ANP: Arg3-Arg4, Ser5-Ser6, Cys7-Phe8, Arg11-Met12, Gly16-Ala17, Gly20-Leu21, Ser25-Phe26 and Arg27-Tyr28. These results indicate that the aprotinin-sensitive activity involved in the metabolism of ANP in circulation could correspond to tissue kallikrein. However, clear identification of ANP as a novel physiological substrate of the enzyme will need further investigation."
96,P01160,Natriuretic peptides A,124-151,SLRRSSCFGGRMDRIGAQSGLGCNSFRY,Atrial natriuretic peptide,5 14 30 31,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}","{'40', '45', '10', '11', '13', '19', '21', '25', '24', '2', '26', '38', '8', '17', '33', '41', '34', '18', '16'}","Hormone that plays a key role in mediating cardio-renal homeostasis, and is involved in vascular remodeling and regulating energy metabolism (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:8087923, PubMed:2532366, PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263, PubMed:16875975). Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins, such as PRKG1, that drive various biological responses (PubMed:25401746, PubMed:9893117, PubMed:1672777, PubMed:1660465, PubMed:2162527, PubMed:2825692, PubMed:7720651, PubMed:22307324, PubMed:8384600, PubMed:21098034). Regulates vasodilation, natriuresis, diuresis and aldosterone synthesis and is therefore essential for regulating blood pressure, controlling the extracellular fluid volume and maintaining the fluid-electrolyte balance (PubMed:8653797, PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:2532366, PubMed:8087923). Also involved in inhibiting cardiac remodeling and cardiac hypertrophy by inducing cardiomyocyte apoptosis and attenuating the growth of cardiomyocytes and fibroblasts (PubMed:16875975). Plays a role in female pregnancy by promoting trophoblast invasion and spiral artery remodeling in uterus, and thus prevents pregnancy-induced hypertension (By similarity). In adipose tissue, acts in various cGMP- and PKG-dependent pathways to regulate lipid metabolism and energy homeostasis (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). This includes up-regulating lipid metabolism and mitochondrial oxygen utilization by activating the AMP-activated protein kinase (AMPK), and increasing energy expenditure by acting via MAPK11 to promote the UCP1-dependent thermogenesis of brown adipose tissue (PubMed:22307324, PubMed:18835931, PubMed:21672517, PubMed:15741263). Binds the clearance receptor NPR3 which removes the hormone from circulation (PubMed:1672777).",10880574,,37,"Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme.","Yan, W. et al.",10880574,10.1073/pnas.150149097,,10880574,"Atrial natriuretic peptide (ANP) is a cardiac hormone essential for the regulation of blood pressure. In cardiac myocytes, ANP is synthesized as a precursor, pro-ANP, that is converted to biologically active ANP by an unknown membrane-associated protease. Recently, we cloned a transmembrane serine protease, corin, that is highly expressed in the heart. In this study, we examine effects of corin on pro-ANP processing. Our results show that recombinant human corin converts pro-ANP to ANP and that the cleavage in pro-ANP by corin is highly sequence specific. Our findings suggest that corin is the long-sought pro-ANP-converting enzyme and that the corin-mediated pro-ANP activation may play a role in regulating blood pressure."
97,P01160,Natriuretic peptides A,127-151,RSSCFGGRMDRIGAQSGLGCNSFRY,Auriculin-B,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",7595132,,31,Kaliuretic peptide and long acting natriuretic peptide as well as atrial natriuretic factor inhibit aldosterone secretion.,"Vesely, D. et al.",7595132,10.1677/joe.0.1460373,,7595132,"The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1-30 (long acting natriuretic peptide), 31-67 (vessel dilator) and 79-98 (kaliuretic peptide) as well as 99-126 (atrial natriuretic factor (ANF)) of the 126 amino acid ANF prohormone inhibit aldosterone secretion. Thirty healthy human subjects were studied following infusion of 100 ng/kg body weight/min for 60 min of each of the respective peptides. Kaliuretic peptide decreased plasma aldosterone concentration by the greatest amount (6-fold) and plasma aldosterone was still significantly decreased (P < 0.001) three hours after stopping the infusion. In contrast, within 30 min of cessation of the ANF infusion, plasma aldosterone levels had returned to pre-infusion values. Long acting natriuretic peptide also significantly (P < 0.01) decreased plasma aldosterone levels which remained significantly (P < 0.001) decreased 3 h after cessation of infusion. Vessel dilator did not decrease plasma aldosterone levels. Kaliuretic peptide, ANF and long acting natriuretic peptide also decreased (P < 0.01) urinary aldosterone concentrations. None of these peptides changed the plasma potassium concentration. We conclude that two new peptide hormones (long acting natriuretic peptide and kaliuretic peptide) inhibit aldosterone secretion. The length of time that aldosterone secretion is inhibited following kaliuretic peptide and long acting natriuretic peptide infusion is significantly longer (P < 0.001) than following ANF infusion."
98,P01160,Natriuretic peptides A,127-151,RSSCFGGRMDRIGAQSGLGCNSFRY,Auriculin-B,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",7720651,,30,Kaliuretic peptide: the most potent inhibitor of Na(+)-K+ ATPase of the atrial natriuretic peptides.,"Chiou, S. et al.",7720651,10.1210/endo.136.5.7720651,,7720651,"The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1-30 (i.e. long-acting natriuretic peptide), 31-67 (vessel dilator), 79-98 (kaliuretic peptide), and 99-126 [atrial natriuretic factor (ANF)] of the 126 amino acid ANF prohormone inhibit sodium-potassium-ATPase as part of their mechanism(s) of action for producing a natriuresis and/or kaliuresis. Kaliuretic peptide, long-acting natriuretic peptide, vessel dilator and ANF at their 10(-11) M concentrations inhibited Na(+)-K(+)-ATPase 39.5%, 27.8%, 19.2%, and 4% respectively, in bovine renal medulla, whereas their inhibition in renal cortical membranes was 37.5%, 27.5%, 20%, and 0%, respectively. Ouabain (0.5 mM) inhibited kidney medullary Na(+)-K(+)-ATPase 45% and in the cortex, 38%. There was no additive effect of any of these peptides with ouabain suggesting that they are interacting with the same site on the Na(+)-K(+)-ATPase as ouabain. To help elucidate the mechanism of these peptides' interaction with Na(+)-K(+)-ATPase, naproxen (0.5 mM), an inhibitor of prostaglandin synthesis, and direct measurement of prostaglandin E2 by RIA were used. Naproxen completely blocked the inhibition of Na(+)-K(+)-ATPase by kaliuretic peptide, long-acting natriuretic peptide, and vessel dilator suggesting that their inhibition of Na(+)-K(+)-ATPase in both the kidney medulla and cortex are mediated by prostaglandins. Direct measurement of prostaglandin E2 revealed that kaliuretic peptide > long-acting natriuretic peptide > vessel dilator increased prostaglandin E2 synthesis, whereas ANF did not have any effect. Of interest, angiotensin II and ouabain inhibition of Na(+)-K(+)-ATPase were also completely blocked by naproxen."
99,P01160,Natriuretic peptides A,127-151,RSSCFGGRMDRIGAQSGLGCNSFRY,Auriculin-B,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",7955907,,26,"N-terminal atrial natriuretic peptide and atrial natriuretic peptide in human plasma: investigation of plasma levels and molecular circulating form(s) using radioimmunoassays for pro-atrial natriuretic peptide (31-67), pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide (99-126).","Buckley, M. et al.",7955907,10.1042/cs0870311,,7955907,"1. The aim of this study was to determine plasma levels of N-terminal atrial natriuretic peptide and atrial natriuretic peptide in normal subjects and in patients with essential hypertension, cardiac transplant and chronic renal failure, using radioimmunoassays directed towards the mid-portion pro-atrial natriuretic peptide (31-67) and pro-atrial natriuretic peptide (1-30) of the N-terminal atrial natriuretic peptide and atrial natriuretic peptide (99-126). The circulating form(s) of the immunoreactive N-terminal atrial natriuretic peptide in plasma extracts has been investigated using all three radioimmunoassays by means of gel filtration chromatography to further clarify the major immunoreactive molecular circulating form(s) of N-terminal atrial natriuretic peptide in man. 2. The plasma level (mean +/- SEM) of N-terminal pro-atrial natriuretic peptide (31-67) in the normal subjects was 547.2 +/- 32.7 pg/ml (n = 36) and was significantly elevated in patients with essential hypertension (730.2 +/- 72.3 pg/ml, P < 0.025, n = 39), in cardiac transplant recipients (3214.0 +/- 432.2 pg/ml, P < 0.001, n = 9) and in patients with chronic renal failure (3571.8 +/- 474.1 pg/ml, P < 0.001, n = 11). Plasma levels of N-terminal pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide were similarly elevated in the same patient groups when compared with the mean plasma values in the normal subjects.(ABSTRACT TRUNCATED AT 250 WORDS)"
100,P01160,Natriuretic peptides A,127-151,RSSCFGGRMDRIGAQSGLGCNSFRY,Auriculin-B,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",11145122,,36,"Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance the urinary excretion rate of beta2-microglobulin.","Vesely, D. et al.",11145122,10.1053/meta.2000.18557,,11145122,"The atrial natriuretic peptide (ANP) gene synthesizes a 126-amino acid (aa) prohormone from which four peptide hormones are derived. These 4 peptide hormones consisting of aa 1 to 30 (ie, long-acting natriuretic peptide [LANP]), aa 31 to 67 (vessel dilator), aa 79 to 98 (kaliuretic peptide), and aa 99 to 126 (ie, ANP) have diuretic, natriuretic, and/or kaliuretic properties. ANP has been reported to have its natriuretic and protein-excreting effects via both the proximal and distal tubules, but where in the kidney the other three peptide hormones have their natriuretic and/or diuretic effects is unknown. Further, it has never been investigated as to whether these three other peptide hormones enhance protein excretion. The present investigation was designed to determine (1) if these atrial peptides enhance protein excretion and (2) if their effects involve the proximal tubules of healthy humans by examining the excretion rate of beta2-microglobulin, a marker of proximal tubule function. Twenty-four healthy human subjects were studied following the infusion of 100 ng/kg body weight/min for 60 minutes of each of the respective peptides. LANP enhanced the excretion rate of beta2-microglobulin 2-fold within 20 minutes of beginning its infusion (P < .05) and was 2.5-fold higher than the preinfusion excretion rate at the end of the infusion. The excretion rate of beta2-microglobulin continued to be significantly (P < .01) increased for 3 hours after cessation of the LANP infusion, with the maximal excretion rate (ie, 3.8-fold increase) at 2.5 hours after stopping the infusion. Vessel dilator showed a more marked enhancement of beta2-microglobulin during its infusion, with the excretion rate increasing 2.5-fold at 20 minutes, and was increased 4-fold (P < .01) at the end of the infusion. With cessation of the vessel dilator infusion, the excretion rate of beta2-microglobulin decreased but was still elevated 2-fold (P < .05) 3 hours after stopping the infusion. Kaliuretic peptide enhanced the beta2-microglobulin excretion rate a maximal 3-fold, which occurred at the end of its infusion. The beta2-microglobulin excretion secondary to kaliuretic peptide remained 2-fold (P < .05) above baseline during the 3-hour postinfusion period. These peptide hormones similarly enhanced the albumin and total protein excretion rates 2- to 4-fold. These results indicate that LANP, vessel dilator, and kaliuretic peptide each (1) enhance protein excretion in healthy humans and (2) inhibit proximal tubular protein reabsorption."
101,P01160,Natriuretic peptides A,127-151,RSSCFGGRMDRIGAQSGLGCNSFRY,Auriculin-B,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",2532366,,18,Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans.,"Vesely, D. et al.",2532366,10.3181/00379727-192-42990,,2532366,"The role of peptides from the N terminus and C terminus of the 126 amino acid atrial natriuretic factor (ANF) prohormone in modulating renal sodium and water handling has not been defined. Since water immersion to the neck (NI) provides an acute central volume expansion identical to that produced by 2 liters of saline but without plasma compositional change, immersion to the neck was used to assess the N-terminal and C-terminal portions of the ANF prohormone response to acute central blood volume expansion in seven seated sodium-replete normal subjects. Both the C terminus, which contains amino acids 99-126 and is identical to ANF, and the whole N terminus (i.e., amino acids 1-98) increased promptly with NI and peaked after 1 hr of immersion. A Mr 3900 peptide from the midportion of the N terminus consistent with amino acids 31-67 (i.e., pro-ANF-31-67) also increased with NI and followed a pattern of increasing circulating concentration nearly identical to that of the whole N terminus of the prohormone, except that its maximal concentration was at the second hour of the 3 hr of NI. With cessation of immersion, ANF decreased to preimmersion levels within 1 hr whereas the N terminus and pro-ANF-31-67, although their circulating concentrations were decreasing, were still significantly elevated at 1 hr. These findings suggest that the increase in plasma ANF, the N terminus of the ANF prohormone, and pro-ANF-31-67 from the midportion of the N terminus, with natriuretic properties similar to ANF, contribute to the natriuretic response to NI, implying a physiologic role for these atrial peptides in modulating volume homeostasis in humans."
102,P01160,Natriuretic peptides A,127-151,RSSCFGGRMDRIGAQSGLGCNSFRY,Auriculin-B,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",8087923,,25,"Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans.","Vesely, D. et al.",8087923,10.1161/01.cir.90.3.1129,,8087923,"Three peptides consisting of amino acids 1-30, 31-67, and 79-98 of the 126-amino acid atrial natriuretic factor prohormone (proANF), which have blood pressure-lowering, diuretic, natriuretic, and/or kaliuretic properties in animals, were investigated to determine if they have similar properties in humans."
103,P01160,Natriuretic peptides A,127-151,RSSCFGGRMDRIGAQSGLGCNSFRY,Auriculin-B,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",2825692,,16,"Atrial natriuretic prohormone peptides 1-30, 31-67, and 79-98 vasodilate the aorta.","Vesely, D. et al.",2825692,10.1016/s0006-291x(87)80307-8,,2825692,"Human prohormone atrial natriuretic peptides 1-30, 31-67, and 79-98 caused vasodilation of porcine aortas which began in 30 seconds and was maximal at 10 minutes. These three peptides were found to be equally potent to atrial natriuretic factor in their vasodilatory activity which was found with or without endothelium present. This vasodilation was associated with a 4 to 5 fold increase in cyclic GMP in the aorta secondary to activation of particulate guanylate cyclase [E.C. 4.6.12]. These data demonstrate that three N-terminal peptide segments of the atrial natriuretic factor prohormone cause vasodilation."
104,P01160,Natriuretic peptides A,127-151,RSSCFGGRMDRIGAQSGLGCNSFRY,Auriculin-B,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",2162527,,20,"Specific binding sites for prohormone atrial natriuretic peptides 1-30, 31-67 and 99-126.","Vesely, D. et al.",2162527,10.1016/0196-9781(90)90070-l,,2162527,"Two peptides with vasodilatory properties consisting of amino acids 1-30 and 31-67 of the 98 a.a. N-terminal end of the prohormone of atrial natriuretic factor (proANF) which circulates in man were investigated to determine if they have specific binding sites on membranes isolated from DDT1 MF-2 smooth muscle cells. Smooth muscle is a known biologic target of these peptides. Competitive binding experiments revealed that proANFs (1-30), (31-67), and (99-126) (i.e., C-terminus; ANF) each had specific and separate binding sites. The dissociation constants for proANFs (1-30), (31-67), and (99-126) binding were 0.11 nM, 4 nM, and 7.3 nM, respectively. The binding site concentrations for proANFs (1-30), (31-67), and ANF were 2.57, 59.91 and 40 fmols/10(6) cells, respectively. The number of binding sites per cell were 1548, 36,087, and 24,090, respectively, for proANFs (1-30), (31-67), and (99-126) (ANF). Each peptide bound to DDT1 MF-2 membranes between 10(-8) to 10(-11) M but could only bind to the other peptides' receptors at concentrations of 10(-6) and 10(-7)M. These results suggest that proANF(1-30) and proANF(31-67) do not work through the ANF receptor but rather have their own separate and distinct receptors that mediate their biologic effects."
105,P01160,Natriuretic peptides A,127-151,RSSCFGGRMDRIGAQSGLGCNSFRY,Auriculin-B,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",8653797,,29,Temporal (circadian) and functional relationship between atrial natriuretic peptides and blood pressure.,"Sothern, R. et al.",8653797,10.3109/07420529509064506,,8653797,"Long-acting natriuretic peptide, vessel dilator, and atrial natriuretic factor consisting of amino acids (a.a.) 1 to 30, 31 to 67, and 99 to 126 of the 126-a.a. atrial natriuretic factor (ANF) prohormone, respectively, circulate in humans and have potent vasodilatory properties. To determine if these atrial natriuretic peptides are directly related to blood pressure in clinically healthy normotensive humans, we obtained 24-h profiles of vessel dilator, long-acting natriuretic peptide, ANF, and blood pressure in 10 men in 1988 and 11 men in 1993 (seven men were studied twice) to compare circulating concentrations of atrial natriuretic peptides with naturally occurring changes in blood pressure. Overall, vessel dilator, long-acting natriuretic peptide, and ANF each had significant (p<0.001) circadian rhythms, with peak concentrations late during sleep (at 04:00 h) being nearly twice their concentrations in the afternoon and evening. This high-amplitude circadian change allowed for the refinement of normal limits for ANF peptides by computing 3-hourly tolerance intervals (chronodesms) against which to compare time-specified single samples for normality. Systolic, diastolic, and mean arterial blood pressure also had significant circadian rhythms (p<0.001) with peaks and troughs that were exactly opposite those of the ANF peptides. In addition to this inverse temporal relationship, there was a significant inverse correlation between absolute values for blood pressure and each ANF peptide (p<0.001), implying a functional relationship. These data suggest that in addition to other well-established neurochemical factors, the ANF peptides (vessel dilator, long-acting natriuretic peptide, and ANF) are important for the maintenance of blood pressure and modulation of its circadian rhythm."
106,P01160,Natriuretic peptides A,127-150,RSSCFGGRMDRIGAQSGLGCNSFR,Auriculin-A,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",7595132,,31,Kaliuretic peptide and long acting natriuretic peptide as well as atrial natriuretic factor inhibit aldosterone secretion.,"Vesely, D. et al.",7595132,10.1677/joe.0.1460373,,7595132,"The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1-30 (long acting natriuretic peptide), 31-67 (vessel dilator) and 79-98 (kaliuretic peptide) as well as 99-126 (atrial natriuretic factor (ANF)) of the 126 amino acid ANF prohormone inhibit aldosterone secretion. Thirty healthy human subjects were studied following infusion of 100 ng/kg body weight/min for 60 min of each of the respective peptides. Kaliuretic peptide decreased plasma aldosterone concentration by the greatest amount (6-fold) and plasma aldosterone was still significantly decreased (P < 0.001) three hours after stopping the infusion. In contrast, within 30 min of cessation of the ANF infusion, plasma aldosterone levels had returned to pre-infusion values. Long acting natriuretic peptide also significantly (P < 0.01) decreased plasma aldosterone levels which remained significantly (P < 0.001) decreased 3 h after cessation of infusion. Vessel dilator did not decrease plasma aldosterone levels. Kaliuretic peptide, ANF and long acting natriuretic peptide also decreased (P < 0.01) urinary aldosterone concentrations. None of these peptides changed the plasma potassium concentration. We conclude that two new peptide hormones (long acting natriuretic peptide and kaliuretic peptide) inhibit aldosterone secretion. The length of time that aldosterone secretion is inhibited following kaliuretic peptide and long acting natriuretic peptide infusion is significantly longer (P < 0.001) than following ANF infusion."
107,P01160,Natriuretic peptides A,127-150,RSSCFGGRMDRIGAQSGLGCNSFR,Auriculin-A,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",7720651,,30,Kaliuretic peptide: the most potent inhibitor of Na(+)-K+ ATPase of the atrial natriuretic peptides.,"Chiou, S. et al.",7720651,10.1210/endo.136.5.7720651,,7720651,"The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1-30 (i.e. long-acting natriuretic peptide), 31-67 (vessel dilator), 79-98 (kaliuretic peptide), and 99-126 [atrial natriuretic factor (ANF)] of the 126 amino acid ANF prohormone inhibit sodium-potassium-ATPase as part of their mechanism(s) of action for producing a natriuresis and/or kaliuresis. Kaliuretic peptide, long-acting natriuretic peptide, vessel dilator and ANF at their 10(-11) M concentrations inhibited Na(+)-K(+)-ATPase 39.5%, 27.8%, 19.2%, and 4% respectively, in bovine renal medulla, whereas their inhibition in renal cortical membranes was 37.5%, 27.5%, 20%, and 0%, respectively. Ouabain (0.5 mM) inhibited kidney medullary Na(+)-K(+)-ATPase 45% and in the cortex, 38%. There was no additive effect of any of these peptides with ouabain suggesting that they are interacting with the same site on the Na(+)-K(+)-ATPase as ouabain. To help elucidate the mechanism of these peptides' interaction with Na(+)-K(+)-ATPase, naproxen (0.5 mM), an inhibitor of prostaglandin synthesis, and direct measurement of prostaglandin E2 by RIA were used. Naproxen completely blocked the inhibition of Na(+)-K(+)-ATPase by kaliuretic peptide, long-acting natriuretic peptide, and vessel dilator suggesting that their inhibition of Na(+)-K(+)-ATPase in both the kidney medulla and cortex are mediated by prostaglandins. Direct measurement of prostaglandin E2 revealed that kaliuretic peptide > long-acting natriuretic peptide > vessel dilator increased prostaglandin E2 synthesis, whereas ANF did not have any effect. Of interest, angiotensin II and ouabain inhibition of Na(+)-K(+)-ATPase were also completely blocked by naproxen."
108,P01160,Natriuretic peptides A,127-150,RSSCFGGRMDRIGAQSGLGCNSFR,Auriculin-A,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",7955907,,26,"N-terminal atrial natriuretic peptide and atrial natriuretic peptide in human plasma: investigation of plasma levels and molecular circulating form(s) using radioimmunoassays for pro-atrial natriuretic peptide (31-67), pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide (99-126).","Buckley, M. et al.",7955907,10.1042/cs0870311,,7955907,"1. The aim of this study was to determine plasma levels of N-terminal atrial natriuretic peptide and atrial natriuretic peptide in normal subjects and in patients with essential hypertension, cardiac transplant and chronic renal failure, using radioimmunoassays directed towards the mid-portion pro-atrial natriuretic peptide (31-67) and pro-atrial natriuretic peptide (1-30) of the N-terminal atrial natriuretic peptide and atrial natriuretic peptide (99-126). The circulating form(s) of the immunoreactive N-terminal atrial natriuretic peptide in plasma extracts has been investigated using all three radioimmunoassays by means of gel filtration chromatography to further clarify the major immunoreactive molecular circulating form(s) of N-terminal atrial natriuretic peptide in man. 2. The plasma level (mean +/- SEM) of N-terminal pro-atrial natriuretic peptide (31-67) in the normal subjects was 547.2 +/- 32.7 pg/ml (n = 36) and was significantly elevated in patients with essential hypertension (730.2 +/- 72.3 pg/ml, P < 0.025, n = 39), in cardiac transplant recipients (3214.0 +/- 432.2 pg/ml, P < 0.001, n = 9) and in patients with chronic renal failure (3571.8 +/- 474.1 pg/ml, P < 0.001, n = 11). Plasma levels of N-terminal pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide were similarly elevated in the same patient groups when compared with the mean plasma values in the normal subjects.(ABSTRACT TRUNCATED AT 250 WORDS)"
109,P01160,Natriuretic peptides A,127-150,RSSCFGGRMDRIGAQSGLGCNSFR,Auriculin-A,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",11145122,,36,"Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance the urinary excretion rate of beta2-microglobulin.","Vesely, D. et al.",11145122,10.1053/meta.2000.18557,,11145122,"The atrial natriuretic peptide (ANP) gene synthesizes a 126-amino acid (aa) prohormone from which four peptide hormones are derived. These 4 peptide hormones consisting of aa 1 to 30 (ie, long-acting natriuretic peptide [LANP]), aa 31 to 67 (vessel dilator), aa 79 to 98 (kaliuretic peptide), and aa 99 to 126 (ie, ANP) have diuretic, natriuretic, and/or kaliuretic properties. ANP has been reported to have its natriuretic and protein-excreting effects via both the proximal and distal tubules, but where in the kidney the other three peptide hormones have their natriuretic and/or diuretic effects is unknown. Further, it has never been investigated as to whether these three other peptide hormones enhance protein excretion. The present investigation was designed to determine (1) if these atrial peptides enhance protein excretion and (2) if their effects involve the proximal tubules of healthy humans by examining the excretion rate of beta2-microglobulin, a marker of proximal tubule function. Twenty-four healthy human subjects were studied following the infusion of 100 ng/kg body weight/min for 60 minutes of each of the respective peptides. LANP enhanced the excretion rate of beta2-microglobulin 2-fold within 20 minutes of beginning its infusion (P < .05) and was 2.5-fold higher than the preinfusion excretion rate at the end of the infusion. The excretion rate of beta2-microglobulin continued to be significantly (P < .01) increased for 3 hours after cessation of the LANP infusion, with the maximal excretion rate (ie, 3.8-fold increase) at 2.5 hours after stopping the infusion. Vessel dilator showed a more marked enhancement of beta2-microglobulin during its infusion, with the excretion rate increasing 2.5-fold at 20 minutes, and was increased 4-fold (P < .01) at the end of the infusion. With cessation of the vessel dilator infusion, the excretion rate of beta2-microglobulin decreased but was still elevated 2-fold (P < .05) 3 hours after stopping the infusion. Kaliuretic peptide enhanced the beta2-microglobulin excretion rate a maximal 3-fold, which occurred at the end of its infusion. The beta2-microglobulin excretion secondary to kaliuretic peptide remained 2-fold (P < .05) above baseline during the 3-hour postinfusion period. These peptide hormones similarly enhanced the albumin and total protein excretion rates 2- to 4-fold. These results indicate that LANP, vessel dilator, and kaliuretic peptide each (1) enhance protein excretion in healthy humans and (2) inhibit proximal tubular protein reabsorption."
110,P01160,Natriuretic peptides A,127-150,RSSCFGGRMDRIGAQSGLGCNSFR,Auriculin-A,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",2532366,,18,Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans.,"Vesely, D. et al.",2532366,10.3181/00379727-192-42990,,2532366,"The role of peptides from the N terminus and C terminus of the 126 amino acid atrial natriuretic factor (ANF) prohormone in modulating renal sodium and water handling has not been defined. Since water immersion to the neck (NI) provides an acute central volume expansion identical to that produced by 2 liters of saline but without plasma compositional change, immersion to the neck was used to assess the N-terminal and C-terminal portions of the ANF prohormone response to acute central blood volume expansion in seven seated sodium-replete normal subjects. Both the C terminus, which contains amino acids 99-126 and is identical to ANF, and the whole N terminus (i.e., amino acids 1-98) increased promptly with NI and peaked after 1 hr of immersion. A Mr 3900 peptide from the midportion of the N terminus consistent with amino acids 31-67 (i.e., pro-ANF-31-67) also increased with NI and followed a pattern of increasing circulating concentration nearly identical to that of the whole N terminus of the prohormone, except that its maximal concentration was at the second hour of the 3 hr of NI. With cessation of immersion, ANF decreased to preimmersion levels within 1 hr whereas the N terminus and pro-ANF-31-67, although their circulating concentrations were decreasing, were still significantly elevated at 1 hr. These findings suggest that the increase in plasma ANF, the N terminus of the ANF prohormone, and pro-ANF-31-67 from the midportion of the N terminus, with natriuretic properties similar to ANF, contribute to the natriuretic response to NI, implying a physiologic role for these atrial peptides in modulating volume homeostasis in humans."
111,P01160,Natriuretic peptides A,127-150,RSSCFGGRMDRIGAQSGLGCNSFR,Auriculin-A,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",8087923,,25,"Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans.","Vesely, D. et al.",8087923,10.1161/01.cir.90.3.1129,,8087923,"Three peptides consisting of amino acids 1-30, 31-67, and 79-98 of the 126-amino acid atrial natriuretic factor prohormone (proANF), which have blood pressure-lowering, diuretic, natriuretic, and/or kaliuretic properties in animals, were investigated to determine if they have similar properties in humans."
112,P01160,Natriuretic peptides A,127-150,RSSCFGGRMDRIGAQSGLGCNSFR,Auriculin-A,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",2825692,,16,"Atrial natriuretic prohormone peptides 1-30, 31-67, and 79-98 vasodilate the aorta.","Vesely, D. et al.",2825692,10.1016/s0006-291x(87)80307-8,,2825692,"Human prohormone atrial natriuretic peptides 1-30, 31-67, and 79-98 caused vasodilation of porcine aortas which began in 30 seconds and was maximal at 10 minutes. These three peptides were found to be equally potent to atrial natriuretic factor in their vasodilatory activity which was found with or without endothelium present. This vasodilation was associated with a 4 to 5 fold increase in cyclic GMP in the aorta secondary to activation of particulate guanylate cyclase [E.C. 4.6.12]. These data demonstrate that three N-terminal peptide segments of the atrial natriuretic factor prohormone cause vasodilation."
113,P01160,Natriuretic peptides A,127-150,RSSCFGGRMDRIGAQSGLGCNSFR,Auriculin-A,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",2162527,,20,"Specific binding sites for prohormone atrial natriuretic peptides 1-30, 31-67 and 99-126.","Vesely, D. et al.",2162527,10.1016/0196-9781(90)90070-l,,2162527,"Two peptides with vasodilatory properties consisting of amino acids 1-30 and 31-67 of the 98 a.a. N-terminal end of the prohormone of atrial natriuretic factor (proANF) which circulates in man were investigated to determine if they have specific binding sites on membranes isolated from DDT1 MF-2 smooth muscle cells. Smooth muscle is a known biologic target of these peptides. Competitive binding experiments revealed that proANFs (1-30), (31-67), and (99-126) (i.e., C-terminus; ANF) each had specific and separate binding sites. The dissociation constants for proANFs (1-30), (31-67), and (99-126) binding were 0.11 nM, 4 nM, and 7.3 nM, respectively. The binding site concentrations for proANFs (1-30), (31-67), and ANF were 2.57, 59.91 and 40 fmols/10(6) cells, respectively. The number of binding sites per cell were 1548, 36,087, and 24,090, respectively, for proANFs (1-30), (31-67), and (99-126) (ANF). Each peptide bound to DDT1 MF-2 membranes between 10(-8) to 10(-11) M but could only bind to the other peptides' receptors at concentrations of 10(-6) and 10(-7)M. These results suggest that proANF(1-30) and proANF(31-67) do not work through the ANF receptor but rather have their own separate and distinct receptors that mediate their biologic effects."
114,P01160,Natriuretic peptides A,127-150,RSSCFGGRMDRIGAQSGLGCNSFR,Auriculin-A,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",8653797,,29,Temporal (circadian) and functional relationship between atrial natriuretic peptides and blood pressure.,"Sothern, R. et al.",8653797,10.3109/07420529509064506,,8653797,"Long-acting natriuretic peptide, vessel dilator, and atrial natriuretic factor consisting of amino acids (a.a.) 1 to 30, 31 to 67, and 99 to 126 of the 126-a.a. atrial natriuretic factor (ANF) prohormone, respectively, circulate in humans and have potent vasodilatory properties. To determine if these atrial natriuretic peptides are directly related to blood pressure in clinically healthy normotensive humans, we obtained 24-h profiles of vessel dilator, long-acting natriuretic peptide, ANF, and blood pressure in 10 men in 1988 and 11 men in 1993 (seven men were studied twice) to compare circulating concentrations of atrial natriuretic peptides with naturally occurring changes in blood pressure. Overall, vessel dilator, long-acting natriuretic peptide, and ANF each had significant (p<0.001) circadian rhythms, with peak concentrations late during sleep (at 04:00 h) being nearly twice their concentrations in the afternoon and evening. This high-amplitude circadian change allowed for the refinement of normal limits for ANF peptides by computing 3-hourly tolerance intervals (chronodesms) against which to compare time-specified single samples for normality. Systolic, diastolic, and mean arterial blood pressure also had significant circadian rhythms (p<0.001) with peaks and troughs that were exactly opposite those of the ANF peptides. In addition to this inverse temporal relationship, there was a significant inverse correlation between absolute values for blood pressure and each ANF peptide (p<0.001), implying a functional relationship. These data suggest that in addition to other well-established neurochemical factors, the ANF peptides (vessel dilator, long-acting natriuretic peptide, and ANF) are important for the maintenance of blood pressure and modulation of its circadian rhythm."
115,P01160,Natriuretic peptides A,128-151,SSCFGGRMDRIGAQSGLGCNSFRY,Atriopeptin-3,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",7595132,,31,Kaliuretic peptide and long acting natriuretic peptide as well as atrial natriuretic factor inhibit aldosterone secretion.,"Vesely, D. et al.",7595132,10.1677/joe.0.1460373,,7595132,"The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1-30 (long acting natriuretic peptide), 31-67 (vessel dilator) and 79-98 (kaliuretic peptide) as well as 99-126 (atrial natriuretic factor (ANF)) of the 126 amino acid ANF prohormone inhibit aldosterone secretion. Thirty healthy human subjects were studied following infusion of 100 ng/kg body weight/min for 60 min of each of the respective peptides. Kaliuretic peptide decreased plasma aldosterone concentration by the greatest amount (6-fold) and plasma aldosterone was still significantly decreased (P < 0.001) three hours after stopping the infusion. In contrast, within 30 min of cessation of the ANF infusion, plasma aldosterone levels had returned to pre-infusion values. Long acting natriuretic peptide also significantly (P < 0.01) decreased plasma aldosterone levels which remained significantly (P < 0.001) decreased 3 h after cessation of infusion. Vessel dilator did not decrease plasma aldosterone levels. Kaliuretic peptide, ANF and long acting natriuretic peptide also decreased (P < 0.01) urinary aldosterone concentrations. None of these peptides changed the plasma potassium concentration. We conclude that two new peptide hormones (long acting natriuretic peptide and kaliuretic peptide) inhibit aldosterone secretion. The length of time that aldosterone secretion is inhibited following kaliuretic peptide and long acting natriuretic peptide infusion is significantly longer (P < 0.001) than following ANF infusion."
116,P01160,Natriuretic peptides A,128-151,SSCFGGRMDRIGAQSGLGCNSFRY,Atriopeptin-3,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",7720651,,30,Kaliuretic peptide: the most potent inhibitor of Na(+)-K+ ATPase of the atrial natriuretic peptides.,"Chiou, S. et al.",7720651,10.1210/endo.136.5.7720651,,7720651,"The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1-30 (i.e. long-acting natriuretic peptide), 31-67 (vessel dilator), 79-98 (kaliuretic peptide), and 99-126 [atrial natriuretic factor (ANF)] of the 126 amino acid ANF prohormone inhibit sodium-potassium-ATPase as part of their mechanism(s) of action for producing a natriuresis and/or kaliuresis. Kaliuretic peptide, long-acting natriuretic peptide, vessel dilator and ANF at their 10(-11) M concentrations inhibited Na(+)-K(+)-ATPase 39.5%, 27.8%, 19.2%, and 4% respectively, in bovine renal medulla, whereas their inhibition in renal cortical membranes was 37.5%, 27.5%, 20%, and 0%, respectively. Ouabain (0.5 mM) inhibited kidney medullary Na(+)-K(+)-ATPase 45% and in the cortex, 38%. There was no additive effect of any of these peptides with ouabain suggesting that they are interacting with the same site on the Na(+)-K(+)-ATPase as ouabain. To help elucidate the mechanism of these peptides' interaction with Na(+)-K(+)-ATPase, naproxen (0.5 mM), an inhibitor of prostaglandin synthesis, and direct measurement of prostaglandin E2 by RIA were used. Naproxen completely blocked the inhibition of Na(+)-K(+)-ATPase by kaliuretic peptide, long-acting natriuretic peptide, and vessel dilator suggesting that their inhibition of Na(+)-K(+)-ATPase in both the kidney medulla and cortex are mediated by prostaglandins. Direct measurement of prostaglandin E2 revealed that kaliuretic peptide > long-acting natriuretic peptide > vessel dilator increased prostaglandin E2 synthesis, whereas ANF did not have any effect. Of interest, angiotensin II and ouabain inhibition of Na(+)-K(+)-ATPase were also completely blocked by naproxen."
117,P01160,Natriuretic peptides A,128-151,SSCFGGRMDRIGAQSGLGCNSFRY,Atriopeptin-3,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",7955907,,26,"N-terminal atrial natriuretic peptide and atrial natriuretic peptide in human plasma: investigation of plasma levels and molecular circulating form(s) using radioimmunoassays for pro-atrial natriuretic peptide (31-67), pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide (99-126).","Buckley, M. et al.",7955907,10.1042/cs0870311,,7955907,"1. The aim of this study was to determine plasma levels of N-terminal atrial natriuretic peptide and atrial natriuretic peptide in normal subjects and in patients with essential hypertension, cardiac transplant and chronic renal failure, using radioimmunoassays directed towards the mid-portion pro-atrial natriuretic peptide (31-67) and pro-atrial natriuretic peptide (1-30) of the N-terminal atrial natriuretic peptide and atrial natriuretic peptide (99-126). The circulating form(s) of the immunoreactive N-terminal atrial natriuretic peptide in plasma extracts has been investigated using all three radioimmunoassays by means of gel filtration chromatography to further clarify the major immunoreactive molecular circulating form(s) of N-terminal atrial natriuretic peptide in man. 2. The plasma level (mean +/- SEM) of N-terminal pro-atrial natriuretic peptide (31-67) in the normal subjects was 547.2 +/- 32.7 pg/ml (n = 36) and was significantly elevated in patients with essential hypertension (730.2 +/- 72.3 pg/ml, P < 0.025, n = 39), in cardiac transplant recipients (3214.0 +/- 432.2 pg/ml, P < 0.001, n = 9) and in patients with chronic renal failure (3571.8 +/- 474.1 pg/ml, P < 0.001, n = 11). Plasma levels of N-terminal pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide were similarly elevated in the same patient groups when compared with the mean plasma values in the normal subjects.(ABSTRACT TRUNCATED AT 250 WORDS)"
118,P01160,Natriuretic peptides A,128-151,SSCFGGRMDRIGAQSGLGCNSFRY,Atriopeptin-3,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",11145122,,36,"Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance the urinary excretion rate of beta2-microglobulin.","Vesely, D. et al.",11145122,10.1053/meta.2000.18557,,11145122,"The atrial natriuretic peptide (ANP) gene synthesizes a 126-amino acid (aa) prohormone from which four peptide hormones are derived. These 4 peptide hormones consisting of aa 1 to 30 (ie, long-acting natriuretic peptide [LANP]), aa 31 to 67 (vessel dilator), aa 79 to 98 (kaliuretic peptide), and aa 99 to 126 (ie, ANP) have diuretic, natriuretic, and/or kaliuretic properties. ANP has been reported to have its natriuretic and protein-excreting effects via both the proximal and distal tubules, but where in the kidney the other three peptide hormones have their natriuretic and/or diuretic effects is unknown. Further, it has never been investigated as to whether these three other peptide hormones enhance protein excretion. The present investigation was designed to determine (1) if these atrial peptides enhance protein excretion and (2) if their effects involve the proximal tubules of healthy humans by examining the excretion rate of beta2-microglobulin, a marker of proximal tubule function. Twenty-four healthy human subjects were studied following the infusion of 100 ng/kg body weight/min for 60 minutes of each of the respective peptides. LANP enhanced the excretion rate of beta2-microglobulin 2-fold within 20 minutes of beginning its infusion (P < .05) and was 2.5-fold higher than the preinfusion excretion rate at the end of the infusion. The excretion rate of beta2-microglobulin continued to be significantly (P < .01) increased for 3 hours after cessation of the LANP infusion, with the maximal excretion rate (ie, 3.8-fold increase) at 2.5 hours after stopping the infusion. Vessel dilator showed a more marked enhancement of beta2-microglobulin during its infusion, with the excretion rate increasing 2.5-fold at 20 minutes, and was increased 4-fold (P < .01) at the end of the infusion. With cessation of the vessel dilator infusion, the excretion rate of beta2-microglobulin decreased but was still elevated 2-fold (P < .05) 3 hours after stopping the infusion. Kaliuretic peptide enhanced the beta2-microglobulin excretion rate a maximal 3-fold, which occurred at the end of its infusion. The beta2-microglobulin excretion secondary to kaliuretic peptide remained 2-fold (P < .05) above baseline during the 3-hour postinfusion period. These peptide hormones similarly enhanced the albumin and total protein excretion rates 2- to 4-fold. These results indicate that LANP, vessel dilator, and kaliuretic peptide each (1) enhance protein excretion in healthy humans and (2) inhibit proximal tubular protein reabsorption."
119,P01160,Natriuretic peptides A,128-151,SSCFGGRMDRIGAQSGLGCNSFRY,Atriopeptin-3,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",2532366,,18,Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans.,"Vesely, D. et al.",2532366,10.3181/00379727-192-42990,,2532366,"The role of peptides from the N terminus and C terminus of the 126 amino acid atrial natriuretic factor (ANF) prohormone in modulating renal sodium and water handling has not been defined. Since water immersion to the neck (NI) provides an acute central volume expansion identical to that produced by 2 liters of saline but without plasma compositional change, immersion to the neck was used to assess the N-terminal and C-terminal portions of the ANF prohormone response to acute central blood volume expansion in seven seated sodium-replete normal subjects. Both the C terminus, which contains amino acids 99-126 and is identical to ANF, and the whole N terminus (i.e., amino acids 1-98) increased promptly with NI and peaked after 1 hr of immersion. A Mr 3900 peptide from the midportion of the N terminus consistent with amino acids 31-67 (i.e., pro-ANF-31-67) also increased with NI and followed a pattern of increasing circulating concentration nearly identical to that of the whole N terminus of the prohormone, except that its maximal concentration was at the second hour of the 3 hr of NI. With cessation of immersion, ANF decreased to preimmersion levels within 1 hr whereas the N terminus and pro-ANF-31-67, although their circulating concentrations were decreasing, were still significantly elevated at 1 hr. These findings suggest that the increase in plasma ANF, the N terminus of the ANF prohormone, and pro-ANF-31-67 from the midportion of the N terminus, with natriuretic properties similar to ANF, contribute to the natriuretic response to NI, implying a physiologic role for these atrial peptides in modulating volume homeostasis in humans."
120,P01160,Natriuretic peptides A,128-151,SSCFGGRMDRIGAQSGLGCNSFRY,Atriopeptin-3,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",8087923,,25,"Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans.","Vesely, D. et al.",8087923,10.1161/01.cir.90.3.1129,,8087923,"Three peptides consisting of amino acids 1-30, 31-67, and 79-98 of the 126-amino acid atrial natriuretic factor prohormone (proANF), which have blood pressure-lowering, diuretic, natriuretic, and/or kaliuretic properties in animals, were investigated to determine if they have similar properties in humans."
121,P01160,Natriuretic peptides A,128-151,SSCFGGRMDRIGAQSGLGCNSFRY,Atriopeptin-3,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",2825692,,16,"Atrial natriuretic prohormone peptides 1-30, 31-67, and 79-98 vasodilate the aorta.","Vesely, D. et al.",2825692,10.1016/s0006-291x(87)80307-8,,2825692,"Human prohormone atrial natriuretic peptides 1-30, 31-67, and 79-98 caused vasodilation of porcine aortas which began in 30 seconds and was maximal at 10 minutes. These three peptides were found to be equally potent to atrial natriuretic factor in their vasodilatory activity which was found with or without endothelium present. This vasodilation was associated with a 4 to 5 fold increase in cyclic GMP in the aorta secondary to activation of particulate guanylate cyclase [E.C. 4.6.12]. These data demonstrate that three N-terminal peptide segments of the atrial natriuretic factor prohormone cause vasodilation."
122,P01160,Natriuretic peptides A,128-151,SSCFGGRMDRIGAQSGLGCNSFRY,Atriopeptin-3,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",2162527,,20,"Specific binding sites for prohormone atrial natriuretic peptides 1-30, 31-67 and 99-126.","Vesely, D. et al.",2162527,10.1016/0196-9781(90)90070-l,,2162527,"Two peptides with vasodilatory properties consisting of amino acids 1-30 and 31-67 of the 98 a.a. N-terminal end of the prohormone of atrial natriuretic factor (proANF) which circulates in man were investigated to determine if they have specific binding sites on membranes isolated from DDT1 MF-2 smooth muscle cells. Smooth muscle is a known biologic target of these peptides. Competitive binding experiments revealed that proANFs (1-30), (31-67), and (99-126) (i.e., C-terminus; ANF) each had specific and separate binding sites. The dissociation constants for proANFs (1-30), (31-67), and (99-126) binding were 0.11 nM, 4 nM, and 7.3 nM, respectively. The binding site concentrations for proANFs (1-30), (31-67), and ANF were 2.57, 59.91 and 40 fmols/10(6) cells, respectively. The number of binding sites per cell were 1548, 36,087, and 24,090, respectively, for proANFs (1-30), (31-67), and (99-126) (ANF). Each peptide bound to DDT1 MF-2 membranes between 10(-8) to 10(-11) M but could only bind to the other peptides' receptors at concentrations of 10(-6) and 10(-7)M. These results suggest that proANF(1-30) and proANF(31-67) do not work through the ANF receptor but rather have their own separate and distinct receptors that mediate their biologic effects."
123,P01160,Natriuretic peptides A,128-151,SSCFGGRMDRIGAQSGLGCNSFRY,Atriopeptin-3,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",8653797,,29,Temporal (circadian) and functional relationship between atrial natriuretic peptides and blood pressure.,"Sothern, R. et al.",8653797,10.3109/07420529509064506,,8653797,"Long-acting natriuretic peptide, vessel dilator, and atrial natriuretic factor consisting of amino acids (a.a.) 1 to 30, 31 to 67, and 99 to 126 of the 126-a.a. atrial natriuretic factor (ANF) prohormone, respectively, circulate in humans and have potent vasodilatory properties. To determine if these atrial natriuretic peptides are directly related to blood pressure in clinically healthy normotensive humans, we obtained 24-h profiles of vessel dilator, long-acting natriuretic peptide, ANF, and blood pressure in 10 men in 1988 and 11 men in 1993 (seven men were studied twice) to compare circulating concentrations of atrial natriuretic peptides with naturally occurring changes in blood pressure. Overall, vessel dilator, long-acting natriuretic peptide, and ANF each had significant (p<0.001) circadian rhythms, with peak concentrations late during sleep (at 04:00 h) being nearly twice their concentrations in the afternoon and evening. This high-amplitude circadian change allowed for the refinement of normal limits for ANF peptides by computing 3-hourly tolerance intervals (chronodesms) against which to compare time-specified single samples for normality. Systolic, diastolic, and mean arterial blood pressure also had significant circadian rhythms (p<0.001) with peaks and troughs that were exactly opposite those of the ANF peptides. In addition to this inverse temporal relationship, there was a significant inverse correlation between absolute values for blood pressure and each ANF peptide (p<0.001), implying a functional relationship. These data suggest that in addition to other well-established neurochemical factors, the ANF peptides (vessel dilator, long-acting natriuretic peptide, and ANF) are important for the maintenance of blood pressure and modulation of its circadian rhythm."
124,P01160,Natriuretic peptides A,128-150,SSCFGGRMDRIGAQSGLGCNSFR,Atriopeptin-2,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",7595132,,31,Kaliuretic peptide and long acting natriuretic peptide as well as atrial natriuretic factor inhibit aldosterone secretion.,"Vesely, D. et al.",7595132,10.1677/joe.0.1460373,,7595132,"The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1-30 (long acting natriuretic peptide), 31-67 (vessel dilator) and 79-98 (kaliuretic peptide) as well as 99-126 (atrial natriuretic factor (ANF)) of the 126 amino acid ANF prohormone inhibit aldosterone secretion. Thirty healthy human subjects were studied following infusion of 100 ng/kg body weight/min for 60 min of each of the respective peptides. Kaliuretic peptide decreased plasma aldosterone concentration by the greatest amount (6-fold) and plasma aldosterone was still significantly decreased (P < 0.001) three hours after stopping the infusion. In contrast, within 30 min of cessation of the ANF infusion, plasma aldosterone levels had returned to pre-infusion values. Long acting natriuretic peptide also significantly (P < 0.01) decreased plasma aldosterone levels which remained significantly (P < 0.001) decreased 3 h after cessation of infusion. Vessel dilator did not decrease plasma aldosterone levels. Kaliuretic peptide, ANF and long acting natriuretic peptide also decreased (P < 0.01) urinary aldosterone concentrations. None of these peptides changed the plasma potassium concentration. We conclude that two new peptide hormones (long acting natriuretic peptide and kaliuretic peptide) inhibit aldosterone secretion. The length of time that aldosterone secretion is inhibited following kaliuretic peptide and long acting natriuretic peptide infusion is significantly longer (P < 0.001) than following ANF infusion."
125,P01160,Natriuretic peptides A,128-150,SSCFGGRMDRIGAQSGLGCNSFR,Atriopeptin-2,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",7720651,,30,Kaliuretic peptide: the most potent inhibitor of Na(+)-K+ ATPase of the atrial natriuretic peptides.,"Chiou, S. et al.",7720651,10.1210/endo.136.5.7720651,,7720651,"The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1-30 (i.e. long-acting natriuretic peptide), 31-67 (vessel dilator), 79-98 (kaliuretic peptide), and 99-126 [atrial natriuretic factor (ANF)] of the 126 amino acid ANF prohormone inhibit sodium-potassium-ATPase as part of their mechanism(s) of action for producing a natriuresis and/or kaliuresis. Kaliuretic peptide, long-acting natriuretic peptide, vessel dilator and ANF at their 10(-11) M concentrations inhibited Na(+)-K(+)-ATPase 39.5%, 27.8%, 19.2%, and 4% respectively, in bovine renal medulla, whereas their inhibition in renal cortical membranes was 37.5%, 27.5%, 20%, and 0%, respectively. Ouabain (0.5 mM) inhibited kidney medullary Na(+)-K(+)-ATPase 45% and in the cortex, 38%. There was no additive effect of any of these peptides with ouabain suggesting that they are interacting with the same site on the Na(+)-K(+)-ATPase as ouabain. To help elucidate the mechanism of these peptides' interaction with Na(+)-K(+)-ATPase, naproxen (0.5 mM), an inhibitor of prostaglandin synthesis, and direct measurement of prostaglandin E2 by RIA were used. Naproxen completely blocked the inhibition of Na(+)-K(+)-ATPase by kaliuretic peptide, long-acting natriuretic peptide, and vessel dilator suggesting that their inhibition of Na(+)-K(+)-ATPase in both the kidney medulla and cortex are mediated by prostaglandins. Direct measurement of prostaglandin E2 revealed that kaliuretic peptide > long-acting natriuretic peptide > vessel dilator increased prostaglandin E2 synthesis, whereas ANF did not have any effect. Of interest, angiotensin II and ouabain inhibition of Na(+)-K(+)-ATPase were also completely blocked by naproxen."
126,P01160,Natriuretic peptides A,128-150,SSCFGGRMDRIGAQSGLGCNSFR,Atriopeptin-2,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",7955907,,26,"N-terminal atrial natriuretic peptide and atrial natriuretic peptide in human plasma: investigation of plasma levels and molecular circulating form(s) using radioimmunoassays for pro-atrial natriuretic peptide (31-67), pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide (99-126).","Buckley, M. et al.",7955907,10.1042/cs0870311,,7955907,"1. The aim of this study was to determine plasma levels of N-terminal atrial natriuretic peptide and atrial natriuretic peptide in normal subjects and in patients with essential hypertension, cardiac transplant and chronic renal failure, using radioimmunoassays directed towards the mid-portion pro-atrial natriuretic peptide (31-67) and pro-atrial natriuretic peptide (1-30) of the N-terminal atrial natriuretic peptide and atrial natriuretic peptide (99-126). The circulating form(s) of the immunoreactive N-terminal atrial natriuretic peptide in plasma extracts has been investigated using all three radioimmunoassays by means of gel filtration chromatography to further clarify the major immunoreactive molecular circulating form(s) of N-terminal atrial natriuretic peptide in man. 2. The plasma level (mean +/- SEM) of N-terminal pro-atrial natriuretic peptide (31-67) in the normal subjects was 547.2 +/- 32.7 pg/ml (n = 36) and was significantly elevated in patients with essential hypertension (730.2 +/- 72.3 pg/ml, P < 0.025, n = 39), in cardiac transplant recipients (3214.0 +/- 432.2 pg/ml, P < 0.001, n = 9) and in patients with chronic renal failure (3571.8 +/- 474.1 pg/ml, P < 0.001, n = 11). Plasma levels of N-terminal pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide were similarly elevated in the same patient groups when compared with the mean plasma values in the normal subjects.(ABSTRACT TRUNCATED AT 250 WORDS)"
127,P01160,Natriuretic peptides A,128-150,SSCFGGRMDRIGAQSGLGCNSFR,Atriopeptin-2,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",11145122,,36,"Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance the urinary excretion rate of beta2-microglobulin.","Vesely, D. et al.",11145122,10.1053/meta.2000.18557,,11145122,"The atrial natriuretic peptide (ANP) gene synthesizes a 126-amino acid (aa) prohormone from which four peptide hormones are derived. These 4 peptide hormones consisting of aa 1 to 30 (ie, long-acting natriuretic peptide [LANP]), aa 31 to 67 (vessel dilator), aa 79 to 98 (kaliuretic peptide), and aa 99 to 126 (ie, ANP) have diuretic, natriuretic, and/or kaliuretic properties. ANP has been reported to have its natriuretic and protein-excreting effects via both the proximal and distal tubules, but where in the kidney the other three peptide hormones have their natriuretic and/or diuretic effects is unknown. Further, it has never been investigated as to whether these three other peptide hormones enhance protein excretion. The present investigation was designed to determine (1) if these atrial peptides enhance protein excretion and (2) if their effects involve the proximal tubules of healthy humans by examining the excretion rate of beta2-microglobulin, a marker of proximal tubule function. Twenty-four healthy human subjects were studied following the infusion of 100 ng/kg body weight/min for 60 minutes of each of the respective peptides. LANP enhanced the excretion rate of beta2-microglobulin 2-fold within 20 minutes of beginning its infusion (P < .05) and was 2.5-fold higher than the preinfusion excretion rate at the end of the infusion. The excretion rate of beta2-microglobulin continued to be significantly (P < .01) increased for 3 hours after cessation of the LANP infusion, with the maximal excretion rate (ie, 3.8-fold increase) at 2.5 hours after stopping the infusion. Vessel dilator showed a more marked enhancement of beta2-microglobulin during its infusion, with the excretion rate increasing 2.5-fold at 20 minutes, and was increased 4-fold (P < .01) at the end of the infusion. With cessation of the vessel dilator infusion, the excretion rate of beta2-microglobulin decreased but was still elevated 2-fold (P < .05) 3 hours after stopping the infusion. Kaliuretic peptide enhanced the beta2-microglobulin excretion rate a maximal 3-fold, which occurred at the end of its infusion. The beta2-microglobulin excretion secondary to kaliuretic peptide remained 2-fold (P < .05) above baseline during the 3-hour postinfusion period. These peptide hormones similarly enhanced the albumin and total protein excretion rates 2- to 4-fold. These results indicate that LANP, vessel dilator, and kaliuretic peptide each (1) enhance protein excretion in healthy humans and (2) inhibit proximal tubular protein reabsorption."
128,P01160,Natriuretic peptides A,128-150,SSCFGGRMDRIGAQSGLGCNSFR,Atriopeptin-2,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",2532366,,18,Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans.,"Vesely, D. et al.",2532366,10.3181/00379727-192-42990,,2532366,"The role of peptides from the N terminus and C terminus of the 126 amino acid atrial natriuretic factor (ANF) prohormone in modulating renal sodium and water handling has not been defined. Since water immersion to the neck (NI) provides an acute central volume expansion identical to that produced by 2 liters of saline but without plasma compositional change, immersion to the neck was used to assess the N-terminal and C-terminal portions of the ANF prohormone response to acute central blood volume expansion in seven seated sodium-replete normal subjects. Both the C terminus, which contains amino acids 99-126 and is identical to ANF, and the whole N terminus (i.e., amino acids 1-98) increased promptly with NI and peaked after 1 hr of immersion. A Mr 3900 peptide from the midportion of the N terminus consistent with amino acids 31-67 (i.e., pro-ANF-31-67) also increased with NI and followed a pattern of increasing circulating concentration nearly identical to that of the whole N terminus of the prohormone, except that its maximal concentration was at the second hour of the 3 hr of NI. With cessation of immersion, ANF decreased to preimmersion levels within 1 hr whereas the N terminus and pro-ANF-31-67, although their circulating concentrations were decreasing, were still significantly elevated at 1 hr. These findings suggest that the increase in plasma ANF, the N terminus of the ANF prohormone, and pro-ANF-31-67 from the midportion of the N terminus, with natriuretic properties similar to ANF, contribute to the natriuretic response to NI, implying a physiologic role for these atrial peptides in modulating volume homeostasis in humans."
129,P01160,Natriuretic peptides A,128-150,SSCFGGRMDRIGAQSGLGCNSFR,Atriopeptin-2,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",8087923,,25,"Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans.","Vesely, D. et al.",8087923,10.1161/01.cir.90.3.1129,,8087923,"Three peptides consisting of amino acids 1-30, 31-67, and 79-98 of the 126-amino acid atrial natriuretic factor prohormone (proANF), which have blood pressure-lowering, diuretic, natriuretic, and/or kaliuretic properties in animals, were investigated to determine if they have similar properties in humans."
130,P01160,Natriuretic peptides A,128-150,SSCFGGRMDRIGAQSGLGCNSFR,Atriopeptin-2,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",2825692,,16,"Atrial natriuretic prohormone peptides 1-30, 31-67, and 79-98 vasodilate the aorta.","Vesely, D. et al.",2825692,10.1016/s0006-291x(87)80307-8,,2825692,"Human prohormone atrial natriuretic peptides 1-30, 31-67, and 79-98 caused vasodilation of porcine aortas which began in 30 seconds and was maximal at 10 minutes. These three peptides were found to be equally potent to atrial natriuretic factor in their vasodilatory activity which was found with or without endothelium present. This vasodilation was associated with a 4 to 5 fold increase in cyclic GMP in the aorta secondary to activation of particulate guanylate cyclase [E.C. 4.6.12]. These data demonstrate that three N-terminal peptide segments of the atrial natriuretic factor prohormone cause vasodilation."
131,P01160,Natriuretic peptides A,128-150,SSCFGGRMDRIGAQSGLGCNSFR,Atriopeptin-2,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",2162527,,20,"Specific binding sites for prohormone atrial natriuretic peptides 1-30, 31-67 and 99-126.","Vesely, D. et al.",2162527,10.1016/0196-9781(90)90070-l,,2162527,"Two peptides with vasodilatory properties consisting of amino acids 1-30 and 31-67 of the 98 a.a. N-terminal end of the prohormone of atrial natriuretic factor (proANF) which circulates in man were investigated to determine if they have specific binding sites on membranes isolated from DDT1 MF-2 smooth muscle cells. Smooth muscle is a known biologic target of these peptides. Competitive binding experiments revealed that proANFs (1-30), (31-67), and (99-126) (i.e., C-terminus; ANF) each had specific and separate binding sites. The dissociation constants for proANFs (1-30), (31-67), and (99-126) binding were 0.11 nM, 4 nM, and 7.3 nM, respectively. The binding site concentrations for proANFs (1-30), (31-67), and ANF were 2.57, 59.91 and 40 fmols/10(6) cells, respectively. The number of binding sites per cell were 1548, 36,087, and 24,090, respectively, for proANFs (1-30), (31-67), and (99-126) (ANF). Each peptide bound to DDT1 MF-2 membranes between 10(-8) to 10(-11) M but could only bind to the other peptides' receptors at concentrations of 10(-6) and 10(-7)M. These results suggest that proANF(1-30) and proANF(31-67) do not work through the ANF receptor but rather have their own separate and distinct receptors that mediate their biologic effects."
132,P01160,Natriuretic peptides A,128-150,SSCFGGRMDRIGAQSGLGCNSFR,Atriopeptin-2,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",8653797,,29,Temporal (circadian) and functional relationship between atrial natriuretic peptides and blood pressure.,"Sothern, R. et al.",8653797,10.3109/07420529509064506,,8653797,"Long-acting natriuretic peptide, vessel dilator, and atrial natriuretic factor consisting of amino acids (a.a.) 1 to 30, 31 to 67, and 99 to 126 of the 126-a.a. atrial natriuretic factor (ANF) prohormone, respectively, circulate in humans and have potent vasodilatory properties. To determine if these atrial natriuretic peptides are directly related to blood pressure in clinically healthy normotensive humans, we obtained 24-h profiles of vessel dilator, long-acting natriuretic peptide, ANF, and blood pressure in 10 men in 1988 and 11 men in 1993 (seven men were studied twice) to compare circulating concentrations of atrial natriuretic peptides with naturally occurring changes in blood pressure. Overall, vessel dilator, long-acting natriuretic peptide, and ANF each had significant (p<0.001) circadian rhythms, with peak concentrations late during sleep (at 04:00 h) being nearly twice their concentrations in the afternoon and evening. This high-amplitude circadian change allowed for the refinement of normal limits for ANF peptides by computing 3-hourly tolerance intervals (chronodesms) against which to compare time-specified single samples for normality. Systolic, diastolic, and mean arterial blood pressure also had significant circadian rhythms (p<0.001) with peaks and troughs that were exactly opposite those of the ANF peptides. In addition to this inverse temporal relationship, there was a significant inverse correlation between absolute values for blood pressure and each ANF peptide (p<0.001), implying a functional relationship. These data suggest that in addition to other well-established neurochemical factors, the ANF peptides (vessel dilator, long-acting natriuretic peptide, and ANF) are important for the maintenance of blood pressure and modulation of its circadian rhythm."
133,P01160,Natriuretic peptides A,128-148,SSCFGGRMDRIGAQSGLGCNS,Atriopeptin-1,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",7595132,,31,Kaliuretic peptide and long acting natriuretic peptide as well as atrial natriuretic factor inhibit aldosterone secretion.,"Vesely, D. et al.",7595132,10.1677/joe.0.1460373,,7595132,"The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1-30 (long acting natriuretic peptide), 31-67 (vessel dilator) and 79-98 (kaliuretic peptide) as well as 99-126 (atrial natriuretic factor (ANF)) of the 126 amino acid ANF prohormone inhibit aldosterone secretion. Thirty healthy human subjects were studied following infusion of 100 ng/kg body weight/min for 60 min of each of the respective peptides. Kaliuretic peptide decreased plasma aldosterone concentration by the greatest amount (6-fold) and plasma aldosterone was still significantly decreased (P < 0.001) three hours after stopping the infusion. In contrast, within 30 min of cessation of the ANF infusion, plasma aldosterone levels had returned to pre-infusion values. Long acting natriuretic peptide also significantly (P < 0.01) decreased plasma aldosterone levels which remained significantly (P < 0.001) decreased 3 h after cessation of infusion. Vessel dilator did not decrease plasma aldosterone levels. Kaliuretic peptide, ANF and long acting natriuretic peptide also decreased (P < 0.01) urinary aldosterone concentrations. None of these peptides changed the plasma potassium concentration. We conclude that two new peptide hormones (long acting natriuretic peptide and kaliuretic peptide) inhibit aldosterone secretion. The length of time that aldosterone secretion is inhibited following kaliuretic peptide and long acting natriuretic peptide infusion is significantly longer (P < 0.001) than following ANF infusion."
134,P01160,Natriuretic peptides A,128-148,SSCFGGRMDRIGAQSGLGCNS,Atriopeptin-1,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",7720651,,30,Kaliuretic peptide: the most potent inhibitor of Na(+)-K+ ATPase of the atrial natriuretic peptides.,"Chiou, S. et al.",7720651,10.1210/endo.136.5.7720651,,7720651,"The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1-30 (i.e. long-acting natriuretic peptide), 31-67 (vessel dilator), 79-98 (kaliuretic peptide), and 99-126 [atrial natriuretic factor (ANF)] of the 126 amino acid ANF prohormone inhibit sodium-potassium-ATPase as part of their mechanism(s) of action for producing a natriuresis and/or kaliuresis. Kaliuretic peptide, long-acting natriuretic peptide, vessel dilator and ANF at their 10(-11) M concentrations inhibited Na(+)-K(+)-ATPase 39.5%, 27.8%, 19.2%, and 4% respectively, in bovine renal medulla, whereas their inhibition in renal cortical membranes was 37.5%, 27.5%, 20%, and 0%, respectively. Ouabain (0.5 mM) inhibited kidney medullary Na(+)-K(+)-ATPase 45% and in the cortex, 38%. There was no additive effect of any of these peptides with ouabain suggesting that they are interacting with the same site on the Na(+)-K(+)-ATPase as ouabain. To help elucidate the mechanism of these peptides' interaction with Na(+)-K(+)-ATPase, naproxen (0.5 mM), an inhibitor of prostaglandin synthesis, and direct measurement of prostaglandin E2 by RIA were used. Naproxen completely blocked the inhibition of Na(+)-K(+)-ATPase by kaliuretic peptide, long-acting natriuretic peptide, and vessel dilator suggesting that their inhibition of Na(+)-K(+)-ATPase in both the kidney medulla and cortex are mediated by prostaglandins. Direct measurement of prostaglandin E2 revealed that kaliuretic peptide > long-acting natriuretic peptide > vessel dilator increased prostaglandin E2 synthesis, whereas ANF did not have any effect. Of interest, angiotensin II and ouabain inhibition of Na(+)-K(+)-ATPase were also completely blocked by naproxen."
135,P01160,Natriuretic peptides A,128-148,SSCFGGRMDRIGAQSGLGCNS,Atriopeptin-1,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",7955907,,26,"N-terminal atrial natriuretic peptide and atrial natriuretic peptide in human plasma: investigation of plasma levels and molecular circulating form(s) using radioimmunoassays for pro-atrial natriuretic peptide (31-67), pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide (99-126).","Buckley, M. et al.",7955907,10.1042/cs0870311,,7955907,"1. The aim of this study was to determine plasma levels of N-terminal atrial natriuretic peptide and atrial natriuretic peptide in normal subjects and in patients with essential hypertension, cardiac transplant and chronic renal failure, using radioimmunoassays directed towards the mid-portion pro-atrial natriuretic peptide (31-67) and pro-atrial natriuretic peptide (1-30) of the N-terminal atrial natriuretic peptide and atrial natriuretic peptide (99-126). The circulating form(s) of the immunoreactive N-terminal atrial natriuretic peptide in plasma extracts has been investigated using all three radioimmunoassays by means of gel filtration chromatography to further clarify the major immunoreactive molecular circulating form(s) of N-terminal atrial natriuretic peptide in man. 2. The plasma level (mean +/- SEM) of N-terminal pro-atrial natriuretic peptide (31-67) in the normal subjects was 547.2 +/- 32.7 pg/ml (n = 36) and was significantly elevated in patients with essential hypertension (730.2 +/- 72.3 pg/ml, P < 0.025, n = 39), in cardiac transplant recipients (3214.0 +/- 432.2 pg/ml, P < 0.001, n = 9) and in patients with chronic renal failure (3571.8 +/- 474.1 pg/ml, P < 0.001, n = 11). Plasma levels of N-terminal pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide were similarly elevated in the same patient groups when compared with the mean plasma values in the normal subjects.(ABSTRACT TRUNCATED AT 250 WORDS)"
136,P01160,Natriuretic peptides A,128-148,SSCFGGRMDRIGAQSGLGCNS,Atriopeptin-1,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",11145122,,36,"Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance the urinary excretion rate of beta2-microglobulin.","Vesely, D. et al.",11145122,10.1053/meta.2000.18557,,11145122,"The atrial natriuretic peptide (ANP) gene synthesizes a 126-amino acid (aa) prohormone from which four peptide hormones are derived. These 4 peptide hormones consisting of aa 1 to 30 (ie, long-acting natriuretic peptide [LANP]), aa 31 to 67 (vessel dilator), aa 79 to 98 (kaliuretic peptide), and aa 99 to 126 (ie, ANP) have diuretic, natriuretic, and/or kaliuretic properties. ANP has been reported to have its natriuretic and protein-excreting effects via both the proximal and distal tubules, but where in the kidney the other three peptide hormones have their natriuretic and/or diuretic effects is unknown. Further, it has never been investigated as to whether these three other peptide hormones enhance protein excretion. The present investigation was designed to determine (1) if these atrial peptides enhance protein excretion and (2) if their effects involve the proximal tubules of healthy humans by examining the excretion rate of beta2-microglobulin, a marker of proximal tubule function. Twenty-four healthy human subjects were studied following the infusion of 100 ng/kg body weight/min for 60 minutes of each of the respective peptides. LANP enhanced the excretion rate of beta2-microglobulin 2-fold within 20 minutes of beginning its infusion (P < .05) and was 2.5-fold higher than the preinfusion excretion rate at the end of the infusion. The excretion rate of beta2-microglobulin continued to be significantly (P < .01) increased for 3 hours after cessation of the LANP infusion, with the maximal excretion rate (ie, 3.8-fold increase) at 2.5 hours after stopping the infusion. Vessel dilator showed a more marked enhancement of beta2-microglobulin during its infusion, with the excretion rate increasing 2.5-fold at 20 minutes, and was increased 4-fold (P < .01) at the end of the infusion. With cessation of the vessel dilator infusion, the excretion rate of beta2-microglobulin decreased but was still elevated 2-fold (P < .05) 3 hours after stopping the infusion. Kaliuretic peptide enhanced the beta2-microglobulin excretion rate a maximal 3-fold, which occurred at the end of its infusion. The beta2-microglobulin excretion secondary to kaliuretic peptide remained 2-fold (P < .05) above baseline during the 3-hour postinfusion period. These peptide hormones similarly enhanced the albumin and total protein excretion rates 2- to 4-fold. These results indicate that LANP, vessel dilator, and kaliuretic peptide each (1) enhance protein excretion in healthy humans and (2) inhibit proximal tubular protein reabsorption."
137,P01160,Natriuretic peptides A,128-148,SSCFGGRMDRIGAQSGLGCNS,Atriopeptin-1,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",2532366,,18,Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans.,"Vesely, D. et al.",2532366,10.3181/00379727-192-42990,,2532366,"The role of peptides from the N terminus and C terminus of the 126 amino acid atrial natriuretic factor (ANF) prohormone in modulating renal sodium and water handling has not been defined. Since water immersion to the neck (NI) provides an acute central volume expansion identical to that produced by 2 liters of saline but without plasma compositional change, immersion to the neck was used to assess the N-terminal and C-terminal portions of the ANF prohormone response to acute central blood volume expansion in seven seated sodium-replete normal subjects. Both the C terminus, which contains amino acids 99-126 and is identical to ANF, and the whole N terminus (i.e., amino acids 1-98) increased promptly with NI and peaked after 1 hr of immersion. A Mr 3900 peptide from the midportion of the N terminus consistent with amino acids 31-67 (i.e., pro-ANF-31-67) also increased with NI and followed a pattern of increasing circulating concentration nearly identical to that of the whole N terminus of the prohormone, except that its maximal concentration was at the second hour of the 3 hr of NI. With cessation of immersion, ANF decreased to preimmersion levels within 1 hr whereas the N terminus and pro-ANF-31-67, although their circulating concentrations were decreasing, were still significantly elevated at 1 hr. These findings suggest that the increase in plasma ANF, the N terminus of the ANF prohormone, and pro-ANF-31-67 from the midportion of the N terminus, with natriuretic properties similar to ANF, contribute to the natriuretic response to NI, implying a physiologic role for these atrial peptides in modulating volume homeostasis in humans."
138,P01160,Natriuretic peptides A,128-148,SSCFGGRMDRIGAQSGLGCNS,Atriopeptin-1,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",8087923,,25,"Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans.","Vesely, D. et al.",8087923,10.1161/01.cir.90.3.1129,,8087923,"Three peptides consisting of amino acids 1-30, 31-67, and 79-98 of the 126-amino acid atrial natriuretic factor prohormone (proANF), which have blood pressure-lowering, diuretic, natriuretic, and/or kaliuretic properties in animals, were investigated to determine if they have similar properties in humans."
139,P01160,Natriuretic peptides A,128-148,SSCFGGRMDRIGAQSGLGCNS,Atriopeptin-1,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",2825692,,16,"Atrial natriuretic prohormone peptides 1-30, 31-67, and 79-98 vasodilate the aorta.","Vesely, D. et al.",2825692,10.1016/s0006-291x(87)80307-8,,2825692,"Human prohormone atrial natriuretic peptides 1-30, 31-67, and 79-98 caused vasodilation of porcine aortas which began in 30 seconds and was maximal at 10 minutes. These three peptides were found to be equally potent to atrial natriuretic factor in their vasodilatory activity which was found with or without endothelium present. This vasodilation was associated with a 4 to 5 fold increase in cyclic GMP in the aorta secondary to activation of particulate guanylate cyclase [E.C. 4.6.12]. These data demonstrate that three N-terminal peptide segments of the atrial natriuretic factor prohormone cause vasodilation."
140,P01160,Natriuretic peptides A,128-148,SSCFGGRMDRIGAQSGLGCNS,Atriopeptin-1,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",2162527,,20,"Specific binding sites for prohormone atrial natriuretic peptides 1-30, 31-67 and 99-126.","Vesely, D. et al.",2162527,10.1016/0196-9781(90)90070-l,,2162527,"Two peptides with vasodilatory properties consisting of amino acids 1-30 and 31-67 of the 98 a.a. N-terminal end of the prohormone of atrial natriuretic factor (proANF) which circulates in man were investigated to determine if they have specific binding sites on membranes isolated from DDT1 MF-2 smooth muscle cells. Smooth muscle is a known biologic target of these peptides. Competitive binding experiments revealed that proANFs (1-30), (31-67), and (99-126) (i.e., C-terminus; ANF) each had specific and separate binding sites. The dissociation constants for proANFs (1-30), (31-67), and (99-126) binding were 0.11 nM, 4 nM, and 7.3 nM, respectively. The binding site concentrations for proANFs (1-30), (31-67), and ANF were 2.57, 59.91 and 40 fmols/10(6) cells, respectively. The number of binding sites per cell were 1548, 36,087, and 24,090, respectively, for proANFs (1-30), (31-67), and (99-126) (ANF). Each peptide bound to DDT1 MF-2 membranes between 10(-8) to 10(-11) M but could only bind to the other peptides' receptors at concentrations of 10(-6) and 10(-7)M. These results suggest that proANF(1-30) and proANF(31-67) do not work through the ANF receptor but rather have their own separate and distinct receptors that mediate their biologic effects."
141,P01160,Natriuretic peptides A,128-148,SSCFGGRMDRIGAQSGLGCNS,Atriopeptin-1,1,"{'5': '10880574', '6': '11145122', '7': '14559895', '8': '15741263', '9': '16254193', '10': '1660465', '11': '1672777', '12': '16870210', '13': '16875975', '14': '1826098', '15': '18614783', '16': '18835931', '17': '21098034', '18': '2162527', '19': '21672517', '20': '22291141', '21': '22307324', '22': '23275345', '23': '2528951', '24': '2532366', '25': '25401746', '26': '2825692', '27': '2972276', '28': '2972874', '29': '30534047', '30': '3838202', '31': '6230082', '32': '6238331', '33': '7595132', '34': '7720651', '35': '7831500', '36': '7955907', '37': '7984506', '38': '8087923', '39': '8351194', '40': '8384600', '41': '8653797', '42': '8779891', '43': '8853410', '44': '9794555', '45': '9893117', '46': '2162527', '47': '22291141', '48': '2528951', '49': '2972874', '50': '3158606', '51': '3838202', '52': '6203042', '53': '6542248', '54': '6547996', '55': '8087923', '56': '8351194', '57': '8653797', '58': '8853410', '60': '7720651', '61': '7955907', '62': '7984506', '63': '8087923'}",{'1'},"May have a role in cardio-renal homeostasis through regulation of natriuresis, diuresis, vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132, PubMed:2532366). In vitro, promotes the production of cGMP and induces vasodilation (PubMed:2825692). May promote natriuresis, at least in part, by enhancing prostaglandin E2 synthesis resulting in the inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on the involvement of this peptide in mammal blood volume and blood pressure homeostasis are conflicting; according to a report, in vivo it is not sufficient to activate cGMP and does not inhibit collecting duct transport nor effect diuresis and natriuresis (By similarity). Appears to bind to specific receptors that are distinct from the receptors bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527, PubMed:2825692). Possibly enhances protein excretion in urine by decreasing proximal tubular protein reabsorption (PubMed:11145122).; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis and in vitro, vasodilates renal artery strips.; May have a role in cardio-renal homeostasis through regulation of regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, vasodilates intestinal smooth muscle but not smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal and vascular smooth muscle strips.; May have a role in cardio-renal homeostasis through regulation of natriuresis and vasodilation. In vivo promotes natriuresis. In vitro, selectively vasodilates intestinal smooth muscle but not vascular smooth muscle strips.",8653797,,29,Temporal (circadian) and functional relationship between atrial natriuretic peptides and blood pressure.,"Sothern, R. et al.",8653797,10.3109/07420529509064506,,8653797,"Long-acting natriuretic peptide, vessel dilator, and atrial natriuretic factor consisting of amino acids (a.a.) 1 to 30, 31 to 67, and 99 to 126 of the 126-a.a. atrial natriuretic factor (ANF) prohormone, respectively, circulate in humans and have potent vasodilatory properties. To determine if these atrial natriuretic peptides are directly related to blood pressure in clinically healthy normotensive humans, we obtained 24-h profiles of vessel dilator, long-acting natriuretic peptide, ANF, and blood pressure in 10 men in 1988 and 11 men in 1993 (seven men were studied twice) to compare circulating concentrations of atrial natriuretic peptides with naturally occurring changes in blood pressure. Overall, vessel dilator, long-acting natriuretic peptide, and ANF each had significant (p<0.001) circadian rhythms, with peak concentrations late during sleep (at 04:00 h) being nearly twice their concentrations in the afternoon and evening. This high-amplitude circadian change allowed for the refinement of normal limits for ANF peptides by computing 3-hourly tolerance intervals (chronodesms) against which to compare time-specified single samples for normality. Systolic, diastolic, and mean arterial blood pressure also had significant circadian rhythms (p<0.001) with peaks and troughs that were exactly opposite those of the ANF peptides. In addition to this inverse temporal relationship, there was a significant inverse correlation between absolute values for blood pressure and each ANF peptide (p<0.001), implying a functional relationship. These data suggest that in addition to other well-established neurochemical factors, the ANF peptides (vessel dilator, long-acting natriuretic peptide, and ANF) are important for the maintenance of blood pressure and modulation of its circadian rhythm."
142,Q9UBU3,,24-51,GSSFLSPEHQRVQQRKESKKPPAKLQPR,Ghrelin-28,,"{'4': '10604470', '5': '10930375', '6': '12414809', '7': '15340161', '8': '15489334', '9': '18443287', '10': '12414809', '11': '17727735'}",{'4'},"Ghrelin is the ligand for growth hormone secretagogue receptor type 1 (GHSR) (PubMed:10604470). Induces the release of growth hormone from the pituitary (PubMed:10604470). Has an appetite-stimulating effect, induces adiposity and stimulates gastric acid secretion. Involved in growth regulation.",10604470,,1,Ghrelin is a growth-hormone-releasing acylated peptide from stomach.,"Kojima, M. et al.",10604470,10.1038/45230,,10604470,"Small synthetic molecules called growth-hormone secretagogues (GHSs) stimulate the release of growth hormone (GH) from the pituitary. They act through GHS-R, a G-protein-coupled receptor for which the ligand is unknown. Recent cloning of GHS-R strongly suggests that an endogenous ligand for the receptor does exist and that there is a mechanism for regulating GH release that is distinct from its regulation by hypothalamic growth-hormone-releasing hormone (GHRH). We now report the purification and identification in rat stomach of an endogenous ligand specific for GHS-R. The purified ligand is a peptide of 28 amino acids, in which the serine 3 residue is n-octanoylated. The acylated peptide specifically releases GH both in vivo and in vitro, and O-n-octanoylation at serine 3 is essential for the activity. We designate the GH-releasing peptide 'ghrelin' (ghre is the Proto-Indo-European root of the word 'grow'). Human ghrelin is homologous to rat ghrelin apart from two amino acids. The occurrence of ghrelin in both rat and human indicates that GH release from the pituitary may be regulated not only by hypothalamic GHRH, but also by ghrelin."
143,Q9UBU3,,24-50,GSSFLSPEHQRVQQRKESKKPPAKLQP,Ghrelin-27,,"{'4': '10604470', '5': '10930375', '6': '12414809', '7': '15340161', '8': '15489334', '9': '18443287', '10': '12414809', '11': '17727735'}",{'4'},"Ghrelin is the ligand for growth hormone secretagogue receptor type 1 (GHSR) (PubMed:10604470). Induces the release of growth hormone from the pituitary (PubMed:10604470). Has an appetite-stimulating effect, induces adiposity and stimulates gastric acid secretion. Involved in growth regulation.",10604470,,1,Ghrelin is a growth-hormone-releasing acylated peptide from stomach.,"Kojima, M. et al.",10604470,10.1038/45230,,10604470,"Small synthetic molecules called growth-hormone secretagogues (GHSs) stimulate the release of growth hormone (GH) from the pituitary. They act through GHS-R, a G-protein-coupled receptor for which the ligand is unknown. Recent cloning of GHS-R strongly suggests that an endogenous ligand for the receptor does exist and that there is a mechanism for regulating GH release that is distinct from its regulation by hypothalamic growth-hormone-releasing hormone (GHRH). We now report the purification and identification in rat stomach of an endogenous ligand specific for GHS-R. The purified ligand is a peptide of 28 amino acids, in which the serine 3 residue is n-octanoylated. The acylated peptide specifically releases GH both in vivo and in vitro, and O-n-octanoylation at serine 3 is essential for the activity. We designate the GH-releasing peptide 'ghrelin' (ghre is the Proto-Indo-European root of the word 'grow'). Human ghrelin is homologous to rat ghrelin apart from two amino acids. The occurrence of ghrelin in both rat and human indicates that GH release from the pituitary may be regulated not only by hypothalamic GHRH, but also by ghrelin."
144,P01024,Complement C3c alpha' chain fragment 2,1304-1320,SSKITHRIHWESASLLR,Complement C3f fragment,50,"{'6': '10432298', '7': '11387479', '8': '11773063', '9': '12540846', '10': '12754519', '11': '14760718', '12': '15833747', '13': '16263699', '14': '16333141', '15': '16335952', '16': '17051150', '17': '17351618', '18': '17634448', '19': '17684013', '20': '18160402', '21': '18796626', '22': '19112495', '23': '19159218', '24': '19615750', '25': '1976733', '26': '20083651', '27': '20513133', '28': '20951140', '29': '21055811', '30': '21285368', '31': '21317894', '32': '21502375', '33': '21527715', '34': '21555552', '35': '22028381', '36': '24036952', '37': '24367091', '38': '2473125', '39': '2579379', '40': '2584723', '41': '26091039', '42': '28264884', '43': '2849025', '44': '2909530', '45': '2972794', '46': '31507604', '47': '7539791', '48': '7961791', '49': '8175757', '50': '8376604', '51': '8416818', '52': '9059512', '53': '9555951'}","{'14', '44', '24', '52', '6', '12', '50'}","Adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for C5AR2. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of C5AR2 (PubMed:8376604, PubMed:2909530, PubMed:9059512, PubMed:10432298, PubMed:15833747, PubMed:16333141, PubMed:19615750).",8376604,,5,The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis.,"Baldo, A. et al.",8376604,10.1172/jci116733,,8376604,"We have previously characterized an activity from human plasma that markedly stimulates triglyceride synthesis in cultured human skin fibroblasts and human adipocytes. Based on its in vitro activity we named the active component acylation stimulating protein (ASP). The molecular identity of the active serum component has now been determined. NH2-terminal sequence analysis, ion spray ionization mass spectroscopy, and amino acid composition analysis all indicate that the active purified protein is a fragment of the third component of plasma complement, C3a-desArg. As well, reconstitution experiments with complement factors B, D, and complement C3, the components necessary to generate C3a, have confirmed the identity of ASP as C3a. ASP appears to be the final effector molecule generated by a novel regulatory system that modulates the rate of triglyceride synthesis in adipocytes."
145,P01024,Complement C3c alpha' chain fragment 2,1304-1320,SSKITHRIHWESASLLR,Complement C3f fragment,50,"{'6': '10432298', '7': '11387479', '8': '11773063', '9': '12540846', '10': '12754519', '11': '14760718', '12': '15833747', '13': '16263699', '14': '16333141', '15': '16335952', '16': '17051150', '17': '17351618', '18': '17634448', '19': '17684013', '20': '18160402', '21': '18796626', '22': '19112495', '23': '19159218', '24': '19615750', '25': '1976733', '26': '20083651', '27': '20513133', '28': '20951140', '29': '21055811', '30': '21285368', '31': '21317894', '32': '21502375', '33': '21527715', '34': '21555552', '35': '22028381', '36': '24036952', '37': '24367091', '38': '2473125', '39': '2579379', '40': '2584723', '41': '26091039', '42': '28264884', '43': '2849025', '44': '2909530', '45': '2972794', '46': '31507604', '47': '7539791', '48': '7961791', '49': '8175757', '50': '8376604', '51': '8416818', '52': '9059512', '53': '9555951'}","{'14', '44', '24', '52', '6', '12', '50'}","Adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for C5AR2. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of C5AR2 (PubMed:8376604, PubMed:2909530, PubMed:9059512, PubMed:10432298, PubMed:15833747, PubMed:16333141, PubMed:19615750).",10432298,,19,Acylation-stimulating protein (ASP): structure-function determinants of cell surface binding and triacylglycerol synthetic activity.,"Murray, I. et al.",10432298,10.1042/bj3420041,,10432298,"Acylation-stimulating protein (ASP or C3adesArg) is a potent lipogenic factor in human and murine adipocytes and fibroblasts. The arginated form of ASP, i.e. complement C3a (C3a), stimulates immunological responses in human granulocytes, mast cells, guinea pig platelets and guinea pig macrophages; however, ASP is inactive in stimulating these responses. Thus both ASP and C3a are bioactive across species but are not functionally interchangeable. Tertiary structure of both proteins by X-ray crystallography and NMR spectroscopy predicts a tightly linked core region consisting of three alpha-helices linked via three disulphide bonds, with one of the alpha-helices extending out from the core and terminating in a flexible conformationally irregular carboxy-tail region. The present studies were undertaken in order to define the functionally active domains of ASP, distinctive from those of C3a, using chemical modifications, enzymic cleavage and synthetic peptide fragments. The results indicate that: (i) the N-terminal region (<10 amino acids) plays little role in ASP receptor binding and triacylglycerol synthesis stimulation; (ii) the native C-terminal region had no activity, but modifications which increased hydrophobicity increased receptor binding, and led to some activation of triacylglycerol synthesis stimulation; (iii) an intact disulphide-linked core region is essential for triacylglycerol synthesis stimulation activity but not for receptor interaction. Finally, basic charges in the carboxy region (His) are essential for ASP triacylglycerol synthesis stimulation but not for receptor binding, whereas both functions are eliminated by the modification of Lys in the disulphide-linked core region. The present results suggest that there are two functional domains in ASP, one that is responsible for the initial binding to the cell surface receptor, and a second domain that activates and increases triacylglycerol synthesis stimulation. This contrasts markedly with the structure-function studies of C3a where both binding competency and function were dependent on the C-terminal Arg. Thus ASP demonstrates distinct bioactivity."
146,P01024,Complement C3c alpha' chain fragment 2,1304-1320,SSKITHRIHWESASLLR,Complement C3f fragment,50,"{'6': '10432298', '7': '11387479', '8': '11773063', '9': '12540846', '10': '12754519', '11': '14760718', '12': '15833747', '13': '16263699', '14': '16333141', '15': '16335952', '16': '17051150', '17': '17351618', '18': '17634448', '19': '17684013', '20': '18160402', '21': '18796626', '22': '19112495', '23': '19159218', '24': '19615750', '25': '1976733', '26': '20083651', '27': '20513133', '28': '20951140', '29': '21055811', '30': '21285368', '31': '21317894', '32': '21502375', '33': '21527715', '34': '21555552', '35': '22028381', '36': '24036952', '37': '24367091', '38': '2473125', '39': '2579379', '40': '2584723', '41': '26091039', '42': '28264884', '43': '2849025', '44': '2909530', '45': '2972794', '46': '31507604', '47': '7539791', '48': '7961791', '49': '8175757', '50': '8376604', '51': '8416818', '52': '9059512', '53': '9555951'}","{'14', '44', '24', '52', '6', '12', '50'}","Adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for C5AR2. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of C5AR2 (PubMed:8376604, PubMed:2909530, PubMed:9059512, PubMed:10432298, PubMed:15833747, PubMed:16333141, PubMed:19615750).",9059512,,17,Acylation-stimulating protein (ASP) regulates glucose transport in the rat L6 muscle cell line.,"Tao, Y. et al.",9059512,10.1016/s0005-2760(96)00144-0,,9059512,"Acylation-stimulating protein (ASP), a human plasma protein, is a potent stimulator of triglyceride synthesis and glucose transport in both human adipocytes and fibroblasts. The purpose of the present in vitro study was to examine the effect of ASP on glucose transport in muscle cells. ASP stimulated 2-deoxy-glucose transport (2-DG) in differentiated rat L6 myotubes in a time (30 min to 24 h) and concentration dependent manner (97% increase). The magnitude of the ASP effect on glucose transport was comparable to the time- and concentration-dependent effects seen with insulin (125% increase), but was additive to insulin, pointing to involvement of differential signalling pathways. ASP stimulation was dependent on cell differentiation in that glucose transport increased by only 12% in myoblasts, comparable to the effect of insulin in myoblasts (15% increase) demonstrating selective responsiveness of the differentiated myotubes to ASP and insulin. The mechanism for the ASP induced increase in glucose transport was also examined. ASP increased the Vmax for 2-DG transport by 183% (4.02 vs. 1.42 nmol/mg cell protein/30 s; ASP vs. Control, respectively). This could be explained by an increased translocation of glucose transporters (GLUT 1, GLUT 4 and GLUT 3) to the plasma membrane surface as demonstrated by Western analysis (+43% P < 0.05, +30% P < 0.05, and +49% P < 0.05, respectively). The effects of ASP were equal to those of insulin (+47%, +26% and +53% for GLUT 1, GLUT 4 and GLUT 3, respectively) and in all cases were paralleled by comparable glucose transport increases under the same incubation conditions. After long-term stimulation (24 h), Western analysis indicated that ASP had a permissive effect on insulin stimulated increases in total GLUT3 and GLUT4 cellular transporter content. These results suggest that muscle is also responsive to ASP and that ASP may play a role in glucose metabolism in both muscle and adipose tissue."
147,P01024,Complement C3c alpha' chain fragment 2,1304-1320,SSKITHRIHWESASLLR,Complement C3f fragment,50,"{'6': '10432298', '7': '11387479', '8': '11773063', '9': '12540846', '10': '12754519', '11': '14760718', '12': '15833747', '13': '16263699', '14': '16333141', '15': '16335952', '16': '17051150', '17': '17351618', '18': '17634448', '19': '17684013', '20': '18160402', '21': '18796626', '22': '19112495', '23': '19159218', '24': '19615750', '25': '1976733', '26': '20083651', '27': '20513133', '28': '20951140', '29': '21055811', '30': '21285368', '31': '21317894', '32': '21502375', '33': '21527715', '34': '21555552', '35': '22028381', '36': '24036952', '37': '24367091', '38': '2473125', '39': '2579379', '40': '2584723', '41': '26091039', '42': '28264884', '43': '2849025', '44': '2909530', '45': '2972794', '46': '31507604', '47': '7539791', '48': '7961791', '49': '8175757', '50': '8376604', '51': '8416818', '52': '9059512', '53': '9555951'}","{'14', '44', '24', '52', '6', '12', '50'}","Adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for C5AR2. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of C5AR2 (PubMed:8376604, PubMed:2909530, PubMed:9059512, PubMed:10432298, PubMed:15833747, PubMed:16333141, PubMed:19615750).",19615750,,34,"C5a- and ASP-mediated C5L2 activation, endocytosis and recycling are lost in S323I-C5L2 mutation.","Cui, W. et al.",19615750,10.1016/j.molimm.2009.06.007,,19615750,"C5L2, a G-protein-coupled receptor (GPCR), has been identified as an ASP (C3adesArg) and C5a receptor. Controversy exists regarding both ligand binding and functionality. ASP activation of C5L2 is proposed to regulate fat storage. C5L2 is also proposed as a decoy receptor for C5a, an inflammatory mediator, based on absence of Ca(2+) or chemotaxis changes."
148,P01024,Complement C3c alpha' chain fragment 2,1304-1320,SSKITHRIHWESASLLR,Complement C3f fragment,50,"{'6': '10432298', '7': '11387479', '8': '11773063', '9': '12540846', '10': '12754519', '11': '14760718', '12': '15833747', '13': '16263699', '14': '16333141', '15': '16335952', '16': '17051150', '17': '17351618', '18': '17634448', '19': '17684013', '20': '18160402', '21': '18796626', '22': '19112495', '23': '19159218', '24': '19615750', '25': '1976733', '26': '20083651', '27': '20513133', '28': '20951140', '29': '21055811', '30': '21285368', '31': '21317894', '32': '21502375', '33': '21527715', '34': '21555552', '35': '22028381', '36': '24036952', '37': '24367091', '38': '2473125', '39': '2579379', '40': '2584723', '41': '26091039', '42': '28264884', '43': '2849025', '44': '2909530', '45': '2972794', '46': '31507604', '47': '7539791', '48': '7961791', '49': '8175757', '50': '8376604', '51': '8416818', '52': '9059512', '53': '9555951'}","{'14', '44', '24', '52', '6', '12', '50'}","Adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for C5AR2. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of C5AR2 (PubMed:8376604, PubMed:2909530, PubMed:9059512, PubMed:10432298, PubMed:15833747, PubMed:16333141, PubMed:19615750).",16333141,,28,Targeting the signaling pathway of acylation stimulating protein.,"Maslowska, M. et al.",16333141,10.1194/jlr.m500500-jlr200,,16333141,"Acylation stimulating protein (ASP; C3adesArg) stimulates triglyceride synthesis (TGS) and glucose transport in preadipocytes/adipocytes through C5L2, a G-protein-coupled receptor. Here, ASP signaling is compared with insulin in 3T3-L1 cells. ASP stimulation is not Galpha(s) or Galpha(i) mediated (pertussis and cholera toxin insensitive), suggesting G(alphaq) as a candidate. Phospholipase C (PLC) is required, because the Ca(2+) chelator 1,2-bis(o-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid tetra(acetoxymethyl) ester and the PLC inhibitor U73122 decreased ASP stimulation of TGS by 93.1% (P < 0.0.001) and 86.1% (P < 0.004), respectively. Wortmannin and LY294002 blocked ASP effect by 69% (P < 0.001) and 116.1% (P < 0.003), respectively, supporting phosphatidylinositol 3-kinase (PI3K) involvement. ASP induced rapid, transient Akt phosphorylation (maximal, 5 min; basal, 45 min), which was blocked by Akt inhibition, resembling treatment by insulin. Downstream of PI3K, mamalian target of rapaycin (mTOR) is required for insulin but not ASP action. By contrast, both ASP and insulin activate the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK(1/2)) pathway, with rapid, pronounced increases in ERK(1/2) phosphorylation, effects partially blocked by PD98059 (64.7% and 65.9% inhibition, respectively; P < 0.001). Time-dependent (maximal, 30 min) transient calcium-dependent phospholipase A(2) (cPLA(2))(-Ser505) phosphorylation (by MAPK/ERK(1/2)) was demonstrated by Western blot analysis. ASP signaling involves sequential activation of PI3K and PLC, with downstream activation of protein kinase C, Akt, MAPK/ERK(1/2), and cPLA(2), all of which leads to an effective and prolonged stimulation of TGS."
149,P01024,Complement C3c alpha' chain fragment 2,1304-1320,SSKITHRIHWESASLLR,Complement C3f fragment,50,"{'6': '10432298', '7': '11387479', '8': '11773063', '9': '12540846', '10': '12754519', '11': '14760718', '12': '15833747', '13': '16263699', '14': '16333141', '15': '16335952', '16': '17051150', '17': '17351618', '18': '17634448', '19': '17684013', '20': '18160402', '21': '18796626', '22': '19112495', '23': '19159218', '24': '19615750', '25': '1976733', '26': '20083651', '27': '20513133', '28': '20951140', '29': '21055811', '30': '21285368', '31': '21317894', '32': '21502375', '33': '21527715', '34': '21555552', '35': '22028381', '36': '24036952', '37': '24367091', '38': '2473125', '39': '2579379', '40': '2584723', '41': '26091039', '42': '28264884', '43': '2849025', '44': '2909530', '45': '2972794', '46': '31507604', '47': '7539791', '48': '7961791', '49': '8175757', '50': '8376604', '51': '8416818', '52': '9059512', '53': '9555951'}","{'14', '44', '24', '52', '6', '12', '50'}","Adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for C5AR2. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of C5AR2 (PubMed:8376604, PubMed:2909530, PubMed:9059512, PubMed:10432298, PubMed:15833747, PubMed:16333141, PubMed:19615750).",15833747,,25,C5L2 is a functional receptor for acylation-stimulating protein.,"Kalant, D. et al.",15833747,10.1074/jbc.m406921200,,15833747,"C5L2 binds acylation-stimulating protein (ASP) with high affinity and is expressed in ASP-responsive cells. Functionality of C5L2 has not yet been demonstrated. Here we show that C5L2 is expressed in human subcutaneous and omental adipose tissue in both preadipocytes and adipocytes. In mice, C5L2 is expressed in all adipose tissues, at levels comparable with other tissues. Stable transfection of human C5L2 cDNA into HEK293 cells results in ASP stimulation of triglyceride synthesis (TGS) (193 +/- 33%, 5 microM ASP, p < 0.001, where basal = 100%) and glucose transport (168 +/- 21%, 10 microM ASP, p < 0.001). C3a similarly stimulates TGS (163 +/- 12%, p < 0.001), but C5a and C5a des-Arg have no effect. The ASP mechanism is to increase Vmax of glucose transport (149%) and triglyceride (TG) synthesis activity (165%) through increased diacylglycerolacyltransferase activity (200%). Antisense oligonucleotide down-regulation of C5L2 in human skin fibroblasts decreases cell surface C5L2 (down to 54 +/- 4% of control, p < 0.001, comparable with nonimmune background). ASP response is coordinately lost (basal TGS = 14.6 +/- 1.6, with ASP = 21.0 +/- 1.4 (144%), with ASP + oligonucleotides = 11.0 +/- 0.8 pmol of TG/mg of cell protein, p < 0.001). In mouse 3T3-L1 preadipocytes, antisense oligonucleotides decrease C5L2 expression to 69.5 +/- 0.5% of control, p < 0.001 (comparable with nonimmune) with a loss of ASP stimulation (basal TGS = 22.4 +/- 2.9, with ASP = 39.6 +/- 8.8 (177%), with ASP + oligonucleotides = 25.3 +/- 3.0 pmol of TG/mg of cell protein, p < 0.001). C5L2 down-regulation and decreased ASP response correlate (r = 0.761, p < 0.0001 for HSF and r = 0.451, p < 0.05 for 3T3-L1). In HEK-hC5L2 expressing fluorescently tagged beta-arrestin, ASP induced beta-arrestin translocation to the plasma membrane and formation of endocytic complexes concurrently with increased phosphorylation of C5L2. This is the first demonstration that C5L2 is a functional receptor, mediating ASP triglyceride stimulation."
150,P01024,Complement C3c alpha' chain fragment 2,1304-1320,SSKITHRIHWESASLLR,Complement C3f fragment,50,"{'6': '10432298', '7': '11387479', '8': '11773063', '9': '12540846', '10': '12754519', '11': '14760718', '12': '15833747', '13': '16263699', '14': '16333141', '15': '16335952', '16': '17051150', '17': '17351618', '18': '17634448', '19': '17684013', '20': '18160402', '21': '18796626', '22': '19112495', '23': '19159218', '24': '19615750', '25': '1976733', '26': '20083651', '27': '20513133', '28': '20951140', '29': '21055811', '30': '21285368', '31': '21317894', '32': '21502375', '33': '21527715', '34': '21555552', '35': '22028381', '36': '24036952', '37': '24367091', '38': '2473125', '39': '2579379', '40': '2584723', '41': '26091039', '42': '28264884', '43': '2849025', '44': '2909530', '45': '2972794', '46': '31507604', '47': '7539791', '48': '7961791', '49': '8175757', '50': '8376604', '51': '8416818', '52': '9059512', '53': '9555951'}","{'14', '44', '24', '52', '6', '12', '50'}","Adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for C5AR2. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of C5AR2 (PubMed:8376604, PubMed:2909530, PubMed:9059512, PubMed:10432298, PubMed:15833747, PubMed:16333141, PubMed:19615750).",2909530,,13,Purification and characterization of acylation stimulating protein.,"Cianflone, K. et al.",2909530,10.1016/s0021-9258(17)31275-9,,2909530,"We have purified to homogeneity and analyzed the amino acid composition of a small (Mr 14,000), basic (pI 9.0) protein from human plasma. This has been named acylation stimulating protein (ASP) because it markedly stimulates triacylglycerol synthesis in human adipocytes. As well, it stimulates triacylglycerol synthesis in human skin fibroblasts cultured from normal individuals. Characteristic saturation curves for the cell metabolic responses to ASP were observed in both cell types with higher stimulation of oleate incorporation into triacylglycerol being observed in adipocytes. The stimulation of triacylglycerol synthesis was much greater with ASP than with insulin. Neither fatty acid binding protein nor albumin was able to mimic the ASP effect."
151,P61278,,31-43,LRQFLQKSLAAAA,Neuronostatin,,"{'5': '29615476', '6': '29615476'}","{'2', '5', '3'}","May enhance low-glucose-induced glucagon release by pancreatic alpha cells (By similarity). This effect may be mediated by binding to GPR107 and PKA activation (By similarity). May regulate cardiac contractile function (By similarity). May compromise cardiomyocyte viability (By similarity). In the central nervous system, may impair memory retention and may affect hippocampal excitability (By similarity). May also have anxiolytic and anorexigenic effects (By similarity). May play a role in arterial pressure regulation (By similarity). May inhibit basal, but not ghrelin- or GnRH-stimulated secretion of GH1 or LH, but does not affect the release of other pituitary hormones, including PRL, ACTH, FSH or TSH. Potentiates inhibitory action of somatostatin on ghrelin-stimulated secretion of GH1, but not that on GnRH-stimulated secretion of LH (PubMed:29615476).",29615476,,7,Neuronostatin exerts actions on pituitary that are unique from its sibling peptide somatostatin.,"Luque, R. et al.",29615476,10.1530/joe-18-0135,,29615476,"Neuronostatin, a somatostatin gene-encoded peptide, exerts important physiological and metabolic actions in diverse tissues. However, the direct biological effects of neuronostatin on pituitary function of humans and primates are still unknown. This study used baboon (<i>Papio anubis</i>) primary pituitary cell cultures, a species that closely models human physiology, to demonstrate that neuronostatin inhibits basal, but not ghrelin-/GnRH-stimulated, growth hormone (GH) and luteinizing hormone (LH) secretion in a dose- and time-dependent fashion, without affecting the secretion of other pituitary hormones (prolactin, ACTH, FSH, thyroid-stimulating hormone (TSH)) or changing mRNA levels. Actions of neuronostatin differs from somatostatin which in this study reduced GH/PRL/ACTH/LH/TSH secretion and GH/PRL/POMC/LH gene expression. Remarkably, we found that inhibitory actions of neuronostatin are likely mediated through: (1) the orphan receptor GPCR107 (found to be highly expressed in pituitary compared to somatostatin-receptors), (2) common (i.e. adenylyl cyclase/protein kinase A/MAPK/extra-/intracellular Ca<sup>2+</sup> mobilization, but not phospholipase C/protein kinase C/mTOR) and distinct (i.e. PI3K) signaling pathways than somatostatin and; (3) dissimilar molecular mechanisms than somatostatin (i.e. upregulation of GPCR107 and downregulation of GHS-R/Kiss1-R expression by neuronostatin and, upregulation of sst1-5 expression by somatostatin). Altogether, the results of this study provide the first evidence that there is a functional neuronostatin signaling circuit, unique from somatostatin, which may work in concert with somatostatin to fine-tune hormone release from somatostropes and gonadotropes."
152,P61278,,103-116,AGCKNFFWKTFTSC,Somatostatin-14,,"{'5': '29615476', '6': '29615476'}",{'5'},"Inhibits the secretion of pituitary hormones, including that of growth hormone/somatotropin (GH1), PRL, ACTH, luteinizing hormone (LH) and TSH. Also impairs ghrelin- and GnRH-stimulated secretion of GH1 and LH; the inhibition of ghrelin-stimulated secretion of GH1 can be further increased by neuronostatin.",29615476,,7,Neuronostatin exerts actions on pituitary that are unique from its sibling peptide somatostatin.,"Luque, R. et al.",29615476,10.1530/joe-18-0135,,29615476,"Neuronostatin, a somatostatin gene-encoded peptide, exerts important physiological and metabolic actions in diverse tissues. However, the direct biological effects of neuronostatin on pituitary function of humans and primates are still unknown. This study used baboon (<i>Papio anubis</i>) primary pituitary cell cultures, a species that closely models human physiology, to demonstrate that neuronostatin inhibits basal, but not ghrelin-/GnRH-stimulated, growth hormone (GH) and luteinizing hormone (LH) secretion in a dose- and time-dependent fashion, without affecting the secretion of other pituitary hormones (prolactin, ACTH, FSH, thyroid-stimulating hormone (TSH)) or changing mRNA levels. Actions of neuronostatin differs from somatostatin which in this study reduced GH/PRL/ACTH/LH/TSH secretion and GH/PRL/POMC/LH gene expression. Remarkably, we found that inhibitory actions of neuronostatin are likely mediated through: (1) the orphan receptor GPCR107 (found to be highly expressed in pituitary compared to somatostatin-receptors), (2) common (i.e. adenylyl cyclase/protein kinase A/MAPK/extra-/intracellular Ca<sup>2+</sup> mobilization, but not phospholipase C/protein kinase C/mTOR) and distinct (i.e. PI3K) signaling pathways than somatostatin and; (3) dissimilar molecular mechanisms than somatostatin (i.e. upregulation of GPCR107 and downregulation of GHS-R/Kiss1-R expression by neuronostatin and, upregulation of sst1-5 expression by somatostatin). Altogether, the results of this study provide the first evidence that there is a functional neuronostatin signaling circuit, unique from somatostatin, which may work in concert with somatostatin to fine-tune hormone release from somatostropes and gonadotropes."
153,P30990,Large neuromedin N,151-163,QLYENKPRRPYIL,Neurotensin,7,"{'2': '11294867', '3': '19122660', '4': '23140271', '5': '6208535', '7': '6208535'}",,,6208535,['Neurotensin may play an endocrine or paracrine role in the regulation of fat metabolism. It causes contraction of smooth muscle.'],4,Hydrolysis of substance p and neurotensin by converting enzyme and neutral endopeptidase.,"Skidgel, R. et al.",6208535,10.1016/0196-9781(84)90020-2,,6208535,"Angiotensin I converting enzyme (ACE) and neutral endopeptidase (""enkephalinase""; NEP), were purified to homogeneity from human kidney. NEP cleaved substance P (SP) at Gln6-Phe7,-Phe8, and Gly9-Leu10 and neurotensin (NT) at Pro10-Tyr11 and Tyr11-Ile12. NEP hydrolyzed 0.1 mM SP, NT and their C-terminal fragments at the following rates (mumol/min/mg): SP1-11 = 7.8, SP4-11 = 11.7, SP5-11 = 15.4, SP6-11 = 15.6, SP8-11 = 6.7, NT1-13 = 2.9, and NT8-13 = 4.0. Purified ACE rapidly inactivated SP as measured in bioassay. HPLC analysis showed that ACE cleaved SP at Phe8-Gly9 and Gly9-Leu10 to release C-terminal tri- and dipeptide (ratio = 4:1). The hydrolysis was Cl- dependent and inhibited by captopril. ACE released mainly C-terminal tripeptide from SP methyl ester, but only dipeptide from SP free acid. Modification of arginine residues in ACE with cyclohexanedione or butanedione similarly inhibited hydrolysis of SP, bradykinin and Bz-Gly-Phe-Arg (80-93%) indicating an active site arginine is required for hydrolysis of SP. ACE hydrolyzed NT at Tyr11-Ile12 to release Ile12-Leu13. SP, NT and their derivatives (0.1 mM) were cleaved by ACE at the following rates (mumol/min/mg): SP1-11 = 1.2, SP methyl ester = 0.7, SP free acid = 8.5, SP4-11 = 2.4, SP5-11 = 0.9, SP6-11 = 1.4, SP8-11 = 0, NT1-13 = 0.2, and NT8-13 = 1.3. Peptide substrates were used as inhibitors of ACE (substrate = FA-Phe-Gly-Gly) and NEP (substrate = Leu5-enkephalin).(ABSTRACT TRUNCATED AT 250 WORDS)"
154,P49913,,132-170,FALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide FALL-39,16,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}","{'16', '19'}",Exhibits antimicrobial activity against E.coli and B.megaterium (in vitro).,8681941,,5,The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes.,"Gudmundsson, G. et al.",8681941,10.1111/j.1432-1033.1996.0325z.x,134-143,8681941,"The peptide FA-LL-37, previously termed FALL-39, was originally predicted from on ORF of a cDNA clone isolated from a human bone marrow library. This peptide was synthesized and found to have antibacterial activity. We have now characterized and sequenced the complete gene for FA-LL-37, termed FALL39. It is a compact gene of 1963 bp with four exons. Exons 1-3 code for a signal sequence and the cathelin region. Exon 4 contains the information for the mature antibacterial peptide. Our results indicate that FALL39 is the only member of the cathelin gene family present in the human genome. Potential binding sites for acute-phase-response factors are identified in the promoter and in intron 2. A possible role for the cytokine interleukin-6 in the regulation of FALL 39 is discussed. Anti-(FA-LL-37) IgG located the peptide in granulocytes and we isolated the mature peptide from these cells after degranulation. Structural analysis determined the mature peptide to be LL-37. To obtain LL-37 for antibacterial assays, synthetic FA-LL-37 was degraded with dipeptidyl-peptidase I. This analysis showed that mature LL-37 is a potent antibacterial peptide."
155,P49913,,132-170,FALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide FALL-39,16,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}","{'16', '19'}",Exhibits antimicrobial activity against E.coli and B.megaterium (in vitro).,7529412,,1,"FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis.","Agerberth, B. et al.",7529412,10.1073/pnas.92.1.195,,7529412,"PR-39, a proline/arginine-rich peptide antibiotic, has been purified from pig intestine and later shown to originate in the bone marrow. Intending to isolate a clone for a human counterpart to PR-39, we synthesized a PCR probe derived from the PR-39 gene. However, when this probe was used to screen a human bone marrow cDNA library, eight clones were obtained with information for another putative human peptide antibiotic, designated FALL-39 after the first four residues. FALL-39 is a 39-residue peptide lacking cysteine and tryptophan. All human peptide antibiotics previously isolated (or predicted) belong to the defensin family and contain three disulfide bridges. The clone for prepro-FALL-39 encodes a cathelin-like precursor protein with 170 amino acid residues. We have postulated a dibasic processing site for the mature FALL-39 and chemically synthesized the putative peptide. In basal medium E, synthetic FALL-39 was highly active against Escherichia coli and Bacillus megaterium. Residues 13-34 in FALL-39 can be predicted to form a perfect amphiphatic helix, and CD spectra showed that medium E induced 30% helix formation in FALL-39. RNA blot analyses disclosed that the gene for FALL-39 is expressed mainly in human bone marrow and testis."
156,P49913,,134-170,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide LL-37,19,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}","{'16', '19'}","Antimicrobial peptide that is an integral component of the innate immune system (PubMed:8681941, PubMed:9736536, PubMed:10417311, PubMed:15778390, PubMed:22879591, PubMed:34708076, PubMed:16637646, PubMed:18818205, PubMed:32753597, PubMed:33060695). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:10417311, PubMed:33060695). Causes membrane permeabilization by forming transmembrane pores (in vitro) (PubMed:22879591, PubMed:32753597, PubMed:33060695). Causes lysis of E.coli (PubMed:10417311). Exhibits antimicrobial activity against Gram-negative bacteria such as P.aeruginosa, S.typhimurium, E.aerogenes, E.coli and P.syringae, Gram-positive bacteria such as L.monocytogenes, S.epidermidis, S.pyogenes and S.aureus, as well as vancomycin-resistant enterococci (in vitro) (PubMed:8681941, PubMed:9736536, PubMed:10417311, PubMed:32753597). Exhibits antimicrobial activity against methicillin-resistant S.aureus, P.mirabilis, and C.albicans in low-salt media, but not in media containing 100 mM NaCl (in vitro) (PubMed:9736536). Forms chiral supramolecular assemblies with quinolone signal (PQS) molecules of P.aeruginosa, which may lead to interference of bacterial quorum signaling and perturbance of bacterial biofilm formation (PubMed:34708076). May form supramolecular fiber-like assemblies on bacterial membranes (PubMed:29133814). Induces cytokine and chemokine production as well as TNF/TNFA and CSF2/GMCSF production in normal human keratinocytes (PubMed:15778390). Exhibits hemolytic activity against red blood cells (PubMed:10417311).; Exhibits antimicrobial activity against E.coli and B.megaterium (in vitro).",33060695,,\,,,,,,33060695,
157,P49913,,134-170,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide LL-37,19,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}","{'16', '19'}","Antimicrobial peptide that is an integral component of the innate immune system (PubMed:8681941, PubMed:9736536, PubMed:10417311, PubMed:15778390, PubMed:22879591, PubMed:34708076, PubMed:16637646, PubMed:18818205, PubMed:32753597, PubMed:33060695). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:10417311, PubMed:33060695). Causes membrane permeabilization by forming transmembrane pores (in vitro) (PubMed:22879591, PubMed:32753597, PubMed:33060695). Causes lysis of E.coli (PubMed:10417311). Exhibits antimicrobial activity against Gram-negative bacteria such as P.aeruginosa, S.typhimurium, E.aerogenes, E.coli and P.syringae, Gram-positive bacteria such as L.monocytogenes, S.epidermidis, S.pyogenes and S.aureus, as well as vancomycin-resistant enterococci (in vitro) (PubMed:8681941, PubMed:9736536, PubMed:10417311, PubMed:32753597). Exhibits antimicrobial activity against methicillin-resistant S.aureus, P.mirabilis, and C.albicans in low-salt media, but not in media containing 100 mM NaCl (in vitro) (PubMed:9736536). Forms chiral supramolecular assemblies with quinolone signal (PQS) molecules of P.aeruginosa, which may lead to interference of bacterial quorum signaling and perturbance of bacterial biofilm formation (PubMed:34708076). May form supramolecular fiber-like assemblies on bacterial membranes (PubMed:29133814). Induces cytokine and chemokine production as well as TNF/TNFA and CSF2/GMCSF production in normal human keratinocytes (PubMed:15778390). Exhibits hemolytic activity against red blood cells (PubMed:10417311).; Exhibits antimicrobial activity against E.coli and B.megaterium (in vitro).",29133814,,,,,,,,29133814,
158,P49913,,134-170,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide LL-37,19,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}","{'16', '19'}","Antimicrobial peptide that is an integral component of the innate immune system (PubMed:8681941, PubMed:9736536, PubMed:10417311, PubMed:15778390, PubMed:22879591, PubMed:34708076, PubMed:16637646, PubMed:18818205, PubMed:32753597, PubMed:33060695). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:10417311, PubMed:33060695). Causes membrane permeabilization by forming transmembrane pores (in vitro) (PubMed:22879591, PubMed:32753597, PubMed:33060695). Causes lysis of E.coli (PubMed:10417311). Exhibits antimicrobial activity against Gram-negative bacteria such as P.aeruginosa, S.typhimurium, E.aerogenes, E.coli and P.syringae, Gram-positive bacteria such as L.monocytogenes, S.epidermidis, S.pyogenes and S.aureus, as well as vancomycin-resistant enterococci (in vitro) (PubMed:8681941, PubMed:9736536, PubMed:10417311, PubMed:32753597). Exhibits antimicrobial activity against methicillin-resistant S.aureus, P.mirabilis, and C.albicans in low-salt media, but not in media containing 100 mM NaCl (in vitro) (PubMed:9736536). Forms chiral supramolecular assemblies with quinolone signal (PQS) molecules of P.aeruginosa, which may lead to interference of bacterial quorum signaling and perturbance of bacterial biofilm formation (PubMed:34708076). May form supramolecular fiber-like assemblies on bacterial membranes (PubMed:29133814). Induces cytokine and chemokine production as well as TNF/TNFA and CSF2/GMCSF production in normal human keratinocytes (PubMed:15778390). Exhibits hemolytic activity against red blood cells (PubMed:10417311).; Exhibits antimicrobial activity against E.coli and B.megaterium (in vitro).",9736536,,11,"Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils.","Turner, J. et al.",9736536,10.1128/aac.42.9.2206,,9736536,"Human neutrophils contain two structurally distinct types of antimicrobial peptides, beta-sheet defensins (HNP-1 to HNP-4) and the alpha-helical peptide LL-37. We used radial diffusion assays and an improved National Committee for Clinical Laboratory Standards-type broth microdilution assay to compare the antimicrobial properties of LL-37, HNP-1, and protegrin (PG-1). Although generally less potent than PG-1, LL-37 showed considerable activity (MIC, <10 microgram/ml) against Pseudomonas aeruginosa, Salmonella typhimurium, Escherichia coli, Listeria monocytogenes, Staphylococcus epidermidis, Staphylococcus aureus, and vancomycin-resistant enterococci, even in media that contained 100 mM NaCl. Certain organisms (methicillin-resistant S. aureus, Proteus mirabilis, and Candida albicans) were resistant to LL-37 in media that contained 100 mM NaCl but were susceptible in low-salt media. Burkholderia cepacia was resistant to LL-37, PG-1, and HNP-1 in low- or high-salt media. LL-37 caused outer and inner membrane permeabilization of E. coli ML-35p. Chromogenic Limulus assays revealed that LL-37 bound to E. coli O111:B4 lipopolysaccharide (LPS) with a high affinity and that this binding showed positive cooperativity (Hill coefficient = 2.02). Circular dichroism spectrometry disclosed that LL-37 underwent conformational change in the presence of lipid A, transitioning from a random coil to an alpha-helical structure. The broad-spectrum antimicrobial properties of LL-37, its presence in neutrophils, and its inducibility in keratinocytes all suggest that this peptide and its precursor (hCAP-18) may protect skin and other tissues from bacterial intrusions and LPS-induced toxicity. The potent activity of LL-37 against P. aeruginosa, including mucoid and antibiotic-resistant strains, suggests that it or related molecules might have utility as topical bronchopulmonary microbicides in cystic fibrosis."
159,P49913,,134-170,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide LL-37,19,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}","{'16', '19'}","Antimicrobial peptide that is an integral component of the innate immune system (PubMed:8681941, PubMed:9736536, PubMed:10417311, PubMed:15778390, PubMed:22879591, PubMed:34708076, PubMed:16637646, PubMed:18818205, PubMed:32753597, PubMed:33060695). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:10417311, PubMed:33060695). Causes membrane permeabilization by forming transmembrane pores (in vitro) (PubMed:22879591, PubMed:32753597, PubMed:33060695). Causes lysis of E.coli (PubMed:10417311). Exhibits antimicrobial activity against Gram-negative bacteria such as P.aeruginosa, S.typhimurium, E.aerogenes, E.coli and P.syringae, Gram-positive bacteria such as L.monocytogenes, S.epidermidis, S.pyogenes and S.aureus, as well as vancomycin-resistant enterococci (in vitro) (PubMed:8681941, PubMed:9736536, PubMed:10417311, PubMed:32753597). Exhibits antimicrobial activity against methicillin-resistant S.aureus, P.mirabilis, and C.albicans in low-salt media, but not in media containing 100 mM NaCl (in vitro) (PubMed:9736536). Forms chiral supramolecular assemblies with quinolone signal (PQS) molecules of P.aeruginosa, which may lead to interference of bacterial quorum signaling and perturbance of bacterial biofilm formation (PubMed:34708076). May form supramolecular fiber-like assemblies on bacterial membranes (PubMed:29133814). Induces cytokine and chemokine production as well as TNF/TNFA and CSF2/GMCSF production in normal human keratinocytes (PubMed:15778390). Exhibits hemolytic activity against red blood cells (PubMed:10417311).; Exhibits antimicrobial activity against E.coli and B.megaterium (in vitro).",15778390,,15,Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities.,"Braff, M. et al.",15778390,10.4049/jimmunol.174.7.4271,,15778390,"Cathelicidins and other antimicrobial peptides are deployed at epithelial surfaces to defend against infection. These molecules have broad-spectrum killing activity against microbes and can have effects on specific mammalian cell types, potentially stimulating additional immune defense through direct chemotactic activity or induction of cytokine release. In humans, the cathelicidin hCAP18/LL-37 is processed to LL-37 in neutrophils, but on skin it can be further proteolytically processed to shorter forms. The influence of these cathelicidin peptides on keratinocyte function is not known. In the current study, DNA microarray analysis and confirmatory protein analysis showed that LL-37 affects the expression of several chemokines and cytokines by keratinocytes. Analysis of a synthetic peptide library derived from LL-37 showed that antimicrobial activity against bacterial, fungal, and viral skin pathogens resides within specific domains of the parent peptide, but antimicrobial activity does not directly correlate with the ability to stimulate IL-8 production in keratinocytes. IL-8 release was induced by d- and l-amino acid forms of cathelicidin and correlated with membrane permeability, suggesting that highly structure-specific binding to a cell surface receptor is not likely. However, this effect was inhibited by either pertussis toxin or AG1478, an epidermal growth factor receptor tyrosine kinase inhibitor, suggesting that cathelicidin may indirectly stimulate multiple signaling pathways associated with cell surface receptors. Taken together, these observations suggest that proteolytic processing may alter the balance between cathelicidin antimicrobial and host immunostimulatory functions."
160,P49913,,134-170,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide LL-37,19,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}","{'16', '19'}","Antimicrobial peptide that is an integral component of the innate immune system (PubMed:8681941, PubMed:9736536, PubMed:10417311, PubMed:15778390, PubMed:22879591, PubMed:34708076, PubMed:16637646, PubMed:18818205, PubMed:32753597, PubMed:33060695). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:10417311, PubMed:33060695). Causes membrane permeabilization by forming transmembrane pores (in vitro) (PubMed:22879591, PubMed:32753597, PubMed:33060695). Causes lysis of E.coli (PubMed:10417311). Exhibits antimicrobial activity against Gram-negative bacteria such as P.aeruginosa, S.typhimurium, E.aerogenes, E.coli and P.syringae, Gram-positive bacteria such as L.monocytogenes, S.epidermidis, S.pyogenes and S.aureus, as well as vancomycin-resistant enterococci (in vitro) (PubMed:8681941, PubMed:9736536, PubMed:10417311, PubMed:32753597). Exhibits antimicrobial activity against methicillin-resistant S.aureus, P.mirabilis, and C.albicans in low-salt media, but not in media containing 100 mM NaCl (in vitro) (PubMed:9736536). Forms chiral supramolecular assemblies with quinolone signal (PQS) molecules of P.aeruginosa, which may lead to interference of bacterial quorum signaling and perturbance of bacterial biofilm formation (PubMed:34708076). May form supramolecular fiber-like assemblies on bacterial membranes (PubMed:29133814). Induces cytokine and chemokine production as well as TNF/TNFA and CSF2/GMCSF production in normal human keratinocytes (PubMed:15778390). Exhibits hemolytic activity against red blood cells (PubMed:10417311).; Exhibits antimicrobial activity against E.coli and B.megaterium (in vitro).",8681941,,5,The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes.,"Gudmundsson, G. et al.",8681941,10.1111/j.1432-1033.1996.0325z.x,134-143,8681941,"The peptide FA-LL-37, previously termed FALL-39, was originally predicted from on ORF of a cDNA clone isolated from a human bone marrow library. This peptide was synthesized and found to have antibacterial activity. We have now characterized and sequenced the complete gene for FA-LL-37, termed FALL39. It is a compact gene of 1963 bp with four exons. Exons 1-3 code for a signal sequence and the cathelin region. Exon 4 contains the information for the mature antibacterial peptide. Our results indicate that FALL39 is the only member of the cathelin gene family present in the human genome. Potential binding sites for acute-phase-response factors are identified in the promoter and in intron 2. A possible role for the cytokine interleukin-6 in the regulation of FALL 39 is discussed. Anti-(FA-LL-37) IgG located the peptide in granulocytes and we isolated the mature peptide from these cells after degranulation. Structural analysis determined the mature peptide to be LL-37. To obtain LL-37 for antibacterial assays, synthetic FA-LL-37 was degraded with dipeptidyl-peptidase I. This analysis showed that mature LL-37 is a potent antibacterial peptide."
161,P49913,,134-170,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide LL-37,19,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}","{'16', '19'}","Antimicrobial peptide that is an integral component of the innate immune system (PubMed:8681941, PubMed:9736536, PubMed:10417311, PubMed:15778390, PubMed:22879591, PubMed:34708076, PubMed:16637646, PubMed:18818205, PubMed:32753597, PubMed:33060695). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:10417311, PubMed:33060695). Causes membrane permeabilization by forming transmembrane pores (in vitro) (PubMed:22879591, PubMed:32753597, PubMed:33060695). Causes lysis of E.coli (PubMed:10417311). Exhibits antimicrobial activity against Gram-negative bacteria such as P.aeruginosa, S.typhimurium, E.aerogenes, E.coli and P.syringae, Gram-positive bacteria such as L.monocytogenes, S.epidermidis, S.pyogenes and S.aureus, as well as vancomycin-resistant enterococci (in vitro) (PubMed:8681941, PubMed:9736536, PubMed:10417311, PubMed:32753597). Exhibits antimicrobial activity against methicillin-resistant S.aureus, P.mirabilis, and C.albicans in low-salt media, but not in media containing 100 mM NaCl (in vitro) (PubMed:9736536). Forms chiral supramolecular assemblies with quinolone signal (PQS) molecules of P.aeruginosa, which may lead to interference of bacterial quorum signaling and perturbance of bacterial biofilm formation (PubMed:34708076). May form supramolecular fiber-like assemblies on bacterial membranes (PubMed:29133814). Induces cytokine and chemokine production as well as TNF/TNFA and CSF2/GMCSF production in normal human keratinocytes (PubMed:15778390). Exhibits hemolytic activity against red blood cells (PubMed:10417311).; Exhibits antimicrobial activity against E.coli and B.megaterium (in vitro).",7529412,,1,"FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis.","Agerberth, B. et al.",7529412,10.1073/pnas.92.1.195,,7529412,"PR-39, a proline/arginine-rich peptide antibiotic, has been purified from pig intestine and later shown to originate in the bone marrow. Intending to isolate a clone for a human counterpart to PR-39, we synthesized a PCR probe derived from the PR-39 gene. However, when this probe was used to screen a human bone marrow cDNA library, eight clones were obtained with information for another putative human peptide antibiotic, designated FALL-39 after the first four residues. FALL-39 is a 39-residue peptide lacking cysteine and tryptophan. All human peptide antibiotics previously isolated (or predicted) belong to the defensin family and contain three disulfide bridges. The clone for prepro-FALL-39 encodes a cathelin-like precursor protein with 170 amino acid residues. We have postulated a dibasic processing site for the mature FALL-39 and chemically synthesized the putative peptide. In basal medium E, synthetic FALL-39 was highly active against Escherichia coli and Bacillus megaterium. Residues 13-34 in FALL-39 can be predicted to form a perfect amphiphatic helix, and CD spectra showed that medium E induced 30% helix formation in FALL-39. RNA blot analyses disclosed that the gene for FALL-39 is expressed mainly in human bone marrow and testis."
162,P49913,,134-170,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide LL-37,19,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}","{'16', '19'}","Antimicrobial peptide that is an integral component of the innate immune system (PubMed:8681941, PubMed:9736536, PubMed:10417311, PubMed:15778390, PubMed:22879591, PubMed:34708076, PubMed:16637646, PubMed:18818205, PubMed:32753597, PubMed:33060695). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:10417311, PubMed:33060695). Causes membrane permeabilization by forming transmembrane pores (in vitro) (PubMed:22879591, PubMed:32753597, PubMed:33060695). Causes lysis of E.coli (PubMed:10417311). Exhibits antimicrobial activity against Gram-negative bacteria such as P.aeruginosa, S.typhimurium, E.aerogenes, E.coli and P.syringae, Gram-positive bacteria such as L.monocytogenes, S.epidermidis, S.pyogenes and S.aureus, as well as vancomycin-resistant enterococci (in vitro) (PubMed:8681941, PubMed:9736536, PubMed:10417311, PubMed:32753597). Exhibits antimicrobial activity against methicillin-resistant S.aureus, P.mirabilis, and C.albicans in low-salt media, but not in media containing 100 mM NaCl (in vitro) (PubMed:9736536). Forms chiral supramolecular assemblies with quinolone signal (PQS) molecules of P.aeruginosa, which may lead to interference of bacterial quorum signaling and perturbance of bacterial biofilm formation (PubMed:34708076). May form supramolecular fiber-like assemblies on bacterial membranes (PubMed:29133814). Induces cytokine and chemokine production as well as TNF/TNFA and CSF2/GMCSF production in normal human keratinocytes (PubMed:15778390). Exhibits hemolytic activity against red blood cells (PubMed:10417311).; Exhibits antimicrobial activity against E.coli and B.megaterium (in vitro).",34708076,,18,Quorum Sensing Pseudomonas Quinolone Signal Forms Chiral Supramolecular Assemblies With the Host Defense Peptide LL-37.,"Zsila, F. et al.",34708076,10.3389/fmolb.2021.742023,,34708076,"Host defense antimicrobial peptides (HDPs) constitute an integral component of the innate immune system having nonspecific activity against a broad spectrum of microorganisms. They also have diverse biological functions in wound healing, angiogenesis, and immunomodulation, where it has also been demonstrated that they have a high affinity to interact with human lipid signaling molecules. Within bacterial biofilms, quorum sensing (QS), the vital bacterial cell-to-cell communication system, is maintained by similar diffusible small molecules which control phenotypic traits, virulence factors, biofilm formation, and dispersion. Efficient eradication of bacterial biofilms is of particular importance as these colonies greatly help individual cells to tolerate antibiotics and develop antimicrobial resistance. Regarding the antibacterial function, for several HDPs, including the human cathelicidin LL-37, affinity to eradicate biofilms can exceed their activity to kill individual bacteria. However, related underlying molecular mechanisms have not been explored yet. Here, we employed circular dichroism (CD) and UV/VIS spectroscopic analysis, which revealed that LL-37 exhibits QS signal affinity. This archetypal representative of HDPs interacts with the <i>Pseudomonas</i> quinolone signal (PQS) molecules, producing co-assemblies with peculiar optical activity. The binding of PQS onto the asymmetric peptide chains results in chiral supramolecular architectures consisting of helically disposed, J-aggregated molecules. Besides the well-known bacterial membrane disruption activity, our data propose a novel action mechanism of LL-37. As a specific case of the so-called quorum quenching, QS signal molecules captured by the peptide are sequestered inside co-assemblies, which may interfere with the microbial QS network helping to prevent and eradicate bacterial infections."
163,P49913,,134-170,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide LL-37,19,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}","{'16', '19'}","Antimicrobial peptide that is an integral component of the innate immune system (PubMed:8681941, PubMed:9736536, PubMed:10417311, PubMed:15778390, PubMed:22879591, PubMed:34708076, PubMed:16637646, PubMed:18818205, PubMed:32753597, PubMed:33060695). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:10417311, PubMed:33060695). Causes membrane permeabilization by forming transmembrane pores (in vitro) (PubMed:22879591, PubMed:32753597, PubMed:33060695). Causes lysis of E.coli (PubMed:10417311). Exhibits antimicrobial activity against Gram-negative bacteria such as P.aeruginosa, S.typhimurium, E.aerogenes, E.coli and P.syringae, Gram-positive bacteria such as L.monocytogenes, S.epidermidis, S.pyogenes and S.aureus, as well as vancomycin-resistant enterococci (in vitro) (PubMed:8681941, PubMed:9736536, PubMed:10417311, PubMed:32753597). Exhibits antimicrobial activity against methicillin-resistant S.aureus, P.mirabilis, and C.albicans in low-salt media, but not in media containing 100 mM NaCl (in vitro) (PubMed:9736536). Forms chiral supramolecular assemblies with quinolone signal (PQS) molecules of P.aeruginosa, which may lead to interference of bacterial quorum signaling and perturbance of bacterial biofilm formation (PubMed:34708076). May form supramolecular fiber-like assemblies on bacterial membranes (PubMed:29133814). Induces cytokine and chemokine production as well as TNF/TNFA and CSF2/GMCSF production in normal human keratinocytes (PubMed:15778390). Exhibits hemolytic activity against red blood cells (PubMed:10417311).; Exhibits antimicrobial activity against E.coli and B.megaterium (in vitro).",16637646,,,,,,,,16637646,
164,P49913,,134-170,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide LL-37,19,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}","{'16', '19'}","Antimicrobial peptide that is an integral component of the innate immune system (PubMed:8681941, PubMed:9736536, PubMed:10417311, PubMed:15778390, PubMed:22879591, PubMed:34708076, PubMed:16637646, PubMed:18818205, PubMed:32753597, PubMed:33060695). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:10417311, PubMed:33060695). Causes membrane permeabilization by forming transmembrane pores (in vitro) (PubMed:22879591, PubMed:32753597, PubMed:33060695). Causes lysis of E.coli (PubMed:10417311). Exhibits antimicrobial activity against Gram-negative bacteria such as P.aeruginosa, S.typhimurium, E.aerogenes, E.coli and P.syringae, Gram-positive bacteria such as L.monocytogenes, S.epidermidis, S.pyogenes and S.aureus, as well as vancomycin-resistant enterococci (in vitro) (PubMed:8681941, PubMed:9736536, PubMed:10417311, PubMed:32753597). Exhibits antimicrobial activity against methicillin-resistant S.aureus, P.mirabilis, and C.albicans in low-salt media, but not in media containing 100 mM NaCl (in vitro) (PubMed:9736536). Forms chiral supramolecular assemblies with quinolone signal (PQS) molecules of P.aeruginosa, which may lead to interference of bacterial quorum signaling and perturbance of bacterial biofilm formation (PubMed:34708076). May form supramolecular fiber-like assemblies on bacterial membranes (PubMed:29133814). Induces cytokine and chemokine production as well as TNF/TNFA and CSF2/GMCSF production in normal human keratinocytes (PubMed:15778390). Exhibits hemolytic activity against red blood cells (PubMed:10417311).; Exhibits antimicrobial activity against E.coli and B.megaterium (in vitro).",10417311,,12,Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity.,"Oren, Z. et al.",10417311,10.1042/bj3410501,,10417311,"The antimicrobial peptide LL-37 belongs to the cathelicidin family and is the first amphipathic alpha-helical peptide isolated from human. LL-37 is considered to play an important role in the first line of defence against local infection and systemic invasion of pathogens at sites of inflammation and wounds. Understanding its mode of action may assist in the development of antimicrobial agents mimicking those of the human immune system. In vitro studies revealed that LL-37 is cytotoxic to both bacterial and normal eukaryotic cells. To gain insight into the mechanism of its non-cell-selective cytotoxicity, we synthesized and structurally and functionally characterized LL-37, its N-terminal truncated form FF-33, and their fluorescent derivatives (which retained structure and activity). The results showed several differences, between LL-37 and other native antimicrobial peptides, that may shed light on its in vivo activities. Most interestingly, LL-37 exists in equilibrium between monomers and oligomers in solution at very low concentrations. Also, it is significantly resistant to proteolytic degradation in solution, and when bound to both zwitterionic (mimicking mammalian membranes) and negatively charged membranes (mimicking bacterial membranes). The results also showed a role for the N-terminus in proteolytic resistance and haemolytic activity, but not in antimicrobial activity. The LL-37 mode of action with negatively charged membranes suggests a detergent-like effect via a 'carpet-like' mechanism. However, the ability of LL-37 to oligomerize in zwitterionic membranes might suggest the formation of a transmembrane pore in normal eukaryotic cells. To examine this possibility we used polarized attenuated total reflectance Fourier-transform infrared spectroscopy and found that the peptide is predominantly alpha-helical and oriented nearly parallel with the surface of zwitterionic-lipid membranes. This result does not support the channel-forming hypothesis, but rather it supports the detergent-like effect."
165,P49913,,134-170,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide LL-37,19,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}","{'16', '19'}","Antimicrobial peptide that is an integral component of the innate immune system (PubMed:8681941, PubMed:9736536, PubMed:10417311, PubMed:15778390, PubMed:22879591, PubMed:34708076, PubMed:16637646, PubMed:18818205, PubMed:32753597, PubMed:33060695). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:10417311, PubMed:33060695). Causes membrane permeabilization by forming transmembrane pores (in vitro) (PubMed:22879591, PubMed:32753597, PubMed:33060695). Causes lysis of E.coli (PubMed:10417311). Exhibits antimicrobial activity against Gram-negative bacteria such as P.aeruginosa, S.typhimurium, E.aerogenes, E.coli and P.syringae, Gram-positive bacteria such as L.monocytogenes, S.epidermidis, S.pyogenes and S.aureus, as well as vancomycin-resistant enterococci (in vitro) (PubMed:8681941, PubMed:9736536, PubMed:10417311, PubMed:32753597). Exhibits antimicrobial activity against methicillin-resistant S.aureus, P.mirabilis, and C.albicans in low-salt media, but not in media containing 100 mM NaCl (in vitro) (PubMed:9736536). Forms chiral supramolecular assemblies with quinolone signal (PQS) molecules of P.aeruginosa, which may lead to interference of bacterial quorum signaling and perturbance of bacterial biofilm formation (PubMed:34708076). May form supramolecular fiber-like assemblies on bacterial membranes (PubMed:29133814). Induces cytokine and chemokine production as well as TNF/TNFA and CSF2/GMCSF production in normal human keratinocytes (PubMed:15778390). Exhibits hemolytic activity against red blood cells (PubMed:10417311).; Exhibits antimicrobial activity against E.coli and B.megaterium (in vitro).",22879591,,17,Cathepsin G-regulated release of formyl peptide receptor agonists modulate neutrophil effector functions.,"Woloszynek, J. et al.",22879591,10.1074/jbc.m112.394452,,22879591,"Neutrophil serine proteases play an important role in inflammation by modulating neutrophil effector functions. We have previously shown that neutrophils deficient in the serine proteases cathepsin G and neutrophil elastase (CG/NE neutrophils) exhibit severe defects in chemokine CXCL2 release and reactive oxygen species (ROS) production when activated on immobilized immune complex. Exogenously added active CG rescues these defects, but the mechanism remains undefined. Using a protease-based proteomic approach, we found that, in vitro, the addition of exogenous CG to immune complex-stimulated CG/NE neutrophils led to a decrease in the level of cell-associated annexin A1 (AnxA1) and cathelin-related antimicrobial peptide (CRAMP), both known inflammatory mediators. We further confirmed that, in vivo, CG was required for the extracellular release of AnxA1 and CRAMP in a subcutaneous air pouch model. In vitro, CG efficiently cleaved AnxA1, releasing the active N-terminal peptide Ac2-26, and processed CRAMP in limited fashion. Ac2-26 and CRAMP peptides enhanced the release of CXCL2 by CG/NE neutrophils in a dose-dependent manner via formyl peptide receptor (FPR) stimulation. Blockade of FPRs by an antagonist, Boc2 (t-Boc-Phe-d-Leu-Phe-d-Leu-Phe), abrogates CXCL2 release, whereas addition of FPR agonists, fMLF and F2L, relieves Boc2 inhibition. Furthermore, the addition of active CG, but not inactive CG, also relieves Boc2 inhibition. These findings suggest that CG modulates neutrophil effector functions partly by controlling the release (and proteolysis) of FPR agonists. Unexpectedly, we found that mature CRAMP, but not Ac2-26, induced ROS production through an FPR-independent pathway."
166,P49913,,134-170,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide LL-37,19,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}","{'16', '19'}","Antimicrobial peptide that is an integral component of the innate immune system (PubMed:8681941, PubMed:9736536, PubMed:10417311, PubMed:15778390, PubMed:22879591, PubMed:34708076, PubMed:16637646, PubMed:18818205, PubMed:32753597, PubMed:33060695). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:10417311, PubMed:33060695). Causes membrane permeabilization by forming transmembrane pores (in vitro) (PubMed:22879591, PubMed:32753597, PubMed:33060695). Causes lysis of E.coli (PubMed:10417311). Exhibits antimicrobial activity against Gram-negative bacteria such as P.aeruginosa, S.typhimurium, E.aerogenes, E.coli and P.syringae, Gram-positive bacteria such as L.monocytogenes, S.epidermidis, S.pyogenes and S.aureus, as well as vancomycin-resistant enterococci (in vitro) (PubMed:8681941, PubMed:9736536, PubMed:10417311, PubMed:32753597). Exhibits antimicrobial activity against methicillin-resistant S.aureus, P.mirabilis, and C.albicans in low-salt media, but not in media containing 100 mM NaCl (in vitro) (PubMed:9736536). Forms chiral supramolecular assemblies with quinolone signal (PQS) molecules of P.aeruginosa, which may lead to interference of bacterial quorum signaling and perturbance of bacterial biofilm formation (PubMed:34708076). May form supramolecular fiber-like assemblies on bacterial membranes (PubMed:29133814). Induces cytokine and chemokine production as well as TNF/TNFA and CSF2/GMCSF production in normal human keratinocytes (PubMed:15778390). Exhibits hemolytic activity against red blood cells (PubMed:10417311).; Exhibits antimicrobial activity against E.coli and B.megaterium (in vitro).",18818205,,,,,,,,18818205,
167,P49913,,134-170,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide LL-37,19,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}","{'16', '19'}","Antimicrobial peptide that is an integral component of the innate immune system (PubMed:8681941, PubMed:9736536, PubMed:10417311, PubMed:15778390, PubMed:22879591, PubMed:34708076, PubMed:16637646, PubMed:18818205, PubMed:32753597, PubMed:33060695). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:10417311, PubMed:33060695). Causes membrane permeabilization by forming transmembrane pores (in vitro) (PubMed:22879591, PubMed:32753597, PubMed:33060695). Causes lysis of E.coli (PubMed:10417311). Exhibits antimicrobial activity against Gram-negative bacteria such as P.aeruginosa, S.typhimurium, E.aerogenes, E.coli and P.syringae, Gram-positive bacteria such as L.monocytogenes, S.epidermidis, S.pyogenes and S.aureus, as well as vancomycin-resistant enterococci (in vitro) (PubMed:8681941, PubMed:9736536, PubMed:10417311, PubMed:32753597). Exhibits antimicrobial activity against methicillin-resistant S.aureus, P.mirabilis, and C.albicans in low-salt media, but not in media containing 100 mM NaCl (in vitro) (PubMed:9736536). Forms chiral supramolecular assemblies with quinolone signal (PQS) molecules of P.aeruginosa, which may lead to interference of bacterial quorum signaling and perturbance of bacterial biofilm formation (PubMed:34708076). May form supramolecular fiber-like assemblies on bacterial membranes (PubMed:29133814). Induces cytokine and chemokine production as well as TNF/TNFA and CSF2/GMCSF production in normal human keratinocytes (PubMed:15778390). Exhibits hemolytic activity against red blood cells (PubMed:10417311).; Exhibits antimicrobial activity against E.coli and B.megaterium (in vitro).",32753597,,,,,,,,32753597,
168,P49913,,134-162,LLGDFFRKSKEKIGKEFKRIVQRIKDFLR,Antibacterial peptide LL-29,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",14978112,,14,Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense.,"Murakami, M. et al.",14978112,10.4049/jimmunol.172.5.3070,,14978112,"The production of antimicrobial peptides and proteins is essential for defense against infection. Many of the known human antimicrobial peptides are multifunctional, with stimulatory activities such as chemotaxis while simultaneously acting as natural antibiotics. In humans, eccrine appendages express DCD and CAMP, genes encoding proteins processed into the antimicrobial peptides dermcidin and LL-37. In this study we show that after secretion onto the skin surface, the CAMP gene product is processed by a serine protease-dependent mechanism into multiple novel antimicrobial peptides distinct from the cathelicidin LL-37. These peptides show enhanced antimicrobial action, acquiring the ability to kill skin pathogens such as Staphylococcus aureus and Candida albicans. Furthermore, although LL-37 may influence the host inflammatory response by stimulating IL-8 release from keratinocytes, this activity is lost in subsequently processed peptides. Thus, a single gene product encoding an important defense molecule alters structure and function in the topical environment to shift the balance of activity toward direct inhibition of microbial colonization."
169,P49913,,134-162,LLGDFFRKSKEKIGKEFKRIVQRIKDFLR,Antibacterial peptide LL-29,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",9736536,,11,"Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils.","Turner, J. et al.",9736536,10.1128/aac.42.9.2206,,9736536,"Human neutrophils contain two structurally distinct types of antimicrobial peptides, beta-sheet defensins (HNP-1 to HNP-4) and the alpha-helical peptide LL-37. We used radial diffusion assays and an improved National Committee for Clinical Laboratory Standards-type broth microdilution assay to compare the antimicrobial properties of LL-37, HNP-1, and protegrin (PG-1). Although generally less potent than PG-1, LL-37 showed considerable activity (MIC, <10 microgram/ml) against Pseudomonas aeruginosa, Salmonella typhimurium, Escherichia coli, Listeria monocytogenes, Staphylococcus epidermidis, Staphylococcus aureus, and vancomycin-resistant enterococci, even in media that contained 100 mM NaCl. Certain organisms (methicillin-resistant S. aureus, Proteus mirabilis, and Candida albicans) were resistant to LL-37 in media that contained 100 mM NaCl but were susceptible in low-salt media. Burkholderia cepacia was resistant to LL-37, PG-1, and HNP-1 in low- or high-salt media. LL-37 caused outer and inner membrane permeabilization of E. coli ML-35p. Chromogenic Limulus assays revealed that LL-37 bound to E. coli O111:B4 lipopolysaccharide (LPS) with a high affinity and that this binding showed positive cooperativity (Hill coefficient = 2.02). Circular dichroism spectrometry disclosed that LL-37 underwent conformational change in the presence of lipid A, transitioning from a random coil to an alpha-helical structure. The broad-spectrum antimicrobial properties of LL-37, its presence in neutrophils, and its inducibility in keratinocytes all suggest that this peptide and its precursor (hCAP-18) may protect skin and other tissues from bacterial intrusions and LPS-induced toxicity. The potent activity of LL-37 against P. aeruginosa, including mucoid and antibiotic-resistant strains, suggests that it or related molecules might have utility as topical bronchopulmonary microbicides in cystic fibrosis."
170,P49913,,134-162,LLGDFFRKSKEKIGKEFKRIVQRIKDFLR,Antibacterial peptide LL-29,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",16637646,,,,,,,,16637646,
171,P49913,,134-162,LLGDFFRKSKEKIGKEFKRIVQRIKDFLR,Antibacterial peptide LL-29,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",22879591,,17,Cathepsin G-regulated release of formyl peptide receptor agonists modulate neutrophil effector functions.,"Woloszynek, J. et al.",22879591,10.1074/jbc.m112.394452,,22879591,"Neutrophil serine proteases play an important role in inflammation by modulating neutrophil effector functions. We have previously shown that neutrophils deficient in the serine proteases cathepsin G and neutrophil elastase (CG/NE neutrophils) exhibit severe defects in chemokine CXCL2 release and reactive oxygen species (ROS) production when activated on immobilized immune complex. Exogenously added active CG rescues these defects, but the mechanism remains undefined. Using a protease-based proteomic approach, we found that, in vitro, the addition of exogenous CG to immune complex-stimulated CG/NE neutrophils led to a decrease in the level of cell-associated annexin A1 (AnxA1) and cathelin-related antimicrobial peptide (CRAMP), both known inflammatory mediators. We further confirmed that, in vivo, CG was required for the extracellular release of AnxA1 and CRAMP in a subcutaneous air pouch model. In vitro, CG efficiently cleaved AnxA1, releasing the active N-terminal peptide Ac2-26, and processed CRAMP in limited fashion. Ac2-26 and CRAMP peptides enhanced the release of CXCL2 by CG/NE neutrophils in a dose-dependent manner via formyl peptide receptor (FPR) stimulation. Blockade of FPRs by an antagonist, Boc2 (t-Boc-Phe-d-Leu-Phe-d-Leu-Phe), abrogates CXCL2 release, whereas addition of FPR agonists, fMLF and F2L, relieves Boc2 inhibition. Furthermore, the addition of active CG, but not inactive CG, also relieves Boc2 inhibition. These findings suggest that CG modulates neutrophil effector functions partly by controlling the release (and proteolysis) of FPR agonists. Unexpectedly, we found that mature CRAMP, but not Ac2-26, induced ROS production through an FPR-independent pathway."
172,P49913,,134-162,LLGDFFRKSKEKIGKEFKRIVQRIKDFLR,Antibacterial peptide LL-29,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",18818205,,,,,,,,18818205,
173,P49913,,134-156,LLGDFFRKSKEKIGKEFKRIVQR,Antibacterial peptide LL-23,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",14978112,,14,Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense.,"Murakami, M. et al.",14978112,10.4049/jimmunol.172.5.3070,,14978112,"The production of antimicrobial peptides and proteins is essential for defense against infection. Many of the known human antimicrobial peptides are multifunctional, with stimulatory activities such as chemotaxis while simultaneously acting as natural antibiotics. In humans, eccrine appendages express DCD and CAMP, genes encoding proteins processed into the antimicrobial peptides dermcidin and LL-37. In this study we show that after secretion onto the skin surface, the CAMP gene product is processed by a serine protease-dependent mechanism into multiple novel antimicrobial peptides distinct from the cathelicidin LL-37. These peptides show enhanced antimicrobial action, acquiring the ability to kill skin pathogens such as Staphylococcus aureus and Candida albicans. Furthermore, although LL-37 may influence the host inflammatory response by stimulating IL-8 release from keratinocytes, this activity is lost in subsequently processed peptides. Thus, a single gene product encoding an important defense molecule alters structure and function in the topical environment to shift the balance of activity toward direct inhibition of microbial colonization."
174,P49913,,134-156,LLGDFFRKSKEKIGKEFKRIVQR,Antibacterial peptide LL-23,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",9736536,,11,"Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils.","Turner, J. et al.",9736536,10.1128/aac.42.9.2206,,9736536,"Human neutrophils contain two structurally distinct types of antimicrobial peptides, beta-sheet defensins (HNP-1 to HNP-4) and the alpha-helical peptide LL-37. We used radial diffusion assays and an improved National Committee for Clinical Laboratory Standards-type broth microdilution assay to compare the antimicrobial properties of LL-37, HNP-1, and protegrin (PG-1). Although generally less potent than PG-1, LL-37 showed considerable activity (MIC, <10 microgram/ml) against Pseudomonas aeruginosa, Salmonella typhimurium, Escherichia coli, Listeria monocytogenes, Staphylococcus epidermidis, Staphylococcus aureus, and vancomycin-resistant enterococci, even in media that contained 100 mM NaCl. Certain organisms (methicillin-resistant S. aureus, Proteus mirabilis, and Candida albicans) were resistant to LL-37 in media that contained 100 mM NaCl but were susceptible in low-salt media. Burkholderia cepacia was resistant to LL-37, PG-1, and HNP-1 in low- or high-salt media. LL-37 caused outer and inner membrane permeabilization of E. coli ML-35p. Chromogenic Limulus assays revealed that LL-37 bound to E. coli O111:B4 lipopolysaccharide (LPS) with a high affinity and that this binding showed positive cooperativity (Hill coefficient = 2.02). Circular dichroism spectrometry disclosed that LL-37 underwent conformational change in the presence of lipid A, transitioning from a random coil to an alpha-helical structure. The broad-spectrum antimicrobial properties of LL-37, its presence in neutrophils, and its inducibility in keratinocytes all suggest that this peptide and its precursor (hCAP-18) may protect skin and other tissues from bacterial intrusions and LPS-induced toxicity. The potent activity of LL-37 against P. aeruginosa, including mucoid and antibiotic-resistant strains, suggests that it or related molecules might have utility as topical bronchopulmonary microbicides in cystic fibrosis."
175,P49913,,134-156,LLGDFFRKSKEKIGKEFKRIVQR,Antibacterial peptide LL-23,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",16637646,,,,,,,,16637646,
176,P49913,,134-156,LLGDFFRKSKEKIGKEFKRIVQR,Antibacterial peptide LL-23,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",22879591,,17,Cathepsin G-regulated release of formyl peptide receptor agonists modulate neutrophil effector functions.,"Woloszynek, J. et al.",22879591,10.1074/jbc.m112.394452,,22879591,"Neutrophil serine proteases play an important role in inflammation by modulating neutrophil effector functions. We have previously shown that neutrophils deficient in the serine proteases cathepsin G and neutrophil elastase (CG/NE neutrophils) exhibit severe defects in chemokine CXCL2 release and reactive oxygen species (ROS) production when activated on immobilized immune complex. Exogenously added active CG rescues these defects, but the mechanism remains undefined. Using a protease-based proteomic approach, we found that, in vitro, the addition of exogenous CG to immune complex-stimulated CG/NE neutrophils led to a decrease in the level of cell-associated annexin A1 (AnxA1) and cathelin-related antimicrobial peptide (CRAMP), both known inflammatory mediators. We further confirmed that, in vivo, CG was required for the extracellular release of AnxA1 and CRAMP in a subcutaneous air pouch model. In vitro, CG efficiently cleaved AnxA1, releasing the active N-terminal peptide Ac2-26, and processed CRAMP in limited fashion. Ac2-26 and CRAMP peptides enhanced the release of CXCL2 by CG/NE neutrophils in a dose-dependent manner via formyl peptide receptor (FPR) stimulation. Blockade of FPRs by an antagonist, Boc2 (t-Boc-Phe-d-Leu-Phe-d-Leu-Phe), abrogates CXCL2 release, whereas addition of FPR agonists, fMLF and F2L, relieves Boc2 inhibition. Furthermore, the addition of active CG, but not inactive CG, also relieves Boc2 inhibition. These findings suggest that CG modulates neutrophil effector functions partly by controlling the release (and proteolysis) of FPR agonists. Unexpectedly, we found that mature CRAMP, but not Ac2-26, induced ROS production through an FPR-independent pathway."
177,P49913,,134-156,LLGDFFRKSKEKIGKEFKRIVQR,Antibacterial peptide LL-23,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",18818205,,,,,,,,18818205,
178,P49913,,138-170,FFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide FF-33,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",14978112,,14,Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense.,"Murakami, M. et al.",14978112,10.4049/jimmunol.172.5.3070,,14978112,"The production of antimicrobial peptides and proteins is essential for defense against infection. Many of the known human antimicrobial peptides are multifunctional, with stimulatory activities such as chemotaxis while simultaneously acting as natural antibiotics. In humans, eccrine appendages express DCD and CAMP, genes encoding proteins processed into the antimicrobial peptides dermcidin and LL-37. In this study we show that after secretion onto the skin surface, the CAMP gene product is processed by a serine protease-dependent mechanism into multiple novel antimicrobial peptides distinct from the cathelicidin LL-37. These peptides show enhanced antimicrobial action, acquiring the ability to kill skin pathogens such as Staphylococcus aureus and Candida albicans. Furthermore, although LL-37 may influence the host inflammatory response by stimulating IL-8 release from keratinocytes, this activity is lost in subsequently processed peptides. Thus, a single gene product encoding an important defense molecule alters structure and function in the topical environment to shift the balance of activity toward direct inhibition of microbial colonization."
179,P49913,,138-170,FFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide FF-33,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",9736536,,11,"Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils.","Turner, J. et al.",9736536,10.1128/aac.42.9.2206,,9736536,"Human neutrophils contain two structurally distinct types of antimicrobial peptides, beta-sheet defensins (HNP-1 to HNP-4) and the alpha-helical peptide LL-37. We used radial diffusion assays and an improved National Committee for Clinical Laboratory Standards-type broth microdilution assay to compare the antimicrobial properties of LL-37, HNP-1, and protegrin (PG-1). Although generally less potent than PG-1, LL-37 showed considerable activity (MIC, <10 microgram/ml) against Pseudomonas aeruginosa, Salmonella typhimurium, Escherichia coli, Listeria monocytogenes, Staphylococcus epidermidis, Staphylococcus aureus, and vancomycin-resistant enterococci, even in media that contained 100 mM NaCl. Certain organisms (methicillin-resistant S. aureus, Proteus mirabilis, and Candida albicans) were resistant to LL-37 in media that contained 100 mM NaCl but were susceptible in low-salt media. Burkholderia cepacia was resistant to LL-37, PG-1, and HNP-1 in low- or high-salt media. LL-37 caused outer and inner membrane permeabilization of E. coli ML-35p. Chromogenic Limulus assays revealed that LL-37 bound to E. coli O111:B4 lipopolysaccharide (LPS) with a high affinity and that this binding showed positive cooperativity (Hill coefficient = 2.02). Circular dichroism spectrometry disclosed that LL-37 underwent conformational change in the presence of lipid A, transitioning from a random coil to an alpha-helical structure. The broad-spectrum antimicrobial properties of LL-37, its presence in neutrophils, and its inducibility in keratinocytes all suggest that this peptide and its precursor (hCAP-18) may protect skin and other tissues from bacterial intrusions and LPS-induced toxicity. The potent activity of LL-37 against P. aeruginosa, including mucoid and antibiotic-resistant strains, suggests that it or related molecules might have utility as topical bronchopulmonary microbicides in cystic fibrosis."
180,P49913,,138-170,FFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide FF-33,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",16637646,,,,,,,,16637646,
181,P49913,,138-170,FFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide FF-33,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",22879591,,17,Cathepsin G-regulated release of formyl peptide receptor agonists modulate neutrophil effector functions.,"Woloszynek, J. et al.",22879591,10.1074/jbc.m112.394452,,22879591,"Neutrophil serine proteases play an important role in inflammation by modulating neutrophil effector functions. We have previously shown that neutrophils deficient in the serine proteases cathepsin G and neutrophil elastase (CG/NE neutrophils) exhibit severe defects in chemokine CXCL2 release and reactive oxygen species (ROS) production when activated on immobilized immune complex. Exogenously added active CG rescues these defects, but the mechanism remains undefined. Using a protease-based proteomic approach, we found that, in vitro, the addition of exogenous CG to immune complex-stimulated CG/NE neutrophils led to a decrease in the level of cell-associated annexin A1 (AnxA1) and cathelin-related antimicrobial peptide (CRAMP), both known inflammatory mediators. We further confirmed that, in vivo, CG was required for the extracellular release of AnxA1 and CRAMP in a subcutaneous air pouch model. In vitro, CG efficiently cleaved AnxA1, releasing the active N-terminal peptide Ac2-26, and processed CRAMP in limited fashion. Ac2-26 and CRAMP peptides enhanced the release of CXCL2 by CG/NE neutrophils in a dose-dependent manner via formyl peptide receptor (FPR) stimulation. Blockade of FPRs by an antagonist, Boc2 (t-Boc-Phe-d-Leu-Phe-d-Leu-Phe), abrogates CXCL2 release, whereas addition of FPR agonists, fMLF and F2L, relieves Boc2 inhibition. Furthermore, the addition of active CG, but not inactive CG, also relieves Boc2 inhibition. These findings suggest that CG modulates neutrophil effector functions partly by controlling the release (and proteolysis) of FPR agonists. Unexpectedly, we found that mature CRAMP, but not Ac2-26, induced ROS production through an FPR-independent pathway."
182,P49913,,138-170,FFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide FF-33,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",18818205,,,,,,,,18818205,
183,P49913,,140-170,RKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide RK-31,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",14978112,,14,Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense.,"Murakami, M. et al.",14978112,10.4049/jimmunol.172.5.3070,,14978112,"The production of antimicrobial peptides and proteins is essential for defense against infection. Many of the known human antimicrobial peptides are multifunctional, with stimulatory activities such as chemotaxis while simultaneously acting as natural antibiotics. In humans, eccrine appendages express DCD and CAMP, genes encoding proteins processed into the antimicrobial peptides dermcidin and LL-37. In this study we show that after secretion onto the skin surface, the CAMP gene product is processed by a serine protease-dependent mechanism into multiple novel antimicrobial peptides distinct from the cathelicidin LL-37. These peptides show enhanced antimicrobial action, acquiring the ability to kill skin pathogens such as Staphylococcus aureus and Candida albicans. Furthermore, although LL-37 may influence the host inflammatory response by stimulating IL-8 release from keratinocytes, this activity is lost in subsequently processed peptides. Thus, a single gene product encoding an important defense molecule alters structure and function in the topical environment to shift the balance of activity toward direct inhibition of microbial colonization."
184,P49913,,140-170,RKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide RK-31,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",9736536,,11,"Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils.","Turner, J. et al.",9736536,10.1128/aac.42.9.2206,,9736536,"Human neutrophils contain two structurally distinct types of antimicrobial peptides, beta-sheet defensins (HNP-1 to HNP-4) and the alpha-helical peptide LL-37. We used radial diffusion assays and an improved National Committee for Clinical Laboratory Standards-type broth microdilution assay to compare the antimicrobial properties of LL-37, HNP-1, and protegrin (PG-1). Although generally less potent than PG-1, LL-37 showed considerable activity (MIC, <10 microgram/ml) against Pseudomonas aeruginosa, Salmonella typhimurium, Escherichia coli, Listeria monocytogenes, Staphylococcus epidermidis, Staphylococcus aureus, and vancomycin-resistant enterococci, even in media that contained 100 mM NaCl. Certain organisms (methicillin-resistant S. aureus, Proteus mirabilis, and Candida albicans) were resistant to LL-37 in media that contained 100 mM NaCl but were susceptible in low-salt media. Burkholderia cepacia was resistant to LL-37, PG-1, and HNP-1 in low- or high-salt media. LL-37 caused outer and inner membrane permeabilization of E. coli ML-35p. Chromogenic Limulus assays revealed that LL-37 bound to E. coli O111:B4 lipopolysaccharide (LPS) with a high affinity and that this binding showed positive cooperativity (Hill coefficient = 2.02). Circular dichroism spectrometry disclosed that LL-37 underwent conformational change in the presence of lipid A, transitioning from a random coil to an alpha-helical structure. The broad-spectrum antimicrobial properties of LL-37, its presence in neutrophils, and its inducibility in keratinocytes all suggest that this peptide and its precursor (hCAP-18) may protect skin and other tissues from bacterial intrusions and LPS-induced toxicity. The potent activity of LL-37 against P. aeruginosa, including mucoid and antibiotic-resistant strains, suggests that it or related molecules might have utility as topical bronchopulmonary microbicides in cystic fibrosis."
185,P49913,,140-170,RKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide RK-31,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",16637646,,,,,,,,16637646,
186,P49913,,140-170,RKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide RK-31,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",22879591,,17,Cathepsin G-regulated release of formyl peptide receptor agonists modulate neutrophil effector functions.,"Woloszynek, J. et al.",22879591,10.1074/jbc.m112.394452,,22879591,"Neutrophil serine proteases play an important role in inflammation by modulating neutrophil effector functions. We have previously shown that neutrophils deficient in the serine proteases cathepsin G and neutrophil elastase (CG/NE neutrophils) exhibit severe defects in chemokine CXCL2 release and reactive oxygen species (ROS) production when activated on immobilized immune complex. Exogenously added active CG rescues these defects, but the mechanism remains undefined. Using a protease-based proteomic approach, we found that, in vitro, the addition of exogenous CG to immune complex-stimulated CG/NE neutrophils led to a decrease in the level of cell-associated annexin A1 (AnxA1) and cathelin-related antimicrobial peptide (CRAMP), both known inflammatory mediators. We further confirmed that, in vivo, CG was required for the extracellular release of AnxA1 and CRAMP in a subcutaneous air pouch model. In vitro, CG efficiently cleaved AnxA1, releasing the active N-terminal peptide Ac2-26, and processed CRAMP in limited fashion. Ac2-26 and CRAMP peptides enhanced the release of CXCL2 by CG/NE neutrophils in a dose-dependent manner via formyl peptide receptor (FPR) stimulation. Blockade of FPRs by an antagonist, Boc2 (t-Boc-Phe-d-Leu-Phe-d-Leu-Phe), abrogates CXCL2 release, whereas addition of FPR agonists, fMLF and F2L, relieves Boc2 inhibition. Furthermore, the addition of active CG, but not inactive CG, also relieves Boc2 inhibition. These findings suggest that CG modulates neutrophil effector functions partly by controlling the release (and proteolysis) of FPR agonists. Unexpectedly, we found that mature CRAMP, but not Ac2-26, induced ROS production through an FPR-independent pathway."
187,P49913,,140-170,RKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide RK-31,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",18818205,,,,,,,,18818205,
188,P49913,,141-170,KSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide KS-30,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",14978112,,14,Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense.,"Murakami, M. et al.",14978112,10.4049/jimmunol.172.5.3070,,14978112,"The production of antimicrobial peptides and proteins is essential for defense against infection. Many of the known human antimicrobial peptides are multifunctional, with stimulatory activities such as chemotaxis while simultaneously acting as natural antibiotics. In humans, eccrine appendages express DCD and CAMP, genes encoding proteins processed into the antimicrobial peptides dermcidin and LL-37. In this study we show that after secretion onto the skin surface, the CAMP gene product is processed by a serine protease-dependent mechanism into multiple novel antimicrobial peptides distinct from the cathelicidin LL-37. These peptides show enhanced antimicrobial action, acquiring the ability to kill skin pathogens such as Staphylococcus aureus and Candida albicans. Furthermore, although LL-37 may influence the host inflammatory response by stimulating IL-8 release from keratinocytes, this activity is lost in subsequently processed peptides. Thus, a single gene product encoding an important defense molecule alters structure and function in the topical environment to shift the balance of activity toward direct inhibition of microbial colonization."
189,P49913,,141-170,KSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide KS-30,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",9736536,,11,"Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils.","Turner, J. et al.",9736536,10.1128/aac.42.9.2206,,9736536,"Human neutrophils contain two structurally distinct types of antimicrobial peptides, beta-sheet defensins (HNP-1 to HNP-4) and the alpha-helical peptide LL-37. We used radial diffusion assays and an improved National Committee for Clinical Laboratory Standards-type broth microdilution assay to compare the antimicrobial properties of LL-37, HNP-1, and protegrin (PG-1). Although generally less potent than PG-1, LL-37 showed considerable activity (MIC, <10 microgram/ml) against Pseudomonas aeruginosa, Salmonella typhimurium, Escherichia coli, Listeria monocytogenes, Staphylococcus epidermidis, Staphylococcus aureus, and vancomycin-resistant enterococci, even in media that contained 100 mM NaCl. Certain organisms (methicillin-resistant S. aureus, Proteus mirabilis, and Candida albicans) were resistant to LL-37 in media that contained 100 mM NaCl but were susceptible in low-salt media. Burkholderia cepacia was resistant to LL-37, PG-1, and HNP-1 in low- or high-salt media. LL-37 caused outer and inner membrane permeabilization of E. coli ML-35p. Chromogenic Limulus assays revealed that LL-37 bound to E. coli O111:B4 lipopolysaccharide (LPS) with a high affinity and that this binding showed positive cooperativity (Hill coefficient = 2.02). Circular dichroism spectrometry disclosed that LL-37 underwent conformational change in the presence of lipid A, transitioning from a random coil to an alpha-helical structure. The broad-spectrum antimicrobial properties of LL-37, its presence in neutrophils, and its inducibility in keratinocytes all suggest that this peptide and its precursor (hCAP-18) may protect skin and other tissues from bacterial intrusions and LPS-induced toxicity. The potent activity of LL-37 against P. aeruginosa, including mucoid and antibiotic-resistant strains, suggests that it or related molecules might have utility as topical bronchopulmonary microbicides in cystic fibrosis."
190,P49913,,141-170,KSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide KS-30,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",16637646,,,,,,,,16637646,
191,P49913,,141-170,KSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide KS-30,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",22879591,,17,Cathepsin G-regulated release of formyl peptide receptor agonists modulate neutrophil effector functions.,"Woloszynek, J. et al.",22879591,10.1074/jbc.m112.394452,,22879591,"Neutrophil serine proteases play an important role in inflammation by modulating neutrophil effector functions. We have previously shown that neutrophils deficient in the serine proteases cathepsin G and neutrophil elastase (CG/NE neutrophils) exhibit severe defects in chemokine CXCL2 release and reactive oxygen species (ROS) production when activated on immobilized immune complex. Exogenously added active CG rescues these defects, but the mechanism remains undefined. Using a protease-based proteomic approach, we found that, in vitro, the addition of exogenous CG to immune complex-stimulated CG/NE neutrophils led to a decrease in the level of cell-associated annexin A1 (AnxA1) and cathelin-related antimicrobial peptide (CRAMP), both known inflammatory mediators. We further confirmed that, in vivo, CG was required for the extracellular release of AnxA1 and CRAMP in a subcutaneous air pouch model. In vitro, CG efficiently cleaved AnxA1, releasing the active N-terminal peptide Ac2-26, and processed CRAMP in limited fashion. Ac2-26 and CRAMP peptides enhanced the release of CXCL2 by CG/NE neutrophils in a dose-dependent manner via formyl peptide receptor (FPR) stimulation. Blockade of FPRs by an antagonist, Boc2 (t-Boc-Phe-d-Leu-Phe-d-Leu-Phe), abrogates CXCL2 release, whereas addition of FPR agonists, fMLF and F2L, relieves Boc2 inhibition. Furthermore, the addition of active CG, but not inactive CG, also relieves Boc2 inhibition. These findings suggest that CG modulates neutrophil effector functions partly by controlling the release (and proteolysis) of FPR agonists. Unexpectedly, we found that mature CRAMP, but not Ac2-26, induced ROS production through an FPR-independent pathway."
192,P49913,,141-170,KSKEKIGKEFKRIVQRIKDFLRNLVPRTES,Antibacterial peptide KS-30,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",18818205,,,,,,,,18818205,
193,P49913,,151-170,KRIVQRIKDFLRNLVPRTES,Antibacterial peptide KR-20,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",14978112,,14,Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense.,"Murakami, M. et al.",14978112,10.4049/jimmunol.172.5.3070,,14978112,"The production of antimicrobial peptides and proteins is essential for defense against infection. Many of the known human antimicrobial peptides are multifunctional, with stimulatory activities such as chemotaxis while simultaneously acting as natural antibiotics. In humans, eccrine appendages express DCD and CAMP, genes encoding proteins processed into the antimicrobial peptides dermcidin and LL-37. In this study we show that after secretion onto the skin surface, the CAMP gene product is processed by a serine protease-dependent mechanism into multiple novel antimicrobial peptides distinct from the cathelicidin LL-37. These peptides show enhanced antimicrobial action, acquiring the ability to kill skin pathogens such as Staphylococcus aureus and Candida albicans. Furthermore, although LL-37 may influence the host inflammatory response by stimulating IL-8 release from keratinocytes, this activity is lost in subsequently processed peptides. Thus, a single gene product encoding an important defense molecule alters structure and function in the topical environment to shift the balance of activity toward direct inhibition of microbial colonization."
194,P49913,,151-170,KRIVQRIKDFLRNLVPRTES,Antibacterial peptide KR-20,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",9736536,,11,"Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils.","Turner, J. et al.",9736536,10.1128/aac.42.9.2206,,9736536,"Human neutrophils contain two structurally distinct types of antimicrobial peptides, beta-sheet defensins (HNP-1 to HNP-4) and the alpha-helical peptide LL-37. We used radial diffusion assays and an improved National Committee for Clinical Laboratory Standards-type broth microdilution assay to compare the antimicrobial properties of LL-37, HNP-1, and protegrin (PG-1). Although generally less potent than PG-1, LL-37 showed considerable activity (MIC, <10 microgram/ml) against Pseudomonas aeruginosa, Salmonella typhimurium, Escherichia coli, Listeria monocytogenes, Staphylococcus epidermidis, Staphylococcus aureus, and vancomycin-resistant enterococci, even in media that contained 100 mM NaCl. Certain organisms (methicillin-resistant S. aureus, Proteus mirabilis, and Candida albicans) were resistant to LL-37 in media that contained 100 mM NaCl but were susceptible in low-salt media. Burkholderia cepacia was resistant to LL-37, PG-1, and HNP-1 in low- or high-salt media. LL-37 caused outer and inner membrane permeabilization of E. coli ML-35p. Chromogenic Limulus assays revealed that LL-37 bound to E. coli O111:B4 lipopolysaccharide (LPS) with a high affinity and that this binding showed positive cooperativity (Hill coefficient = 2.02). Circular dichroism spectrometry disclosed that LL-37 underwent conformational change in the presence of lipid A, transitioning from a random coil to an alpha-helical structure. The broad-spectrum antimicrobial properties of LL-37, its presence in neutrophils, and its inducibility in keratinocytes all suggest that this peptide and its precursor (hCAP-18) may protect skin and other tissues from bacterial intrusions and LPS-induced toxicity. The potent activity of LL-37 against P. aeruginosa, including mucoid and antibiotic-resistant strains, suggests that it or related molecules might have utility as topical bronchopulmonary microbicides in cystic fibrosis."
195,P49913,,151-170,KRIVQRIKDFLRNLVPRTES,Antibacterial peptide KR-20,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",16637646,,,,,,,,16637646,
196,P49913,,151-170,KRIVQRIKDFLRNLVPRTES,Antibacterial peptide KR-20,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",22879591,,17,Cathepsin G-regulated release of formyl peptide receptor agonists modulate neutrophil effector functions.,"Woloszynek, J. et al.",22879591,10.1074/jbc.m112.394452,,22879591,"Neutrophil serine proteases play an important role in inflammation by modulating neutrophil effector functions. We have previously shown that neutrophils deficient in the serine proteases cathepsin G and neutrophil elastase (CG/NE neutrophils) exhibit severe defects in chemokine CXCL2 release and reactive oxygen species (ROS) production when activated on immobilized immune complex. Exogenously added active CG rescues these defects, but the mechanism remains undefined. Using a protease-based proteomic approach, we found that, in vitro, the addition of exogenous CG to immune complex-stimulated CG/NE neutrophils led to a decrease in the level of cell-associated annexin A1 (AnxA1) and cathelin-related antimicrobial peptide (CRAMP), both known inflammatory mediators. We further confirmed that, in vivo, CG was required for the extracellular release of AnxA1 and CRAMP in a subcutaneous air pouch model. In vitro, CG efficiently cleaved AnxA1, releasing the active N-terminal peptide Ac2-26, and processed CRAMP in limited fashion. Ac2-26 and CRAMP peptides enhanced the release of CXCL2 by CG/NE neutrophils in a dose-dependent manner via formyl peptide receptor (FPR) stimulation. Blockade of FPRs by an antagonist, Boc2 (t-Boc-Phe-d-Leu-Phe-d-Leu-Phe), abrogates CXCL2 release, whereas addition of FPR agonists, fMLF and F2L, relieves Boc2 inhibition. Furthermore, the addition of active CG, but not inactive CG, also relieves Boc2 inhibition. These findings suggest that CG modulates neutrophil effector functions partly by controlling the release (and proteolysis) of FPR agonists. Unexpectedly, we found that mature CRAMP, but not Ac2-26, induced ROS production through an FPR-independent pathway."
197,P49913,,151-170,KRIVQRIKDFLRNLVPRTES,Antibacterial peptide KR-20,4,"{'2': '10417311', '3': '11389039', '4': '14978112', '5': '15778390', '6': '16637646', '7': '18818205', '8': '22185690', '9': '22879591', '10': '23406372', '11': '29133814', '12': '32753597', '13': '33060695', '14': '34708076', '15': '35061360', '16': '7529412', '17': '7615076', '18': '7890387', '19': '8681941', '20': '8946956', '21': '9736536', '22': '14978112', '23': '7529412', '24': '7615076', '25': '8681941', '26': '8946956', '27': '9736536'}",{'4'},"Antimicrobial protein that is an integral component of the innate immune system (PubMed:22879591, PubMed:16637646, PubMed:18818205, PubMed:9736536, PubMed:14978112). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112).; Moderately antibacterial.; Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112).; Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells.",18818205,,,,,,,,18818205,
198,P02788,Lactotransferrin,171-201,FFSASCVPGADKGQFPNLCRLCAGTGENKCA,Kaliocin-1,,"{'2': '10089347', '3': '10792619', '4': '10828980', '5': '11083624', '6': '11128996', '7': '11179314', '8': '11702692', '9': '12037297', '10': '12037568', '11': '12450380', '12': '12535064', '13': '12693969', '14': '1369293', '15': '14573629', '16': '14702039', '17': '15166119', '18': '15222485', '19': '15299444', '20': '15299793', '21': '15489334', '22': '15687491', '23': '1581307', '24': '1599934', '25': '16048952', '26': '16201406', '27': '16842782', '28': '17079302', '29': '17481742', '30': '17543335', '31': '17567961', '32': '18780401', '33': '19033648', '34': '19159218', '35': '20345905', '36': '20404350', '37': '22320386', '38': '22406253', '39': '22900286', '40': '2374734', '41': '2402455', '42': '25946035', '43': '2981589', '44': '3169987', '45': '6802759', '46': '8069634', '47': '8371268', '48': '8594202', '49': '8703903', '50': '8931543', '51': '9003186', '52': '9122171', '53': '9359845', '54': '9873069', '65': '14702039', '66': '9122171', '68': '12535064'}",{'13'},Has antimicrobial activity and is able to permeabilize different ions through liposomal membranes.,12693969,,38,Potassium efflux induced by a new lactoferrin-derived peptide mimicking the effect of native human lactoferrin on the bacterial cytoplasmic membrane.,"Viejo-Diaz, M. et al.",12693969,10.1023/a:1022657630698,,12693969,"A 31-amino acid synthetic peptide (NH(2)-FFSASCVPGADKGQFPNLCRLCAGTGENKCA-COOH) was chemically synthesized based on the amino acid sequence of a region of human lactoferrin homologous to other sequences present in the N- and C-lobes of all members of the transferrin family proteins. The peptide, termed kaliocin-1, and lactoferrin showed a bactericidal effect in assays performed in low-ionic-strength conditions. This is the first time that it is shown that the antimicrobial effect of lactoferrin depends on the extracellular cation concentration. The antimicrobial effect of kaliocin-1 was lower than that of human lactoferrin, but their activities were inhibited by Na(+) or K(+) in a cation concentration-dependent manner. In addition, the peptide was able to mimic native lactoferrin, inducing K(+)-efflux and a selective dissipation of the transmembrane electrical potential of Escherichia coli cells without causing extensive damage to the outer and inner bacterial membranes. In contrast, the peptide, but not lactoferrin, was able to permeabilize different ions through liposomal membranes. The hypothetical interaction of kaliocin-1 with a bacterial membrane compound is discussed based in the different ion flux induced on cellular and artificial membranes as well as data from circular dichroism assays. Kaliocin-1 was not cytotoxic and could be a suitable model for the design of analogs able to mimic the antibacterial effect of human lactoferrin."
199,P02788,Lactotransferrin,338-343,YLGSGY,Lactoferroxin-A,,"{'2': '10089347', '3': '10792619', '4': '10828980', '5': '11083624', '6': '11128996', '7': '11179314', '8': '11702692', '9': '12037297', '10': '12037568', '11': '12450380', '12': '12535064', '13': '12693969', '14': '1369293', '15': '14573629', '16': '14702039', '17': '15166119', '18': '15222485', '19': '15299444', '20': '15299793', '21': '15489334', '22': '15687491', '23': '1581307', '24': '1599934', '25': '16048952', '26': '16201406', '27': '16842782', '28': '17079302', '29': '17481742', '30': '17543335', '31': '17567961', '32': '18780401', '33': '19033648', '34': '19159218', '35': '20345905', '36': '20404350', '37': '22320386', '38': '22406253', '39': '22900286', '40': '2374734', '41': '2402455', '42': '25946035', '43': '2981589', '44': '3169987', '45': '6802759', '46': '8069634', '47': '8371268', '48': '8594202', '49': '8703903', '50': '8931543', '51': '9003186', '52': '9122171', '53': '9359845', '54': '9873069', '65': '14702039', '66': '9122171', '68': '12535064'}",{'14'},Has opioid antagonist activity (PubMed:1369293). Shows preference for mu-receptor (PubMed:1369293).,1369293,,31,Isolation and characterization of opioid antagonist peptides derived from human lactoferrin.,"Tani, F. et al.",1369293,10.1271/bbb1961.54.1803,,1369293,"Peptides with affinity for opioid receptors were found in an artificially methyl-esterified peptic digest of human lactoferrin. Three active peptides were purified by two steps of reverse-phase high-performance liquid chromatography. Their structures were Tyr-Leu-Gly-Ser-Gly-Tyr-OCH3, Arg-Tyr-Tyr-Gly-Tyr-OCH2, and Lys-Tyr-Leu-Gly-Pro-Gln-Tyr-OCH3, which respectively correspond to the methyl esters of residues 318-323, 536-540, and 673-679 of human lactoferrin. The IC50 values of these peptides were 15, 10 and 23 microM, respectively, in a radioreceptor assay in the presence of 1 nM [3H]naloxone. In the myenteric plexus preparation of the longitudinal muscle of guinea pig ileum, the individual peptides had no opioid agonist activities, but they antagonized [Met5]enkephalin and morphiceptin when they were at a concentration of 10(-6)-10(-5) M, suggesting that these were the opioid antagonist peptides. These three opioid antagonist peptides were named lactoferroxin A, B and C, after casoxin, the opioid antagonist peptide derived from bovine kappa-casein. Concerning the antagonist activities of lactoferroxins for opioid receptor sub-types, lactoferroxin A showed preference for mu-receptors, while lactoferroxin B and C had somewhat higher degrees of preference for kappa-receptors than for mu-receptors. A study of the structure-activity relationship of the three lactoferroxins and their synthetic analogues showed that these opioid antagonist peptides derived from food protein could be expressed by the general formula XA-Tyr-XB-Tyr-OCH3. An amino acid in position XA may affect the specificity of the antagonist peptide for opioid receptor sub-types."
200,P02788,Lactotransferrin,543-547,RYYGY,Lactoferroxin-B,,"{'2': '10089347', '3': '10792619', '4': '10828980', '5': '11083624', '6': '11128996', '7': '11179314', '8': '11702692', '9': '12037297', '10': '12037568', '11': '12450380', '12': '12535064', '13': '12693969', '14': '1369293', '15': '14573629', '16': '14702039', '17': '15166119', '18': '15222485', '19': '15299444', '20': '15299793', '21': '15489334', '22': '15687491', '23': '1581307', '24': '1599934', '25': '16048952', '26': '16201406', '27': '16842782', '28': '17079302', '29': '17481742', '30': '17543335', '31': '17567961', '32': '18780401', '33': '19033648', '34': '19159218', '35': '20345905', '36': '20404350', '37': '22320386', '38': '22406253', '39': '22900286', '40': '2374734', '41': '2402455', '42': '25946035', '43': '2981589', '44': '3169987', '45': '6802759', '46': '8069634', '47': '8371268', '48': '8594202', '49': '8703903', '50': '8931543', '51': '9003186', '52': '9122171', '53': '9359845', '54': '9873069', '65': '14702039', '66': '9122171', '68': '12535064'}",{'14'},Has opioid antagonist activity (PubMed:1369293). Shows higher degrees of preference for kappa-receptors than for mu-receptors (PubMed:1369293).,1369293,,31,Isolation and characterization of opioid antagonist peptides derived from human lactoferrin.,"Tani, F. et al.",1369293,10.1271/bbb1961.54.1803,,1369293,"Peptides with affinity for opioid receptors were found in an artificially methyl-esterified peptic digest of human lactoferrin. Three active peptides were purified by two steps of reverse-phase high-performance liquid chromatography. Their structures were Tyr-Leu-Gly-Ser-Gly-Tyr-OCH3, Arg-Tyr-Tyr-Gly-Tyr-OCH2, and Lys-Tyr-Leu-Gly-Pro-Gln-Tyr-OCH3, which respectively correspond to the methyl esters of residues 318-323, 536-540, and 673-679 of human lactoferrin. The IC50 values of these peptides were 15, 10 and 23 microM, respectively, in a radioreceptor assay in the presence of 1 nM [3H]naloxone. In the myenteric plexus preparation of the longitudinal muscle of guinea pig ileum, the individual peptides had no opioid agonist activities, but they antagonized [Met5]enkephalin and morphiceptin when they were at a concentration of 10(-6)-10(-5) M, suggesting that these were the opioid antagonist peptides. These three opioid antagonist peptides were named lactoferroxin A, B and C, after casoxin, the opioid antagonist peptide derived from bovine kappa-casein. Concerning the antagonist activities of lactoferroxins for opioid receptor sub-types, lactoferroxin A showed preference for mu-receptors, while lactoferroxin B and C had somewhat higher degrees of preference for kappa-receptors than for mu-receptors. A study of the structure-activity relationship of the three lactoferroxins and their synthetic analogues showed that these opioid antagonist peptides derived from food protein could be expressed by the general formula XA-Tyr-XB-Tyr-OCH3. An amino acid in position XA may affect the specificity of the antagonist peptide for opioid receptor sub-types."
201,P02788,Lactotransferrin,680-686,KYLGPQY,Lactoferroxin-C,,"{'2': '10089347', '3': '10792619', '4': '10828980', '5': '11083624', '6': '11128996', '7': '11179314', '8': '11702692', '9': '12037297', '10': '12037568', '11': '12450380', '12': '12535064', '13': '12693969', '14': '1369293', '15': '14573629', '16': '14702039', '17': '15166119', '18': '15222485', '19': '15299444', '20': '15299793', '21': '15489334', '22': '15687491', '23': '1581307', '24': '1599934', '25': '16048952', '26': '16201406', '27': '16842782', '28': '17079302', '29': '17481742', '30': '17543335', '31': '17567961', '32': '18780401', '33': '19033648', '34': '19159218', '35': '20345905', '36': '20404350', '37': '22320386', '38': '22406253', '39': '22900286', '40': '2374734', '41': '2402455', '42': '25946035', '43': '2981589', '44': '3169987', '45': '6802759', '46': '8069634', '47': '8371268', '48': '8594202', '49': '8703903', '50': '8931543', '51': '9003186', '52': '9122171', '53': '9359845', '54': '9873069', '65': '14702039', '66': '9122171', '68': '12535064'}",{'14'},Has opioid antagonist activity (PubMed:1369293). Shows higher degrees of preference for kappa-receptors than for mu-receptors (PubMed:1369293).,1369293,,31,Isolation and characterization of opioid antagonist peptides derived from human lactoferrin.,"Tani, F. et al.",1369293,10.1271/bbb1961.54.1803,,1369293,"Peptides with affinity for opioid receptors were found in an artificially methyl-esterified peptic digest of human lactoferrin. Three active peptides were purified by two steps of reverse-phase high-performance liquid chromatography. Their structures were Tyr-Leu-Gly-Ser-Gly-Tyr-OCH3, Arg-Tyr-Tyr-Gly-Tyr-OCH2, and Lys-Tyr-Leu-Gly-Pro-Gln-Tyr-OCH3, which respectively correspond to the methyl esters of residues 318-323, 536-540, and 673-679 of human lactoferrin. The IC50 values of these peptides were 15, 10 and 23 microM, respectively, in a radioreceptor assay in the presence of 1 nM [3H]naloxone. In the myenteric plexus preparation of the longitudinal muscle of guinea pig ileum, the individual peptides had no opioid agonist activities, but they antagonized [Met5]enkephalin and morphiceptin when they were at a concentration of 10(-6)-10(-5) M, suggesting that these were the opioid antagonist peptides. These three opioid antagonist peptides were named lactoferroxin A, B and C, after casoxin, the opioid antagonist peptide derived from bovine kappa-casein. Concerning the antagonist activities of lactoferroxins for opioid receptor sub-types, lactoferroxin A showed preference for mu-receptors, while lactoferroxin B and C had somewhat higher degrees of preference for kappa-receptors than for mu-receptors. A study of the structure-activity relationship of the three lactoferroxins and their synthetic analogues showed that these opioid antagonist peptides derived from food protein could be expressed by the general formula XA-Tyr-XB-Tyr-OCH3. An amino acid in position XA may affect the specificity of the antagonist peptide for opioid receptor sub-types."
202,P01178,Neurophysin 1,20-28,CYIQNCPLG,Oxytocin,2,"{'2': '13591312', '3': '18174156', '4': '6574452', '5': '7262323'}",,,13591312,"['Neurophysin 1 specifically binds oxytocin.', 'Oxytocin causes contraction of the smooth muscle of the uterus and of the mammary gland. Acts by binding to oxytocin receptor (OXTR) (PubMed:18174156).']",10,On the nature of oxytocin and vasopressin from human pituitary.,"Light, A. et al.",13591312,10.3181/00379727-98-24154,20-28,13591312,
203,P01298,,30-65,APLEPVYPGDNATPEQMAQYAADLRRYINMLTRPRY,Pancreatic polypeptide,,"{'2': '514078', '3': '7493937', '4': '7592911', '5': '828120', '6': '24291217', '7': '6373251', '8': '828120'}","{'3', '4'}",Hormone secreted by pancreatic cells that acts as a regulator of pancreatic and gastrointestinal functions probably by signaling through the G protein-coupled receptor NPY4R2.,7592911,,11,"Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY.","Bard, J. et al.",7592911,10.1074/jbc.270.45.26762,,7592911,"The pancreatic polypeptide family includes pancreatic polypeptide (PP), neuropeptide Y (NPY), and peptide YY (PYY). Members of the PP family regulate numerous physiological processes, including appetite, gastrointestinal transit, anxiety, and blood pressure. Of the multiple Y-type receptors proposed for PP family members, only the Y1 subtype has been cloned previously. We now report the cloning of an additional Y-type receptor, designated Y4, by homology screening of a human placental genomic library with transmembrane (TM) probes derived from the rat Y1 gene. The Y4 genomic clone encodes a predicted protein of 375 amino acids that is most homologous to Y1 receptors from human, rat, and mouse (42% overall; 55% in TM). 125I-PYY binding to transiently expressed Y4 receptors was saturable (pKd = 9.89) and displaceable by human PP family derivatives: PP (pKi = 10.25) approximately PP2-36 (pKi = 10.06) > PYY (pKi = 9.06) approximately [Leu31,Pro34]NPY (pKi = 8.95) > NPY (pKi = 8.68) > PP13-36 (pKi = 7.13) > PP31-36 (pKi = 6.46) > PP31-36 free acid (pKi < 5). Human PP decreased [cAMP] and increased intracellular [Ca2+] in Y4-transfected LMTK- cells. Y4 mRNA was detected by reverse transcriptase-polymerase chain reaction in human brain, coronary artery, and ileum, suggesting potential roles for Y4 receptors in central nervous system, cardiovascular, and gastrointestinal function."
204,P01298,,30-65,APLEPVYPGDNATPEQMAQYAADLRRYINMLTRPRY,Pancreatic polypeptide,,"{'2': '514078', '3': '7493937', '4': '7592911', '5': '828120', '6': '24291217', '7': '6373251', '8': '828120'}","{'3', '4'}",Hormone secreted by pancreatic cells that acts as a regulator of pancreatic and gastrointestinal functions probably by signaling through the G protein-coupled receptor NPY4R2.,7493937,,12,Cloning of a human receptor of the NPY receptor family with high affinity for pancreatic polypeptide and peptide YY.,"Lundell, I. et al.",7493937,10.1074/jbc.270.49.29123,,7493937,"Neuropeptide Y (NPY), peptide YY (PYY), and pancreatic polypeptide (PP) are structurally related peptides found in all higher vertebrates. NPY is expressed exclusively in neurons, whereas PYY and PP are produced primarily in gut endocrine cells. Several receptor subtypes have been identified pharmacologically, but only the NPY/PYY receptor of subtype Y1 has been cloned. This is a heptahelix receptor that couples to G proteins. We utilized Y1 sequence information from several species to clone a novel human receptor with 43% amino acid sequence identity to human Y1 and 53% identity in the transmembrane regions. The novel receptor displays a pharmacological profile that distinguishes it from all previously described NPY family receptors. It binds PP with an affinity (Ki) of 13.8 pM, PYY with 1.44 nM, and NPY with 9.9 nM. Because these data may identify the receptor as primarily a PP receptor, we have named it PP1. In stably transfected Chinese hamster ovary cells the PP1 receptor inhibits forskolin-stimulated cAMP synthesis. Northern hybridization detected mRNA in colon, small intestine, pancreas, and prostate. As all three peptides are present in the gut through either endocrine release or innervation, all three peptides may be physiological ligands to the novel NPY family receptor PP1."
205,P01258,,85-116,CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP,Calcitonin,4,"{'4': '5760861', '6': '1761559'}",,,5760861,"['Calcitonin causes a rapid but short-lived drop in the level of calcium and phosphate in blood by promoting the incorporation of those ions in the bones.', 'Katacalcin is a potent plasma calcium-lowering peptide.']",12,Human calcitonin. Structure of calcitonin M and D.,"Neher, R. et al.",5760861,10.1002/hlca.19680510811,85-116,5760861,
206,P04083,Annexin A1,26-Feb,AMVSEFLKQAWFIENEEQEYVQTVK,Annexin Ac2-26,13,"{'7': '10673436', '8': '10772777', '9': '15187149', '10': '15485879', '11': '17008549', '12': '19625660', '13': '22879591', '14': '2457390', '15': '2532504', '16': '25664854', '17': '2936963', '18': '32272059', '19': '3303336', '20': '8425544', '21': '8557678', '22': '1832554', '23': '22879591', '25': '19608861', '26': '20068231', '27': '23186163', '28': '24275569', '29': '25114211', '30': '25772364', '31': '28112733'}","{'9', '13', '16'}","Functions at least in part by activating the formyl peptide receptors and downstream signaling cascades (PubMed:22879591, PubMed:15187149, PubMed:25664854). Promotes chemotaxis of granulocytes and monocytes via activation of the formyl peptide receptors (PubMed:15187149). Promotes rearrangement of the actin cytoskeleton, cell polarization and cell migration (PubMed:15187149). Promotes resolution of inflammation and wound healing (PubMed:25664854). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591).",15187149,,12,An annexin 1 N-terminal peptide activates leukocytes by triggering different members of the formyl peptide receptor family.,"Ernst, S. et al.",15187149,10.4049/jimmunol.172.12.7669,,15187149,"The human N-formyl peptide receptor (FPR) is a key modulator of chemotaxis directing granulocytes toward sites of bacterial infections. FPR is the founding member of a subfamily of G protein-coupled receptors thought to function in inflammatory processes. The other two members, FPR-like (FPRL)1 and FPRL2, have a greatly reduced affinity for bacterial peptides or do not bind them at all, with FPRL2 being considered an orphan receptor so far. In this study we show that a peptide derived from the N-terminal domain of the anti-inflammatory protein annexin 1 (lipocortin 1) can activate all three FPR family members at similar concentrations. The annexin 1 peptide initiates chemotactic responses in human monocytes that express all three FPR family members and also desensitizes the cells toward subsequent stimulation with bacterial peptide agonists. Experiments using HEK 293 cells stably expressing a single FPR family member reveal that all three receptors can be activated and desensitized by the N-terminal annexin 1 peptide. These observations identify the annexin 1 peptide as the first endogenous ligand of FPRL2 and indicate that annexin 1 participates in regulating leukocyte emigration into inflamed tissue by activating and desensitizing different receptors of the FPR family."
207,P04083,Annexin A1,26-Feb,AMVSEFLKQAWFIENEEQEYVQTVK,Annexin Ac2-26,13,"{'7': '10673436', '8': '10772777', '9': '15187149', '10': '15485879', '11': '17008549', '12': '19625660', '13': '22879591', '14': '2457390', '15': '2532504', '16': '25664854', '17': '2936963', '18': '32272059', '19': '3303336', '20': '8425544', '21': '8557678', '22': '1832554', '23': '22879591', '25': '19608861', '26': '20068231', '27': '23186163', '28': '24275569', '29': '25114211', '30': '25772364', '31': '28112733'}","{'9', '13', '16'}","Functions at least in part by activating the formyl peptide receptors and downstream signaling cascades (PubMed:22879591, PubMed:15187149, PubMed:25664854). Promotes chemotaxis of granulocytes and monocytes via activation of the formyl peptide receptors (PubMed:15187149). Promotes rearrangement of the actin cytoskeleton, cell polarization and cell migration (PubMed:15187149). Promotes resolution of inflammation and wound healing (PubMed:25664854). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591).",25664854,,25,Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair.,"Leoni, G. et al.",25664854,10.1172/jci76693,,25664854,"Epithelial restitution is an essential process that is required to repair barrier function at mucosal surfaces following injury. Prolonged breaches in epithelial barrier function result in inflammation and further damage; therefore, a better understanding of the epithelial restitution process has potential for improving the development of therapeutics. In this work, we demonstrate that endogenous annexin A1 (ANXA1) is released as a component of extracellular vesicles (EVs) derived from intestinal epithelial cells, and these ANXA1-containing EVs activate wound repair circuits. Compared with healthy controls, patients with active inflammatory bowel disease had elevated levels of secreted ANXA1-containing EVs in sera, indicating that ANXA1-containing EVs are systemically distributed in response to the inflammatory process and could potentially serve as a biomarker of intestinal mucosal inflammation. Local intestinal delivery of an exogenous ANXA1 mimetic peptide (Ac2-26) encapsulated within targeted polymeric nanoparticles (Ac2-26 Col IV NPs) accelerated healing of murine colonic wounds after biopsy-induced injury. Moreover, one-time systemic administration of Ac2-26 Col IV NPs accelerated recovery following experimentally induced colitis. Together, our results suggest that local delivery of proresolving peptides encapsulated within nanoparticles may represent a potential therapeutic strategy for clinical situations characterized by chronic mucosal injury, such as is seen in patients with IBD."
208,P04083,Annexin A1,26-Feb,AMVSEFLKQAWFIENEEQEYVQTVK,Annexin Ac2-26,13,"{'7': '10673436', '8': '10772777', '9': '15187149', '10': '15485879', '11': '17008549', '12': '19625660', '13': '22879591', '14': '2457390', '15': '2532504', '16': '25664854', '17': '2936963', '18': '32272059', '19': '3303336', '20': '8425544', '21': '8557678', '22': '1832554', '23': '22879591', '25': '19608861', '26': '20068231', '27': '23186163', '28': '24275569', '29': '25114211', '30': '25772364', '31': '28112733'}","{'9', '13', '16'}","Functions at least in part by activating the formyl peptide receptors and downstream signaling cascades (PubMed:22879591, PubMed:15187149, PubMed:25664854). Promotes chemotaxis of granulocytes and monocytes via activation of the formyl peptide receptors (PubMed:15187149). Promotes rearrangement of the actin cytoskeleton, cell polarization and cell migration (PubMed:15187149). Promotes resolution of inflammation and wound healing (PubMed:25664854). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591).",22879591,,20,Cathepsin G-regulated release of formyl peptide receptor agonists modulate neutrophil effector functions.,"Woloszynek, J. et al.",22879591,10.1074/jbc.m112.394452,,22879591,"Neutrophil serine proteases play an important role in inflammation by modulating neutrophil effector functions. We have previously shown that neutrophils deficient in the serine proteases cathepsin G and neutrophil elastase (CG/NE neutrophils) exhibit severe defects in chemokine CXCL2 release and reactive oxygen species (ROS) production when activated on immobilized immune complex. Exogenously added active CG rescues these defects, but the mechanism remains undefined. Using a protease-based proteomic approach, we found that, in vitro, the addition of exogenous CG to immune complex-stimulated CG/NE neutrophils led to a decrease in the level of cell-associated annexin A1 (AnxA1) and cathelin-related antimicrobial peptide (CRAMP), both known inflammatory mediators. We further confirmed that, in vivo, CG was required for the extracellular release of AnxA1 and CRAMP in a subcutaneous air pouch model. In vitro, CG efficiently cleaved AnxA1, releasing the active N-terminal peptide Ac2-26, and processed CRAMP in limited fashion. Ac2-26 and CRAMP peptides enhanced the release of CXCL2 by CG/NE neutrophils in a dose-dependent manner via formyl peptide receptor (FPR) stimulation. Blockade of FPRs by an antagonist, Boc2 (t-Boc-Phe-d-Leu-Phe-d-Leu-Phe), abrogates CXCL2 release, whereas addition of FPR agonists, fMLF and F2L, relieves Boc2 inhibition. Furthermore, the addition of active CG, but not inactive CG, also relieves Boc2 inhibition. These findings suggest that CG modulates neutrophil effector functions partly by controlling the release (and proteolysis) of FPR agonists. Unexpectedly, we found that mature CRAMP, but not Ac2-26, induced ROS production through an FPR-independent pathway."
209,P02675,Fibrinogen beta chain,31-44,QGVNDNEEGFFSAR,Fibrinopeptide B,8,"{'4': '10074346', '5': '10391209', '6': '10666208', '7': '11468164', '8': '12665801', '9': '15070683', '10': '1565641', '11': '16263699', '12': '16335952', '13': '1634610', '14': '19159218', '15': '19296670', '16': '2018836', '17': '2143188', '18': '25427968', '19': '3156856', '20': '3194892', '21': '420779', '22': '9333233', '23': '936108', '24': '9628725', '29': '10074346', '30': '19296670', '31': '6575689', '32': '9628725'}",,,12665801,"['Cleaved by the protease thrombin to yield monomers which, together with fibrinogen alpha (FGA) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the antibacterial immune response via both innate and T-cell mediated pathways.']",14,Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides.,"Gevaert, K. et al.",12665801,10.1038/nbt810,45-53,12665801,"Current non-gel techniques for analyzing proteomes rely heavily on mass spectrometric analysis of enzymatically digested protein mixtures. Prior to analysis, a highly complex peptide mixture is either separated on a multidimensional chromatographic system or it is first reduced in complexity by isolating sets of representative peptides. Recently, we developed a peptide isolation procedure based on diagonal electrophoresis and diagonal chromatography. We call it combined fractional diagonal chromatography (COFRADIC). In previous experiments, we used COFRADIC to identify more than 800 Escherichia coli proteins by tandem mass spectrometric (MS/MS) analysis of isolated methionine-containing peptides. Here, we describe a diagonal method to isolate N-terminal peptides. This reduces the complexity of the peptide sample, because each protein has one N terminus and is thus represented by only one peptide. In this new procedure, free amino groups in proteins are first blocked by acetylation and then digested with trypsin. After reverse-phase (RP) chromatographic fractionation of the generated peptide mixture, internal peptides are blocked using 2,4,6-trinitrobenzenesulfonic acid (TNBS); they display a strong hydrophobic shift and therefore segregate from the unaltered N-terminal peptides during a second identical separation step. N-terminal peptides can thereby be specifically collected for further liquid chromatography (LC)-MS/MS analysis. Omitting the acetylation step results in the isolation of non-lysine-containing N-terminal peptides from in vivo blocked proteins."
210,P01210,,100-104,YGGFM,Met-enkephalin,7,"{'6': '2982830', '7': '656131', '8': '7057924', '9': '9126357', '10': '2982830', '11': '656131', '12': '9126357', '14': '2982830'}",{'8'},"Neuropeptide that competes with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress.",7057924,,1,Primary structure of the human Met- and Leu-enkephalin precursor and its mRNA.,"Comb, M. et al.",7057924,10.1038/295663a0,,7057924,"The nucleotide sequence of a complete cDNA copy of enkephalin precursor mRNA from human phaeochromocytoma is reported. The corresponding amino acid sequence shows that the precursor is 267 amino acids long and contains six interspersed Met-enkephalin sequences and one Leu-enkephalin sequence. Five of the seven enkephalins are flanked on both sides by pairs of basic amino acid residues. The precursors does not contain the sequences of the opioid peptides, dynorphin, alpha-neo-endorphin or beta-endorphin."
211,P01210,,100-104,YGGFM,Met-enkephalin,7,"{'6': '2982830', '7': '656131', '8': '7057924', '9': '9126357', '10': '2982830', '11': '656131', '12': '9126357', '14': '2982830'}",{'8'},"Neuropeptide that competes with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress.",656131,,7,Hydrolysis of enkephalin by cultured human endothelial cells and by purified peptidyl dipeptidase.,"Erdoes, E. et al.",656131,10.1016/0006-2952(78)90542-7,,656131,
212,P01210,,107-111,YGGFM,Met-enkephalin,7,"{'6': '2982830', '7': '656131', '8': '7057924', '9': '9126357', '10': '2982830', '11': '656131', '12': '9126357', '14': '2982830'}",{'8'},"Neuropeptide that competes with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress.",7057924,,1,Primary structure of the human Met- and Leu-enkephalin precursor and its mRNA.,"Comb, M. et al.",7057924,10.1038/295663a0,,7057924,"The nucleotide sequence of a complete cDNA copy of enkephalin precursor mRNA from human phaeochromocytoma is reported. The corresponding amino acid sequence shows that the precursor is 267 amino acids long and contains six interspersed Met-enkephalin sequences and one Leu-enkephalin sequence. Five of the seven enkephalins are flanked on both sides by pairs of basic amino acid residues. The precursors does not contain the sequences of the opioid peptides, dynorphin, alpha-neo-endorphin or beta-endorphin."
213,P01210,,107-111,YGGFM,Met-enkephalin,7,"{'6': '2982830', '7': '656131', '8': '7057924', '9': '9126357', '10': '2982830', '11': '656131', '12': '9126357', '14': '2982830'}",{'8'},"Neuropeptide that competes with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress.",656131,,7,Hydrolysis of enkephalin by cultured human endothelial cells and by purified peptidyl dipeptidase.,"Erdoes, E. et al.",656131,10.1016/0006-2952(78)90542-7,,656131,
214,P01210,,136-140,YGGFM,Met-enkephalin,,"{'6': '2982830', '7': '656131', '8': '7057924', '9': '9126357', '10': '2982830', '11': '656131', '12': '9126357', '14': '2982830'}",{'8'},"Neuropeptide that competes with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress.",7057924,,1,Primary structure of the human Met- and Leu-enkephalin precursor and its mRNA.,"Comb, M. et al.",7057924,10.1038/295663a0,,7057924,"The nucleotide sequence of a complete cDNA copy of enkephalin precursor mRNA from human phaeochromocytoma is reported. The corresponding amino acid sequence shows that the precursor is 267 amino acids long and contains six interspersed Met-enkephalin sequences and one Leu-enkephalin sequence. Five of the seven enkephalins are flanked on both sides by pairs of basic amino acid residues. The precursors does not contain the sequences of the opioid peptides, dynorphin, alpha-neo-endorphin or beta-endorphin."
215,P01210,,186-193,YGGFMRGL,Met-enkephalin-Arg-Gly-Leu,6,"{'6': '2982830', '7': '656131', '8': '7057924', '9': '9126357', '10': '2982830', '11': '656131', '12': '9126357', '14': '2982830'}",,,2982830,"['Neuropeptide that competes with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress.', 'Neuropeptide that competes with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress.', 'Met-enkephalin-Arg-Phe neuropeptide acts as a strong ligand of Mu-type opioid receptor OPRM1. Met-enkephalin-Arg-Phe-binding to OPRM1 in the nucleus accumbens of the brain increases activation of OPRM1, leading to long-term synaptic depression of glutamate release.', 'Increases glutamate release in the striatum and decreases GABA concentration in the striatum.', 'Increases glutamate release in the striatum.']",8,Proteolytic conversion of [Met]enkephalin-Arg6-Gly7-Leu8 by brain synaptic membranes. Characterization of formed peptides and mechanism of proteolysis.,"Norman, J. et al.",2982830,10.1016/s0021-9258(18)89410-8,,2982830,"The degradation of the enkephalin-containing octapeptide Tyr-Gly-Gly-Phe-Met-Arg-Gly-Leu (YGGFMRGL) was systematically investigated by incubating the peptide with synaptic membranes from rat striatum or with purified peptidases. The degradation products were derivatized with 4-dimethylamino-azobenzene-4'-isothiocyanate and then analyzed by high pressure liquid chromatography and by amino-terminal analysis. The incubation of YGGFMRGL with synaptic membranes yielded YGG, YGGF, YGGFM, and MR in a manner that was linear with respect to time. The corresponding carboxyl-terminal fragments FMRGL, MRGL, and RGL could not be detected, which suggests that the degradation of YGGFMRGL by synaptic membranes occurs by carboxypeptidase activity. The incubation of YGGFMRGL with different purified peptidases produced cleavage patterns unique from that seen with synaptic membranes. Enkephalinase recognized only the Gly-Phe bond to produce YGG and FMRGL. Thermolysin recognized the Gly-Phe bond and the Phe-Met bond to yield YGG, YGGF, FMRGL, and MRGL. Angiotensin-converting enzyme (ACE) produced primarily YGGF, MR, and lesser amounts of YGGFMR and YG. The formation of YGG, YGGF, and YGGFM by synaptic membranes could be stimulated 3-fold by the addition of 30 mM NaCl and inhibited by MK-422, an ACE inhibitor, with an IC50 of 3 nM. These data suggest that ACE, a dipeptidyl carboxypeptidase, is the primary enzyme involved in the degradation of YGGFMRGL in brain. ACE apparently works in concert with another carboxypeptidase in brain to yield YGGFM and YGG since the carboxyl-terminal peptides RGL and FMRGL could not be detected."
216,P01210,,210-214,YGGFM,Met-enkephalin,,"{'6': '2982830', '7': '656131', '8': '7057924', '9': '9126357', '10': '2982830', '11': '656131', '12': '9126357', '14': '2982830'}",{'8'},"Neuropeptide that competes with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress.",7057924,,1,Primary structure of the human Met- and Leu-enkephalin precursor and its mRNA.,"Comb, M. et al.",7057924,10.1038/295663a0,,7057924,"The nucleotide sequence of a complete cDNA copy of enkephalin precursor mRNA from human phaeochromocytoma is reported. The corresponding amino acid sequence shows that the precursor is 267 amino acids long and contains six interspersed Met-enkephalin sequences and one Leu-enkephalin sequence. Five of the seven enkephalins are flanked on both sides by pairs of basic amino acid residues. The precursors does not contain the sequences of the opioid peptides, dynorphin, alpha-neo-endorphin or beta-endorphin."
217,P01210,,230-234,YGGFL,Leu-enkephalin,,"{'6': '2982830', '7': '656131', '8': '7057924', '9': '9126357', '10': '2982830', '11': '656131', '12': '9126357', '14': '2982830'}",{'8'},"Neuropeptide that competes with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress.",7057924,,1,Primary structure of the human Met- and Leu-enkephalin precursor and its mRNA.,"Comb, M. et al.",7057924,10.1038/295663a0,,7057924,"The nucleotide sequence of a complete cDNA copy of enkephalin precursor mRNA from human phaeochromocytoma is reported. The corresponding amino acid sequence shows that the precursor is 267 amino acids long and contains six interspersed Met-enkephalin sequences and one Leu-enkephalin sequence. Five of the seven enkephalins are flanked on both sides by pairs of basic amino acid residues. The precursors does not contain the sequences of the opioid peptides, dynorphin, alpha-neo-endorphin or beta-endorphin."
231,P59665,HP 1-56,65-94,ACYCRIPACIAGERRYGTCIYQGRLWAFCC,Neutrophil defensin 1,,"{'1': '15064728', '2': '15340161', '3': '15616305', '4': '17142766', '5': '17452329', '6': '18191790', '7': '20214904', '8': '20220136', '9': '21904558', '10': '24236072', '11': '27031443', '12': '2917986', '13': '35080426'}",,,,"['Effector molecule of the innate immune system that acts via antibiotic-like properties against a broad array of infectious agents including bacteria, fungi, and viruses or by promoting the activation and maturation of some APCs (PubMed:15616305, PubMed:17142766, PubMed:20220136, PubMed:24236072). Interacts with the essential precursor of cell wall synthesis lipid II to inhibit bacterial cell wall synthesis (PubMed:20214904). Inhibits adenovirus infection via inhibition of viral disassembly at the vertex region, thereby restricting the release of internal capsid protein pVI, which is required for endosomal membrane penetration during cell entry (PubMed:18191790). In addition, interaction with adenovirus capsid leads to the redirection of viral particles to TLR4 thereby promoting a NLRP3-mediated inflammasome response and interleukin 1-beta (IL-1beta) release (PubMed:35080426). Induces the production of proinflammatory cytokines including type I interferon (IFN) in plasmacytoid dendritic cells (pDCs) by triggering the degradation of NFKBIA and nuclear translocation of IRF1, both of which are required for activation of pDCs (PubMed:27031443).']",9,Primary structures of three human neutrophil defensins.,"Selsted, M. et al.",4056036,10.1172/jci112121,65-94,4056036,"The primary structures of three human neutrophil antimicrobial peptides (HNP) were determined. The peptides, HNP-1, HNP-2, and HNP-3, which we have termed defensins, were rich in cystine, arginine, and aromatic residues, but were devoid of free sulfhydryl groups and carbohydrate moieties. They were 29-30 residues in length and identical in sequence in all but their amino terminal residues. The defensins were homologous in sequence to peptides of similar size and biological activity previously purified from rabbit polymorphonuclear leukocytes, but unrelated to other neutrophil proteins of known sequence. 11 amino acid residues of the human defensins, including all six cysteinyl residues, were invariantly conserved in the six rabbit members of this multigene peptide family. That similarly structured antimicrobial peptides are present in both rabbit and human leukocytes supports their purported role as cidal agents in phagocyte-mediated host defense."
246,P10082,,29-64,YPIKPEAPREDASPEELNRYYASLRHYLNLVTRQRY,Peptide YY,,"{'4': '15489334', '5': '21314817', '6': '2587421', '7': '3202875', '8': '8318545', '11': '2587421', '12': '8318545'}",,,,"['This gut peptide inhibits exocrine pancreatic secretion, has a vasoconstrictory action and inhibitis jejunal and colonic mobility.']",6,Isolation and primary structure of human peptide YY.,"Tatemoto, K. et al.",3202875,10.1016/s0006-291x(88)80308-5,29-64,3202875,"The isolation, primary structure and chemical synthesis of human peptide YY (PYY) are described. The peptide was purified from human colonic extracts using a chemical method which detected the C-terminal tyrosine amide structure of PYY. Human PYY consists of 36 amino acid residues and the complete amino acid sequence is: Tyr-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu- Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu- Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2. The differences between the structures of porcine and human PYY are at positions 3 (Ala/Ile replacement) and 18 (Ser/Asn). Synthetic human PYY prepared using a solid-phase synthetic technique was found to be structurally identical to the natural peptide."
247,P10082,,29-64,YPIKPEAPREDASPEELNRYYASLRHYLNLVTRQRY,Peptide YY,,"{'4': '15489334', '5': '21314817', '6': '2587421', '7': '3202875', '8': '8318545', '11': '2587421', '12': '8318545'}",,,,"['This gut peptide inhibits exocrine pancreatic secretion, has a vasoconstrictory action and inhibitis jejunal and colonic mobility.']",7,A new molecular form of PYY: structural characterization of human PYY(3-36) and PYY(1-36).,"Eberlein, G. et al.",2587421,10.1016/0196-9781(89)90116-2,29-64,2587421,"A radioimmunoassay was developed using an antibody raised in rabbits against synthetic porcine PYY. This radioimmunoassay was used to detect PYY immunoreactivity in human intestinal extracts. Human colonic mucosa was extracted with acid, centrifuged and the supernatant concentrated by low pressure preparative reverse phase chromatography. A subsequent C-18 reverse phase HPLC step separated two peaks of PYY immunoreactivity. Each peak was purified by sequential steps of ion-exchange FPLC and reverse phase HPLC. In the final purification step single absorbance peaks were associated with PYY immunoreactivity. Microsequence, amino acid, and mass spectral analysis of the intact and tryptic fragments of the two peptides were consistent with the structures: YPIKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY-amide [human PYY(1-36)] and--IKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY-amide [human PYY(3-36)]. Human PYY(1-36) differs from porcine PYY only at position 3, with Ile instead of Ala, and position 18, with Asn instead of Ser. PYY(3-36) may differ in its biological activity from the intact peptide. Its high proportions in the colon suggest that it is released into the circulation where it could act as a partial antagonist of PYY(1-36)."
249,P10997,,34-70,KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY,Islet amyloid polypeptide,,"{'2': '17051221', '3': '17374526', '4': '19244249', '5': '19475663', '6': '2651160', '7': '3053705', '8': '3317417', '9': '8772735', '10': '9794116'}",,,,"['Selectively inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle, while not affecting adipocyte glucose metabolism.']",10,Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients.,"Cooper, G. et al.",3317417,10.1073/pnas.84.23.8628,34-70,3317417,"Deposition of amyloid in pancreatic islets is a common feature in human type 2 diabetic subjects but because of its insolubility and low tissue concentrations, the structure of its monomer has not been determined. We describe a peptide, of calculated molecular mass 3905 Da, that was a major protein component of amyloid-rich pancreatic extracts of three type 2 diabetic patients. After collagenase treatment, an extract containing 20-50% amyloid was solubilized by sonication into 70% formic acid and the peptide was purified by gel filtration followed by reverse-phase high-performance liquid chromatography. We term this peptide diabetes-associated peptide, as it was not detected in extracts of pancreas from any of six normal subjects. Diabetes-associated peptide contains 37 amino acids and is 46% identical to the sequences of rat and human calcitonin gene-related peptide, indicating that these peptides are related in evolution. Sequence identities with conserved residues of the insulin A chain were also seen in a 16-residue segment. On extraction, the islet amyloid is particulate and insoluble like the core particles of Alzheimer disease. Their monomers have similar molecular masses, each having a hydropathic region that can probably form beta-pleated sheets. The accumulation of amyloid, including diabetes-associated peptide, in islets may impair islet function in type 2 diabetes mellitus."
250,P10997,,34-70,KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY,Islet amyloid polypeptide,,"{'2': '17051221', '3': '17374526', '4': '19244249', '5': '19475663', '6': '2651160', '7': '3053705', '8': '3317417', '9': '8772735', '10': '9794116'}",,,,"['Selectively inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle, while not affecting adipocyte glucose metabolism.']",12,Isolation and identification of islet amyloid polypeptide in normal human pancreas.,"Nakazato, M. et al.",2091067,10.1016/0167-0115(90)90004-g,34-70,2091067,"To identify islet amyloid polypeptide (IAPP) present in normal human pancreas, we isolated the peptide from a soluble peptide fraction of amyloid deposit-free pancreata of two non-diabetic patients by using reverse-phase high performance liquid chromatography coupled with a radioimmunoassay specific for human IAPP. IAPP(1-37) and IAPP(17-37) were isolated and their complete amino acid sequences were determined up to the C-terminus. Identification of IAPP in normal human pancreas suggests the possible biological function of IAPP as a novel pancreatic hormone in humans."
251,P10997,,34-70,KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY,Islet amyloid polypeptide,,"{'2': '17051221', '3': '17374526', '4': '19244249', '5': '19475663', '6': '2651160', '7': '3053705', '8': '3317417', '9': '8772735', '10': '9794116'}",,,,"['Selectively inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle, while not affecting adipocyte glucose metabolism.']",14,Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells.,"Westermark, P. et al.",3035556,10.1073/pnas.84.11.3881,34-70,3035556,"Amyloid deposits localized to the islets of Langerhans are typical of non-insulin-dependent human diabetes mellitus and of diabetes mellitus in adult cats. Amyloid deposits also commonly occur in insulin-producing pancreatic tumors. We have purified a major protein--insulinoma or islet amyloid polypeptide (IAPP)--from human and cat islet amyloid and from amyloid of a human insulinoma. IAPP from human insulinoma contained 37 amino acid residues and had a theoretical molecular mass of 3850 Da. The amino acid sequence is unique but has greater than 40% identity with the human calcitonin gene-related peptide. A partial amino acid sequence of cat islet IAPP corresponding to positions 1-27 of human insulinoma IAPP was identical to the human IAPP except for substitutions in three positions. An antiserum raised to a synthetic human insulinoma IAPP-(7-17) undecapeptide showed specific immunohistochemical reactivity with human and cat islet amyloid and with islet B cells. The significance of this pancreatic neuropeptide-like protein is unknown, but it is suggested that it may exert an important endocrine regulatory effect."
254,P09668,Cathepsin H light chain,98-105,EPQNCSAT,Cathepsin H mini chain,,"{'5': '11796715', '6': '14702039', '7': '15489334', '8': '16959974', '9': '19159218', '10': '2587265', '11': '2849458', '12': '3342889'}",,,,['Important for the overall degradation of proteins in lysosomes.'],7,Amino acid sequences of the human kidney cathepsins H and L.,"Ritonja, A. et al.",3342889,10.1016/0014-5793(88)80028-0,98-105,3342889,"The complete amino acid sequences of human kidney cathepsin H (EC 3.4.22.16) and human kidney cathepsin L (EC 3.4.22.15) were determined. Cathepsin H contains 230 residues and has an Mr of 25116. The sequence was obtained by sequencing the light, heavy and mini chain and the peptides produced by cyanogen bromide cleavage of the single-chain form of the enzyme. The glycosylated mini chain is a proteolytic fragment of the propeptide of cathepsin H. Human cathepsin L has 217 amino acid residues and an Mr of 23720. Its amino acid sequence was deduced from N-terminal sequences of the heavy and light chains and from the sequences of cyanogen bromide fragments of the heavy chain. The fragments were aligned by comparison with known sequences of cathepsins H and L from other species. Cathepsins H and L exhibit a high degree of sequence homology to cathepsin B (EC 3.4.22.1) and other cysteine proteinases of the papain superfamily."
257,P01286,,32-75,YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL,Somatoliberin,,"{'2': '24029240', '3': '6812220', '4': '15489334', '5': '6192430', '7': '26324071'}",,,,['GRF is released by the hypothalamus and acts on the adenohypophyse to stimulate the secretion of growth hormone.'],6,Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly.,"Guillemin, R. et al.",6812220,10.1126/science.6812220,32-75,6812220,A 44 amino acid peptide with growth hormone-releasing activity has been isolated from a human tumor of the pancreas that had caused acromegaly. The primary structure of the tumor-derived peptide is H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala- Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly -Ala-Arg-Ala-Arg-Leu-NH2. The synthetic replicate has full biological activity in vitro and in vivo specifically to stimulate the secretion of immunoreactive growth hormone. The tumor-derived peptide is identical in biological activity and similar in physiochemical properties to the still uncharacterized growth hormone-releasing factor present in extracts of hypothalamic tissues.
262,P04004,Vitronectin V10 subunit,20-63,DQESCKGRCTEGFNVDKKCQCDELCSYYQSCCTDYTAECKPQVT,Somatomedin-B,,"{'5': '12019263', '6': '12808446', '7': '14760718', '8': '15489334', '9': '16335952', '10': '1696913', '11': '1704366', '12': '1709100', '13': '17558413', '14': '19139490', '15': '19159218', '16': '2448300', '17': '2479556', '18': '25136834', '19': '29567995', '20': '631332', '21': '7522053', '22': '8900153', '23': '9733784', '26': '16807684', '27': '18088087', '28': '24275569'}",,,,"['Vitronectin is a cell adhesion and spreading factor found in serum and tissues. Vitronectin interact with glycosaminoglycans and proteoglycans. Is recognized by certain members of the integrin family and serves as a cell-to-substrate adhesion molecule. Inhibitor of the membrane-damaging effect of the terminal cytolytic complement pathway.', 'Somatomedin-B is a growth hormone-dependent serum factor with protease-inhibiting activity.']",8,Primary structure of somatomedin B: a growth hormone-dependent serum factor with protease inhibiting activity.,"Fryklund, L. et al.",631332,10.1016/0014-5793(78)80132-x,20-63,631332,
264,P01298,,69-88,HKEDTLAFSEWGSPHAAVPR,Pancreatic icosapeptide,,"{'2': '514078', '3': '7493937', '4': '7592911', '5': '828120', '6': '24291217', '7': '6373251', '8': '828120'}",,,,['Hormone secreted by pancreatic cells that acts as a regulator of pancreatic and gastrointestinal functions probably by signaling through the G protein-coupled receptor NPY4R2.'],8,"Human pancreatic icosapeptide: isolation, sequence, and immunocytochemical localization of the COOH-terminal fragment of the pancreatic polypeptide precursor.","Schwartz, T. et al.",6366786,10.1073/pnas.81.3.708,69-88,6366786,"In dogs, the COOH-terminal part of the pancreatic polypeptide precursor gives rise to a stable icosapeptide product against which an antiserum has been raised. By immunohistochemistry, icosapeptide immunoreactivity was localized in human pancrease exclusively to cells that also stored pancreatic polypeptide. Analytical peptide chemistry demonstrated that a peptide corresponding to the canine icosapeptide could be extracted from the pancreatic polypeptide-rich duodenal part of the human pancreas. The human pancreatic icosapeptide was isolated by acid ethanol extraction, gel filtration, anion-exchange chromatography, and reverse-phase high-performance liquid chromatography. The COOH-terminal sequence of the human icosapeptide is very similar to that of the canine icosapeptide, whereas none of the first nine amino acid residues are identical. When the primary structure of peptides from three different species are compared, it is apparent that the pancreatic polypeptide part of the common precursor is a well-conserved sequence as compared to the icosapeptide part, although 8 out of 11 residues in the COOH-terminal sequence of the icosapeptide are identical in all three species."
267,P01282,,81-122,HADGVFTSDFSKLLGQLSAKKYLESLMGKRVSSNISEDPVPV,Intestinal peptide PHV-42,,"{'3': '15013843', '4': '3748844', '5': '15489334'}",,,,"['VIP causes vasodilation, lowers arterial blood pressure, stimulates myocardial contractility, increases glycogenolysis and relaxes the smooth muscle of trachea, stomach and gall bladder.', 'PHM and PHV also cause vasodilation. PHM-27 is a potent agonist of the calcitonin receptor CALCR, with similar efficacy as calcitonin.']",11,"Isolation, characterization, and pharmacological actions of peptide histidine valine 42, a novel prepro-vasoactive intestinal peptide-derived peptide.","Yiangou, Y. et al.",3654650,10.1016/s0021-9258(18)47896-9,81-122,3654650,"The primary structure and biological activity of a novel prepro-vasoactive intestinal peptide (prepro-VIP)-derived peptide has been determined from an adrenal pheochromocytoma. The peptide was purified sufficiently for characterization by fast atom bombardment mapping after cation-exchange and reverse-phase fast protein liquid chromatography. The sequence of this novel peptide corresponds exactly to prepro-VIP-81-122 and has been designated peptide histidine valine 42 (PHV-42). Synthetic PHV-42 reduced both the force and frequency of spontaneous contractions of isolated rat uterus and was at least 12 times more potent than peptide histidine methionine (prepro-VIP-81-107), and over a hundred times more potent than noradrenaline. PHV-42 was also more potent than peptide histidine methionine in relaxing smooth muscle preparations of rat stomach and guinea pig trachea, but was approximately 4-fold less potent in reducing blood pressure than VIP. PHV-42 thus forms a separate subsystem in the VIP family of peptides and may be the most biologically active product of prepro-VIP in certain tissues such as the uterus and trachea."
270,P09681,,52-93,YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ,Gastric inhibitory polypeptide,,{'3': '15489334'},,,,['Potent stimulator of insulin secretion and relatively poor inhibitor of gastric acid secretion.'],4,The isolation and sequencing of human gastric inhibitory peptide (GIP).,"Moody, A. et al.",6745415,10.1016/0014-5793(84)81114-x,52-93,6745415,"Human GIP 1-42 and fragments of human GIP corresponding to GIP 10-42, GIP 11-42, and GIP 17-42 were isolated from acid-ethanol extracts of human small intestines with the aid of an anti-GIP serum specific for the extreme C-terminal portion of the GIP molecule. The full sequence of human GIP has been established by Edman degradation of these peptides and fragments thereof by automatic gas-phase sequencing. Human GIP differs from porcine GIP at residues 18 and 34. The sequence of human GIP is thus: (Formula: see text) Amino acid residues 18 and 34 are Arg and Ser, respectively, in porcine GIP."
273,P60022,,33-68,DHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK,Beta-defensin 1,,"{'2': '23938203', '3': '25122636', '4': '7628632', '6': '25944712'}",,,,['Has bactericidal activity. May act as a ligand for C-C chemokine receptor CCR6. Positively regulates the sperm motility and bactericidal activity in a CCR6-dependent manner. Binds to CCR6 and triggers Ca2+ mobilization in the sperm which is important for its motility (PubMed:25122636).'],5,hBD-1: a novel beta-defensin from human plasma.,"Bensch, K. et al.",7628632,10.1016/0014-5793(95)00687-5,33-68,7628632,We report the isolation and characterization of a novel peptide with significant sequence homology to beta-defensins from human blood filtrate. The human beta-defensin-1 (hBD-1) is a short basic peptide of 36 amino acid residues. It contains six cysteines forming three intramolecular disulfide bonds. The molecular mass of hBD-1 is 3928.6 Da. Cloning of the specific cDNA confirmed the amino acid sequence of the native peptide. hBD-1 shares the nine conserved amino acids characteristic for beta-defensins from respiratory epithelial cells and neutrophils of cattle and chicken leukocytes. hBD-1 is present in nanomolar concentration in human plasma.
288,P01308,,25-54,FVNQHLCGSHLVEALYLVCGERGFFYTPKT,Insulin B chain,,"{'1': '1433291', '2': '14426955', '3': '1601997', '4': '17855560', '5': '18162506', '6': '18192540', '7': '20226046', '8': '2196279', '9': '25423173', '10': '3470784', '11': '3537011', '12': '4019786', '13': '5101771', '14': '6312455', '15': '6424111', '16': '8421693', '17': '9235985'}",,,,"['Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver.']",12,Amino-acid sequence of human insulin.,"Nicol, D. et al.",14426955,10.1038/187483a0,25-54,14426955,
293,P01350,,76-92,QGPWLEEEEEAYGWMDF,Gastrin,,"{'2': '11052986', '3': '2730647', '4': '3223964', '5': '5921183', '6': '7530658', '7': '7621822', '8': '8055952'}",,,,['Gastrin stimulates the stomach mucosa to produce and secrete hydrochloric acid and the pancreas to secrete its digestive enzymes. It also stimulates smooth muscle contraction and increases blood circulation and water secretion in the stomach and intestine.'],9,Structures of human gastrins I and II.,"Bentley, P. et al.",5921183,10.1038/209583b0,76-92,5921183,
294,P01350,,76-92,QGPWLEEEEEAYGWMDF,Gastrin,,"{'2': '11052986', '3': '2730647', '4': '3223964', '5': '5921183', '6': '7530658', '7': '7621822', '8': '8055952'}",,,,['Gastrin stimulates the stomach mucosa to produce and secrete hydrochloric acid and the pancreas to secrete its digestive enzymes. It also stimulates smooth muscle contraction and increases blood circulation and water secretion in the stomach and intestine.'],11,Aminoacid constitution of two gastrins isolated from Zollinger-Ellison tumour tissue.,"Gregory, R. et al.",5822140,10.1136/gut.10.8.603,76-92,5822140,"Two peptides which are potent stimulants of gastric acid secretion are isolated from Zollinger-Ellison tumour tissue. They have aminoacid constitutions identical with those of human gastrin types I and II as isolated from human antral mucosa, and they are present in similar proportions. Their electrophoretic and chromatographic behaviour corresponds to that of human gastrins. Evidence is presented in respect of the one isolated in greater amount that its aminoacid sequence is probably identical with that of human gastrin type I."
,,,,62,,,,,,,,,,,,88,,,
